IntelGenx Technologies Corp.: Form S-1 - Filed by newsfilecorp.com

0001062993-13-003530.txt : 20130722 0001062993-13-003530.hdr.sgml : 20130722 20130722145242 ACCESSION NUMBER: 0001062993-13-003530 CONFORMED SUBMISSION TYPE: S-1 PUBLIC DOCUMENT COUNT: 12 FILED AS OF DATE: 20130722 DATE AS OF CHANGE: 20130722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IntelGenx Technologies Corp. CENTRAL INDEX KEY: 0001098880 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870638336 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1 SEC ACT: 1933 Act SEC FILE NUMBER: 333-190065 FILM NUMBER: 13979098 BUSINESS ADDRESS: STREET 1: 6425 ABRAMS CITY: VILLE SAINT LAURENT STATE: A8 ZIP: H4S 1X9 BUSINESS PHONE: 514-331-7440 MAIL ADDRESS: STREET 1: 6425 ABRAMS CITY: VILLE SAINT LAURENT STATE: A8 ZIP: H4S 1X9 FORMER COMPANY: FORMER CONFORMED NAME: BIG FLASH CORP DATE OF NAME CHANGE: 19991112 S-1 1 forms1.htm FORM S-1 IntelGenx Technologies Corp.: Form S-1 - Filed by newsfilecorp.com

As filed with the Securities and Exchange Commission on [_______]

Registration Statement No. ___________

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM S-1
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

IntelGenx Technologies Corp.
(Exact Name of Registrant as Specified in its Charter)

Delaware	2834	87-0638336
(State or other jurisdiction of	(Primary Standard Industrial	(I.R.S. Employer
incorporation or organization)	Classification Code Number)	Identification Number)

6425 Abrams, Ville Saint Laurent

Quebec, H4S 1X9 Canada

(514) 331-7440

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Horst G. Zerbe

Chief Executive Officer

IntelGenx Technologies Corp.

6425 Abrams, Ville Saint Laurent

Quebec, H4S 1X9 Canada

(514) 331-7440

(Name, address, including zip code, and telephone number, including area code, of agent for service)

With Copies of Communications to:

Richard Raymer

Dorsey & Whitney LLP

TD Canada Trust Tower

Brookfield Place, 161 Bay Street, Suite 4310

Toronto, Ontario M5J 2S1 Canada

Tel: (416) 367-7388

Approximate Date of Commencement of Proposed Sale to the Public: As soon as possible after this Registration Statement becomes effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), check the following box. [X]

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [_]

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [_]

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [_]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [_]	Accelerated filer [_]

Non-accelerated filer [_] (Do not check if a smaller reporting company)	Smaller reporting company [X]

CALCULATION OF REGISTRATION FEE

		Proposed
		Maximum		Amount of
		Aggregate		Registration
Title of Each Class of Securities to be Registered (1)		Offering Price (2)		Fee

Units, each consisting of(2)	$	6,000,000	$	818.4
(i) Common stock (3)		--		--
(ii) Warrants to purchase Common Stock(3)		--		--
Common stock issuable upon exercise of Warrants (2)	$	3,000,000	$	409.2
Placement Agent Warrants (3)		--		--
Common Stock issuable upon exercise of Placement Agent Warrants (2)	$	360,000	$	49.1
Total:		9,360,000	$	1276.70

(1) Pursuant to Rule 416 under the Securities Act, this registration statement also covers such indeterminate number of additional shares of common stock as may be issuable with respect to the shares being registered hereunder as a result of stock splits, stock dividends, recapitalizations or similar transactions.

(2) Estimated pursuant to Rule 457(o) solely for the purpose of calculating the registration fee.

(3) No registration fee is required pursuant to Rule 457(g).

The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED [__________]

PROSPECTUS

INTELGENX TECHNOLOGIES CORP.

_____ Units

Each Unit Consisting of One Share of Common Stock
and
____ of a Warrant to Purchase One Share of Common Stock

We are offering up to [ * ] units, each of which consists of one share of our common stock and [ * ] of a warrant, each to purchase one share of our common stock at an exercise price of [ * ] per share. The warrants will be immediately exercisable and will expire on the [ * ] anniversary of the issuance date. No units will be issued, however, and purchasers will receive only shares of common stock and warrants. The common stock and the warrants may be transferred separately immediately upon issuance.

Our common stock is quoted on the OTCQX under the symbol “IGXT” and on the TSX Venture Exchange (the “TSX-V”) under the symbol “IGX”. The closing price of our common stock as quoted on the OTCQX on July 18, 2013 was $0.65, and the closing price of our common stock on the TSX-V on July 18, 2013 was CDN $0.70. There is no trading market for the warrants and we do not intend to list the warrants on any national securities exchange or quotation system. Without an active market, the liquidity of the warrants will be limited.

Investing in our securities involves a high degree of risk. You should invest in the common stock only if you can afford to lose your entire investment. See “Risk Factors” beginning on page 11.

______ has agreed to act as our exclusive placement agent in connection with this offering. The placement agent is not purchasing the units offered by us, and is not required to sell any specific number or dollar amount of units, but will assist us in this offering on a commercially reasonable “best efforts” basis. We have agreed to pay the placement agent a cash fee equal to 6% of the gross proceeds of the offering of units by us and to issue to the placement agent warrants to purchase a number of shares of our common stock equal to 6% of the aggregate number of units sold in the offering if the offering raises a minimum of $6,000,000. The placement agent warrants shall have the same terms, including the exercise price, as the warrants issued to investors, except that the placement agent warrants will comply with FINRA Rule 5110(g)(1). The registration statement of which this prospectus is a part also covers the placement agent warrants and the shares of common stock issuable upon the exercise thereof. We also have agreed to reimburse the placement agent for its reasonable out-of-pocket expenses up to $50,000. See “Plan of Distribution” beginning on page 53 for more information on this offering and the placement agent arrangements. All costs associated with the registration will be borne by us.

		Per Unit		Total

Public offering price	$		$
Placement agent’s fees (1)	$		$
Proceeds to us, before expenses (2)	$		$

(1) For the purpose of estimating the placement agent’s fees, we have assumed that they will receive their maximum commission on all sales made in the offering.

(2) We estimate the total expenses of this offering, excluding the placement agent fees, will be approximately $[•]. Because there is no minimum offering amount required as a condition to closing in this offering, the actual public offering amount, placement agent fees, and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering set forth above. Once the offering price has been determined, the common stock offering price and warrant exercise price will remain fixed for the duration of the offering.

This offering will terminate on [•], 2013, unless the offering is fully subscribed before that date or we decide to terminate the offering prior to that date. In either event, the offering may be closed without further notice to you. We expect that delivery of the units being offered pursuant to this prospectus will be made to the purchasers on or about [•] 2013.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus is ____________, 2013

TABLE OF CONTENTS

FORWARD-LOOKING STATEMENTS	7
PROSPECTUS SUMMARY	7
THE OFFERING	9
SUMMARY HISTORICAL FINANCIAL INFORMATION	10
RISK FACTORS	11
USE OF PROCEEDS	18
DILUTION	18
DESCRIPTION OF BUSINESS	19
DESCRIPTION OF PROPERTY	26
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	27
MARKET INFORMATION	38
DIRECTORS AND EXECUTIVE OFFICERS	40
CORPORATE GOVERNANCE	42
EXECUTIVE COMPENSATION	46
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT	49
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS	51
DESCRIPTION OF CAPITAL STOCK	51
DESCRIPTION OF SECURITIES WE ARE OFFERING	52
LEGAL PROCEEDINGS	53
PLAN OF DISTRIBUTION	53
NOTICE TO INVESTORS	55
LEGAL MATTERS	57
EXPERTS	57
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND	57
FINANCIAL DISCLOSURE	57
WHERE YOU CAN FIND ADDITIONAL INFORMATION	57
FINANCIAL STATEMENTS	58
EXHIBIT INDEX	61

You should rely only on the information contained in this prospectus and any related free writing prospectus that we may provide to you in connection with this offering. We have not, and the placement agent has not, authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and the placement agent is not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. Neither the delivery of this prospectus nor any sale made in connection with this prospectus shall, under any circumstances, create any implication that there has been no change in our affairs since the date of this prospectus or that the information contained in this prospectus is correct as of any time after its date.

FORWARD-LOOKING STATEMENTS

Certain statements included or incorporated by reference in this prospectus constitute forward-looking statements within the meaning of applicable securities laws. All statements contained in this prospectus that are not clearly historical in nature are forward-looking, and the words “anticipate”, “believe”, “continue”, “expect”, “estimate”, “intend”, “may”, “plan”, “will”, “shall” and other similar expressions are generally intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934. All forward-looking statements are based on our beliefs and assumptions based on information available at the time the assumption was made. These forward-looking statements are not based on historical facts but on management’s expectations regarding future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Forward-looking statements involve significant known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those implied by forward-looking statements. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this prospectus or incorporated by reference herein are based upon what management believes to be reasonable assumptions, there is no assurance that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this prospectus or as of the date specified in the documents incorporated by reference herein, as the case may be. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which such statements were made or to reflect the occurrence of unanticipated events, except as may be required by applicable securities laws. The factors listed above in the section captioned "Risk Factors", as well as any cautionary language in this prospectus, provide examples of risks, uncertainties and events that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. Before you invest in the common stock, you should be aware that the occurrence of the events described as risk factors and elsewhere in this prospectus could have a material adverse effect on our business, operating results and financial condition.

PROSPECTUS SUMMARY

This summary highlights selected information contained elsewhere in this prospectus. To fully understand this offering, you should read the entire prospectus carefully, including the more detailed information regarding our company, the risks of purchasing our common stock discussed under "risk factors," and our financial statements and the accompanying notes. In this prospectus, the words "Company," "IntelGenx" "we," "us," and "our," refer collectively to IntelGenx Technologies Corp. and IntelGenx Corp., our wholly-owned Canadian subsidiary.

All amounts are US$ unless otherwise indicated. Unless otherwise indicated, the term "year," "fiscal year" or "fiscal" refers to our fiscal year ending December 31^st.

Corporate History

Our predecessor company, Big Flash Corp., was incorporated in Delaware on July 27, 1999. On April 28, 2006, Big Flash, through its Canadian holding corporation, completed the acquisition of IntelGenx Corp., a Canadian company incorporated on June 15, 2003. Big Flash did not have any operations prior to the acquisition of IntelGenx Corp. In connection with the acquisition, we changed our name from Big Flash Corp. to IntelGenx Technologies Corp. IntelGenx Corp. has continued operations as our operating subsidiary.

Our Business

Overview

We are a drug delivery company focusing on the development of novel, orally administered drug delivery products based on our proprietary oral drug delivery technologies. We have positioned ourselves as a provider of product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets.

Drug delivery systems are an important tool in the hands of physicians for purposes of optimizing drug therapy. For the pharmaceutical industry, drug delivery systems represent an opportunity to extend the market exclusivity and product lifecycle of drugs whose patent protection is nearing expiration.

A significant portion of our current products under development focus on controlled release delivery systems. Controlled release delivery systems play an important role in the development of orally administered drug delivery systems. Controlled release technology provides patients with the required amount of medication over a pre-determined, prolonged period of time. Because of the reduced fluctuation of the active drug in the blood and the avoidance of plasma spikes, controlled release products are deemed safer and more tolerable than conventional dosage forms, and have shown better patient compliance.

Our primary business strategy is to develop pharmaceutical products based upon our proprietary drug delivery technologies and license the commercial rights to companies in the pharmaceutical industry once the viability of a product has been demonstrated. In exchange for licensing rights to our products, we seek funding consisting of a combination of one or more of the following: advance down payments, milestone fees, reimbursement for development costs, and royalties on sales. In addition, we may receive a manufacturing royalty from our contract manufacturers for the exclusive right to manufacture our products. The companies we partner with are typically responsible for managing the regulatory approval process of the product with the United States Food and Drug Administration (“FDA”) and/or other regulatory bodies, as well as for the marketing and distribution of the products. On a case-by-case basis, we may be responsible for providing all or part of the documentation required for the regulatory submission. In addition to pursuing partnering arrangements that provide for the full funding of a drug development project, we may undertake development of selected product opportunities until the marketing and distribution stage. We would first assess the potential and associated costs for successful development of a product, and then determine at which stage it would be most prudent to seek a partner, balancing costs against the potential for higher returns later in the development process.

Our Offices and Other Corporate Information

Our executive offices are located at 6425 Abrams, Ville Saint-Laurent, Quebec, H4S 1X9, Canada, and our telephone number is (514) 331-7440. Our web site address is http://www.IntelGenx.com. Information contained on our web site is not a part of this prospectus.

THE OFFERING

Securities offered:	Up to ___________ units. Each unit will consist of one share of our common stock and of a warrant, each to purchase one share of our common stock. The warrants will be exercisable immediately at an exercise price of $ per share and will expire on the anniversary of the date of issuance. See “Description of Securities We Are Offering.”
Common stock outstanding prior to the offering:	50,302,921 shares (1)
Common stock included in the units	___________ shares, excluding shares issuable upon the exercise of the warrants.
Common stock to be outstanding after the offering:	___________shares, assuming full exercise of the warrants (2)
Use of proceeds:	We intend to use the net proceeds from this offering to ______. See “Use of Proceeds” on page ___.
OTCQX Ticker Symbol:	IGXT
TSX Venture Exchange Symbol:	IGX
Listing:	Our common stock is quoted on the OTCQX under the symbol “IGXT” and on the TSX Venture Exchange under the symbol “IGX”. There is no trading market for the warrants and we do not intend to list the warrants on any national securities exchange or quotation system. Without an active market, the liquidity of the warrants will be limited.
Risk Factors	See “Risk Factors” beginning on page 11 and other information in this prospectus for a discussion of the factors you should consider before you decide to invest in our securities.

(1) As of March 31, 2013
(2) Assumes the sale of all of the units offered hereby. The number of shares of common stock shown above to be outstanding after this offering is based on 50,302,921 shares outstanding as of March 31, 2013 and excludes, as of that date:

1,015,588 shares of common stock issuable upon exercise of outstanding stock options, including those options issued outside our stock option plans, at a weighted average exercise price of $0.59 per share;
5,741,665 additional shares of common stock reserved for issuance under various outstanding warrant agreements, at a weighted average exercise price of $___ per share;
1,194,968 additional shares of common stock reserved for future issuance under our amended and restated 2006 option plans;
shares of common stock issuable upon the exercise of the warrants offered hereby; and
shares of common stock issuable upon the exercise of the placement agent warrants.

SUMMARY HISTORICAL FINANCIAL INFORMATION

The following tables set forth our summary historical financial information. You should read this information together with the financial statements and the notes thereto appearing elsewhere in this prospectus and the information under "Management’s Discussion and Analysis of Financial Condition and Results of Operations."

RESULTS OF OPERATIONS:

		For the			For the
In U.S.$ thousands		Three Months			Year Ended
		Ended March			December
		31, 2013			31, 2012
		(Unaudited)			(Audited)

Revenues
Royalties	$	80		$	-
License and other revenue		77			1,198
Total Revenues		157			1,198
Expenses
Research and development expense		167			1,723
Selling, general and administrative expense		456			1,689
Amortization of tangible assets		10			37
Amortization of intangible assets		10			9
Total costs and expenses		643			3,458
Loss from operations		(486	)		(2,260	)
Other income		-			10
Net loss		(486	)
Foreign translation currency adjustment		(36	)		100
Comprehensive loss		(522	)		(2,150	)

Basic and diluted weighted average number of shares outstanding		50,236,255			49,637,908
Basic and diluted loss per common share		(0.01	)		(0.04	)

BALANCE SHEETS:

		March 31,		December 31,
In U.S.$ thousands		2013		2012
		(Unaudited)		(Audited)

Current assets	$	2,670	$	3,656
Leasehold improvements and equipment		438		387
Intangible assets		106		116
Total assets		3,214		4,159
Current liabilities		806		1,366
Deferred license revenue – non-current portion		539		615
Shareholders’ equity		1,869		2,178
Total liabilities		3,214		4,159

RISK FACTORS

Our business faces many risks. Any of the risks discussed below, or elsewhere in this report or in our other filings with the Securities and Exchange Commission (“SEC”), could have a material impact on our business, financial condition, or results of operations.

Risks Related to Our Business

We continue to sustain losses and our revenues are not sufficient to sustain our operations.

Even though we ceased being a “development stage” company in April 2006, we are still subject to all of the risks associated with having a limited operating history and pursuing the development of new products. Our cash flows may be insufficient to meet expenses relating to our operations and the development of our business, and may be insufficient to allow us to develop new products. We currently conduct research and development using our proprietary platform technologies to develop oral controlled release and other delivery products. We do not know whether we will be successful in the development of such products. We have an accumulated deficit of approximately $14,463 thousand since our inception in 2003 through December 31, 2012. To date, these losses have been financed principally through sales of equity securities, long-term debt and debt from related parties. Our revenues for the past five years ended December 31, 2012, December 31, 2011, December 31, 2010, December 31, 2009 and December 31, 2008 were $1,198 thousand, $440 thousand, $1,337 thousand, $1,279 thousand and $977 thousand respectively. Our revenues in 2012 consisted primarily of milestone payments and the amortization of deferred revenue related to the commercialization of Forfivo XL™, our first FDA-approved product, which was commercialized in October 2012. Revenue generated to date has not been sufficient to sustain our operations. In order to achieve profitability, our revenue streams will have to increase and there is no assurance that revenues will increase to such a level.

We may incur losses associated with foreign currency fluctuations.

The majority of our expenses are paid in Canadian dollars, while a significant portion of our revenues are in U.S. dollars. Our financial results are subject to the impact of currency exchange rate fluctuations. Adverse movements in exchange rates could have a material adverse effect on our financial condition and results of operations.

We may need additional capital to fulfill our business strategies. We may also incur unforeseen costs. Failure to obtain such capital would adversely affect our business.

We will need to expend significant capital in order to continue with our research and development by hiring additional research staff and acquiring additional equipment. If our cash flows from operations are insufficient to fund our expected capital needs, or our needs are greater than anticipated, we may be required to raise additional funds in the future through private or public sales of equity securities or the incurrence of indebtedness. Additional funding may not be available on favorable terms, or at all. If we borrow additional funds, we likely will be obligated to make periodic interest or other debt service payments and may be subject to additional restrictive covenants. If we fail to obtain sufficient additional capital in the future, we could be forced to curtail our growth strategy by reducing or delaying capital expenditures, selling assets or downsizing or restructuring our operations. If we raise additional funds through public or private sales of equity securities, the sales may be at prices below the market price of our stock and our shareholders may suffer significant dilution.

The loss of the services of key personnel would adversely affect our business.

Our future success depends to a significant degree on the skills, experience and efforts of our executive officers and senior management staff. The loss of the services of existing personnel would be detrimental to our research and development programs and to our overall business.

We are dependent on business partners to conduct clinical trials of, obtain regulatory approvals for, and manufacture, market, and sell our controlled release products.

We depend heavily on our pharmaceutical partners to pay for part or all of the research and development expenses associated with developing a new product and to obtain approval from regulatory bodies such as the FDA to commercialize these products. We also depend on our partners to distribute these products after receiving regulatory approval. Our revenues from research and development fees, milestone payments and royalty fees are derived from our partners. Our inability to find pharmaceutical partners who are willing to pay us these fees in order to develop new products would negatively impact our business and our cash flows.

We have limited experience in manufacturing, marketing and selling pharmaceutical products. Accordingly, if we cannot maintain our existing partnerships or establish new partnerships with respect to our other products in development, we will have to establish our own capabilities or discontinue the commercialization of the affected product. Developing our own capabilities would be expensive and time consuming and could delay the commercialization of the affected product. There can be no assurance that we would be able to develop these capabilities.

Our existing agreements with pharmaceutical industry partners are generally subject to termination by the counterparty on short notice upon the occurrence of certain circumstances, including, but not limited to, the following: a determination that the product in development is not likely to be successfully developed or not likely to receive regulatory approval; our failure to satisfy our obligations under the agreement, or the occurrence of a bankruptcy event. If any of our partnerships are terminated, we may be required to devote additional resources to the product, seek a new partner on short notice, or abandon the product development efforts. The terms of any additional partnerships or other arrangements that we establish may not be favorable to us.

We are also at risk that these partnerships or other arrangements may not be successful. Factors that may affect the success of our partnerships include the following:

Our partners may incur financial and cash-flow difficulties that force them to limit or reduce their participation in our joint projects;
Our partners may be pursuing alternative technologies or developing alternative products that are competitive to our product, either on their own or in partnership with others;
Our partners may reduce marketing or sales efforts, or discontinue marketing or sales of our products, which may reduce our revenues received on the products;
Our partners may have difficulty obtaining the raw materials to manufacture our products in a timely and cost effective manner or experience delays in production, which could affect the sales of our products and our royalty revenues earned;
Our partners may terminate their partnerships with us. This could make it difficult for us to attract new partners or adversely affect perception of us in the business and financial communities;
Our partners may pursue higher priority programs or change the focus of their development programs, which could affect the partner’s commitment to us. Pharmaceutical and biotechnology companies historically have re-evaluated their priorities from time to time, including following mergers and consolidations, a common occurrence in recent years; and
Our partners may become the target of litigation for purported patent or intellectual property infringement, which could delay or prohibit commercialization of our products and which would reduce our revenue from such products.

We face competition in our industry, and many of our competitors have substantially greater experience and resources than we do.

We compete with other companies within the drug delivery industry, many of which have more capital, more extensive research and development capabilities and greater human resources than we do. Some of these drug delivery competitors include Monosol Rx, Tesa-Labtec GmbH, BioDelivery Sciences International, Inc. and LTS Lohmann Therapy Systems Corp. Our competitors may develop new or enhanced products or processes that may be more effective, less expensive, safer or more readily available than any products or processes that we develop, or they may develop proprietary positions that prevent us from being able to successfully commercialize new products or processes that we develop. As a result, our products or processes may not compete successfully, and research and development by others may render our products or processes obsolete or uneconomical. Competition may increase as technological advances are made and commercial applications broaden.

We rely upon third-party manufacturers, which puts us at risk for supplier business interruptions.

We have entered into agreements with third party manufacturers to manufacture certain of our products once we complete development and after we receive regulatory approval. If our third-party manufacturers fail to perform, our ability to market products and to generate revenue would be adversely affected. Our failure to deliver products in a timely manner could lead to the dissatisfaction of our distribution partners and damage our reputation, causing our distribution partners to cancel existing agreements with us and to stop doing business with us.

The third-party manufacturers that we depend on to manufacture our products are required to adhere to FDA regulations regarding cGMP, which include testing, control and documentation requirements. Ongoing compliance with cGMP and other regulatory requirements is monitored by periodic inspection by the FDA and comparable agencies in other countries. Failure by our third-party manufacturers to comply with cGMP and other regulatory requirements could result in actions against them by regulatory agencies and jeopardize our ability to obtain products on a timely basis.

We are subject to extensive government regulation including the requirement of approval before our products may be marketed. Even if we obtain marketing approval, our products will be subject to ongoing regulatory review.

We, our partners, our products, and our product candidates are subject to extensive regulation by governmental authorities in the United States and other countries. Failure to comply with applicable requirements could result in warning letters, fines and other civil penalties, delays in approving or refusal to approve a product candidate, product recall or seizure, withdrawal of product approvals, interruption of manufacturing or clinical trials, operating restrictions, injunctions, and criminal prosecution.

Our products cannot be marketed in the United States without FDA approval. Obtaining FDA approval requires substantial time, effort, and financial resources, and there can be no assurance that any approval will be granted on a timely basis, if at all. We rely on our partners for the preparation of applications and for obtaining regulatory approvals. If the FDA does not approve our product candidates in a timely fashion, or does not approve them at all, our business and financial condition may be adversely affected. Further, the terms of approval of any marketing application, including the labeling content, may be more restrictive than we desire and could affect the marketability of our or our collaborator’s products. Subsequent discovery of problems with an approved product may result in restrictions on the product or its withdrawal from the market. In addition, both before and after regulatory approval, we, our collaborators, our products, and our product candidates are subject to numerous FDA requirements covering testing, manufacturing, quality control, cGMP, adverse event reporting, labeling, advertising, promotion, distribution, and export. Our partners and we are subject to surveillance and periodic inspections to ascertain compliance with these regulations. Further, the relevant law and regulations may change in ways that could affect us, our partners, our products, and our product candidates. Failure to comply with regulatory requirements could have a material adverse impact on our business.

Regulations regarding the manufacture and sale of our future products are subject to change. We cannot predict what impact, if any, such changes may have on our business, financial condition or results of operations. Failure to comply with applicable regulatory requirements could have a material adverse effect on our business, financial condition and results of operations.

Additionally, the time required for obtaining regulatory approval is uncertain. We may encounter delays or product rejections based upon changes in FDA policies, including cGMP, during periods of product development. We may encounter similar delays in countries outside of the United States. We may not be able to obtain these regulatory acceptances on a timely basis, or at all.

The failure to obtain timely regulatory acceptance of our products, any product marketing limitations, or any product withdrawals would have a material adverse effect on our business, financial condition and results of operations. In addition, before it grants approvals, the FDA or any foreign regulatory authority may impose numerous other requirements with which we must comply. Regulatory acceptance, if granted, may include significant limitations on the indicated uses for which the product may be marketed. FDA enforcement policy strictly prohibits the marketing of accepted products for unapproved uses. Product acceptance could be withdrawn or civil and/or criminal sanctions could be imposed for our failure to comply with regulatory standards or the occurrence of unforeseen problems following initial marketing.

We may not be able to expand or enhance our existing product lines with new products limiting our ability to grow.

If we are not successful in the development and introduction of new products, our ability to grow will be impeded. We may not be able to identify products to enhance or expand our product lines. Even if we can identify potential products, our investment in research and development might be significant before we could bring the products to market. Moreover, even if we identify a potential product and expend significant dollars on development, we may never be able to bring the product to market or achieve market acceptance for such product. As a result, we may never recover our expenses.

The market may not be receptive to products incorporating our drug delivery technologies.

The commercial success of any of our products that are approved for marketing by the FDA and other regulatory authorities will depend upon their acceptance by the medical community and third party payers as clinically useful, cost-effective and safe. To date, only two products based upon our technologies have been marketed in the United States, which limits our ability to provide guidance or assurance as to market acceptance.

Factors that we believe could materially affect market acceptance of these products include:

the timing of the receipt of marketing approvals and the countries in which such approvals are obtained;
the safety and efficacy of the product as compared to competitive products;
the relative convenience and ease of administration as compared to competitive products;
the strength of marketing distribution support; and
the cost-effectiveness of the product and the ability to receive third party reimbursement.

We are subject to environmental regulations and any failure to comply may result in substantial fines and sanctions.

Our operations are subject to Canadian and international environmental laws and regulations governing, among other things, emissions to air, discharges to waters and the generation, handling, storage, transportation, treatment and disposal of raw materials, waste and other materials. Many of these laws and regulations provide for substantial fines and criminal sanctions for violations. We believe that we are and have been operating our business and facility in a manner that complies in all material respects with environmental, health and safety laws and regulations; however, we may incur material costs or liabilities if we fail to operate in full compliance. We do not maintain environmental damage insurance coverage with respect to the products which we manufacture.

We may have to make significant expenditures in the future to comply with evolving environmental, health and safety requirements, including new requirements that may be adopted or imposed in the future. To meet changing licensing and regulatory standards, we may have to make significant additional site or operational modifications that could involve substantial expenditures or reduction or suspension of some of our operations. We cannot be certain that we have identified all environmental and health and safety matters affecting our activities and in the future our environmental, health and safety problems, and the costs to remediate them, may be materially greater than we expect.

Risks Related to Our Intellectual Property

If we are not able to adequately protect our intellectual property, we may not be able to compete effectively.

Our success depends, to a significant degree, upon the protection of our proprietary technologies. While we currently own four U.S. patents and have applied for six U.S. patents, we will need to pursue additional protection for our intellectual property as we develop new products and enhance existing products. We may not be able to obtain appropriate protection for our intellectual property in a timely manner, or at all. Our inability to obtain appropriate protections for our intellectual property may allow competitors to enter our markets and produce or sell the same or similar products.

If we are forced to resort to legal proceedings to enforce our intellectual property rights, the proceedings could be burdensome and expensive. In addition, our proprietary rights could be at risk if we are unsuccessful in, or cannot afford to pursue, those proceedings.

We also rely on trade secrets and contract law to protect some of our proprietary technology. We have entered into confidentiality and invention agreements with our employees and consultants. Nevertheless, these agreements may not be honored and they may not effectively protect our right to our un-patented trade secrets and know-how. Moreover, others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets and know-how.

In 1995, the U.S. Patent and Trademark Office adopted changes to the U.S. patent law that made the term of issued patents 20 years from the date of filing rather than 17 years from the date of issuance, subject to specified transition periods. Beginning in June 1995, the patent term became 20 years from the earliest effective filing date of the underlying patent application. These changes may reduce the effective term of protection for patents that are pending for more than three years. While we cannot predict the effect that these changes will have on our business, they could have a material adverse effect on our ability to protect our proprietary information. Furthermore, the possibility of extensive delays in the patent issuance process could effectively reduce the term during which a marketed product is protected by patents.

We may need to obtain licenses to patents or other proprietary rights from third parties. We may not be able to obtain the licenses required under any patents or proprietary rights or they may not be available on acceptable terms. If we do not obtain required licenses, we may encounter delays in product development or find that the development, manufacture or sale of products requiring licenses could be foreclosed. We may, from time to time, support and collaborate in research conducted by universities and governmental research organizations. We may not be able to acquire exclusive rights to the inventions or technical information derived from these collaborations, and disputes may arise over rights in derivative or related research programs conducted by us or our collaborators.

If we infringe on the rights of third parties, we may not be able to sell our products, and we may have to defend against litigation and pay damages.

If a competitor were to assert that our products infringe on its patent or other intellectual property rights, we could incur substantial litigation costs and be forced to pay substantial damages. Such litigation costs could be as a result of direct litigation against us, or as a result of litigation against one or more of our partners to whom we have contractually agreed to indemnify in the event that our intellectual property is the cause of a successful litigious action against our partner. Third-party infringement claims, regardless of their outcome, would not only consume significant financial resources, but would also divert our management’s time and attention. Such claims could also cause our customers or potential customers to purchase competitors’ products or defer or limit their purchase or use of our affected products until resolution of the claim. If any of our products are found to violate third-party intellectual property rights, we may have to re-engineer one or more of our products, or we may have to obtain licenses from third parties to continue offering our products without substantial re-engineering. Our efforts to re-engineer or obtain licenses could require significant expenditures and may not be successful.

Our controlled release products that are generic versions of branded controlled release products that are covered by one or more patents may be subject to litigation, which could delay FDA approval and commercial launch of our products.

We expect to file or have our collaborators file new drug application (“NDAs”) or Abbreviated NDA (“ANDAs”) for our controlled release products under development that are covered by one or more patents of the branded product. It is likely that the owners of the patents covering the brand name product or the sponsors of the NDA with respect to the branded product will sue or undertake regulatory initiatives to preserve marketing exclusivity. Any significant delay in obtaining FDA approval to market our products as a result of litigation, as well as the expense of such litigation, whether or not we or our collaborators are successful, could have a materially adverse effect on our business, financial condition and results of operations.

Risks Related to Our Securities:

The price of our common stock could be subject to significant fluctuations.

Any of the following factors could affect the market price of our common stock:

Our failure to achieve and maintain profitability;
Changes in earnings estimates and recommendations by financial analysts;
Actual or anticipated variations in our quarterly results of operations;
Changes in market valuations of similar companies;
Announcements by us or our competitors of significant contracts, new products, acquisitions, commercial relationships, joint ventures or capital commitments;
The loss of major customers or product or component suppliers;
The loss of significant partnering relationships; and
General market, political and economic conditions.

We have a significant number of convertible securities outstanding that could be exercised in the future. Subsequent resale of these and other shares could cause our stock price to decline. This could also make it more difficult to raise funds at acceptable levels pursuant to future securities offerings.

We have a concentration of stock ownership and control, and a small number of shareholders have the ability to exert significant control in matters requiring shareholder vote and may have interests that conflict with yours.

Directors and Officers hold 22.1% of our common stock. See “Security Ownership of Certain Beneficial Owners and Management” on page 49. As a result, such shareholders, acting together, may have the ability to control matters requiring shareholder approval, including the election of directors and approval of mergers and other significant corporate transactions. This concentration of ownership may have the effect of delaying, preventing or deterring a change in control of our company. It may also deprive our shareholders of an opportunity to receive a premium for their shares as part of a sale of our company and may affect the market price of our common stock. In deciding how to vote on such matters, those shareholders’ interests may conflict with yours.

Changes in the independence of our directors could result in governance risks.

Currently, we have a majority of independent directors, but in the future we cannot guarantee that our Board of Directors (the “Board”) will always have a majority of independent directors. In the absence of a majority of independent directors, our chief executive officer, who is also a principal shareholder and director, could establish policies and enter into transactions without independent review and approval. This could present the potential for a conflict of interest between us and our shareholders generally and the controlling officers, stockholders or directors.

Our common stock is a high risk investment.

There is a limited trading market for our common stock, which may affect the ability of shareholders to sell our common stock and the prices at which they may be able to sell our common stock.

The market price of our common stock has been volatile and fluctuates widely in response to various factors which are beyond our control. The price of our common stock is not necessarily indicative of our operating performance or long term business prospects. In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock. In the United States, our common stock is considered a “penny stock”. The SEC has adopted regulations which generally define a “penny stock” to be an equity security that has a market price of less than $5.00 per share or an exercise price of less than $5.00 per share, subject to specific exemptions. This designation requires any broker or dealer selling these securities to disclose certain information concerning the transaction, obtain a written agreement from the purchaser and determine that the purchaser is reasonably suitable to purchase the securities. These rules may restrict the ability of brokers or dealers to sell our common stock and may affect the ability of investors to sell their shares.

As a result of the foregoing, our common stock should be considered a high risk investment.

The application of the “penny stock” rules to our common stock could limit the trading and liquidity of our common stock, adversely affect the market price of our common stock and increase stockholder transaction costs to sell those shares.

As long as the trading price of our common stock is below $5.00 per share, the open market trading of our common stock will be subject to the “penny stock” rules, unless we otherwise qualify for an exemption from the “penny stock” definition. The “penny stock” rules impose additional sales practice requirements on certain broker-dealers who sell securities to persons other than established customers and accredited investors (generally those with assets in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together with their spouse). These regulations, if they apply, require the delivery, prior to any transaction involving a penny stock, of a disclosure schedule explaining the penny stock market and the associated risks. Under these regulations, certain brokers who recommend such securities to persons other than established customers or certain accredited investors must make a special written suitability determination regarding such a purchaser and receive such purchaser’s written agreement to a transaction prior to sale. These regulations may have the effect of limiting the trading activity of our common stock, reducing the liquidity of an investment in our common stock and increasing the transaction costs for sales and purchases of our common stock as compared to other securities.

We became public by means of a reverse merger, and as a result we are subject to the risks associated with the prior activities of the public company with which we merged. In addition, we may not be able to attract the attention of major brokerage firms or institutional buyers.

Additional risks may exist because we became public through a "reverse merger" with a shell corporation. Although the shell did not have recent or past operations or assets and we performed a due diligence review of the public company, there can be no assurance that we will not be exposed to undisclosed liabilities resulting from the prior operations of our company. Security analysts of major brokerage firms and securities institutions may not cover us since there are no broker-dealers who sold our stock in a public offering who would have an incentive to follow or recommend the purchase of our common stock. No assurance can be given that established brokerage firms will want to conduct any financings for us in the future.

Our limited cash resources restrict our ability to pay cash dividends.

Since our inception, we have not paid any cash dividends on our common stock. We currently intend to retain future earnings, if any, to support operations and to finance the growth and development of our business. Therefore, we do not expect to pay cash dividends in the foreseeable future. Any future determination relating to our dividend policy will be made at the discretion of our Board of Directors and will depend on a number of factors, including future earnings, capital requirements, financial conditions and future prospect and other factors that the Board of Directors may deem relevant. If we do not pay any dividends on our common stock, our shareholders will be able to profit from an investment only if the price of the stock appreciates before the shareholder sells it. Investors seeking cash dividends should not purchase our common stock.

If we are the subject of securities analyst reports or if any securities analyst downgrades our common stock or our sector, the price of our common stock could be negatively affected.

Securities analysts may publish reports about us or our industry containing information about us that may affect the trading price of our common stock. In addition, if a securities or industry analyst downgrades the outlook for our stock or one of our competitors’ stock, the trading price of our common stock may also be negatively affected.

Future sales of our common stock by our existing stockholders may negatively impact the trading price of our common stock.

If a substantial number of our existing stockholders decide to sell shares of their common stock in the public market following the completion of this offering, the price at which our common stock trades could decline. Additionally, the public market’s perception that such sales might occur may also depress the price of our common stock.

Risks Relating To the Offering

We will have broad discretion as to the use of the net proceeds from this offering, and we may not use the proceeds effectively.

Our management will have broad discretion as to the application of the net proceeds. Our stockholders may not agree with the manner in which our management chooses to allocate and spend the net proceeds. Moreover, our management may use some of the net proceeds for corporate purposes that may not increase our market value or profitability.

You will experience immediate and substantial dilution as a result of this offering and may experience additional dilution in the future.

You will incur immediate and substantial dilution as a result of this offering. After giving effect to the assumed sale of __________ units in this offering at an assumed public offering price of $____ per unit (the closing bid price of our common stock on July ___, 2013), and after deducting estimated placement agent fees and estimated offering expenses payable by us, and attributing no value to the warrants, if you purchase units in this offering, you will suffer immediate and substantial dilution of approximately $____ per share in the net tangible book value of the common stock you acquire. In the event that you exercise your warrants, you will experience additional dilution to the extent that the exercise price of those warrants is higher than the book value per share of our common stock. See “Dilution” below for a more detailed discussion of the dilution you will incur if you purchase securities in this offering.

There is no public market for the warrants to purchase common stock in this offering.

There is no established public trading market for the warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply for listing the warrants on any securities exchange or quotation system. Without an active market, the liquidity of the warrants will be limited.

Our common stock is not listed on a national securities exchange, and U.S. holders of warrants may not be able to exercise their warrants without compliance with applicable state securities laws and the value of your warrants may be significantly reduced.

Our common stock is not listed on a national securities exchange, and the exercise of the warrants by U.S. holders may not be exempt from state securities laws. As a result, depending on the state of residence of a holder of the warrants, a U.S. holder may not be able to exercise its warrants unless we comply with any state securities law requirements necessary to permit such exercise or an exemption applies. Although we plan to use our reasonable efforts to assure that U.S. holders will be able to exercise their warrants under applicable state securities laws if no exemption exists, there is no assurance that we will be able to do so. As a result, since our common stock is not listed on a national securities exchange, your ability to exercise your warrants may be limited. The value of the warrants may be significantly reduced if U.S. holders are not able to exercise their warrants under applicable state securities laws.

The warrants may not have any value.

The warrants have an exercise price of $ __ per share and expire on the ____ anniversary of the issuance date. In the event our common stock price does not exceed the exercise price of the warrants during the period when the warrants are exercisable, the warrants may not have any value.

Holders of our warrants will have no rights as common stockholders until they acquire our common stock.

Until warrant holders acquire shares of our common stock upon exercise of the warrants, the warrant holders will have no rights with respect to our common stock. Upon exercise of your warrants, you will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date.

USE OF PROCEEDS

We estimate that the net proceeds to us from the sale of the units offered by this prospectus will be approximately $_________assuming the sale by us of [ * ] units at an assumed offering price of $[ * ] per unit (the closing bid price of our common stock on July __, 2013) after deducting estimated placement agent fees and estimated offering expenses payable by us. This amount does not include the proceeds which we may receive in connection with the exercise of the warrants. We cannot predict when or if the warrants will be exercised, and it is possible that the warrants may expire and never be exercised.

Principal Purposes	Estimated Amount to be Expended	Estimated Percentage
Capital investment in VersaFilm™ manufacturing equipment
New facility leasehold improvements
Working capital and other general corporate purposes
Total Available Funds:

If the net proceeds of this offering are less than $________ we will be unable to achieve our planned operations for the next 12 months. If that occurs, we will prioritize programs, and select programs which our management believes can be adequately funded given the amount of proceeds and that provide the best opportunity for return to shareholders.

An $[ * ] increase (decrease) in the assumed offering price of $[ * ] per unit would increase (decrease) the expected net cash proceeds of the offering to us by approximately $[ * ]. An increase (decrease) in the assumed number of units sold in this offering would increase (decrease) the expected net cash proceeds of the offering to us by approximately $[ * ].

DILUTION

If you invest in our securities, you will experience dilution to the extent of the difference between the public offering price of the units (attributing no value to the warrants) and the net tangible book value of our common stock immediately after this offering. Net tangible book value per share is equal to total assets less intangible assets and total liabilities, divided by the number of shares of our outstanding common stock. Our net tangible book value as of March 31, 2013 was approximately $____ million, or $___ per share of common stock.

After giving effect to assumed sale of ______________ units in this offering at an assumed public offering price of $___ per unit (the closing bid price of our common stock on July ___, 2013) after deducting estimated placement agent fees and estimated offering expenses payable by us, and attributing no value to the warrants, our as adjusted net tangible book value as of March 31, 2013 would have been approximately $____ million, or $___ per share. This represents an immediate increase in net tangible book value of $___ per share to existing stockholders and an immediate dilution in net tangible book value of $____ per share to new investors purchasing our units in this offering. The following table illustrates this per share dilution:

Assumed public offering price per unit	$
Net tangible book value per share as of March 31, 2013	$
Increase per share attributable to new investors
As adjusted net tangible book value per share after this offering
Dilution per share to new investors	$

A $0.01 increase (decrease) in the assumed public offering price of $___ per unit would increase (decrease) our as adjusted net tangible book value by approximately $____ and dilution per share to new investors by approximately $____, assuming the number of units offered by us remains the same. A _______ increase (decrease) in the number of units offered by us would increase (decrease) our as adjusted net tangible book value by approximately $____ and dilution per share to new investors by $____, assuming a public offering price of $____ per unit.

Investors that acquire additional shares of our common stock through the exercise of the warrants offered hereby may experience additional dilution depending on our net tangible book value at the time of exercise.

The number of shares of common stock to be outstanding after this offering is based on 50,302,921 shares outstanding as of March 31, 2013 and excludes, as of that date:

1,015,588 shares of common stock issuable upon exercise of outstanding stock options, including those options issued outside our stock option plans, at a weighted average exercise price of $0.59 per share;
5,741,665 additional shares of common stock reserved for issuance under various outstanding warrant agreements, at a weighted average exercise price of $____ per share;
1,194,968 additional shares of common stock reserved for future issuance under our amended and restated 2006 option plans;
shares of common stock issuable upon the exercise of the warrants offered hereby; and
shares of common stock issuable upon the exercise of the placement agent warrants.

DESCRIPTION OF BUSINESS

Overview

Our primary business strategy is to develop pharmaceutical products based upon our proprietary drug delivery technologies and license the commercial rights to companies in the pharmaceutical industry once the viability of a product has been demonstrated. In exchange for licensing rights to our products, we seek funding consisting of a combination of one or more of the following: advance down payments, milestone fees, reimbursement for development costs, and royalties on sales. In addition, we may receive a manufacturing royalty from our contract manufacturers for the exclusive right to manufacture our products. The companies we partner with are typically responsible for managing the regulatory approval process of the product with the FDA and/or other regulatory bodies, as well as for the marketing and distribution of the products. On a case-by-case basis, we may be responsible for providing all or part of the documentation required for the regulatory submission. In addition to pursuing partnering arrangements that provide for the full funding of a drug development project, we may undertake development of selected product opportunities until the marketing and distribution stage. We would first assess the potential and associated costs for successful development of a product, and then determine at which stage it would be most prudent to seek a partner, balancing costs against the potential for higher returns later in the development process.

Technology Platforms

Our product development efforts are based upon three delivery platform technologies: (1) VersaTab™, a Multilayer Tablet technology (2) VersaFilm™, an Oral Film technology, and (3) AdVersa™, a Mucoadhesive Tablet technology. Our Multilayer Tablet platform technology allows for the development of oral controlled-release products. It is designed to be versatile and to reduce manufacturing costs as compared to competing oral extended-release delivery technologies. The Oral Film technology allows for the instant delivery of pharmaceuticals to the oral cavity, while the Mucoadhesive Tablet allows for the controlled release of active substances to the oral mucosa.

The Multilayer Tablet platform technology represents a new generation of controlled release layered tablets designed to modulate the release of active compounds. The technology is based on a multilayer tablet with an active core layer and erodible cover layers. The release of the active drug from the core matrix initially occurs in a first-order fashion. As the cover layers start to erode, their permeability for the active ingredient through the cover layers increases. Thus, the Multilayer Tablet can produce quasi-linear (zero-order) kinetics for releasing a chemical compound over a desired period of time. The erosion rate of the cover layers can be customized according to the physico-chemical properties of the active drug. In addition, our multilayer technology offers the opportunity to develop combination products in a regulatory-compliant format. Combination products are made up of two or more active ingredients that are combined into a single dosage form.

The Oral Film technology consists of a thin (25-35 micron) polymeric film comprised of United States Pharmacopeia (USP) components that are approved by the FDA for use in food, pharmaceutical, and cosmetic products. Derived from the edible film technology used for breath strips and initially developed for the instant delivery of savory flavors to food substrates, the VersaFilm™ technology is designed to provide a rapid response compared to existing conventional tablets. The VersaFilm™ technology is intended for indications requiring rapid onset of action, such as migraine, motion sickness, erectile dysfunction, and nausea.

The Mucoadhesive Tablet is a drug delivery system capable of adhering to the oral mucosa and releasing the drug onto the site of application at a controlled rate. The Mucoadhesive Tablet is designed to provide the following advantages relative to competing technologies: (i) it avoids the first pass effect, whereby the liver metabolizes the active ingredient and greatly reduces the level of drug in the systemic circulation, (ii) it leads to a higher absorption rate in the oral cavity as compared to the conventional oral route, and (iii) it achieves a rapid onset of action for the drug. The Mucoadhesive Tablet technology is designed to be versatile in order to permit the site of application, residence time, and rate of release of the drug to be modulated to achieve the desired results.

Product Portfolio

Our product portfolio includes a blend of generic and branded products based on our proprietary delivery technology (“generic” drugs are essentially copies of drugs that have already received FDA approval). Of the eleven projects currently in our product portfolio, four utilize our VersaTab™ technology, six utilize our VersaFilm™ technology, and one utilizes our AdVersa™ technology.

INT0001/2004. This is the most advanced generic product involving our multilayer tablet technology. Equivalency with the reference product Toprol XL^® and its European equivalent Beloc-ZOK^® has been demonstrated in-vitro. The product has been tested in phase I studies. Pivotal development activities are ongoing.

INT0004/2006. The development of a new, higher strength of the antidepressant Bupropion HCl, the active ingredient in Wellbutrin XL®, has been completed. In November 2011 the FDA approved the drug for patients with Major Depressive Disorder and, in February 2012, we entered into an agreement with Edgemont Pharmaceuticals LLC (“Edgemont”) for commercialization of the product in the United States. Under the terms of the agreement, Edgemont has obtained certain exclusive rights to market and sell the product in the U.S. In exchange IntelGenx received a $1.0 million upfront payment and will be eligible to receive launch related milestones totaling up to $4.0 million. In addition, IntelGenx will be eligible for additional milestones upon achieving certain sales and exclusivity targets of up to a further $23.5 million. IntelGenx will also receive tiered double-digit royalties on the net sales of the product. The agreement has no expiry date but may be terminated in the event of, without limitation (i) failure by either us or Edgemont to perform our respective obligations under the agreement; (ii) if either party files a petition for bankruptcy or insolvency or otherwise winds up, liquidates or dissolves its business, or (iii) otherwise by mutual consent of the parties. The agreement also contains customary confidentiality, indemnification and intellectual property protection provisions.

The product was launched in the U.S. in October 2012 under the brand name Forfivo XL™. As of December 31, 2012 we have received an upfront payment of $1 million and we have invoiced and received a $1 million milestone payment related to the launch. We have begun receiving royalty payments as of the first quarter of 2013.

INT0007/2006. An oral Tadalafil film product based on our proprietary oral film technology is currently in the optimization stage. The product is intended for the treatment of erectile dysfunction (ED). The results of a phase I pilot study that was conducted in the third quarter of 2010 indicate that the product is bioequivalent with the brand product, Cialis^®. A second clinical trial comparing an alternative formulation with the reference listed drug (RLD) was completed in the first quarter of 2013. The results of this study suggest the potential for a faster acting Tadalafil using our VersaFilm™ product.

INT0008/2007. A 505(b)(2) NDA for our novel oral thin-film formulation of Rizatriptan, the active drug in Maxalt-MLT® orally disintegrating tablets was submitted to the FDA on April 3, 2013. The FDA has informed us that the application is sufficiently complete to permit a substantive review in accordance with the FDA’s "standard" classification process and has assigned a PDUFA date of February 3, 2014 at which time the agency will inform the company of the result of its review. Maxalt-MLT® is a leading branded anti-migraine product manufactured by Merck & Co. The thin-film formulation of Rizatriptan has been developed in accordance with the co-development and commercialization agreement with RedHill Biopharma Ltd. using IntelGenx’ proprietary immediate release VersaFilm™ oral drug delivery technology. In December 2011, we received approval by Health Canada to conduct a pivotal bioequivalence study to determine if our product is safe and bioequivalent with the FDA approved reference product, Maxalt-MLT®. The trial was conducted in the second quarter of 2012 and was a randomized, two-period, two-way crossover study in healthy male and female subjects. The study results indicate that the product is safe, and that the 90% confidence intervals of the three relevant parameters Cmax, AUC(0-t) and AUC(0-infinity) are well within the 80 – 125 acceptance range for bioequivalency.

INT0024/2010. An oral tablet product based on our proprietary multilayer tablet technology is currently in the development stage. An interaction study was conducted in the third quarter of 2012 and yielded positive results. The product is intended for the treatment of idiopathic pulmonary fibrosis.

INT0027/2011. An oral controlled-release film product based on our proprietary edible film technology is currently in the development stage.

INT0028/2011. We initially entered into an agreement with Cynapsus Therapeutics Inc. (formerly Cannasat Therapeutics Inc., “Cynapsus”) for the development of a buccal mucoadhesive tablet product containing a cannabinoid-based drug for the treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy. A clinical biostudy undertaken in 2009 on the mucoadhesive tablet developed by us and based on our proprietary AdVersa™ technology indicated improved bioavailability and reduced first-pass metabolization of the drug. In the fourth quarter of 2010, we acquired from Cynapsus full control of, and interest in, this project going forward. We also obtained worldwide rights to US Patent 7,592,328 and all corresponding foreign patents and patent applications to exclusively develop and further provide intellectual property protection for this project.

INT0030/2011. An oral film product based on our proprietary edible film technology is currently in the development stage. The product is intended for the animal health market. An initial acceptability study of the placebo in dogs indicated that the product is well accepted and a larger study is in preparation.

INT0035/2013. An oral oncology product intended to improve the dosing regimen by using our proprietary controlled release technology is currently in the development stage.

INT0036/2013. A fast acting oral product for the treatment of a CNS indication based on our proprietary oral drug delivery technology is currently in the development stage.

The current development status of each of our products as of the date of this report is summarized in the following table:

Product	Application	Status of Development
INT0001/2004	CHF (Coronary Heart Failure), Hypertension	Pivotal batches in preparation.
INT0004/2006	Antidepressant	FDA approved November 2011 and launched in USA as Forfivo XL™ in October, 2012.
INT0007/2006	Erectile Dysfunction	Pilot biostudy completed indicating bioequivalence with brand product. Pilot phase 1 study against the Reference Listed Drug (“RLD”) suggests faster rate of absorption.
INT0008/2007	Migraine	Pivotal biostudy completed indicating bioequivalence with RLD. Pivotal manufacturing activities completed. NDA submitted to FDA April 3, 2013. PDUFA date February 3, 2014.
INT0024/2010	Idiopathic pulmonary fibrosis	Interaction study completed. Formulation optimization in preparation.
INT0027/2011	Undisclosed	Formulation development ongoing.
INT0028/2011	Chronic pain	Clinical development in preparation.
INT0030/2011	Animal health	Acceptability study completed. Product formulation in preparation.
INT0035/2013	Oncology	Formulation development ongoing.
INT0036/2013	CNS	Formulation development ongoing.

Growth Strategy

Our primary growth strategies include: (1) identifying lifecycle management opportunities for existing market leading pharmaceutical products, (2) developing generic drugs with high barriers to entry, (3) developing products for the (non-pharmaceutical) nutritional supplement market, and (4) developing new drug delivery technologies.

Lifecycle Management Opportunities

We are seeking to position our delivery technologies as an opportunity for lifecycle management of products for which patent protection of the active ingredient is nearing expiration. While the patent for the underlying substance cannot be extended, patent protection can be obtained for a new and improved formulation by filing an application with the FDA under Section 505(b)(2) of the U.S. Federal Food, Drug and Cosmetic Act. Such applications, known as a “505(b)(2) NDA”, are permitted for new drug products that incorporate previously approved active ingredients, even if the proposed new drug incorporates an approved active ingredient in a novel formulation or for a new indication. A 505(b)(2) NDA may include information regarding safety and efficacy of a proposed drug that comes from studies not conducted by or for the applicant. The first formulation for a respective active ingredient filed with the FDA under a 505(b)(2) application may qualify for up to three years of market exclusivity upon approval. Based upon a review of past partnerships between third party drug delivery companies and pharmaceutical companies, management believes that drug delivery companies which possess innovative technologies to develop these special dosage formulations present an attractive opportunity to pharmaceutical companies. Accordingly, we believe “505(b)(2) products” represent a viable business opportunity for us.

Generic Drugs with High Barriers to Entry

We plan to pursue the development of generic drugs that have certain barriers to entry, e.g., where product development and manufacturing is complex and can limit the number of potential entrants into the generic market. We plan to pursue such projects only if the number of potential competitors is deemed relatively insignificant.

Nutritional Supplement Products

We plan to develop additional products for the nutritional supplement market based upon our proprietary drug delivery technologies. The market for these supplements is large, with little differentiation between products. Our proprietary technology is aimed at increasing the absorption rate of active ingredients. We believe that supplements represent attractive short-term revenue opportunities since they are not regulated as pharmaceutical products and do not require FDA approval.

Development of New Drug Delivery Technologies

The rapidly disintegrating film technology contained in our VersaFilm™, and our AdVersa™ mucosal adhesive tablet, are two examples of our efforts to develop alternate technology platforms. As we work with various partners on different products, we seek opportunities to develop new proprietary technologies.

Competition

The pharmaceutical industry is highly competitive and is subject to the rapid emergence of new technologies, governmental regulations, healthcare legislation, availability of financing, patent litigation and other factors. Many of our competitors, including Monosol Rx, Tesa-Labtec GmbH, BioDelivery Sciences International, Inc. and LTS Lohmann Therapy Systems Corp., have longer operating histories and greater financial, technical, marketing, legal and other resources than we have. In addition, many of our competitors have significantly greater experience than we have in conducting clinical trials of pharmaceutical products, obtaining FDA and other regulatory approvals of products, and marketing and selling products that have been approved. We expect that we will be subject to competition from numerous other companies that currently operate or are planning to enter the markets in which we compete.

The key factors affecting the development and commercialization of our drug delivery products are likely to include, among other factors:

The safety and efficacy of our products;
The relative speed with which we can develop products;
Generic competition for any product that we develop;
Our ability to defend our existing intellectual property and to broaden our intellectual property and technology base;
Our ability to differentiate our products;
Our ability to develop products that can be manufactured on a cost effective basis;
Our ability to manufacture our products in compliance with current Good Manufacturing Practices (“cGMP”) and any other regulatory requirements; and
Our ability to obtain financing.

In order to establish ourselves as a viable industry partner, we plan to continue to invest in our research and development activities in order to further strengthen our technology base and to develop the ability to manufacture our products through our manufacturing partners at competitive costs.

Our Competitive Strengths

We believe that our key competitive strengths include:

Our intellectual property;
The uniqueness and versatility of our drug delivery technology; and
The potential manufacturing cost savings associated with our technology.

Manufacturing Partnership

We currently manufacture products only for testing purposes in our own laboratories, and we do not manufacture products for pivotal clinical trials or for commercial use. In order to establish ourselves as a full-service partner for our thin film products, we plan to establish a pilot plant for the manufacture of larger scale test batches of products developed using our VersaFilm™ drug delivery technology. VersaFilm™ is IntelGenx’ immediate release polymeric film technology. It is comprised of a thin polymeric film using United States Pharmacopeia (USP) components that are safe and approved by the FDA for use in food, pharmaceutical and cosmetic products. VersaFilm™ provides a patent-protected method of re-formulating approved pharmaceuticals in a more convenient and discrete oral dosage form. We expect to establish our pilot plant by December 31, 2013.

We formed a strategic alliance with LTS Lohmann Therapie-Systeme AG ("LTS") for the manufacturing of certain products developed by us using our VersaFilm™ technology. LTS is regarded as a pioneer in the development and production of transdermal and film form oral systems and has become one of the world’s leading suppliers for the international pharmaceutical industry.

We formed a strategic manufacturing partnership with, and took an ownership position in, Pillar5 Pharma Inc. (“Pillar5”). We have undertaken to use our best efforts to ensure that distributors of our oral solid dose pharmaceutical products that are developed for commercial production, be directed to Pillar5 for the purpose of negotiating a manufacturing agreement requiring Pillar5 to manufacture such products. As consideration for this undertaking, Pillar5 issued to us common shares representing 10% of the issued and outstanding shares of Pillar5. This manufacturing partnership secures the production of clinical test batches and commercial products for our VersaTab™ and AdVersa™ tablet products.

We are not currently a manufacturer and we do not usually purchase large quantities of raw materials. Our manufacturing partners, however, may purchase significant quantities of raw materials, some of which may have long lead times. If raw materials cannot be supplied to our manufacturing partners in a timely and cost effective manner, our manufacturing partners may experience delays in production that may lead to reduced supplies of commercial products being available for sale or distribution. Such shortages could have a detrimental effect on sales of the products and a corresponding reduction on our royalty revenues earned.

Dependence on Major Customers

We do not rely on any one or a few major customers for our end products. However, we depend upon a limited number of partners to develop our products, to provide funding for the development of our products, to assist in obtaining regulatory approvals that are required in order to commercialize these products, and to market and sell our products.

Intellectual Property and Patent Protection

We protect our intellectual property and technology by using the following methods: (i) applying for patent protection in the United States and in the appropriate foreign markets, (ii) non-disclosure agreements, license agreements and appropriate contractual restrictions and controls on the distribution of information, and (iii) trade secrets, common law trademark rights and trademark registrations. We plan to file core technology patents covering the use of our platform technologies in any pharmaceutical products.

We have obtained four (4) patents and have an additional six (6) pending patent applications, as described below. The patents expire 20 years after submission of the initial application.

			Date submitted / issued /
Patent No.	Title	Subject	expiration
US 6,231,957	Rapidly disintegrating flavor wafer for flavor enrichment	The composition, manufacturing, and use of rapidly disintegrating flavored films for releasing flavors to certain substrates	Issued May 15, 2001 Expires May 6, 2019
US 6,660,292	Rapidly disintegrating film for precooked foods	Composition and manufacturing of flavored films for releasing flavors to precooked food substrates	Issued December 9, 2003 Expires June 19, 2021
US 7,132,113	Flavored film	Composition and manufacturing method of multi-layered films	Issued April 16, 2002 Expires April 16, 2022
US Appl. 2007/0190144	Multilayer Tablet	Formulation and Method of Preparation of Multilayered Tablets	Published August 16, 2007
US Appl. 11/782,838 PCT/IB2007/03950	Controlled Release Pharmaceutical Tablets	Formulation and Method Of Making Tablets Containing Bupropion And Mecamylamine	July 25, 2006
US Patent 7674479	Sustained-release Bupropion and Bupropion / Mecamylamine tablets	Formulation and Method Of Making Tablets Containing Bupropion And Mecamylamine	Issued March 9, 2010 Expires July 25, 2027
US Appl. 12/836810	Oral Mucoadhesive dosage form	Direct compression formulation for buccal and sublingual dosage forms	July 15, 2010
US Appl. US 12/936.132	Oral film dosage forms and methods for making same	Optimization of Film strip technology	December 8, 2010
US Appl. 13/079,348	Solid oral dosage forms comprising Tadalafil	Oral films containing Tadalafil	April 04, 2011

Government Regulation

The pharmaceutical industry is highly regulated. The products we participate in developing require certain regulatory approvals. In the United States, drugs are subject to rigorous regulation by the FDA. The U.S. Federal Food, Drug, and Cosmetic Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, record keeping, packaging, labeling, adverse event reporting, advertising, promotion, marketing, distribution, and import and export of pharmaceutical products. Failure to comply with applicable regulatory requirements may subject a company to a variety of administrative or judicially-imposed sanctions and/or the inability to obtain or maintain required approvals or to market drugs. The steps ordinarily required before a new pharmaceutical product may be marketed in the United States include:

preclinical laboratory tests, animal studies and formulation studies under FDA’s good laboratory practices regulations, or GLPs;
the submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials may begin;
the completion of adequate and well-controlled clinical trials according to good clinical practice regulations, or GCPs, to establish the safety and efficacy of the product for each indication for which approval is sought;
after successful completion of the required clinical testing, submission to the FDA of a NDA, or an ANDA, for generic drugs. In certain cases, an application for marketing approval may include information regarding safety and efficacy of a proposed drug that comes from studies not conducted by or for the applicant. Such applications, known as a 505(b)(2) NDA, are permitted for new drug products that incorporate previously approved active ingredients, even if the proposed new drug incorporates an approved active ingredient in a novel formulation or for a new indication;
satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMPs to assure that the facilities, methods and controls are adequate to preserve the drug’s identity, strength, quality and purity; and
FDA review and approval of the NDA or ANDA.

The cost of complying with the foregoing requirements, including preparing and submitting an NDA or ANDA, may be substantial. Accordingly, we typically rely upon our partners in the pharmaceutical industry to spearhead and bear the costs of the FDA approval process. We also seek to mitigate regulatory costs by focusing on 505(b)(2) NDA opportunities. By applying our drug delivery technology to existing drugs, we seek to develop products with lower research & development (“R&D”) expenses and shorter time-to-market timelines as compared to regular NDA products.

Research and Development Expense

Our R&D expenses, net of R&D tax credits, for the year ended December 31, 2012 increased to $1,723 thousand as compared to $1,336 thousand for the year ended December 31, 2011. The increase in R&D expenditure is explained in the section of this report entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations”.

Environmental Regulatory Compliance

We believe that we are in compliance with environmental regulations applicable to our research and development facility located in Ville Saint-Laurent, Quebec.

Employees

As of the date of this filing, we have 11 full-time and no part-time employees. None of our employees are covered by collective bargaining agreements. We believe that our relations with our employees are good.

DESCRIPTION OF PROPERTY

We currently occupy 3,500 square feet of leased space at a rate of CAD$8.88/square foot in an industrial zone at 6425 Abrams, Ville St.-Laurent, Quebec, Canada under a five year renewable lease agreement signed in 2004. We expanded our laboratory and office space at this facility to its maximum during the second quarter of 2006. We extended the term of the lease agreement to, most recently, the day immediately preceding the fulfillment of certain conditions relating to the occupation of new leased premises at 6410-6420 Abrams.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Introduction to Management’s Discussion and Analysis

The purpose of this section, Management’s Discussion and Analysis of Financial Condition and Results of Operations, is to provide a narrative explanation of the financial statements that enables investors to better understand the business of the Company, to enhance the Company’s overall financial disclosures, to provide the context within which the Company’s financial information may be analyzed, and to provide information about the quality of, and potential variability of, the Company’s financial condition, results of operations and cash flows. Unless otherwise indicated, all financial and statistical information included herein relates to continuing operations of the Company. This information should be read in conjunction with the accompanying unaudited Consolidated Financial Statements and Notes thereto.

Company Background

We are a drug delivery company established in 2003 and headquartered in Montreal, Quebec, Canada. Our focus is on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. Our business strategy is to develop pharmaceutical products based on our proprietary drug delivery technologies and, once the viability of a product has been demonstrated, to license the commercial rights to partners in the pharmaceutical industry. In certain cases, we rely upon partners in the pharmaceutical industry to fund development of the licensed products, complete the regulatory approval process with the FDA or other regulatory agencies relating to the licensed products, and assume responsibility for marketing and distributing such products.

In addition, we may choose to pursue the development of certain products until the project reaches the marketing and distribution stage. We will assess the potential for successful development of a product and associated costs, and then determine at which stage it is most prudent to seek a partner, balancing such costs against the potential for additional returns earned by partnering later in the development process.

We have also undertaken a strategy under which we will work with pharmaceutical companies in order to develop new dosage forms for pharmaceutical products for which patent protection is nearing expiration. Under §(505)(b)(2) of the Food, Drug, and Cosmetics Act, the FDA may grant market exclusivity for a term of up to three years of exclusivity following approval of a listed drug that contains previously approved active ingredients but is approved in a new dosage, dosage form, route of administration or combination, or for a new use, the approval of which was required to be supported by new clinical trials, other than bioavailability studies, conducted by or for the sponsor.

We are currently continuing to develop the existing products in our pipeline and may also perform research and development on other potential products as opportunities arise.

We currently purchase and/or lease, on an as-needed basis, the equipment necessary for performing research and development activities related to our products.

We plan to hire new personnel, primarily in the areas of research and development, manufacturing, and administration on an as-needed basis as we enter into partnership agreements, establish our pilot plant VersaFilm™ manufacturing capability, and increase our research and development activities.

Key Developments

On March 27, 2013 we announced that, together with our co-development partner RedHill Biopharma (“RedHill”), we submitted a 505(b)(2) NDA to the FDA for our anti-migraine oral film product.

We had previously announced a successful pre-NDA meeting with the FDA following the successful completion of a bioequivalency study demonstrating that our oral film product is bioequivalent with Maxalt MLT®, a leading branded anti-migraine product manufactured by Merck & Co. According to Merck’s most recent annual report, sales of Maxalt® were $638 million in 2012. The thin-film formulation of Rizatriptan has been developed in accordance with the co-development and commercialisation agreement with RedHill.

Our orally disintegrating film consists of a thin (30 – 50 µm) polymeric film which disintegrates rapidly upon oral administration, thereby releasing the active drug Rizatriptan and making it available for rapid absorption. The film does not require water for administration.

Currency rate fluctuations

Our operating currency is Canadian dollars, while its reporting currency is U.S. dollars. Accordingly, our results of operations and balance sheet position have been affected by currency rate fluctuations. The following management discussion and analysis takes this into consideration whenever material.

Results of Operations for the three month period ended March 31, 2013 compared with the three month period ended March 31, 2012.

										Percentage
In U.S.$ thousands		2013			2012			Increase/		Increase/
								(Decrease)		(Decrease)

Revenue	$	157		$	100		$	57		57%

Research and Development Expenses		202			264			(62	)	(24%	)
Research and Development Tax Credit		(35	)		(25	)		10		40%
Selling, General and Administrative Expenses		456			439			17		4%
Amortization of tangible assets		10			8			2		25%
Amortization of intangible assets		10			-			10		N/A

Net Loss		(486	)		(582	)		(96	)	(17%	)

Revenue

Total revenue in the first three months of 2013 increased to $157 thousand, compared with $100 thousand in the same period of 2012.

All revenue recorded during the first quarter of 2013 relates to Forfivo XL™, our first FDA approved product, which was launched in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP (“Edgemont”). Upon entering into the licensing agreement, Edgemont paid us an upfront fee of $1 million, which we recognized as deferred license revenue. The deferred license revenue is amortized in income over the period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, we recognized $77 thousand in income during the first quarter of 2013. In addition, we recognized approximately $80 thousand of royalty income earned from the sale of Forfivo XL™. The royalties relate to sales of Forfivo XL™ by Edgemont during the first three months post product launch. Forfivo XL™ is indicated for the treatment of Major Depressive Disorder and is the only extended-release bupropion HCl product to provide a once-daily, 450mg dose in a single tablet.

Royalty income in the second quarter of 2013 is expected to be lower than royalty income achieved in the current quarter, as a result of lower than anticipated sales of Forfivo XL™ during the current quarter. Management is assessing this variation in sales performance with a view towards taking steps to support steady sales growth of Forfivo XL™.

Revenue for the three months ended March 31, 2012 relates to the receipt of a $100 thousand development milestone in respect of our anti-migraine project. The milestone became due following the successful completion of the pivotal bioequivalence study. In March 2013 we announced that, together with our co-development partner RedHill, we submitted a 505(b)(2) NDA to the FDA for our anti-migraine oral film product, a novel oral thin-film formulation based on our proprietary VersaFilm™ technology containing Rizatriptan, the active drug in Merck’s Maxalt-MLT® orally disintegrating tablets.

Research and Development Expenses

R&D expenses, net of R&D investment tax credits, totaled $167 thousand in the three months ended March 31, 2013, representing a decrease of $72 thousand, or 30%, to the expense of $239 thousand recorded in the same period of last year.

The decrease in R&D expenses is primarily related to the costs incurred in the first quarter of 2012 that were associated with a pilot clinical study that were not repeated in the first quarter of 2013.

Included within R&D expenses for the first three months of 2013 are R&D Salaries of $153 thousand, of which approximately $3 thousand represents non-cash compensation. This compares to R&D salaries of $149 thousand in the first three months of 2012, of which approximately $5 thousand represented non-cash compensation.

In the three months ended March 31, 2013 we recorded estimated Research and Development Tax Credits and refunds of $35 thousand, compared with $25 thousand that was recorded in the same period of the previous year.

Selling, General and Administrative (“SG&A”) Expenses

SG&A expenses increased by $17 thousand, to $456 thousand, in the first three months of 2013 compared with $439 thousand in the first three months of 2012. The increase is primarily attributable to the addition of Dr. Rajiv Khosla to our management team in a senior consulting capacity ($53 thousand), increased public relations efforts with the appointment of a public relations consultant in May 2012, together with the appointment in July 2012 of an online communications & marketing firm specialized in social media ($21 thousand), partly compensated by a reduction in investor relations expenses of approximately $20 thousand, and a foreign exchange gain of $12 thousand in the first three months of 2013 compared with a foreign exchange loss of $48 thousand in the first three months of 2012. The foreign exchange gains and losses relate primarily to currency fluctuations between the Canadian dollar and the U.S. dollar.

Included in SG&A expenses are approximately $5 thousand (2012: $3 thousand) in non-cash compensation from options granted to management employees in 2011 and 2012, $4 thousand (2012: $6 thousand) in non-cash compensation from options granted to non-employee directors in 2011, and $6 thousand (2012: $Nil) in non-cash compensation from options granted to consultants in 2012.

Amortization of intangible assets

The amortization of intangible assets expense for the first three months of 2013 totaled $10 thousand, compared with $Nil in the same period of last year. The expense relates to the amortization of NDA acquisition costs in respect of the final progress payment to acquire 100% ownership of Forfivo XL™. Commercialization of Forfivo XL™ in October 2012 triggered amortization of the asset over its estimated useful life of 39 months.

Share-Based Compensation Expense, Warrants and Stock Based Payments

Share-based compensation expense, warrants and share-based payments totaled $18 thousand for the three months ended March 31, 2013, compared with $15 thousand for the three months ended March 31, 2012.

We expensed approximately $8 thousand in the first three months of 2013 for options granted to our employees in 2011 and 2012 under the 2006 Stock Option Plan, and approximately $4 thousand for options granted to non-employee directors in 2011, compared with $8 thousand and $6 respectively that was expensed in the same period of the previous year.

We also expensed $6 thousand in the first three months of 2013 for options granted to consultants and $1 thousand in the first three months of 2012 for options granted to investor relation firms for investor relation services.

There remains approximately $53 thousand in stock based compensation to be expensed in fiscal 2013 and 2014, of which $42 thousand relates to the issuance of options to employees and directors of the Company during 2011 and 2012 and $11 thousand relates to the issuance of options to consultants in 2012. We anticipate the issuance of additional options and warrants in the future, which will continue to result in stock-based compensation expense.

Key items from the Balance Sheet.

In U.S.$ thousands		March 31, 2013		December 31, 2012		Increase/ (Decrease)		Percentage Increase/ (Decrease)
Current Assets	$	2,670	$	3,656	$	(986	)	(27%	)
Leasehold improvements and Equipment		438		387		51		13%
Intangible Assets		106		116		(10	)	(9%	)
Current Liabilities		806		1,366		(560	)	(41%	)
Deferred License Revenue		539		615		(76	)	(12%	)
Capital Stock		1		0		1		N/A
Additional Paid-in-Capital		16,554		16,342		212		1%

Current Assets

Current assets totaled $2,670 thousand at March 31, 2013 compared with $3,656 thousand at December 31, 2012. The decrease of $986 thousand is attributable to a decrease in accounts receivable of approximately $1,112 thousand and a decrease in prepaid expenses of approximately $13 thousand, partly offset by an increase in cash and cash equivalents of approximately $109 thousand and an increase in investment tax credits receivable of approximately $30 thousand.

Cash and cash equivalents totaled $2,168 thousand as at March 31, 2013 representing an increase of $109 thousand compared to the balance of $2,059 thousand as at December 31, 2012. The increase in cash on hand relates to net cash provided by operating activities of $10 thousand, together with net cash provided by financing activities of $195 thousand, partly offset with net cash used in investing activities of $69 thousand and an unrealized foreign exchange loss of $27 thousand.

Accounts receivable totaled $170 thousand compared with $1,282 thousand as at December 31, 2012. Included within the accounts receivable balance as at December 31, 2012 is a $1 million milestone that was invoiced to Edgemont Pharmaceuticals in the fourth quarter of 2012 for the launch of Forfivo XL™. We received payment against this invoice in February 2013.

As of March 31, 2013, prepaid expenses totaled $89 thousand compared with $102 thousand as of December 31, 2012. The decrease relates to the allocation of prepaid expenses to the income statement for the first three months of 2013.

R&D investment tax credits receivable totaled $243 thousand as at March 31, 2013 compared with $213 thousand as at December 31, 2012. The amount receivable as at December 31, 2012 relates to credits accrued throughout fiscal 2012, for which we expect to receive reimbursement in the fourth quarter of 2013.

Leasehold Improvements and Equipment

As at March 31, 2013, the net book value of leasehold improvements and equipment amounted to $438 thousand, compared to $387 thousand at December 31, 2012. In the three months ended March 31, 2013 additions to assets totaled $69 thousand and comprised $68 thousand for pilot plant manufacturing equipment for our VersaFilm™ products and $1 thousand for computer equipment. Depreciation on leasehold improvements and equipment in the three months ended March 31, 2013 amounted to $10 thousand and a foreign exchange loss of $8 thousand was recorded.

Intangible Assets

As at March 31, 2013 NDA acquisition costs of $106 thousand (December 31, 2012 - $116 thousand) were recorded as intangible assets on our balance sheet and are related to the acquisition of 100% ownership of Forfivo XL™. The asset will be amortized over its expected useful life of 39 months and amortization commenced upon commercial launch of Forfivo XL™ in the fourth quarter of 2012.

Current Liabilities

Current liabilities totaled $806 thousand as at March 31, 2013 (December 31, 2012 - $1,366 thousand) and consisted of accounts payable and accrued liabilities of $498 thousand (December 31, 2012 - $1,058 thousand) and the current portion of deferred license revenue of $308 thousand (December 31, 2012 - $308 thousand).

Accounts payable and accrued liabilities as at March 31, 2013 amounted to $498 thousand (December 31, 2012 - $1,058 thousand), of which approximately $307 thousand relates to research and development activities, approximately $17 thousand relates to professional fees, and approximately $158 thousand relates to accrued payroll liabilities. The decrease in accounts payable and accrued liabilities as at March 31, 2013, compared with December 31, 2012, primarily relates to the payment of invoices received for the fourth quarter of 2012 and outstanding as at December 31, 2012 in respect of R&D activities.

Deferred License Revenue

Pursuant to the execution of a licensing agreement for Forfivo XL™, we received an upfront fee from Edgemont Pharmaceuticals in the first quarter of 2012, which we recognized as deferred license revenue. The deferred license revenue is amortized in income over the period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, we have a deferred revenue balance of $847 thousand at March 31, 2013 (December 31, 2012: $923 thousand) that has not been recognized as revenue, with $539 thousand recognized as the non-current portion and $308 thousand recognized in current assets as the current portion, versus $615 thousand and $308 thousand respectively as at December 31, 2012.

Shareholders’ Equity

As at March 31, 2013 we had accumulated a deficit of $14,949 thousand compared with an accumulated deficit of $14,463 thousand as at December 31, 2012. Total assets amounted to $3,214 thousand and shareholders’ equity totaled $1,869 thousand as at March 31, 2013, compared with total assets and shareholders’ equity of $4,159 thousand and $2,178 thousand respectively, as at December 31, 2012.

Capital Stock

As at March 31, 2012 capital stock amounted to $503 compared to $499 at December 31, 2012. The increase reflects the issuance of 362,500 shares and 50,000 shares related to the exercise of warrants and stock options, respectively, with all shares issued at par value of $0.00001. Capital stock is disclosed at its par value with the excess of proceeds shown in Additional Paid-in-Capital.

Additional Paid-in-Capital

Additional paid-in capital totaled $16,554 thousand at March 31, 2013, compared with $16,342 thousand at December 31, 2012. The increase relates in part to $18 thousand for stock based compensation, of which $6 thousand is attributable to the amortization of stock options granted to consultants, and $12 thousand is attributable to the amortization of stock options granted to employees and directors. Additional paid-in capital increased further by $171 thousand for warrants exercised, and by $23 thousand for options exercised.

Key items from the Statement of Cash Flows

										Percentage
In U.S.$ thousands		March 31,			March 31,			Increase/		Increase/
		2013			2012			(Decrease)		(Decrease)
Operating Activities	$	10		$	423		$	(413	)	(98%	)
Financing Activities		195		$	233		$	(38	)	(16%	)
Investing Activities		(69	)		(189	)		(120	)	(64%	)
Cash and cash equivalents - end of period		2,168			4,059			(1,891	)	(47%	)

Statement of cash flows

Net cash generated by operating activities was $10 thousand in the three months ended March 31, 2013, compared with $423 thousand for the three months ended March 31, 2012. In the first quarter of 2013, net cash generated by operating activities consisted of an operating loss of $448 thousand net of non-cash related expenses of approximately $38 thousand, and an increase in non-cash operating elements of working capital of $458 thousand.

Operating activities will continue to consume our available funds until we are able to generate increased revenues.

The net cash provided by financing activities was $195 thousand in the first three months of 2013, compared with $233 thousand provided in the same period of the previous year. The net cash provided in the first quarter of 2013 resulted from the exercise of warrants and options, whereas the cash provided in the first quarter of 2012 resulted entirely from the exercise of warrants.

Net cash used in investing activities amounted to $69 thousand in the three months ended March 31, 2013 compared with $189 thousand in the three months ended March 31, 2012. Included within the use of funds in the first quarter of 2013 is an investment of approximately $68 thousand in new equipment for our VersaFilm technology, compared with an investment of approximately $182 thousand in the first quarter of 2012.

The balance of cash and cash equivalents as at March 31, 2013 amounted to $2,168 thousand, compared with $4,059 thousand at March 31, 2012.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements.

Results of Operations – Year ended December 31, 2012 compared to the Year ended December 31, 2011.

										Percentage
In U.S.$ thousands		2012			2011			Increase/		Increase/
								(Decrease)		(Decrease)
Revenue	$	1,198		$	433		$	765		177%
Other Income		10			7			3		43%
Research and Development Expenses		1,935			1,524			411		27%
Research and Development Tax Credit		(212	)		(188	)		24		13%
Management Salaries		716			586			130		22%
General and Administrative Expenses		347			333			14		4%
Professional Fees		582			594			(12	)	(2%	)
Depreciation		46			37			9		24%
Foreign Exchange Loss		41			3			38		1,267%
Interest and Financing Fees		3			3			0		0%
Net Loss		(2,250	)		(2,452	)		(202	)	(8%	)

Revenue and Other Income

Total revenue and other income increased by $768 thousand, or 175%, from $440 thousand in the year ended December 31, 2011 to $1,208 thousand in the year ended December 31, 2012.

Forfivo XL™, our first FDA approved product, was launched in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP (“Edgemont”). Forfivo XL™ is indicated for the treatment of Major Depressive Disorder and is the only extended-release bupropion HCl product to provide a once-daily, 450mg dose in a single tablet. Under the terms of the agreement with Edgemont, the commercial launch of Forfivo XL™ triggered a milestone payment of $1 million, which we invoiced to Edgemont and recognized as revenue in the fourth quarter of 2012. We expect to start receiving royalty payments from commercial sales of the product in the first quarter of 2013.

Upon entering into the licensing agreement, Edgemont paid us an upfront fee of $1 million, which we recognized as deferred license revenue. The deferred license revenue will be amortized in income over the period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, we recognized $77 thousand in income during the fourth quarter of 2012.

Also included in revenue for the year ended December 31, 2012 is the receipt of a $100 thousand development milestone in respect of our Rizatriptan VersaFilm™ project and was related to the successful completion of the pivotal bioequivalence study. Revenue earned from our pharmaceutical partners for development milestones achieved, including non-refundable upfront license fees, were $359 thousand in the year ended December 31, 2011. The decrease is attributable to the timing related to the achievement of development milestones. We are currently negotiating with a number of potential partners related to new development projects for various drug candidates and, whilst the timing of such events is difficult to predict, we are optimistic of securing contracts in the near future.

Sales of our first commercialized product, a pre-natal multivitamin supplement, marketed in the USA as Gesticare®, were discontinued in the third quarter of 2011. We received final royalties from the sale of the product in the fourth quarter of 2011 from Azur Pharma, now part of Jazz Pharmaceuticals plc. In the year ended December 31, 2011 royalty revenues earned from Gesticare® were approximately $74 thousand.

Interest and other income of $10 thousand was recorded in the year ended December 31, 2012, compared with $7 thousand in the previous year. Interest and other income relates primarily to interest earned on deposits at banks.

Research and Development Expenses

R&D expenses totaled $1,935 thousand in the year ended December 31, 2012 compared with $1,524 thousand the previous year, representing an increase of $411 thousand, or 27%.

The increase in R&D expenses is primarily attributable to approximately $289 thousand of costs incurred for the technical transfer of activities in preparation for manufacturing of Forfivo XL™ to our Contract Manufacturing Organization, Pillar5 Pharma, together with the Product Fee for Forfivo XL™ of $100 thousand payable to the FDA.

Included within R&D expenses for 2012 are R&D Salaries of $659 thousand, of which approximately $16 thousand represents non-cash compensation. This compares to R&D salaries of $739 thousand in 2011, of which approximately $18 thousand represented non-cash compensation. The decrease in R&D Salaries is attributable to vacancies in both the first and fourth quarters of 2012, paternity leave in the second and third quarters of 2012, and the foreign exchange impact arising from the translation of our operating currency into our reporting currency.

In the year ended December 31, 2012 we recorded estimated Research and Development Tax Credits and refunds of $212 thousand, compared with $188 that was recorded in the previous year.

Management Salaries and General and Administrative (“G&A”) Expenses

Management salaries increased from $586 thousand in fiscal 2011 to $716 thousand in fiscal 2012, representing an increase of $130 thousand, or 22%. The increase is primarily attributable to approximately $80 thousand in costs related to the appointment of our business development director and an increase of approximately $28 thousand in directors’ fees.

Included in management salaries for fiscal 2012 are approximately $12 thousand (2011: $10 thousand) in non-cash compensation from options granted to management employees in 2010, 2011 and 2012, and $23 thousand (2011: $10 thousand) in non-cash compensation from options granted to non-employee directors in 2010 and 2011.

General and administrative expenses increased marginally from $333 thousand in the year ended December 31, 2011 to $347 thousand in the year ended December 31, 2012.

Professional Fees

Professional fees for the year ended December 31, 2012 decreased slightly to $582 thousand from $594 thousand in the year ended December 31, 2011.

Included within professional fees are shareholder / investor relations expenses of approximately $143 thousand (2011: $179 thousand) of which approximately $1 thousand (2011: $13 thousand) is a non-cash expense for options granted to an investor relation firm for investor relation services.

Share-Based Compensation Expense, Warrants and Stock Based Payments

Share-based compensation expense, warrants and share-based payments totaled $59 thousand for the year ended December 31, 2012, compared to $51 thousand for the year ended December 31, 2011.

We expensed approximately $28 thousand in 2012 for options granted to our employees in 2010, 2011 and 2012 under the 2006 Stock Option Plan, and approximately $23 thousand for options granted to non-employee directors in 2010 and 2011, compared with $28 thousand and $10 respectively that was expensed in the previous year.

We also expensed $1 thousand in 2012 for options granted to investor relation firms for investor relation services, compared to $13 thousand that was expensed in 2011 and we expensed $7 thousand for options granted to consultants (2011: $Nil).

There remains approximately $72 thousand in stock based compensation to be expensed in fiscal 2013 and 2014, of which $55 thousand relates to the issuance of options to our employees and directors during 2011 and 2012 and $17 thousand relates to the issuance of options to consultants during 2012. We anticipate the issuance of additional options and warrants in the future, which will continue to result in stock-based compensation expense.

Depreciation

The depreciation expense for the year ended December 31, 2012 totaled $46 thousand, compared with $37 thousand for the year ended December 31, 2011. The increase primarily relates to the amortization of addition research and development equipment that was purchased during 2012.

Foreign Exchange

A foreign exchange loss of approximately $41 thousand was recorded in the year ended December 31, 2012 compared with a foreign exchange loss of $3 thousand in the previous year. The foreign exchange losses relate primarily to currency fluctuations between the Canadian dollar and the U.S. dollar.

Net Loss

The net loss for the year ended December 31, 2012 was $2,250 thousand and represents an improvement of $202 thousand compared to the net loss of $2,452 thousand for the previous year. The main items resulting in the decrease in net loss are summarized as follows:

	a)	An increase of $765 thousand in revenue, primarily related to the commercialization of Forfivo XL™
	b)	An increase in net R&D expenses of approximately $387 thousand, primarily related the timing of research and development project milestones
	c)	An increase in management salaries of approximately $130 thousand, primarily related to the appointment of our business development director and an increase in directors’ fees
	d)	An increase in foreign exchange loss of $38 thousand

Key Items from the Balance Sheet

								Percentage
In U.S.$ thousands		2012		2011		Increase/		Increase/
						(Decrease)		(Decrease)
Current Assets	$	3,656	$	4,296	$	(640	)	(15%	)
Leasehold Improvements and Equipment		387		149		238		160%
Intangible Assets		116		125		(9	)	(7%	)
Current Liabilities		1,366		666		700		105%
Deferred License Revenue		615		-		615		N/A
Capital Stock		0		0		0		0%
Additional Paid-in-Capital		16,342		15,918		424		3%

Current Assets

Current assets totaled $3,656 thousand at December 31, 2012 compared with $4,296 thousand at December 31, 2011. The decrease of $640 thousand is attributable to a decrease in cash of $1,446 thousand, a decrease in loan receivable of $85 thousand, and a decrease in investment tax credits receivable of $162 thousand, partly offset by an increase in accounts receivable of $1,019 thousand and an increase in prepaid expenses of $34 thousand.

Cash and cash equivalents totaled $2,059 thousand as at December 31, 2012 representing a decrease of $1,446 thousand compared to the balance of $3,505 thousand as at December 31, 2011. The decrease in cash on hand relates to net cash used in operating activities of $1,638 thousand, together with net cash used in investing activities of $270 thousand, partly offset with net cash provided by financing activities of $365 thousand and an unrealized foreign exchange gain of $97 thousand.

Accounts receivable totaled $1,282 thousand (2011: $263 thousand) as at December 31, 2012, of which approximately $146 thousand is a sales tax refund that we expect to receive in the first half of 2013. Included within the accounts receivable balance as at December 31, 2012 is a $1 million milestone that was invoiced to Edgemont Pharmaceuticals in the fourth quarter of 2012 under the terms of our licensing partnership for the launch of Forfivo XL™. Subsequent to the end of the fiscal year, we received payment against this invoice in February 2013.

As of December 31, 2012, prepaid expenses totaled $102 thousand compared with $68 thousand as of December 31, 2011. The increase in prepaid expenses relates to invoices paid prior to December 31, 2012 that are associated with items to be expensed in fiscal 2013, which include the annual fee for our listing on the U.S. stock exchange, European patent expenses, a deposit paid for attendance at a trade exhibition, and audit fees.

An interest-bearing short term loan of $85 thousand was provided to an employee, who is also an officer of the Company, on November 9, 2011. The loan was repaid on February 28, 2012.

In addition, we had R&D investment tax credits receivable of approximately $213 thousand as at December 31, 2012 compared with $375 thousand as at December 31, 2011. The amount receivable as at December 31, 2012 relates to credits accrued throughout fiscal 2012. We expect to receive reimbursement in the fourth quarter of 2013. The balance that was outstanding as at December 31, 2011 related to credits accrued throughout fiscal 2010 and fiscal 2011 of which $193 thousand was received in January 2012 and the balance of $182 thousand was received in November 2012.

Leasehold Improvements and Equipment

As at December 31, 2012, the net book value of property and equipment amounted to $387 thousand, compared to $149 thousand at December 31, 2011. In the year ended December 31, 2012 additions to assets totaled $270 thousand and comprised $224 thousand for pilot plant manufacturing equipment for our VersaFilm™ products, $44 thousand for laboratory equipment, $1 thousand for furniture and $1 thousand for computer equipment. Depreciation on Leasehold Improvements and equipment in the year ended December 31, 2012 amounted to $37 thousand and a foreign exchange gain of $5 thousand was recorded.

Intangible Assets

As at December 31, 2012 NDA acquisition costs of $116 thousand (December 31, 2011 - $125 thousand) were recorded as intangible assets on our balance sheet and are related to the acquisition of 100% ownership of Forfivo XL™. The asset will be amortized over its expected useful life and amortization commenced upon commercial launch of Forfivo XL™ in the fourth quarter of 2012.

Current Liabilities

Current liabilities totaled $1,366 thousand as at December 31, 2012 (December 31, 2011 - $666 thousand) and consisted of accounts payable and accrued liabilities of $1,058 thousand (December 31, 2011 - $666 thousand) as detailed above, and the current portion of deferred license revenue of $308 thousand (December 31, 2011 - $Nil).

Accounts payable and accrued liabilities as at December 31, 2012 amounted to $1,058 thousand (December 31, 2011 - $666 thousand), of which approximately $795 thousand relates to research and development activities, approximately $70 thousand relates to professional fees, and approximately $165 thousand relates to accrued payroll liabilities. The increase in accounts payable and accrued liabilities as at December 31, 2012, compared with December 31, 2011, primarily relates to an invoice received for the technical transfer of manufacturing activities of Forfivo XL™ to our Contract Manufacturing Organization, Pillar5 Pharma, together with an invoice received from FDA related to Forfivo XL™.

Deferred License Revenue

Pursuant to the execution of a licensing agreement for Forfivo XL™, we received an upfront fee from Edgemont Pharmaceuticals in the first quarter of 2012, which we recognized as deferred license revenue. The deferred license revenue will be amortized in income over the period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, we have a deferred revenue balance of $923 thousand at December 31, 2012 that has not been recognized as revenue, with $615 thousand recognized as the non-current portion and $308 thousand recognized in current assets as the current portion.

Shareholders’ Equity

As at December 31, 2012 we had accumulated a deficit of $14,463 thousand compared with an accumulated deficit of $12,213 thousand as at December 31, 2011. Total assets amounted to $4,159 thousand and shareholders’ equity totaled $2,178 thousand as at December 31, 2012, compared with total assets and shareholders’ equity of $4,570 thousand and $3,904 thousand respectively, as at December 31, 2011.

Contractual Obligations and Commitments

Excluding trade accounts payable and accrued liabilities, we are committed to the following contractual obligations and commitments:

In U.S.$ thousands		2013
		(Less than 1		1 Year or More
		Year)
Operating Lease Obligations	$	15	$	0
Investor Relations	$	5	$	0
Total	$	20	$	0

Capital Stock

As at December 31, 2012 capital stock amounted to $499 compared to $489 at December 31, 2011. The increase reflects the issuance of 945,393 shares and 50,000 shares related to the exercise of warrants and stock options, respectively, with all shares issued at par value of $0.00001. Capital stock is disclosed at its par value with the excess of proceeds shown in Additional Paid-in-Capital.

Additional Paid-in-Capital

Additional paid-in capital totaled $16,342 thousand at December 31, 2012, as compared to $15,918 thousand at December 31, 2011. The increase relates in part to $59 thousand for stock based compensation of which $1 thousand is attributable to the amortization of stock options granted to our investor relations consultants, $7 thousand is attributable to the amortization of stock options granted to other consultants, and $51 thousand is attributable to the amortization of stock options granted to employees and directors. Additional paid-in capital increased further by $337 thousand for warrants exercised, and by $28 thousand for options exercised.

Key items from the Statement of Cash Flows

										Percentage
In U.S.$ thousands		2012			2011			Increase/		Increase/
								(Decrease)		(Decrease)
Operating Activities	$	(1,638	)	$	(2,316	)	$	(678	)	(29%	)
Financing Activities		365			4,780			(4,415	)	(92%	)
Investing Activities		(270	)		(159	)		111		70%
Cash and cash equivalents – end of period		2,059			3,505			(1,446	)	(41%	)

Statement of cash flows

Net cash used by operating activities was $1,638 thousand in the year ended December 31, 2012, compared to $2,316 thousand for the year ended December 31, 2011. In fiscal 2012, net cash used by operating activities consisted of an operating loss of $2,145 thousand (2011 - $2,311 thousand) and an increase in non-cash operating elements of working capital of $507 thousand compared with a decrease of $5 thousand in 2011.

Operating activities will continue to consume our available funds until we are able to generate increased revenues.

The net cash provided by financing activities was $365 thousand in fiscal 2012, compared to $4,780 thousand provided in the previous year. The net cash provided in 2012 resulted from proceeds of $337 thousand from the exercise of warrants and a further $28 thousand from the exercise of options. Of the net cash provided by financing activities in the previous year, $3,230 thousand came from a private placement completed in the second quarter of 2011, less $369 thousand used to pay related transaction costs, plus proceeds of $1,600 thousand from the exercise of warrants and a further $319 thousand from the exercise of options.

Net cash used in investing activities amounted to $270 thousand in the year ended December 31, 2012 compared to $159 thousand in the year ended December 31, 2011. The net cash used in investing activities in 2012 relates exclusively to the purchase of fixed assets and comprised $224 thousand for pilot plant manufacturing equipment for our VersaFilm™ products, $44 thousand for laboratory equipment, $1 thousand for furniture and $1 thousand for computer equipment. Included within the use of funds in 2011 are intangible assets of approximately $125 thousand related to the acquisition of 100% ownership of Forfivo XL™, our novel, high strength formulation of Bupropion HCl the active ingredient in Wellbutrin XL® indicated for the treatment of patients with Major Depressive Disorder.

The balance of cash and cash equivalents as at December 31, 2012 amounted to $2,059 thousand, compared to $3,505 thousand at December 31, 2011.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements as contemplated by Item 303 (A)(4)(ii) of Regulation S-K under the Securities Act.

MARKET INFORMATION

Our common stock was quoted on the OTC Bulletin Board under the symbol “IGXT” from January 2007 until June 2012 and, subsequent to our upgrade in June 2012, has been quoted on the OTCQX. Our common stock has also been listed on the TSX Venture Exchange under the symbol “IGX” since May 2008. The table below sets forth the high and low bid prices of our common stock as reported by the OTC Bulletin Board/OTCQX and the TSX for the periods indicated. These prices represent inter-dealer quotations without retail markup, markdown, or commission and may not necessarily represent actual transactions.

		OTCQX/OTCBB				TSX-V
		High		Low		High		Low
		(U.S.$)		(U.S.$)		(CAD$)		(CAD$)

2013
First Quarter	$	0.747	$	0.47	$	0.73	$	0.475
Second Quarter	$	0.699	$	0.55	$	0.70	$	0.55

2012
Fourth Quarter	$	0.725	$	0.560	$	0.750	$	0.540
Third Quarter	$	0.674	$	0.460	$	0.700	$	0.540
Second Quarter	$	0.580	$	0.445	$	0.590	$	0.450
First Quarter	$	0.740	$	0.450	$	0.750	$	0.460

2011
Fourth Quarter	$	0.720	$	0.410	$	0.700	$	0.405
Third Quarter	$	0.985	$	0.580	$	0.950	$	0.590
Second Quarter	$	0.840	$	0.550	$	0.820	$	0.500
First Quarter	$	0.690	$	0.350	$	0.670	$	0.370

Number of Shareholders

On July 18, 2013 there were approximately 62 holders of record of our common stock, one of which was Cede & Co., a nominee for Depository Trust Company, and one of which was The Canadian Depository for Securities Limited, or CDS. All of our common shares held by brokerage firms, banks and other financial institutions in the United States and Canada as nominees for beneficial owners are considered to be held of record by Cede & Co. in respect of brokerage firms, banks and other financial institutions in the United States, and by CDS in respect of brokerage firms, banks and other financial institutions located in Canada. Cede & Co. and CDS are each considered to be one shareholder of record.

Dividend Policy

We have never declared or paid any cash dividends on our common stock. We currently intend to retain any earnings to support operations and to finance the growth and development of our business. Therefore, we do not expect to pay cash dividends in the foreseeable future. Any future determination relating to our dividend policy will be made at the discretion of our Board of Directors and will depend on a number of factors, including future earnings, capital requirements, financial conditions and future prospect and other factors that the board of directors may deem relevant.

Equity Compensation Plan Information as of December 31, 2012

2006 Stock Option Plan

A majority of our shareholders approved the 2006 Stock Option Plan at our Annual General Meeting of Stockholders held on August 10, 2006. Under the 2006 Stock Option Plan, up to 1,600,749 shares of common stock may be issued upon the exercise of options granted to directors, management, employees and consultants.

In May of 2008, the term of all options granted under the 2006 Stock Option Plan was amended to provide for a term not to exceed five years, in order to ensure compliance with applicable rules and regulation of the TSX Venture Exchange.

At the Annual General Meeting of Stockholders on September 8, 2008, our shareholders approved an amendment to the 2006 Stock Option Plan in order to increase the number of shares available under the plan by 473,251, to 2,074,000.

At the Annual General Meeting of Stockholders on June 3, 2010, our shareholders approved an amendment to the 2006 Stock Option Plan in order to increase the number of shares available under the plan by 1,234,127 to 3,308,127.

At the Annual General Meeting of Stockholders on May 7, 2013, our shareholders approved an amendment to the 2006 Stock Option Plan in order to increase the number of shares available under the plan by 1,722,165 to 5,030,292.

	Number of Securities			Weighted-	Number of securities
	to be issued upon			Average	remaining available
	exercise of			Exercise Price of	for future issuance
	outstanding options,			outstanding	under equity
	warrants and rights			options,	compensation plans
				warrants and rights	(excluding securities
					reflected in the first
					column)
Equity Compensation Plans Approved by Security Holders	1,065,588	⁽¹⁾	$	0.58	1,194,968
Equity Compensation Plans Not Approved by Security Holders	None			None	None
Total	1,065,588		$	0.58	1,194,968

(1)	Includes shares of our common stock issuable pursuant to options granted under the 2006 Stock Option Plan.
(2)	Represents the maximum number of shares of our common stock available for grants under the 2006 Stock Option Plan as of December 31, 2012.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

There were no purchases or repurchases of our equity securities by us or any affiliated purchasers.

DIRECTORS AND EXECUTIVE OFFICERS

The following table sets forth certain information as of July 18, 2013 concerning the directors and officers. The biographies of each of the director nominees below contain information regarding the individual’s service as a director, business experience, director positions held currently or at any time during the last ten years, information regarding involvement in certain legal or administrative proceedings, if applicable, and the experiences, qualifications, attributes or skills that caused the Board of Directors to determine that the person should serve as a director for the Company.

Name	Age	Position	Position since
Horst G. Zerbe	66	President and Chief Executive Officer, Director	April 2006
Paul A. Simmons	51	Chief Financial Officer	September 2008
Rajiv Khosla	51	Chief Operating Officer	April 2013
J. Bernard Boudreau⁽¹⁾⁽²⁾	68	Director	June 2006
Ian Troup⁽¹⁾⁽²⁾	70	Director	May 2008
Bernd J. Melchers ⁽¹⁾	61	Director	April 2009
John Marinucci	56	Director	August 2010
Ingrid Zerbe	59	Corporate Secretary and Director of Finance and Administration	April 2006

(1)	Audit Committee member
(2)	Compensation Committee member

All directors hold office until the next annual meeting of shareholders and until their successors have been duly elected and qualified. There are no agreements with respect to the election of directors. Officers are appointed annually by the board of directors and each executive officer serves at the discretion of the board.

Horst G. Zerbe, Ph.D.

Dr. Zerbe (66) has more than 30 years’ experience in the pharmaceutical industry. He has been the President, Chief Executive Officer, and Chairman of IntelGenx Technologies Corp. since April 2006. In addition, Dr. Zerbe has served as the President, Chief Executive Officer and Director of IntelGenx Corp., our Canadian Subsidiary, since 2005. From 1998 to 2005, he served as the president of Smartrix Technologies Inc. in Montreal; prior thereto, from 1994 to 1998, he was Vice President of R&D at LTS Lohmann Therapy Systems in West Caldwell, NJ. Dr. Zerbe has extensive executive level experience, and has been responsible for many strategic and business initiatives. Dr. Zerbe has been involved in new drug development and the acquisition and disposition of new drug candidates and other technology, licensing and distribution matters that are likely to affect our company’s own business efforts. He has published numerous scientific papers in recognized journals and holds over 30 patents. Dr. Zerbe is married to Ingrid Zerbe, our Corporate Secretary and Director of Finance and Administration.

Paul A. Simmons, AFCA

Mr. Simmons (51) was appointed as our Chief Financial Officer in September 2008. From 2003-2008, Mr. Simmons was employed by the CLAAS Group, a leading manufacturer of agricultural harvesting machinery. Mr. Simmons was initially based at Group HQ in Germany as Head of Corporate Controlling. In August 2005, he transferred to the Baler Manufacturing subsidiary (Usines CLAAS France) as Director of Finance and Administration, where he was responsible for developing and implementing a business turnaround plan. Following the success of the turnaround, Mr. Simmons was transferred in September 2006 to the French subsidiary Renault Agriculture as Head of Corporate and Industrial Controlling with the mandate to restructure and integrate the newly acquired Tractor Manufacturing Division into the CLAAS Group.

Mr. Simmons’ international finance credentials include an Association of Financial Controllers and Administrators (AFCA) certification, and a designation with the Association of Accounting Technicians (AAT). He has expertise in both U.S. Generally Accepted Accounting Principles (GAAP) and International Financial Reporting Standards (IFRS).

Rajiv Khosla, RPh, Ph.D., MBA

Dr. Khosla (51) was appointed as our Chief Operating Officer in April of 2013. He was a director of IntelGenx Technologies Corp. from May 2011until his appointment as COO in April. From May 2011 to May 2012 he was President, Chief Executive Officer and a member of the board of directors of Orasi Medical, a leading provider of clinical neurophysiology biomarkers, which was focused on the industrialization and standardization of magnetoencephalography (MEG) in central nervous system drug and therapeutic device development. In January 2011, Dr. Khosla founded CEUTEC LLC, a private company that offers a full-service of business development activities to Biotech, Specialty Pharma and Venture Capital/Private Equity Firms. From September 2005 to December 2010, Dr. Khosla was Vice President of Business Development at Biovail Corporation, a Canadian pharmaceutical company operating internationally. During his tenure at Biovail, Dr. Khosla led the transaction process for over 75 deal opportunities in a variety of therapeutic areas, including the central nervous system, dermatology, women’s health, cardiovascular and gastrointestinal, drug delivery, orphan drugs, generics and pipeline partnerships. From 2003 to 2005, Dr. Khosla held the position of Vice President and General Manager, Pharmaceutical, of Sensient Technologies. From 1998 to 2003, Dr. Khosla served as Senior Business Director, Healthcare at ICI Group, where he managed a new worldwide healthcare business.

Dr. Khosla possesses a Ph.D. in pharmaceutical science, with a thesis on Oral Drug Delivery Technology, which he completed in 1987. Additionally, Dr. Khosla holds an Executive MBA from the Henley Business School in England, a Bachelor of Pharmacy (Honours) from the University of Nottingham, England and is also a registered pharmacist in the UK.

J. Bernard Boudreau, QC, PC

Mr. Boudreau (68) has been a director of IntelGenx Technologies Corp. since June 2006. From 2005 to 2008, Mr. Boudreau served as the Vice-President of Pharmeng International Inc., a pharmaceutical manufacturing and consulting company listed on the Toronto Stock Exchange. Since 2001, he has been President and CEO of Radcliffe Consulting and Investment Limited, a private consulting firm located in Halifax, N.S. Mr. Boudreau has also served on the Board of Directors of a number of public and private companies, including Export Development Canada and the Bank of Canada. He also currently serves on the board of directors at Pillar5 Pharma, a privately owned Canadian Company, and one of our manufacturing partners.

Mr. Boudreau has a distinguished record as a lawyer, businessman and public figure. His litigation experience includes successful appearances at every level of the judicial system in Nova Scotia. He was appointed as Queen’s Counsel in 1985. Mr. Boudreau was first elected to the provincial legislature of Nova Scotia in 1988. He served as Chair of the Public Accounts Committee and opposition critic for Finance and Economic Development. In 1993, he was re-elected as a member of government and held responsibilities as Minister of Finance, Minister of Health, Chair of the Cabinet Priorities and Planning Committee. Mr. Boudreau served as Government Leader in the Senate of Canada and Member of the federal Cabinet between 1999 and 2001.

Ian (John) Troup, B.Sc.

Mr. Troup (70) has been a director of IntelGenx Technologies Corp. since May 2008. From April 2008 to February 2010, Mr. Troup was a Director of Vital Medix, an early stage drug development company. In July 2007, he was appointed to the Board of Medisyn Technologies Inc., a privately held "in silica" drug discovery and development company. From September 1995 until his retirement in December 2003, Mr. Troup was President and Chief Operating Officer of Upsher-Smith Laboratories, a privately held pharmaceutical company. Prior to this, he served as President of Schwarz Pharma in the UK for seven years, followed by serving as President of Schwarz Pharma USA in Minnesota for an additional nine years.

Born and educated in Scotland, Mr. Troup has worked in the pharmaceutical industry for over 35 years. Originally an industrial chemist, he held executive positions in sales and marketing for several leading companies. His experience includes new product development and launch, M&A and strategic planning.

Bernd J. Melchers, B.A.

Mr. Melchers (61) has been a director of IntelGenx Technologies Corp. since April 2009. From January 2001 until his retirement in December 2004, Mr. Melchers was Managing Director of 3M Dyneon Holding GmbH, Germany and Global Chief Financial Officer of the world wide operating 3M Dyneon Group, a subsidiary of 3M Corporation headquartered in Minnesota. Prior to this he served, from July 1995 to December 2000, as the Controller at the European Business Center of 3M Medical Markets Europe in Belgium. Prior to this, he held various senior Financial Manager positions at the Medical-Surgical Division of 3M in St. Paul, Minnesota, at 3M Health Care Products, Germany, and at 3M Pharmaceutical Products, Germany.

John Marinucci, C.A., C.P.A., ICD.D, HRCCC

Mr. Marinucci (56) has been a Director of IntelGenx Technologies Corp. since August 2010. From April 2002 until March 2009, Mr. Marinucci was President and Chief Executive Officer at New Flyer Industries Inc. (NFI), a publicly traded company listed on the Toronto Stock Exchange. NFI is the largest North American manufacturer of heavy-duty transit buses. Mr. Marinucci retired from this position on March 31, 2009 and remains on the board of directors. Prior to this he was, from March 1994 to April 2002, President and Chief Operating Officer at National Steel Car Limited (NSC) and is a former President of the Canadian Association of Railway Suppliers. Currently he also serves on the Board of Directors of New Flyer, CWB Group, Seaport Intermodal Inc. and he is the Chair of Board of Governors for Mohawk College. He also currently serves on the board of directors at Pillar5 Pharma, a privately owned Canadian Company, and one of our manufacturing partners. Mr. Marinucci is a chartered accountant and a member of the Institute of Corporate Directors.

Ingrid Zerbe

Mrs. Zerbe is our Corporate Secretary and is also our Director of Finance and Administration. Mrs. Zerbe is the founder of IntelGenx Corp., our Canadian Subsidiary. She served as the president of IntelGenx Corp, since its incorporation in June 2003 until December 2005. She has been a Director of the subsidiary since its incorporation in June 2003 and a Director of the parent company from April 2006 until August 2006. Prior to founding IntelGenx, she worked in the travel industry. She holds a bachelor degree in economics from a business school in Bottrop, Germany, and a bachelor degree in social sciences from the University of Dortmund, Germany. Mrs. Zerbe is married to Dr. Horst Zerbe, who is a Director and our President and Chief Executive Officer.

Key Personnel

Nadine Paiement, MSc

Ms. Paiement serves as our Director of Research & Development. She joined IntelGenx in 2006. Ms. Paiement holds a M.Sc. degree in Polymer Chemistry from Sherbrooke University, and is co-inventor of IntelGenx’ Tri-Layer technology. Prior to joining IntelGenx, she worked for five years as a formulation scientist at Smartrix Technologies, Inc.

CORPORATE GOVERNANCE

Board Leadership Structure

The Company’s Board of Directors is responsible for overseeing the business and affairs of the Company. Members of the Board are kept informed of our business through discussions with the Chief Executive Officer and other officers, by reviewing materials provided to them and by participating in meetings of the Board and its committees.

The Board is currently comprised of Mr. Horst G. Zerbe, who serves as our Chairman, President and Chief Executive Officer, and four independent directors. The Company does not have an independent lead director. The Board believes that there is no single best organizational model that is the most effective in all circumstances and that the shareholders’ interests are best served by allowing the Board to retain the flexibility to determine the optimal organizational structure for the Company at a given time, including whether the Chairman role should be held by an independent director or a senior executive who serves on the Board.

We believe that the Company, like many U.S. companies, is currently best served by having one person serve as both Chief Executive Officer and Chairman of the Board. The Board believes that through this leadership structure, Mr. Zerbe is able to draw on his intimate knowledge of the daily operations of the Company and its relationships with partners, customers and employees to provide the Board with leadership in setting its agenda and properly focusing its discussions. As the individual with primary responsibility for managing our day-to-day operations, Mr. Zerbe is also best-positioned to chair regular Board meetings and ensure that key business issues are brought to the Board’s attention. The combined role as Chairman and Chief Executive Officer also ensures that the Company presents its message and strategy to shareholders, partners, customers, employees and other stakeholders with a unified, single voice.

Independence of Members of the Board of Directors

The Board of Directors has determined that four of our directors, Bernie Boudreau, Ian Troup, Bernd Melchers and John Marinucci are independent within the meaning of the director independence standards of both The Nasdaq Stock Market, LLC and the SEC, including Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended.

Meetings of the Board of Directors

The Company’s Board of Directors held four meetings during our 2012 Fiscal Year. All our directors attended at least 75% of the meetings and of the committee meetings on which they served.

The Company encourages the members of the board to attend the Annual General Meeting to be available to answer shareholder’s questions. All of our directors attended the last Annual Meeting in May 2013.

Compensation of the Board of Directors

Directors are reimbursed for their out-of-pocket expenses incurred in attending meetings of the Board of Directors. As described below in "Director Compensation", during our 2012 Fiscal Year, our non-employee directors of the board received an annual stipend of $12,007 (CAD$12,000), paid in quarterly installments. Furthermore, an attendance fee of $1,000 (CAD$1,000) was paid per board meeting. The chairmen of the board committees received an additional $500(CAD$500) and the members of the committees received an additional $250 (CAD$250) for attending the committee meetings.

Committees of the Board of Directors

The Board of Directors has two standing committees: the Audit Committee and the Compensation Committee. There is no Nomination Committee.

Audit Committee. The Audit Committee is currently composed of J. Bernard Boudreau, Bernd Melchers and John Marinucci. The Audit Committee held four meetings during our 2012 Fiscal Year.

Our Audit Committee assists our board of directors in fulfilling its responsibilities for oversight and supervision of financial and accounting matters. The chairman of the Audit Committee is J. Bernard Boudreau. Our Audit Committee’s responsibilities include, among others (i) recommending to the board of directors the engagement of the external auditor and the terms of the external auditor’s engagement; (ii) overseeing the work of the external auditor, including dispute resolution between management and the external auditor, if required; (iii) pre-approving all non-audit services to be provided to us by our external auditor; (iv) reviewing our financial statements, management’s discussion and analysis and annual and interim earnings press releases before this information is publicly disclosed; (v) assessing the adequacy of procedures for our public disclosure of financial information; (vi) establishing procedures to deal with complaints received by us relating to our accounting and auditing matters; and (vii) reviewing our hiring policies regarding employees of our external auditor or former auditor. We have adopted, along with our Audit Committee, a written charter of the Audit Committee setting out the mandate and responsibilities of the Audit Committee which provides that the Audit Committee convene no less than four times per year.

The Audit Committee Charter is posted on our website at http://www.intelgenx.com.

Accordingly, the Audit Committee discusses with Richter LLP, our auditors, our audited financial statements, including, among other things, the quality of our accounting principles, the methodologies and accounting principles applied to significant transactions, the underlying processes and estimates used by our management in our financial statements and the basis for the auditor’s conclusions regarding the reasonableness of those estimates, in addition to the auditor’s independence.

Audit Committee Financial Expert. Mr. Bernd Melchers and Mr. John Marinucci are audit committee financial experts under the rules of the SEC. Mr. Melchers is an “independent director” as defined in the Nasdaq Stock Market, Inc. Marketplace Rules and meets the independence and experience requirements of the SEC.

Compensation Committee. The Compensation Committee of the Board of Directors currently consists of Ian Troup and J. Bernard Boudreau. The Compensation Committee held its formal annual meeting on November 29, 2012 for the 2012 fiscal year.

Our Compensation Committee reviews and makes recommendations to our board of directors concerning the compensation of our executive officers and key employees which include the review of our executive compensation and other human resource policies, the review and administration of any bonuses and stock options and major changes to our benefit plans and the review of and recommendations regarding the performance of the Chief Executive Officer and the Chief Financial Officer of the Company. Our Compensation Committee is comprised of non-management members of our board of directors and is required to convene at least annually. Mr. Ian Troup is the chairman of the committee. The Compensation Committee does not have a charter.

Compensation Committee Interlocks and Insider Participation. As stated above, the Compensation Committee consists of J. Bernard Boudreau and Ian Troup. There are no interlocking relationships, as described by the Securities and Exchange Commission, between the Compensation Committee members.

Board’s Role in Risk Oversight

Our management has responsibility for managing day-to-day risk and for bringing the most material risks facing the Company to the Board’s attention. The Board takes an active role in risk oversight related to the Company both as a full Board and through its committees. To facilitate the Board’s risk oversight responsibility, management provides the Board with information about its identification, assessment and management of critical risks and its risk mitigation strategies. This information is communicated to the Board and its committees at regular and special meetings, through reports, presentations and discussions with key management personnel and representatives of outside advisors, such as our independent auditors, as appropriate.

During regular Audit Committee meetings, committee members discuss the financial results for the most recent fiscal quarter with the independent auditors, Chief Financial Officer and Chief Executive Officer. The Audit Committee also meets with and provides instruction to the independent auditors outside the presence of management. These discussions allow the members of the Audit Committee to analyze any significant risks that could materially impact the financial health of our business.

The Compensation Committee oversees the company’s executive compensation arrangements, including the identification and management of risks that may arise from the Company’s compensation policies and practices.

Executive Compensation

The key objectives of the Company’s executive compensation policies are to attract and retain key executives who are important to the long-term success of the Company and to provide incentives for these executives to achieve high levels of job performance and enhancement of shareholder value. The Company seeks to achieve these objectives by paying its executives a competitive level of base compensation for companies of similar size and industry and by providing its executives an opportunity for further reward for outstanding performance in both the short term and the long term.

Executive Officer Compensation. The Company’s executive officer compensation program is comprised of three elements: base salary, annual cash bonus and long-term incentive compensation in the form of stock option grants.

Salary. The Compensation Committee and the Board of Directors will review base salaries for the Company’s executive officers, taking into account individual experience, job responsibility and individual performance during the prior year. These factors are not assigned a specific weight in establishing individual base salaries. The Compensation Committee will also consider the Company’s executive officers’ salaries relative to salary information for executives in similar industries and similarly sized companies.

Cash Bonuses. The purpose of the cash bonus component of the compensation program is to provide a direct financial incentive in the form of cash bonuses to executives.

Stock Options. Stock options are the primary vehicle for rewarding long-term achievement of Company goals. The objectives of the program are to align employee and shareholder long-term interests by creating a strong and direct link between compensation and increases in share value. Under the Company’s Stock Option Plan, the Board of Directors or the Compensation Committee may authorize the grant of options to purchase common stock of the Company to key employees of the Company. The options generally vest in increments over a period of two years established at the time of grant.

Nomination of Directors

We do not have a standing nominating committee and there is no written charter governing the nomination process. Nominations are made annually by our Board of Directors. Our Board of Directors believes it is appropriate for the full Board of Directors to serve this function.

The Board’s process for identifying and evaluating potential nominees includes soliciting recommendations from directors and officers of the Company, holding meetings from time to time to evaluate biographical information and background materials relating to potential candidates and interviews with candidates. Additionally, the Board will consider persons recommended by shareholders of the Company in selecting the Board’s nominees for election.

In considering whether to nominate any particular candidate, our Board of Directors applies various criteria, including the candidate’s integrity, business acumen, knowledge of our business and industry, age, experience, diligence, the ability to act in the interests of all stockholders and any potential conflicts of interest. In addition to the foregoing criteria, our Board of Directors also considers diversity in its evaluation of candidates for board membership. Our Board of Directors believes that diversity with respect to viewpoint, skills and experience should be an important factor in board composition. Our Board of Directors does not assign specific weight to particular criteria, and no particular criterion is a prerequisite for each prospective nominee. Our Board of Directors believes that the backgrounds and qualifications of its directors, considered as a group, should provide a composite mix of experience, knowledge and abilities that will allow our Board of Directors to fulfill its responsibilities.

Stockholders may recommend individuals to our Board of Directors for consideration as potential director candidates by submitting their names, together with appropriate biographical information and background materials to our principal office, 6425 Abrams, Ville St.-Laurent, Quebec H4S 1X9, Attn: Secretary. Assuming that appropriate biographical and background material has been provided on a timely basis, our Board of Directors will evaluate stockholder-recommended candidates by following substantially the same process, and applying substantially the same criteria, as it follows for candidates submitted by others. If our Board of Directors determines to nominate a stockholder-recommended candidate and recommends his or her election, then his or her name will be included in our proxy card for the next annual meeting.

Involvement in Certain Legal Proceedings

None of our officers or directors have, during the last ten years: (i) been convicted in or is currently subject to a pending a criminal proceeding; (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to any federal or state securities or banking laws including, without limitation, in any way limiting involvement in any business activity, or finding any violation with respect to such law, nor (iii) has any bankruptcy petition been filed by or against the business of which such person was an executive officer or a general partner, whether at the time of the bankruptcy or for the two years prior thereto, other than Mr. Boudreau who was formerly the Vice President of Pharmeng International Inc. from 2005 to 2008, which since filed for bankruptcy on April 14, 2009. He was also a Director of Pharmeng until April 13, 2009.

Communications with the Board

Any record or beneficial owner of the Company’s common stock who wishes to communicate with the Board of Directors should contact the Chairman of the Board or the Chairman of the Audit Committee. If particular communications are directed to the full Board, independent directors as a group, or individual directors, the Chairman of the Board or the Chairman of the Audit Committee, as applicable, will route these communications to appropriate committees or directors if the intended recipients are clearly indicated.

Any record or beneficial owner of the Company’s common stock who has concerns about the Company’s accounting, internal accounting controls, or auditing matters relating to the Company should also contact the Audit Committee.

Written communications should be addressed to IntelGenx Technologies Corp., 6425 Abrams, Ville St-Laurent, Quebec H4S 1X9, Canada, Attention: Chairman of the Board/Chairman of the Audit Committee. Communications that are intended to be anonymous should be sent to the same address but without indicating your name or address, and with an interior envelope addressed to the specific committees or directors you wish to communicate with.

EXECUTIVE COMPENSATION

The following table sets forth all compensation awarded to, or earned by our executive officers for the years indicated.

Name and principal position (a)	Year (b)	Salary ($) (c)	Bonus ($) (d)	Stock Awards (e)	Option (3) Awards ($) (f)	Nonequity incentive plan compensation ($) (g)	Nonqualified deferred compensation earnings ($) (h)	All Other Compensation ($) (i)	Total ($) (j)
Horst Zerbe, President and CEO⁽¹⁾	2012 2011	220,132 202,860	30,018 40,572	Nil Nil	8,300 13,624	Nil Nil	Nil Nil	Nil Nil	258,450 257,056
Paul A. Simmons CFO⁽²⁾	2012 2011	175,005 161,274	25,015 35,500	Nil Nil	6,917 11,921	Nil Nil	Nil Nil	Nil Nil	206,937 208,695

Footnotes:

(1) Mr. Zerbe received a cash bonus in the amount of $30,018 and options to purchase 30,000 shares of common stock.

(2) Mr. Simmons received a cash bonus in the amount of $25,015 and options to purchase 25,000 shares of common stock.

(3) The amounts in this column represent the grant date fair value of stock option grants in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718 (“FASB ASC Topic 718”). The value of the grants has been determined using the Black-Scholes method and is based on the following assumptions: risk-free rate of return of 0.34%, dividend rate of 0%, volatility rate of 78% and an average term of 3.13 years. An Adjustment of 5% has been determined for the risk of forfeiture. No adjustment has been made for non-transferability.

Compensation Discussion and Analysis

Employment Agreements

Horst Zerbe.

Effective December 1, 2005, we entered into an employment agreement with Dr. Horst Zerbe, our President and Chief Executive Officer. The agreement is for an indefinite period of time. Under the agreement, Dr. Zerbe is entitled to receive: (1) a minimum base salary of CAN$175,000 per year; and (2) an annual bonus equal to 50% of base salary upon the performance of certain milestones set out by the board of directors.

As per recommendation of the Compensation Committee the board of directors approved the increase of Mr. Zerbe’s minimum base salary by 5% to CAN$ 183,750 effective as of September 2008 (US$171,364 at year-end 2008). Effective November 15, 2009 the board of directors approved the increase of Mr. Zerbe’s minimum base salary to CAN$ 200,000 (US$ 190,300 at year-end 2009). The base salary was not increased from 2010 and remained at CAN$200,000 (US$202,860) throughout 2011. In November 2011, following the recommendation of the Compensation Committee, the board of directors approved a one-time cash bonus of CAD$40,000 and the grant of options to purchase 40,000 shares of common stock under the company’s 2006 Stock Options Plan. Furthermore Mr. Zerbe’s base salary increased to CAN$220,000 for the year 2012.

In November 2012, following the recommendation of the Compensation Committee, the board of directors approved a one-time cash bonus of CAD$30,000 and the grant of 30,000 shares of common stock under the company’s 2006 Stock Option Plan.

Paul A. Simmons.

Effective September 1, 2008, we entered into an employment agreement with Mr. Paul A. Simmons to serve as our Chief Financial Officer. Under the agreement, Mr. Simmons is entitled to receive: (1) a minimum base salary of CAN$150,000 (US$110,965 at year-end 2008) per year, and (2) option grants under the 2006 Stock Option Plan, and (3) an annual bonus up to 30% of his base salary upon the achievement of specific performance targets established by the board of directors.

As per recommendation of the Compensation Committee the board of directors approved the increase of Mr. Simmons’ minimum base salary by 6% to CAN$ 159,000 (US$ 151,290 at year-end 2009) effective as of August 2009.

The base salary was not increased from 2010 but remained at CAN$159,000 (US$161,274) throughout 2011). In November 2011, following the recommendation of the Compensation Committee, the board of directors approved a one-time cash bonus of CAD$35,000 and the grant of options to purchase 35,000 shares of common stock under the company’s 2006 Stock Options Plan. Furthermore Mr. Simmons’ base salary increased to CAN$174,900 for the year 2012.

In November 2012, following the recommendation of the Compensation Committee, the board of directors approved a one-time cash bonus of CAD$25,000 and the grant of 25,000 shares of common stock under the company’s 2006 Stock Option Plan.

Incentive Plan Awards

The following table presents information regarding the outstanding equity awards held by each of the named officers as of December 31, 2012, including the vesting dates for the portions of these awards that had not vested as of that date.

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END

Name (a)	Number of Securities Underlying Unexercised Options (#) Exercisable (b)	Number of Securities Underlying Unexercised Options (#) Unexercisable (c)	Option Awards Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) (d)	Option Exercise Price ($) (e)	Option Expiration Date (f)
Horst G. Zerbe	Nil 20,000 25,000 ²	30,000⁴ 20,000² Nil	Nil Nil Nil	0.60 0.54 0.61	Dec. 4, 2017 Nov. 29, 2016 Nov. 24, 2014
Paul A. Simmons	Nil 17,500 25,000² 100,000¹	25,000⁴ 17,500² Nil Nil	Nil Nil Nil Nil	0.60 0.54 0.61 0.85	Dec. 4, 2017 Nov. 29, 2016 Nov. 24, 2014 Sept. 8, 2013

Footnotes:

(1) On September 8, 2008, 100,000 options were granted to Mr. Paul A. Simmons in connection with his employment agreement. The options vest over two years, all of which were exercisable as of year-end 2011.

(2) On November 24, 2009, the board of directors approved the grant of 25,000 options to purchase common stock to each of Mr. Horst Zerbe and Mr. Paul A. Simmons. The options vest over two years, all of which were exercisable as of year-end 2011.

(3) On November 29, 2011, the board of directors approved the grant of 40,000 options to purchase common stock to Mr. Horst Zerbe and 35,000 options to purchase common stock to Mr. Paul A. Simmons. The options vest over two years, 17,500 and 20,000 of which are exercisable as of year-end 2012.

(4) On November 29, 2012, the board of directors approved the grant of 30,000 options to purchase common stock to Mr. Horst Zerbe and 25,000 options to purchase common stock to Mr. Paul A. Simmons. The options vest over two years, none of which are exercisable as of year-end 2012.

Director Compensation

The following table sets forth compensation paid to each named director during the year end December 31, 2012.

In addition, directors are reimbursed for reasonable expenses incurred in their capacity as directors, including travel and other out-of-pocket expenses incurred in connection with meetings of the board of directors or any committee of the board of directors.

DIRECTOR COMPENSATION
Name (a)	Fees Earned or Paid in Cash ($) (b)	Stock Awards ($) (c)	Option Awards ($) (d)	Non-Equity Incentive Plan Compensation ($) (e)	Non-Qualified Deferred Compensation Earnings ($) (f)	All Other Compensation ($) (g)	Total ($) (j)
J. Bernard Boudreau⁽²⁾	23,264⁽¹⁾	Nil	Nil	Nil	Nil	Nil	23,264
John (Ian) Troup⁽²⁾	17,102⁽¹⁾	Nil	Nil	Nil	Nil	Nil	17,010
Bernd J. Melchers⁽²⁾	17,102¹⁾	Nil	Nil	Nil	Nil	Nil	17,010
John Marinucci⁽²⁾	15,572¹⁾	Nil	Nil	Nil	Nil	Nil	15,572
Rajiv Khosla⁽²⁾	15,009¹⁾	Nil	Nil	Nil	Nil	Nil	15,009

Footnotes:

(1) During fiscal 2009, the board of directors resolved, that the non-employee directors of the board received an annual stipend of CAD$12,000, paid in quarterly installments. Furthermore an attendance fee of CAD$1,000 was paid per board meeting. The chairmen of the board committees are entitled to receive an additional CAD$500 and the members of the committees received an additional CAD$250 for attending the committee meetings. Since November 2008, non-employee directors were entitled to a cash compensation fee of CAD$500 per board meeting attendance and CAD$100 per board meeting attendance by conference call. The cash amounts represent the equivalent U.S. Dollar value measured at the appropriate year end exchange rate used in the financial statements or the actual U.S. Dollar amounts paid at the time of payment.

(2) At December 31, 2012 Mr. Boudreau, Mr. Troup, Mr. Melchers, Mr. Marinucci and Mr. Khosla respectively held 70,588, 100,000, 100,000, 75,000 and 37,500 vested options to purchase common stock

Directors’ and Officers’ Liability Insurance

During 2012, we carried directors’ and officers’ liability insurance at an approximate annual cost of $37,610 for an insured amount of $2 Million.

Compensation Committee Report

The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis appearing in this document with management and based upon this review and discussion recommended to the Board that the Compensation Discussion and Analysis be included in this registration statement.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information concerning the beneficial ownership of our shares of common stock by our directors and executive officers, and by each beneficial owner of five percent (5%) or more of our outstanding common stock. Based on information available to us, all persons named in the table have sole voting and investment power with respect to all shares of common stock beneficially owned by them, unless otherwise indicated. Beneficial ownership is determined in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended. In computing the number of shares beneficially owned by a person or a group and the percentage ownership of that person or group, shares of our common stock subject to options or warrants currently exercisable or exercisable within 60 days after the date of this prospectus are deemed outstanding, but are not deemed outstanding for the purpose of computing the percentage of ownership of any other person. Applicable percentage ownership is based upon 52,710,421 shares of common stock outstanding as of July 18, 2013. Unless otherwise indicated, the address of each of the named persons is care of IntelGenx Technologies Corp., 6425 Abrams, Ville St-Laurent, Quebec, H4S 1X9.

Name and Address	Amount and Nature of	Percent of
Of Owner	Beneficial Ownership	Class
Horst G. Zerbe⁽¹⁾	4,997,143.5 ⁽¹⁾	9.5%
Ingrid Zerbe⁽²⁾	5,967,606.5 ⁽²⁾	11.3%
Bernard J. Boudreau ⁽³⁾	125,588 ⁽³⁾	*
Ian Troup⁽⁴⁾	100,000 ⁽⁴⁾	*
Paul A. Simmons⁽⁵⁾	157,500 ⁽⁵⁾	*
Bernd J. Melchers⁽⁶⁾	145,000 ⁽⁶⁾	*
John Marinucci⁽⁷⁾	75,000 ⁽⁷⁾	*
Rajiv Khosla⁽⁸⁾	56,250 ⁽⁸⁾	*
All directors and officers as a group (8 persons)	11,624,088	22.1%
BluMont Capital Corporation⁽⁹⁾	6,467,645 (9)	12.3%

* Less than 1%.

(1) In connection with the acquisition of IntelGenx in 2006, Horst Zerbe became our President, Chief Executive Officer and Director and acquired 4,709,643.5 exchangeable shares of our Canadian holding corporation 6544631Canada Inc., a Canadian special purpose corporation which wholly owns IntelGenx Corp. (the “Exchangeable Shares”). The 4,709,643.5 Exchangeable Shares are exchangeable, on a one for one basis, into shares of common stock of IntelGenx Technologies Corp. at Horst Zerbe’s discretion. On July 28, 2011 Horst Zerbe exchanged 470,964 of the exchangeable shares into common shares of IntelGenx Technologies Corp. Prior to exchanging the Exchangeable Shares for shares of common stock, Horst Zerbe has the right to vote the remaining 4,238,679.5 shares of common stock which are currently held in trust on behalf of Horst Zerbe. All of the 4,709,643.5 shares of common stock have not been registered for resale at this time. In addition to the Exchangeable Shares, Horst Zerbe’s beneficial ownership includes 225,000 shares of common stock resulting from the exercise of 225,000 options to purchase common stock on November 9, 2011. He also received 25,000 options to purchase common stock at an exercise price of $0.61, granted November 24, 2009. The options vested over two years, all of which are exercisable within 60 days of this filing. He also received 40,000 options to purchase common stock at an exercise price of $0.54, granted November 29, 2011. The options vest over two years, 25% every six months, 30,000 of which are exercisable within 60 days of this filing. On December 4, 2012 Horst Zerbe received 30,000 options to purchase common stock at an exercise price of $0.60, The options vest over two years, 25% every six months, 7,500 of which are exercisable within 60 days of this filing.

Horst Zerbe and Ingrid Zerbe are husband and wife.

(2) In connection with the acquisition of IntelGenx in 2006, Ingrid Zerbe became our Corporate Secretary and our Director of Finance and Administration and acquired 4,709,643.5 Exchangeable Shares. In June of 2009 Ingrid Zerbe acquired 1,021,713 Exchangeable Shares from Joel Cohen in a private transaction. The 5,731,356.5 Exchangeable Shares are exchangeable, on a one for one basis, into shares of common stock of IntelGenx Technologies Corp. at Ingrid Zerbe’s discretion. On July 28, 2011 Ingrid Zerbe exchanged 573,135 of the exchangeable shares into common shares of IntelGenx Technologies Corp. Prior to exchanging the Exchangeable Shares, Ingrid Zerbe has the right to vote the remaining 5,158,221.5 shares of common stock which are currently held in trust on behalf of Ingrid Zerbe. All of the 5,731,356.5 shares of common stock have not been registered for resale at this time. In addition to the Exchangeable Shares, Ingrid Zerbe’s beneficial ownership includes 225,000 shares of common stock resulting from the exercise of 225,000 options to purchase common stock on November 9, 2011. She also received 15,000 options to purchase common stock at an exercise price of $0.54, granted November 29, 2011. The options vest over two years, 25% every six months, 11,250 of which are exercisable within 60 days of this filing.

Horst Zerbe and Ingrid Zerbe are husband and wife.

(3) Mr. Boudreau’s beneficial ownership consists of 25,588 options to purchase common stock at an exercise price of $0.85 granted on May 22, 2008. On August 19, 2008 Mr. Boudreau exercised 35,000 options at an exercise price of $0.70 in exchange for the same number of shares of common stock. On November 24, 2009, 25,000 exercisable options to purchase common shares at an exercise price of $0.61 were granted to Mr. Boudreau. He also received 40,000 options to purchase common stock at an exercise price of $0.54, granted November 29, 2011. The options vest over two years, 25% every six months, 30,000 of which are exercisable within 60 days of this filing.

(4) Mr. Troup’s beneficial ownership consists of 75,000 exercisable options to purchase common stock at an exercise price of $0.85, granted in September of 2008. On November 24, 2009, 25,000 exercisable options to purchase common shares at an exercise price of $0.61 were granted to Mr. Troup.

(5) Mr. Simmons’ beneficial ownership consists of 100,000 options to purchase common stock at an exercise price of $0.85, granted in September of 2008. The Options vested over two years, 25% every six months, all of which are exercisable within 60 days of this filing. He also received 25,000 options to purchase common stock at an exercise price of $0.61, granted November 24, 2009. The options vested over two years, all of which are exercisable at the time of this filing. He also received 35,000 options to purchase common stock at an exercise price of $0.54, granted November 29, 2011. The options vest over two years, 25% every six months, 26,250 of which are exercisable within 60 days of this filing. On December 4, 2012 Mr. Simmons received 25,000 options to purchase common stock at an exercise price of $0.60. The options vest over two years, 25% every six months, 6,250 of which are exercisable within 60 days of this filing. On April 24, 2013 Mr. Simmons received 200,000 options to purchase common stock at an exercise price of $0.65. The options vest over two years, 25% every six months, none of which are exercisable within 60 days of this filing.

(6) Mr. Melcher’s beneficial ownership consists of 25,000 exercisable options to purchase common stock at an exercise price of $0.61, granted in November of 2009 and 75,000 options to purchase common stock at an exercise price of $0.45 granted in May of 2010. On April14, 2011 and July 27, 2011 Mr. Melchers purchased 25,000 and 20,000 shares of common stock on the open market respectively.

(7) Mr. Marinucci’s beneficial ownership consists of 75,000 exercisable options to purchase common stock at an exercise price of $0.37, granted in August of 2010. The options vest over two years, 25% every six months, all of which are exercisable within 60 days of this filing.

(8) Mr. Khosla’s beneficial ownership consists of 75,000 exercisable options to purchase common stock at an exercise price of $0.54, granted on November 29, 2011. The options vest over two years, 25% every six months, of which 37,500 are exercisable within 60 days of this filing. Unvested options expired upon the grant on April 24, 2013 of 480,000 options to purchase common stock at an exercise price of $0.65. The options vest on December 31, 2015, none of which are exercisable within 60 days of this filing.

(9) Information regarding BluMont Capital Corporation is based solely upon a Schedule 13G filed by BluMont Capital with the Securities and Exchange Commission on November 9, 2012. Schedule 13G provides that BluMont Capital has sole voting and dispositive power with respect to 6,212,645 shares of the Company’s common stock . BluMont is also holding 225,000 share purchase warrants to acquire 225,000 common shares at an exercise price at $0.50 per share and additional 30,000 share purchase warrants to acquire 30,000 common shares at an exercise price of $0.74 per share. Hugh Cleland, executive vice president and portfolio manager, has voting and dispositive power over the shares beneficially owned by BluMont Capital Corporation. The address for BluMont Capital Corporation is 70 University Avenue, Suite 1200, Toronto, ON M5J 2M4, Canada.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Review, Approval or Ratification of Transactions with Related Persons

Although IntelGenx has not adopted formal procedures for the review, approval or ratification of transactions with related persons, we adhere to a general policy that such transactions should only be entered into if they are on terms that, on the whole, are no more favorable, or no less favorable, than those available from unaffiliated third parties and their approval is in accordance with applicable law. Such transactions require the approval of our board of directors. The term “related party transaction” refers to transactions required to be disclosed in our filings with the SEC pursuant to Item 404 of Regulation S-K.

Family Relationships

Horst G. Zerbe and Ingrid Zerbe are husband and wife.

Director Independence

The Board of Directors has determined that four of our directors, Bernie Boudreau, Ian Troup, Bernd Melchers and John Marinucci, are independent within the meaning of the director independence standards of both The Nasdaq Stock Market, Inc. and the SEC, including Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended.

DESCRIPTION OF CAPITAL STOCK

We have an authorized capital of 100,000,000 shares of common stock, par value $0.00001 per share, and 20,000,000 shares of preferred stock, par value $0.00001 per share. As of July 18, 2013, 52,710,421 shares of common stock were outstanding. There were no shares of preferred stock outstanding as of July 18, 2013.

Common Stock

The holders of common stock are entitled to one vote per share on all matters voted on by stockholders, including the election of directors. Except as otherwise required by law, the holders of common stock exclusively possess all voting power. The holders of common stock are entitled to dividends as may be declared from time to time by the Board from funds available for distribution to holders. No holder of common stock has any pre-emptive right to subscribe to any securities of ours of any kind or class or any cumulative voting rights. The outstanding shares of common stock are, and the shares, upon issuance and sale as contemplated will be, duly authorized, validly issued, fully paid and non-assessable.

Anti-Takeover Effects of Various Provisions of Delaware Law and Our Certificate of Incorporation and By-laws

The Delaware General Corporation Law, our certificate of incorporation and our by-laws contain provisions that may have some anti-takeover effects and may delay, defer or prevent a tender offer or takeover attempt that a stockholder might consider in his, her or its best interest, including those attempts that might result in a premium over the market price for the shares held by stockholders.

Delaware Anti-Takeover Statute

We are subject to Section 203 of the Delaware General Corporation Law (“Section 203”). Subject to specific exceptions, Section 203 prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the time the stockholder becomes an interested stockholder, unless:

the business combination, or the transaction in which the stockholder became an interested stockholder, is approved by our board of directors prior to the time the interested stockholder attained that status;
upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, excluding those shares owned by persons who are directors and also officers and employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

at or after the time a stockholder became an interested stockholder, the business combination is approved by our board of directors and authorized at an annual or special meeting of stockholders by the affirmative vote of at least two-thirds of our outstanding voting stock that is not owned by the interested stockholder.

“Business combinations” include mergers, asset sales and other transactions resulting in a financial benefit to the interested stockholder. Subject to various exceptions, in general, an “interested stockholder” is a stockholder who, together with his, her or its affiliates and associates, owns, or within three years did own, 15% or more of the shares of our outstanding voting stock. These restrictions could prohibit or delay the accomplishment of mergers or other takeover or change of control attempts with respect to us and, therefore, may discourage attempts to acquire us.

Preferred Stock

Our board of directors is authorized to issue all and any of the shares of preferred stock in one or more series, fix the number of shares, determine or alter for each such series voting powers or other rights, qualifications, limitations or restrictions thereof.

Warrants

As of the date of this prospectus, we had outstanding warrants to purchase an aggregate of 611,000 shares of our common stock at an exercise price of S0.4741 (CAD$0.50) . These warrants expire on August 27, 2013. Furthermore, we had outstanding warrants to purchase an aggregate of 2,748,165 shares of our common stock at an exercise price of $0.74 (CAD$0.73) . These warrants expire on June 21, 2014.

DESCRIPTION OF SECURITIES WE ARE OFFERING

We are offering units, each unit consisting of one share of our common stock and ___ of a warrant, each to purchase _____ share of our common stock. The units will not be issued or certificated. The shares of common stock and warrants that we are issuing are immediately separable and will be issued separately. The shares of common stock issuable from time to time upon exercise of the warrants, if any, are also being offered pursuant to this prospectus.

Common Stock

Holders of our common stock have the rights set forth above under the heading “Description of Capital Stock-Common Stock.”

Warrants

The following summary of certain terms and provisions of the warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by the provisions of the warrants, the form of which has been filed as an exhibit to the registration statement of which this prospectus is a part. Prospective investors should carefully review the terms and provisions of the form of the warrant for a complete description of the terms and conditions of the warrants.

Duration and Exercise Price. The warrants offered hereby will entitle the holders thereof to purchase up to an aggregate of ___________ shares of our common stock at an exercise price of $_______ per share, commencing immediately on the issuance date and will expire on the _____ anniversary of the issuance date. The warrants will be issued separately from the common stock included in the units, and may be transferred separately immediately thereafter.

Anti-Dilution Protection. The exercise price and the number of shares issuable upon exercise of the warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting our common stock, and also upon any distributions of assets, including cash, stock or other property to our stockholders. The warrant holders must pay the exercise price in cash upon exercise of the warrants. After the close of business on the expiration date, unexercised warrants will become void.

Fundamental Transactions. In the event of any fundamental transaction, as described in the warrants and generally including any merger with another entity, the sale, transfer or other disposition of all or substantially all of our assets to another entity, or the acquisition by a person of more than 50% of our common stock, then the holders of the warrants will thereafter have the right to receive upon exercise of the warrants such shares of stock, securities or assets as would have been issuable or payable with respect to or in exchange for a number of shares of our common stock equal to the number of shares of our common stock issuable upon exercise of the warrants immediately prior to the fundamental transaction, had the fundamental transaction not taken place, and appropriate provision will be made so that the provisions of the warrants (including, for example, provisions relating to the adjustment of the exercise price) will thereafter be applicable, as nearly equivalent as may be practicable in relation to any share of stock, securities or assets deliverable upon the exercise of the warrants after the fundamental transaction.

Transferability. The warrants may be transferred at the option of the holder upon surrender of the warrants with the appropriate instruments of transfer.

Exchange Listing. We do not plan on making an application to list the warrants on any national securities exchange or quotation system.

Right as a Stockholder. Except by virtue of a holder’s ownership of shares of our common stock, the holders of the warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their warrants.

Exercisability. The warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise. A holder (together with its affiliates) may not exercise any portion of the warrant to the extent that the holder would own more than 4.99% of the outstanding common stock after exercise, except that upon at least 61 days’ prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder’s warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants.

Waivers and Amendments. Subject to certain exceptions, any term of the warrants may be amended or waived with our written consent and the written consent of the holders of at least 66 2/3% of the then-outstanding warrants.

LEGAL PROCEEDINGS

Neither we nor our subsidiary is a party to, nor is any of our property the subject of, any legal proceedings. There are no proceedings pending in which any of our officers, directors or 5% shareholders are adverse to us or any of our subsidiaries or in which they are taking a position or have a material interest that is adverse to us or any of our subsidiaries.

PLAN OF DISTRIBUTION

_________________, which we refer to as the placement agent, has agreed to act as the exclusive placement agent in connection with this offering subject to the terms and conditions of a placement agent agreement, dated , 2013. The placement agent is not purchasing or selling any units offered by this prospectus, nor is it required to arrange the purchase or sale of any specific number or dollar amount of the units, but has agreed to use its commercially reasonable “best efforts” to arrange for the sale of all of the units offered hereby. We will enter into subscription agreements directly with investors in connection with this offering and we may not sell the entire amount of units offered pursuant to this prospectus. The price per unit has been determined based upon arm’s-length negotiations between the purchasers and us.

The placement agent proposes to arrange for the sale to one or more purchasers of the units offered pursuant to this prospectus through direct subscription agreements between the purchasers and us.

Commissions and Expenses

We have agreed to pay the placement agent an aggregate cash placement fee equal to six percent of the gross proceeds in this offering.

The following table shows the per unit and total cash placement agent’s fees we will pay to the placement agent in connection with the sale of the units offered pursuant to this prospectus assuming the purchase of all of the units offered hereby:

Per Unit	$
Total	$

In addition, if the offering raises a minimum of $6,000,000, we have agreed to issue to the placement agent, or its designees, warrants exercisable for an aggregate of six percent of the units issued in this offering. The placement agent warrants will be exercisable at any time after the 180^th day after the effective date of the registration statement of which this prospectus is a part and will expire on 5:00 p.m. (New York time) on the ____ anniversary of the effective date of the registration statement of which this prospectus is a part. This prospectus also covers the sale of the placement agent warrants and the shares of our common stock issuable upon the exercise of the placement agent warrants. The placement agent warrants will have the same terms, including the exercise price, as the warrants issued to investors, except that the placement agent warrants will comply with the requirements of the Financial Institutions Regulatory Authority, Inc., or FINRA. As required by FINRA, neither the placement agent warrants nor any securities issued upon exercise of the placement agent warrants may be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of such securities by any person for a period of 180 days immediately following the effective date of the registration statement of which this prospectus is a part, except the transfer of any security:

by operation of law or by reason of our reorganization;
to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain subject to the lock-up restriction described above for the remainder of the time period;
if the aggregate amount of our securities held by the placement agent or related person do not exceed 1% of the securities being offered;
that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the equity in the fund; or
the exercise or conversion of any security, if all securities received remain subject to the lock-up restriction set forth above for the remainder of the time period.

Because there is no minimum offering amount required as a condition to closing in this offering, the actual total offering commissions, if any, are not presently determinable and may be substantially less than the maximum amount set forth above. We have also agreed to reimburse the placement agent for its out-of-pocket expenses in an aggregate amount not to exceed $50,000.

Our obligation to issue and sell units to the purchasers is subject to the conditions set forth in the subscription agreements, which may be waived by us at our discretion. A purchaser’s obligation to purchase units is subject to the conditions set forth in his or her subscription agreement as well, which may also be waived.

We estimate the total offering expenses of this offering that will be payable by us, excluding the placement agent’s fee, will be approximately $_____, which includes legal and printing costs, various other fees and reimbursement of the placements agent’s expenses. At the closing, The Depository Trust Company will credit the shares of common stock to the respective accounts of the investors. We will mail warrants directly to the investors at the respective addresses set forth in their subscription agreement with us.

Indemnification

We have agreed to indemnify the placement agent against liabilities under the Securities Act of 1933, as amended. We have also agreed to contribute to payments the placement agent may be required to make in respect of such liabilities.

Lock-up Agreements

We and our officers, directors have agreed, subject to certain exceptions, for a period of 30 days after the date of this prospectus, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of, directly or indirectly any common shares or any securities convertible into or exchangeable for our common shares either owned as of the date hereof or thereafter acquired (in our case only at a price less than the public offering price set forth on the cover page of this prospectus) without the prior written consent of the placement agent. This 30-day period may be extended if (1) during the last 17 days of the 30-day period, we issue an earnings release or material news or a material event regarding us occurs or (2) prior to the expiration of the 30-day period, we announce that we will release earnings results during the 16-day period beginning on the last day of the 30-day period, then the period of such extension will be 18-days, beginning on the issuance of the earnings release or the occurrence of the material news or material event. If after any announcement described in clause (2) of the preceding sentence, we announce that we will not release earnings results during the 16-day period, the lock-up period shall expire the later of the expiration of the 30-day period and the end of any extension of such period made pursuant to clause (1) of the preceding sentence. The placement agent may, in its sole discretion and at any time or from time to time before the termination of the lock-up period, without notice, release all or any portion of the securities subject to lock-up agreements. Pursuant to the terms of the lock-up agreements, Horst Zerbe, our chairman and chief executive officer, and/or Ingrid Zerbe, our corporate secretary and director of finance and administration will be permitted to sell or dispose of up to an aggregate of 500,000 shares of our common stock during the lock-up period.

Electronic Distribution

This prospectus may be made available in electronic format on websites or through other online services maintained by the placement agent, or by an affiliate. Other than this prospectus in electronic format, the information on the placement agent’s website and any information contained in any other website maintained by the placement agent is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or the placement agent, and should not be relied upon by investors.

The foregoing does not purport to be a complete statement of the terms and conditions of the placement agent agreement and subscription agreements. A copy of the placement agent agreement and the form of subscription agreement with the investors are included as exhibits to the registration statement of which this prospectus supplement forms a part. See “Where You Can Find Additional Information” on page 57.

Regulation M Restrictions

The placement agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale of the units sold by it while acting as a principal might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, the placement agent would be required to comply with the requirements of the Securities Act and the Securities Exchange Act of 1934, as amended, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of units by the placement agent acting as a principal. Under these rules and regulations, the placement agent:

must not engage in any stabilization activity in connection with our securities; and
must not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution.

Other

From time to time, the placement agent and its affiliates have provided, and may in the future provide, various investment banking, financial advisory and other services to us and our affiliates for which services they have received, and may in the future receive, customary fees. In the course of their businesses, the placement agent and its affiliates may actively trade our securities or loans for their own account or for the accounts of customers, and, accordingly, the placement agent and its affiliates may at any time hold long or short positions in such securities or loans. Except for services provided in connection with this offering, the placement agent has not provided any investment banking or other financial services during the 180-day period preceding the date of this prospectus and we do not expect to retain the placement agent to perform any investment banking or other financial services for at least 90 days after the date of this prospectus.

The offering of securities pursuant to this prospectus shall also comply with the rules and regulations of the TSX-V.

NOTICE TO INVESTORS

Notice to Investors in the United Kingdom

In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a “Relevant Member State”) an offer to the public of any securities which are the subject of the offering contemplated by this prospectus may not be made in that Relevant Member State except that an offer to the public in that Relevant Member State of any such securities may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State:

(a) to legal entities which are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities;

(b) to any legal entity which has two or more of (1) an average of at least 250 employees during the last financial year; (2) a total balance sheet of more than €43,000,000 and (3) an annual net turnover of more than €50,000,000, as shown in its last annual or consolidated accounts;

(c) by the placement agent to fewer than 100 natural or legal persons (other than qualified investors as defined in the Prospectus Directive); or

(d) in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of these securities shall result in a requirement for the publication by the issuer or the underwriter of a prospectus pursuant to Article 3 of the Prospectus Directive.

For the purposes of this provision, the expression an “offer to the public” in relation to any of the securities in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any such securities to be offered so as to enable an investor to decide to purchase any such securities, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State and the expression “Prospectus Directive” means Directive 2003/71/EC and includes any relevant implementing measure in each Relevant Member State.

The placement agent has represented, warranted and agreed that:

(a) it has only communicated or caused to be communicated and will only communicate or cause to be communicated any invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000 (the FSMA)) received by it in connection with the issue or sale of any of the securities in circumstances in which section 21(1) of the FSMA does not apply to the issuer; and

(b) it has complied with and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the securities in, from or otherwise involving the United Kingdom.

European Economic Area

In particular, this document does not constitute an approved prospectus in accordance with European Commission’s Regulation on Prospectuses no. 809/2004 and no such prospectus is to be prepared and approved in connection with this offering. Accordingly, in relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (being the Directive of the European Parliament and of the Council 2003/71/EC and including any relevant implementing measure in each Relevant Member State) (each, a Relevant Member State), with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State (the Relevant Implementation Date) an offer of securities to the public may not be made in that Relevant Member State prior to the publication of a prospectus in relation to such securities which has been approved by the competent authority in that Relevant Member State or, where appropriate, approved in another Relevant Member State and notified to the competent authority in that Relevant Member State, all in accordance with the Prospectus Directive, except that it may, with effect from and including the Relevant Implementation Date, make an offer of securities to the public in that Relevant Member State at any time:

to legal entities which are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities;
to any legal entity which has two or more of (1) an average of at least 250 employees during the last financial year; (2) a total balance sheet of more than €43,000,000; and (3) an annual net turnover of more than €50,000,000, as shown in the last annual or consolidated accounts; or
in any other circumstances which do not require the publication by the Issuer of a prospectus pursuant to Article 3 of the Prospectus Directive.

For the purposes of this provision, the expression an “offer of securities to the public” in relation to any of the securities in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe for the securities, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State. For these purposes the units offered hereby are “securities.”

LEGAL MATTERS

The validity of the common stock offered hereby will be passed upon by Dorsey & Whitney, LLP.

EXPERTS

IntelGenx Technologies Corp. financial statements for the years ended December 31, 2012 and 2011 included in this registration statement have been audited by Richter, LLP, Montreal, Quebec, an independent registered public accounting firm, as stated in their report, and have been so included in reliance upon the report of said firm and their authority as experts in accounting and auditing. This report expresses an unqualified opinion.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

We have had no disagreements with our independent registered public accountants with respect to accounting practices or procedures or financial disclosure.

WHERE YOU CAN FIND ADDITIONAL INFORMATION

We file reports and other information with the Securities and Exchange Commission. We have also filed a registration statement on Form S-1, including exhibits, with the SEC with respect to the shares being offered in this offering. This prospectus is part of the registration statement, but it does not contain all of the information included in the registration statement or exhibits. For further information with respect to us and our common stock, we refer you to the registration statement and to the exhibits and schedules to the registration statement. Statements contained in this prospectus as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. You may inspect a copy of the registration statement and other reports we file with the Securities and Exchange Commission without charge at the SEC’s principal office in Washington, D.C., and copies of all or any part of the registration statement may be obtained from the Public Reference Section of the SEC, 100 F Street NE, Washington, D.C. 20549, upon payment of fees prescribed by the SEC. The SEC maintains an internet site that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the Web site is http://www.sec.gov. The SEC’s toll free investor information service can be reached at 1-800-SEC-0330.

FINANCIAL STATEMENTS

INDEX TO FINANCIAL STATEMENTS OF INTELGENX TECHNOLOGIES CORP.
Consolidated Balance Sheet at March 31, 2013 (unaudited) and December 31, 2012 (audited)	F-1
Consolidated Statement of Shareholders’ Equity for the period ended March 31, 2013 (unaudited)	F-2
Consolidated Statement of Operations and Comprehensive Loss for the three month periods ended March 31, 2013 and 2012 (unaudited)	F-3
Consolidated Statement of Cash Flows for the three month periods ended March 31, 2013 and 2012 (unaudited)	F-4
Notes to Consolidated Interim Financial Statements	F-5 - F-9

Report of Independent Registered Public Accounting Firm	F-10
Consolidated Balance Sheets as at December 31, 2012 and 2011	F-11
Consolidated Statements of Shareholders’ Equity for the year ended December 31, 2011	F-12
Consolidated Statements of Shareholders’ Equity for the year ended December 31, 2012	F-13
Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2012 and 2011	F-14
Consolidated Statements of Cash Flows for the years ended December 31, 2012 and 2011	F-15
Notes to Consolidated Financial Statements	F-16 - F-36

IntelGenx Technologies Corp.

Consolidated Balance Sheet

(Expressed in Thousands of U.S. Dollars ($000’s) Except Share and Per Share Data)

(Unaudited)

		March 31,			December 31,
		2013			2012
Assets
Current
Cash and cash equivalents	$	2,168		$	2,059
Accounts receivable		170			1,282
Prepaid expenses		89			102
Investment tax credits receivable		243			213
Total Current Assets		2,670			3,656
Leasehold Improvements and Equipment, net		438			387
Intangible Assets (note 4)		106			116
Total Assets	$	3,214		$	4,159
Liabilities
Current
Accounts payable and accrued liabilities		498			1,058
Deferred license revenue (note 5)		308			308
Total Current Liabilities		806			1,366
Deferred License Revenue, non-current portion (note 5)		539			615
Total Liabilities		1,345			1,981
Shareholders’ Equity
Capital Stock (note 6)		1			0
Additional Paid-in-Capital		16,554			16,342
Accumulated Deficit		(14,949	)		(14,463	)
Accumulated Other Comprehensive Income		263			299
		1,869			2,178
	$	3,214		$	4,159

See accompanying notes

Approved on Behalf of the Board:

/s/ J. Bernard Boudreau Director

/s/ Horst G. Zerbe Director

F-1

IntelGenx Technologies Corp.

Consolidated Statement of Shareholders’ Equity

For the Period Ended March 31, 2013

(Expressed in Thousands of U.S. Dollars ($000’s) Except Share and Per Share Data)

(Unaudited)

										Accumulated
					Additional					Other			Total
	Capital Stock				Paid-In		Accumulated			Comprehensive			Shareholders’
	Number		Amount		Capital		Deficit			Income			Equity
Balance - December 31, 2012	49,890,421	$	0	$	16,342	$	(14,463	)	$	299		$	2,178
Foreign currency translation adjustment	-		-		-		-			(36	)		(36	)
Warrants exercised (note 7)	362,500		1		171		-			-			172
Options exercised (note 7)	50,000		-		23		-			-			23
Stock-based compensation (note 7)	-		-		18		-			-			18
Net loss for the period	-		-		-		(486	)		-			(486	)
Balance – March 31, 2013	50,302,921	$	1	$	16,554	$	(14,949	)	$	263		$	1,869

See accompanying notes

F-2

IntelGenx Technologies Corp.

Consolidated Statement of Comprehensive Loss

(Expressed in Thousands of U.S. Dollars ($000’s) Except Share and Per Share Data)

(Unaudited)

		For the Three-Month Period
		Ended March 31,
		2013			2012
Revenues
Royalties	$	80		$	-
License and other revenue		77			100
Total Revenues		157			100
Expenses
Research and development expense		167			239
Selling, general and administrative expense		456			439
Amortization of tangible assets		10			8
Amortization of intangible assets		10			-
Total Costs and Expenses		643			686
Loss from Operations		(486	)		(586	)
Other Income
Interest and other income		-			4
Total Other Income		-			4
Net Loss		(486	)		(582	)
Other Comprehensive Loss
Foreign currency translation adjustment		(36	)		91
Comprehensive Loss	$	(522	)	$	(491	)
Basic and Diluted Weighted Average Number of Shares Outstanding		50,236,255			49,324,531
Basic and Diluted Loss Per Common Share (note 9)	$	(0.01	)	$	(0.01	)

See accompanying notes

F-3

IntelGenx Technologies Corp.

Consolidated Statement of Cash Flows

(Expressed in thousands of U.S. Dollars ($000’s) Except Share and Per Share Data)

(Unaudited)

		For the Three-Month Period
		Ended March 31,
		2013			2012
Funds Provided (Used) -
Operating Activities
Net loss	$	(486	)	$	(582	)
Amortization		20			8
Stock-based compensation		18			15
		(448	)		(559	)
Changes in assets and liabilities:
Accounts receivable		1,112			18
Prepaid and other assets		13			(15	)
Other receivables		(30	)		249
Accounts payable and other accrued liabilities		(560	)		(270	)
Deferred revenue		(77	)		1,000
Net change in assets and liabilities		458			982
Net cash provided by operating activities		10			423

Financing Activities
Proceeds from exercise of warrants and stock options		195			233
Net cash provided by financing activities		195			233


Investing Activities
Additions to property and equipment		(69	)		(189	)
Net cash used in investing activities		(69	)		(189	)
Increase in Cash and Cash Equivalents		136			467
Effect of Foreign Exchange on Cash and Cash Equivalents		(27	)		88
Cash and Cash Equivalents
Beginning of Period		2,059			3,505
End of Period	$	2,168		$	4,059

See accompanying notes

F-4

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements

March 31, 2013

(Expressed in U.S. Funds)

(Unaudited)

1.	Basis of Presentation

	The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal and recurring nature.

	These financial statements should be read in conjunction with the audited consolidated financial statements at December 31, 2012. Operating results for the three months ended March 31, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.

	The consolidated financial statements include the accounts of the Company and its subsidiary companies. On consolidation, all inter-entity transactions and balances have been eliminated.

	The financial statements are expressed in U.S. funds.

	Management has performed an evaluation of the Company’s activities through the date and time these financial statements were issued and concluded that there are no additional significant events requiring recognition or disclosure.

2.	Adoption of New Accounting Standards

	Revenue Recognition and Disclosures

	In December 2011, the FASB issued Update No. 2011-11, “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities”. The objective of this Update is to provide enhanced disclosures that will enable users of financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position. This includes the effect or potential effect of rights of setoff associated with an entity’s recognized assets and recognized liabilities within the scope of this Update. The amendments require enhanced disclosures by requiring improved information about derivatives, repurchase agreements and reverse purchase agreements, and securities borrowing and securities lending transactions that are either offset in accordance with specific criteria or subject to a master netting arrangement or similar agreement. In January 2013, the FASB also issued Update No. 2013-01, which clarifies that ordinary trade receivables and receivables are not in the scope of ASU 2011-11. ASU 2011-11and ASU 2013-01are effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. Retrospective disclosure is required for all comparative periods presented. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations.

F-5

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements

March 31, 2013

(Expressed in U.S. Funds)

(Unaudited)

2.	Adoption of New Accounting Standards (Cont’d)

	In February 2013, the FASB has issued Update No. 2013-02, “Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income”. This Update has been issued to improve the transparency of reporting these reclassifications. The amendments in this Update supersede and replace the presentation requirements for reclassifications out of accumulated other comprehensive income in ASUs 2011-05 and 2011-12 for all public and private organizations. The amendments would require an entity to provide additional information about reclassifications out of accumulated other comprehensive income. Public companies are required to comply with these amendments for all reporting periods (interim and annual), effective for reporting periods beginning after December 15, 2012. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations.

3.	Significant Accounting Policies

	Recently Issued Accounting Pronouncements

	In December 2011, the FASB issued Update No. 2011-12, “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05”. The amendments in this Update supersede changes to those paragraphs in Update 2011-05 that pertain to how, when, and where reclassification adjustments are presented. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations, but may affect the presentation of Other Comprehensive Income in the Company’s financial statements.

	In February 2013, the FASB issued Update No. 2013-04, “Liabilities (Topic 405)—Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date”. The amendments in this Update provide guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this Update is fixed at the reporting date, except for obligations addressed within existing guidance in U.S. GAAP. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. The guidance in this Update also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. For public entities, the amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments shall be applied retrospectively to all prior periods presented for those obligations that exist at the beginning of the fiscal year of adoption. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.

F-6

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements

March 31, 2013

(Expressed in U.S. Funds)

(Unaudited)

3.	Significant Accounting Policies (Cont’d)

	In March 2013, the FASB issued Update No. 2013-05, “Foreign Currency Matters (Topic 830)—Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity”. The amendments in this Update resolve the diversity in practice about whether Subtopic 810-10, Consolidation—Overall, or Subtopic 830-30, Foreign Currency Matters—Translation of Financial Statements, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, the amendments in this Update resolve the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. For public entities, the amendments in this ASU are effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2013. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.

4.	Intangible Assets

	As of March 31, 2013 NDA acquisition costs of $106 thousand (December 31, 2012 - $116 thousand) were recorded as intangible assets on the Company’s balance sheet and represent the net book value of the final progress payment related to the acquisition of 100% ownership of Forfivo XL™. The asset will be amortized over its estimated useful life of 39 months. The Company commenced amortization upon commercial launch of the product in October 2012.

5.	Deferred License Revenue

	Deferred license revenue represents upfront payments received for the granting of licenses to the Company’s patents, intellectual property, and proprietary technology, for commercialization. Deferred license revenue is recognized in income over the period where sales of the licensed products will occur.

	Upon entering into the licensing agreement with Edgemont Pharmaceuticals the Company received an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over a period of 39 months, which is the minimum period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $847 thousand at March 31, 2013 that has not been recognized as revenue.

F-7

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements

March 31, 2013

(Expressed in U.S. Funds)

(Unaudited)

6.	Capital Stock

		March 31,		December 31,
		2013		2012
Authorized -
100,000,000 common shares of $0.00001 par value
20,000,000 preferred shares of $0.00001 par value
Issued -
50,302,921 (December 31, 2012 - 49,890,421) common shares	$	503	$	499

7.	Additional Paid-In Capital

	Stock options

	During the three month period ended March 31, 2013 a total of 50,000 (2012 - Nil) stock options were exercised for 50,000 (2012 - Nil) common shares having a par value of $0 thousand in aggregate, for cash consideration of $23 thousand (2012 - $Nil), resulting in an increase in additional paid-in capital of $23 thousand (2012 - $Nil).

	Compensation expenses for stock-based compensation of $18 thousand and $15 thousand were recorded during the three-month period ended March 31, 2013 and 2012 respectively. Of the amount expensed in 2013, $13 thousand (2012 - $14 thousand) relates to stock options granted to employees and directors, and $5 thousand (2012 - $Nil) relates to options granted to independent third party consultants. In addition, $1 thousand was expensed in 2012 related to stock options granted to investor relations firms as compensation for investor relation services. As at March 31, 2013, the Company has $50 thousand (2012 - $69 thousand) of unrecognized stock- based compensation.

	Warrants

	During the three month period ended March 31, 2013 a total of 362,500 (2012 - 1,206,418) warrants were exercised for 362,500 (2012 - 726,830) common shares having a par value of $0 thousand in aggregate, for cash consideration of $172 thousand (2012 - $233 thousand), resulting in an increase in additional paid-in capital of $171 thousand (2012 - $233 thousand).

F-8

IntelGenx Technologies Corp.

Notes to Consolidated Interim Financial Statements

March 31, 2013

(Expressed in U.S. Funds)

(Unaudited)

8.	Related Party Transactions

	Included in management salaries are $2 thousand (2012 - $1 thousand) for options granted to the Chief Financial Officer and $3 thousand (2012 - $2 thousand) for options granted to the Chief Executive Officer under the 2006 Stock Option Plan and $4 thousand (2012 - $7 thousand) for options granted to non-employee directors.

	Also included in management salaries are director fees of $22 thousand (2012 - $27 thousand) for attendance to board meetings and audit committee meetings and $54 thousand (2012 - $Nil) for fees paid to a director under a management consultancy agreement.

	The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed to by the related parties.

9.	Basic and Diluted Loss Per Common Share

	Basic and diluted loss per common share is calculated based on the weighted average number of shares outstanding during the period. The warrants, share-based compensation and convertible notes have been excluded from the calculation of diluted loss per share since they are anti-dilutive.

10.	Subsequent Events

	Subsequent to the end of the quarter, the Company’s board of directors granted options to acquire 680,000 common shares under the 2006 Stock Option Plan, as amended. Of the total stock options granted, 480,000 were granted to the Chief Operating Officer and Chief Scientific Officer, Dr. Rajiv Khosla, and 200,000 were granted to the Chief Financial Officer, Mr. Paul A. Simmons. The options have an exercise price of CAD$0.67 (US$0.65) and expire on April 23, 2018. All of the options granted to Dr. Khosla vest on December 31, 2015. The options granted to Mr. Simmons vest over a period of two years at the rate of 25 % every six months. In addition, 37,500 unvested options that were granted to Dr. Khosla in November 2011 expired upon issuance of the above options.

	Subsequent to the end of the quarter, 995,500 warrants were exercised for 995,500 common shares having a par value of $0 thousand for cash consideration of approximately $472 thousand, resulting in an increase in additional paid-in capital of approximately $472 thousand.

11.	Comparative Figures

	Certain reclassifications of March 31, 2012 amounts have been made to facilitate comparison with the current period.

F-9

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors of
IntelGenx Technologies Corp.

We have audited the accompanying consolidated balance sheets of IntelGenx Technologies Corp. as at December 31, 2012 and 2011 and the related consolidated statements of comprehensive loss, shareholders’ equity and cash flows for the years then ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform an audit to obtain reasonable assurance whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, these consolidated financial statements present fairly in all material respects, the financial position of the Company as at December 31, 2012 and 2011 and the results of its operations and its cash flows for the years then ended in accordance with U.S. generally accepted accounting principles.

Richter LLP (Signed)

Montréal, Québec
March 15, 2013

¹CPA auditor, CA, public accountancy permit No. A110982

514.934.3400 mtlinfo@richter.ca

Richter LLP 1981 McGill College Mtl (Qc) H3A 0G6 www.richter.ca	Member RSM International Montréal, Toronto

F-10

IntelGenx Technologies Corp.

Consolidated Balance Sheets
As at December 31, 2012 and 2011
(Expressed in Thousands of U.S. Dollars ($’000) Except Share and Per Share Data)

		2012			2011

Assets

Current

Cash and cash equivalents	$	2,059		$	3,505
Accounts receivable		1,282			263
Prepaid expenses		102			68
Loan receivable		-			85
Investment tax credits receivable		213			375

		3,656			4,296

Leasehold Improvements and Equipment (note 5)		387			149

Intangible assets (note 6)		116			125

	$	4,159		$	4,570
Liabilities

Current
Accounts payable and accrued liabilities		1,058			666
Deferred license revenue (note 7)		308			-
		1,366			666

Deferred license revenue, non-current portion (note 7)		615			-

Total Liabilities		1,981			666

Commitments (note 8)

Shareholders’ Equity

Capital Stock (note 8)		0			0

Additional Paid-in-Capital		16,342			15,918

Accumulated Deficit		(14,463	)		(12,213	)

Accumulated Other Comprehensive Income		299			199

		2,178			3,904

	$	4,159		$	4,570

See accompanying notes

Approved on Behalf of the Board:

/s/ J. Bernard Boudreau	Director

/s/ Horst G. Zerbe	Director

F - 11

IntelGenx Technologies Corp.

Consolidated Statement of Shareholders’ Equity
For the Year Ended December 31, 2011
(Expressed in Thousands of U.S. Dollars ($’000) Except Share and Per Share Data)

										Accumulated
					Additional					Other		Total
	Capital Stock				Paid-In		Accumulated			Comprehensive		Shareholders’
	Number		Amount		Capital		Deficit			Income		Equity
Balance - December 31, 2010	39,581,271	$	0	$	11,087	$	(9,761	)	$	150	$	1,476
Foreign currency translation adjustment	-		-		-		-			49		49
Issue of common stock, net of transaction costs of $390 (note 9)	4,821,342		-		2,024		-			-		2,024
Warrants issued, net of transaction costs of $132 (note 10)	-		-		685		-			-		685
Agents’ warrants (note 10)	-		-		153		-			-		153
Warrants exercised (note 10)	3,418,009		-		1,458		-			-		1,458
Agents’ warrants exercised (note 10)	299,406		-		142		-			-		142
Options exercised (note 10)	775,000		-		318		-			-		318
Stock-based compensation (note 10)	-		-		51		-			-		51
Net loss for the period	-		-		-		(2,452	)		-		(2,452	)
Balance – December 31, 2011	48,895,028	$	0	$	15,918	$	(12,213	)	$	199	$	3,904

See accompanying notes

F - 12

IntelGenxTechnologies Corp.

Consolidated Statement of Shareholders’ Equity
For the Year Ended December 31, 2012
(Expressed in Thousands of U.S. Dollars ($’000) Except Share and Per Share Data)

										Accumulated
					Additional					Other		Total
	Capital Stock				Paid-In		Accumulated			Comprehensive		Shareholders’
	Number		Amount		Capital		Deficit			Income		Equity
Balance - December 31, 2011	48,895,028	$	0	$	15,918	$	(12,213	)	$	199	$	3,904
Foreign currency translation adjustment	-		-		-		-			100		100
Warrants exercised (note 10)	726,080		-		233		-			-		233
Agents’ warrants exercised (note 10)	219,313		-		104		-			-		104
Options exercised (note 10)	50,000		-		28		-			-		28
Stock-based compensation (note 10)	-		-		59		-			-		59
Net loss for the period	-		-		-		(2,250	)		-		(2,250	)
Balance – December 31, 2012	49,890,421	$	0	$	16,342	$	(14,463	)	$	299	$	2,178

See accompanying notes

F - 13

IntelGenx Technologies Corp.

Consolidated Statements of Comprehensive Loss
For the Years Ended December 31, 2012 and 2011
(Expressed in Thousands of U.S. Dollars ($’000) Except Share and Per Share Data)

		2012			2011
Revenue	$	1,198		$	433
Other Income		10			7
		1,208			440
Expenses
Research and development		1,935			1,524
Research and development tax credits		(212	)		(188	)
Management salaries		716			586
General and administrative		347			333
Professional fees		582			594
Depreciation		46			37
Foreign exchange loss		41			3
Interest and financing fees		3			3
		3,458			2,892
Loss Before Income Taxes		(2,250	)		(2,452	)
Income taxes (note 11)		-			-
Net Loss		(2,250	)		(2,452	)
Other Comprehensive Income
Foreign currency translation adjustment		100			49
Comprehensive Loss	$	(2,150	)	$	(2,403	)
Basic and Diluted Weighted Average Number of Shares Outstanding		49,637,908			43,736,003
Basic and Diluted Loss Per Common Share (note 14)	$	(0.04	)	$	(0.05	)

See accompanying notes

F - 14

IntelGenx Technologies Corp.

Consolidated Statements of Cash Flows
For the Year Ended December 31, 2012 and 2011
(Expressed in Thousands of U.S. Dollars ($’000) Except Share and Per Share Data)

		2012			2011

Funds Provided (Used) -
Operating Activities
Net loss	$	(2,250	)	$	(2,452	)
Depreciation		46			37
Stock-based compensation		59			51
Accounts receivable write-off		-			53
		(2,145	)		(2,311	)
Changes in assets and liabilities
Accounts receivable		(1,019	)		(38	)
Prepaid and other assets		(34	)		(21	)
Other receivables		247			(263	)
Accounts payable and other accrued liabilities		390			317
Deferred revenue		923			-
		507			(5	)
		(1,638	)		(2,316	)

Financing Activities
Issuance of common stock and warrants					3,231
Proceeds from exercise of warrants, agents’ warrants and stock options		365			1,918
Transaction costs		-			(369	)
		365			4,780

Investing Activities
Additions to leasehold improvements and equipment		(270	)		(34	)
Additions to intangible assets		-			(125	)
		(270	)		(159	)
Increase (Decrease) in Cash and Cash Equivalents		(1,543	)		2,305
Effect of Foreign Exchange on Cash and Cash Equivalents		97			56
Cash and Cash Equivalents
Beginning of Year		3,505			1,144
End of Year	$	2,059		$	3,505

See accompanying notes

F - 15

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

1.	Basis of Presentation

	IntelGenx Technologies Corp. (“IntelGenx” or the “Company”) prepares its financial statements in accordance with accounting principles generally accepted in the United States of America (“USA”). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.

	The consolidated financial statements include the accounts of the Company and its subsidiary companies. On consolidation, all inter-entity transactions and balances have been eliminated.

	The financial statements are expressed in U.S. funds.

2.	Nature of Business

	The Company specializes in the development of pharmaceutical products in co-operation with various pharmaceutical companies.

	Technologies

	The Company has developed three proprietary delivery platforms; including an immediate release oral film “VersaFilm™”, a mucoadhesive tablet “AdVersa™” and a multilayer controlled release tablet “VersaTab™”.

	The three technology platforms have been designed to address the challenges commonly encountered in oral drug delivery, such as first-pass metabolism, gastrointestinal (“GI”) side effects, or incomplete absorption of the drug in the GI tract. IntelGenx’ technologies are broadly applicable and have the ability to improve the performance of a wide variety of existing pharmaceutical compounds.

	Product Pipeline

	IntelGenx’ product pipeline currently consists of 9 products in various stages of development, including products for the treatment of hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, idiopathic pulmonary fibrosis, allergies and pain management. Of the products currently under development, 6 utilize the VersaFilm™ technology, 2 utilize the VersaTab™ technology, and one utilizes the AdVersa™ technology.

	Approved and Commercialized Products

	The Company’s first FDA-approved product, Forfivo XL™, was launched in the USA in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP. Forfivo XL™ is indicated for the treatment of Major Depressive Disorder (MDD) and is the only extended-release bupropion HCl product to provide a once-daily, 450mg dose in a single tablet. The active ingredient in Forfivo XL is bupropion, the same active ingredient used in Wellbutrin XL®.

	Sales of the Company’s first commercialized product, a pre-natal multivitamin supplement, marketed in the USA as Gesticare®, were discontinued in the third quarter of 2011. The Company received final royalties from the sale of the product in the fourth quarter of 2011 from Azur Pharma, now part of Jazz Pharmaceuticals plc.

F - 16

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

3.	Adoption of New Accounting Standards

	In May 2011, the FASB issued Update No. 2011-04, “Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs”. The amendments in this Update result in common fair value measurement and disclosure requirements in U.S. GAAP and IFRSs. Consequently, the amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. For many of the requirements, FASB does not intend for the amendments in this Update to result in a change in the application of the requirements in Topic 820. Some of the amendments clarify FASB’s intent about the application of existing fair value measurement requirements. Other amendments change a particular principle or requirement for measuring fair value or for disclosing information about fair value measurements. For public entities, ASU 2011-4 is effective during interim and annual periods beginning after December 15, 2011. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations.

	In June 2011, the FASB issued Update No. 2011-05, “Comprehensive Income (Topic 220): Presentation of Comprehensive Income”. Under the amendments, an entity has the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both choices, an entity is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. This Update eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders’ equity. The amendments in this Update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. ASU 2011-05 should be applied retrospectively. For public entities, the amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. Early adoption is permitted. In December 2011 however, the FASB issued Update No. 2011-12, “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05”. The amendments in this Update supersede changes to those paragraphs in Update 2011-05 that pertain to how, when, and where reclassification adjustments are presented. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations.

F - 17

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

4.	Summary of Significant Accounting Policies

	Revenue Recognition

	The Company recognizes revenue from research and development contracts as the contracted services are performed or when milestones are achieved, in accordance with the terms of the specific agreements and when collection of the payment is reasonably assured. In addition, the performance criteria for the achievement of milestones are met if substantive effort was required to achieve the milestone and the amount of the milestone payment appears reasonably commensurate with the effort expended. Amounts received in advance of the recognition criteria being met, if any, are included in deferred income.

	IntelGenx has license agreements that specify that certain royalties are earned by the Company on sales of licensed products in the licensed territories. Licensees usually report sales and royalty information in the 45 days after the end of the quarter in which the activity takes place and typically do not provide forward estimates or current-quarter information. Because the Company is not able to reasonably estimate the amount of royalties earned during the period in which these licensees actually ship products, royalty revenue is not recognized until the royalties are reported to the Company and the collection of these royalties is reasonably assured.

	In August 2010 the Company entered into a joint development and commercialization agreement with RedHill Biopharma (“RedHill”), an Israeli company, for an anti-migraine product based upon the Company’s VersaFilm™ technology. In accordance with the terms of the agreement, RedHill made up-front and milestone payments in the aggregate amount of $600 thousand, of which $100 thousand was received by the Company in 2012 upon production of pivotal batches. RedHill is required to make additional milestone payments of up to $700,000 as follows:

	$200 thousand upon the filing of an NDA and acceptance of the filing by the U.S. Food and Drug Administration; and

	$500 thousand upon receipt of U.S. Food and Drug Administration marketing approval for the product.

	Product Sales:

	The Company launched Forfivo XL™ in the USA in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP (“Edgemont”). Under the terms of the agreement with Edgemont, the commercial launch of Forfivo XL™ triggered launch-related milestone payments for IntelGenx of up to $4.0 million, of which $1 million was invoiced by the Company to Edgemont and recognized as revenue in the fourth quarter of 2012 and the cash received in February 2013. Additional milestones of up to a further $23.5 million are payable upon achieving certain sales and exclusivity targets and the Company expects to commence receiving royalties from sales of the product in the first quarter of 2013.

	Upon entering into the licensing agreement, Edgemont paid the Company an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over the period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $923 thousand at December 31, 2012 that has not been recognized as revenue.

F - 18

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

4.	Summary of Significant Accounting Policies (cont’d)

	Use of Estimates

	The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management’s judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, the investment tax credits receivable, the determination of the fair value of warrants issued as part of fundraising activities, and the resulting impact on the allocation of the proceeds between the common shares and the warrants.

	Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions.

	Financial Instruments

	The Company estimates the fair value of its financial instruments based on current interest rates, market value and pricing of financial instruments with comparable terms. Unless otherwise indicated, the carrying value of these financial instruments approximates their fair value.

	Cash and Cash Equivalents

	Cash and cash equivalents is comprised of cash on hand and term deposits with original maturity dates of less than three months that are stated at cost, which approximates fair value.

	Accounts Receivable

	The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible. In the first quarter of 2011, the Company wrote-off a receivable in the amount of $53 thousand that was owed to the Company by Circ Pharma Limited, Ireland, which was deemed to be no longer collectible. The Company records recoveries of trade receivables previously written-off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2012 accounts receivable (2011 - $Nil). The accounts receivable balance of $1,282 thousand as at December 31, 2012 includes $1 million from Edgemont that was received by IntelGenx in February 2013.

F - 19

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

4.	Summary of Significant Accounting Policies (Cont’d)

	Investment Tax Credits

	Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed.

	Leasehold Improvements and Equipment

	Leasehold Improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows:

	On the declining balance method -

	Laboratory and office equipment	20%
	Computer equipment	30%

	On the straight-line method -

	Leasehold improvements	over the lease term
	Manufacturing equipment	5 – 10 years

Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred.

Intangible Assets

Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.

Impairment of Long-lived Assets

Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the estimated undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value thereof.

F - 20

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

4.	Summary of Significant Accounting Policies (Cont’d)

	Foreign Currency Translation

	The Company’s reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company’s Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows:

Assets and liabilities - at exchange rates in effect at the balance sheet date;

Revenue and expenses - at average exchange rates prevailing during the year;

Equity - at historical rates.

Gains and losses arising from foreign currency translation are included in other comprehensive income.

Income Taxes

The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Unrecognized Tax Benefits

The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 “Income Taxes”. ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.

Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision.

F - 21

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

4.	Summary of Significant Accounting Policies (Cont’d)

	Share-Based Payments

	The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation—Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company estimates its forfeiture rate in order to determine its compensation expense arising from stock-based awards. The Company uses the Black-Scholes option pricing model to determine the fair value of the options.

	The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year.

	Loss Per Share

	Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share.

F - 22

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

4.	Summary of Significant Accounting Policies (Cont’d)

	Fair Value Measurements

	ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires new disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

	Level 1:	Quoted market prices in active markets for identical assets or liabilities.
	Level 2:	Observable market based inputs or unobservable inputs that are corroborated by market data.
	Level 3:	Unobservable inputs that are not corroborated by market data.

In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. There are no assets or liabilities measured at fair value as at December 31, 2012.

Fair Value of Financial Instruments

The fair value represents management’s best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization.

Recent Accounting Pronouncements

In December 2011, the FASB issued Update No. 2011-11, “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities”. The objective of this Update is to provide enhanced disclosures that will enable users of its financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position. This includes the effect or potential effect of rights of setoff associated with an entity’s recognized assets and recognized liabilities within the scope of this Update. The amendments require enhanced disclosures by requiring improved information about financial instruments and derivative instruments that are either (1) offset in accordance with either Section 210-20-45 or Section 815-10-45 or (2) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either Section 210-20-45 or Section 815-10-45. ASU 2011-11 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. Retrospective disclosure is required for all comparative periods presented. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.

F - 23

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

4.	Summary of Significant Accounting Policies (Cont’d)

	In December 2011, the FASB issued Update No. 2011-12, “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05”. The amendments in this Update supersede changes to those paragraphs in Update 2011-05 that pertain to how, when, and where reclassification adjustments are presented. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations, but will affect the presentation of Other Comprehensive Income in the Company’s financial statements.

5.	Leasehold Improvements and Equipment

						2012		2011
In US$ thousands				Accumulated		Net Carrying		Net Carrying
		Cost		Depreciation		Amount		Amount

Manufacturing equipment	$	225	$	0	$	225	$	0
Laboratory and office equipment		418		265		153		138
Computer equipment		43		34		9		11
Leasehold improvements		63		63		0		0

	$	749	$	362	$	387	$	149

	As of December 31, 2012 no depreciation has been recorded on manufacturing equipment as the equipment is not yet being utilized.

6.	Intangible Assets

	As of December 31, 2012 NDA acquisition costs of $116 thousand (December 31, 2011 - $125 thousand) were recorded as intangible assets on the Company’s balance sheet and represent the net book value of the final progress payment related to the acquisition of 100% ownership of Forfivo XL™. The asset will be amortized over its estimated useful life of 39 months and the Company commenced amortization upon commercial launch of the product in October 2012.

7.	Deferred License Revenue

	Deferred license revenue represents upfront payments received for the granting of licenses to the Company’s patents, intellectual property, and proprietary technology, for commercialization. Deferred license revenue is recognized in income over the period where sales of the licensed products will occur.

	Upon entering into the licensing agreement with Edgemont Pharmaceuticals the Company received an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over a period of 39 months, which is the minimum period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $923 thousand at December 31, 2012 that has not been recognized as revenue.

F - 24

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

8.	Commitments

	The Company currently operates out of a 3,500 square feet leasehold facility consisting of laboratories and office space at 6425 Abrams, Saint-Laurent, Quebec. The original lease agreement expired in August 2009, since when it has been extended for varying periods whilst the Company sought alternative premises. The most recent extension is defined as the day immediately preceding the fulfillment of certain conditions relating to the occupation of new leased premises at 6410-6420 Abrams. In the first half of 2013, the Company plans to enter into an addendum to its existing lease to include the relocation of the Company’s operations to larger premises consisting of approximately 28,600 of rentable square feet. The term of the amended lease is 10 years following relocation, which is expected to commence in the autumn of 2013 upon completion of certain leasehold improvements.

	As of December 31, 2012 future minimum payments under operating leases for facilities were as follows (in thousands):

2013		15
2014		0
Total	$	15

On October 1, 2009, the Company signed new agreements with each of Little Gem Life Science Partners and SectorSpeak Inc. for investor relation services in the USA and in Canada, respectively. Under the terms of these agreements, the Company was required to pay $4.5 thousand a month to Little Gem Life Science Partners and CDN$5.0 thousand (US$5.0 thousand) monthly to Sector Speak Inc. The Company renegotiated these agreements in May 2012 and reduced payments to $2.5 thousand and CDN$2.5 thousand (US$2.5 thousand) respectively. The agreements automatically renew unless specifically terminated.

On May 7, 2010, the Company executed a Project Transfer Agreement with one of its former development partners whereby the Company acquired full rights to, and ownership of, Forfivo XL™, a novel, high strength formulation of Bupropion hydrochloride, the active ingredient in Wellbutrin XL®. In accordance with the Project Transfer Agreement, and following commercial launch of Forfivo XL™ in October 2012, the Company is required to pay to its former development partner 10% of net sales royalties received under the commercialization agreement that was executed with Edgemont Pharmaceuticals in February 2012.

F - 25

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

9.	Capital Stock

		2012		2011
Authorized -
100,000,000 common shares of $0.00001 par value
20,000,000 preferred shares of $0.00001 par value
Issued -
49,890,421 (December 31, 2011 - 48,895,028) common shares	$	499	$	489

On June 21, 2011, as part of two concurrent private placement offerings, the Company issued approximately 4.8 million shares of common stock, and three-year warrants to purchase up to approximately 2.4 million shares of common stock, for aggregate gross proceeds of approximately US$3.2 million. Each warrant entitles the holder to purchase one half of one common share at an exercise price of $0.74 per common share and expires 36 months after the date of issuance. Proceeds were allocated between the common shares and the warrants based on their relative fair value. The common shares were recorded at a value of $2,024 thousand. (See note 10 for the portion allocated to the warrants).

The private placements consisted of a definitive securities purchase agreement with certain accredited and institutional investors for the issuance and sale in a private placement transaction (the "US Private Offering") of 2,582,536 shares and warrants to purchase up to 1,291,268 shares of common stock, for aggregate gross proceeds of approximately $1.7 million, and a definitive subscription agreement solely with Canadian investors for the issuance and sale in a concurrent non-brokered private placement transaction (the "Canadian Private Offering") of 2,238,806 shares and warrants to purchase up to 1,119,403 shares of common stock, for aggregate gross proceeds of approximately $1.5 million.

The Company paid an agent cash commissions in the amount of approximately $121 thousand, representing 7% of the aggregate gross proceeds received by the Company in the US Private Offering, plus expenses in the amount of approximately $28 thousand, and issued warrants to the agent to purchase 180,778 shares of common stock, representing 7% of the amount of shares sold in the US Private Offering. The Company also paid cash finder’s fees in the amount of approximately $105 thousand, representing 7% of the aggregate gross proceeds received by the Company in the Canadian Private Offering; and issued warrants to purchase 156,716 shares of common stock, representing 7% of the amount of shares sold in the Canadian Private Offering. Each warrant entitles the holder to purchase one half of one common share at an exercise price of $0.74 per common share and expires 36 months after the date of issuance.

In addition, the Company paid approximately $114 thousand in cash consideration for other transaction costs, which have been reflected as a reduction of the common shares and the warrants based on their relative fair values. All of the above transaction costs have been reflected as a reduction to the common shares and the warrants based on their relative fair values.

F - 26

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

9.	Capital Stock (Cont’d)

	In the year ended December 31, 2012 a total of 50,000 (2011 – 775,000) stock options were exercised for 50,000 (2011 – 775,000) common shares having a par value of $0 thousand (2011 - $Nil) in aggregate, for cash consideration of $28 thousand ($318 thousand), resulting in an increase in additional paid-in capital of $28 thousand (2011 – $318 thousand).

	During the year ended December 31, 2012 a total of 219,313 (2011 - 299,406) agents’ warrants were exercised for 219,313 (2011 - 299,406) common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $104 thousand (2011 - $142 thousand), resulting in an increase in additional paid- in capital of approximately $104 thousand (2011 - $142 thousand).

	Also in the year ended December 31, 2012 a total of 1,205,668 warrants were exercised, of which 491,382 warrants were exercised for 491,382 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $233 thousand, resulting in an increase in additional paid-in capital of approximately $233 thousand, and a total of 714,286 warrants were exercised for 234,698 common shares in cashless exercises, resulting in an increase in additional paid-in capital of $Nil.

	In the year ended December 31, 2011 a total of 4,366,904 warrants were exercised, of which 2,902,618 warrants were exercised for 2,902,618 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $1,458 thousand, resulting in an increase in additional paid-in capital of approximately $1,458 thousand, and a total of 1,464,286 warrants were exercised for 515,391 common shares in cashless exercises, resulting in an increase in additional paid-in capital of $Nil.

10.	Additional Paid-In Capital

	Stock Options

	In November 2006, the Company adopted the 2006 Stock Incentive Plan ("Plan") for the purpose of issuing both Incentive Options and Nonqualified Options to officers, employees, directors and eligible consultants of the Company. A total of 1,600,749 shares of common stock were reserved for issuance under this plan. Options may be granted under the Plan on terms and at prices as determined by the Board of Directors except that the options cannot be granted at less than 100%, of the fair market value of the common stock on the date of the grant. Each option will be exercisable after the period or periods specified in the option agreement, but no option may be exercised after the expiration of 10 years from the date of grant. All options granted to individuals other than non- employee directors will have a total vesting period of 24 months from the date of grant, with one quarter of the total options granted vesting and becoming exercisable every six months. Options granted to non-employees may vest and become 100% fully exercisable immediately upon grant.

	At the Annual General Meeting on September 8, 2008 the shareholders of the Company approved to amend the 2006 Stock Option Plan to increase the number of shares available for issuance under the Plan from 1,600,749 to 2,074,000, or 10% of the Company’s issued and outstanding common shares as of July 28, 2008.

F - 27

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

10.	Additional Paid-In Capital (Cont’d)

	A modification was made to the 2006 Stock Option Plan. The life of the options was reduced from 10 years to 5 years to comply with the regulations of the Toronto Stock Exchange. Accordingly, because the grant-date fair value of the modified options was less than the fair value of the original options measured immediately before the modification, no incremental share-based compensation expense resulted from the modification.

	At the Annual General Meeting on June 3, 2010, the Shareholders of the Company approved an amendment to the 2006 Stock Option Plan to increase the number of shares available for issuance under the Plan from 2,074,000 to 3,308,127, or 10% of the Company’s issued and outstanding shares as of April 5, 2010.

	On May 12, 2011 the Company granted 50,000 stock options to an employee to purchase common shares. The stock options are exercisable at $0.52 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $16 thousand, using the following assumptions:

	Expected volatility	115%
	Expected life	3.1 years
	Risk-free interest rate	0.96%
	Dividend yield	Nil

On November 29, 2011 the Company granted 115,000 stock options to two non-employee directors, 40,000 stock options to a director, 50,000 stock options to two officers, and 35,000 stock options to two employees, to purchase common shares. The stock options are exercisable at $0.54 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $74 thousand, using the following assumptions:

	Expected volatility	101%
	Expected life	3.1 years
	Risk-free interest rate	0.40%
	Dividend yield	Nil

On June 13, 2012 the Company granted 40,000 stock options to two employees to purchase common shares. The stock options are exercisable at $0.51 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $10 thousand, using the following assumptions:

	Expected volatility	83%
	Expected life	3.1 years
	Risk-free interest rate	0.40%
	Dividend yield	Nil

F - 28

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

10.	Additional Paid-In Capital (Cont’d)

	On August 8, 2012 the Company granted 50,000 stock options to a consultant to purchase common shares. The stock options are exercisable at $0.55 per share and vest over 1 year at 25% every three months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $12 thousand, using the following assumptions:

	Expected volatility	81%
	Expected life	1.8 years
	Risk-free interest rate	0.38%
	Dividend yield	Nil

On December 4, 2012 the Company granted 30,000 stock options to an employee who is also a director and 25,000 stock options to an officer to purchase common shares. The stock options are exercisable at $0.60 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $15 thousand, using the following assumptions:

	Expected volatility	78%
	Expected life	3.1 years
	Risk-free interest rate	0.34%
	Dividend yield	Nil

On December 12, 2012 the Company granted 50,000 stock options to a consultant to purchase common shares. The stock options are exercisable at $0.62 per share and vest over 1 year at 25% every three months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $10 thousand, using the following assumptions:

	Expected volatility	70%
	Expected life	1.8 years
	Risk-free interest rate	0.25%
	Dividend yield	Nil

During the year ended December 31, 2012 a total of 50,000 (2011 – 775,000) stock options were exercised for 50,000 (2011 – 775,000) common shares having a par value of $0 thousand (2011 - $Nil) in aggregate, for cash consideration of $28 thousand ($318 thousand), resulting in an increase in additional paid-in capital of $28 thousand (2011 – $318 thousand). The intrinsic value of the stock options exercised, as at the date of exercise, totaled $4 thousand.

F - 29

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

10.	Additional Paid-In Capital (Cont’d)

	Information with respect to stock option activity for 2011 and 2012 is as follows:

			Weighted average
	Number of options		exercise price
			$

Outstanding – January 1, 2011	1,698,088		0.53

Granted	290,000		0.54
Forfeited	(150,000	)	(0.76	)
Expired	(65,000	)	(0.59	)
Exercised	(775,000	)	(0.41	)

Outstanding – December 31, 2011	998,088		0.59

Granted	195,000		0.57
Forfeited	(45,000	)	(0.49	)
Expired	(32,500	)	(1.15	)
Exercised	(50,000	)	(0.55	)

Outstanding – December 31, 2012	1,065,588		0.58

F - 30

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

10.	Additional Paid-In Capital (Cont’d)

	Details of stock options outstanding as at December 31, 2012 are as follows:

	Outstanding options				Exercisable options

			Weighted			Weighted
		Weighted average	average	Aggregate		average	Aggregate
Exercise	Number of	remaining	exercise	intrinsic	Number of	exercise	intrinsic
prices	options	contractual life	price	value	options	price	value
$		(years)	$	$		$	$

0.31	25,000	1.25	0.31		25,000	0.31
0.37	75,000	2.67	0.37		75,000	0.37
0.45-0.47	175,000	1.42	0.46		175,000	0.46
0.51	40,000	4.50	0.51		0	0.00
0.52-0.54	270,000	3.89	0.54		147,500	0.54
0.55	50,000	2.67	0.55		12,500	0.55
0.60	55,000	5.00	0.60		0	0.00
0.61	125,000	1.51	0.61		125,000	0.61
0.62	50,000	3.00	0.62		0	0.00
0.85	200,588	0.63	0.85		200,588	0.85
	1,065,588	2.60	0.58	114,050	760,588	0.59	86,725

Stock-based compensation expense recognized in 2012 in regards to the stock options was $59 thousand (2011 - $51 thousand). As of December 31, 2012, total unrecognized compensation expense related to unvested stock options was $72 thousand (2011 - $92 thousand), of which $17 thousand (2011 $Nil) relates to options granted to consultants. The amount of $72 thousand will be recognized as an expense over a period of two years. A change in control of the Company due to acquisition would cause the vesting of the stock options granted to employees and directors to accelerate and would result in $55 thousand being charged to stock based compensation expense.

Warrants

On June 21, 2011 the Company issued approximately 4.8 million stock purchase warrants exercisable into approximately 2.4 million common shares at $0.74 per share which expire on June 21, 2014. The stock purchase warrants were issued in connection with the June 21, 2011 private placements described in note 9. The stock purchase warrants were valued at $817 thousand based on their relative fair value, as determined by the Black-Scholes valuation model using the assumptions below:

	Expected volatility	117%
	Expected life	3 years
	Risk-free interest rate	0.69%
	Dividend yield	Nil

F - 31

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

10.	Additional Paid-In Capital (Cont’d)

	On June 21, 2011 the Company issued approximately 0.3 million agents’ stock purchase warrants exercisable into approximately 0.3 million common shares at $0.74 per share which expire on June 21, 2014. The stock purchase warrants were issued in connection with the June 21, 2011 private placements described in note 9. The stock purchase warrants were valued at $153 thousand based on their relative fair value, as determined by the Black-Scholes valuation model using the assumptions below:

	Expected volatility	117%
	Expected life	3 years
	Risk-free interest rate	0.69%
	Dividend yield	Nil

During the year ended December 31, 2012 a total of 219,313 (2011 - 299,406) agents’ warrants were exercised for 219,313 (2011 - 299,406) common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $104 thousand (2011 - $142 thousand), resulting in an increase in additional paid-in capital of approximately $104 thousand (2011 - $142 thousand).

Also in the year ended December 31, 2012 a total of 1,205,668 warrants were exercised, of which 491,382 warrants were exercised for 491,382 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $233 thousand, resulting in an increase in additional paid-in capital of approximately $233 thousand, and a total of 714,286 warrants were exercised for 234,698 common shares in cashless exercises, resulting in an increase in additional paid-in capital of $Nil.

In the year ended December 31, 2011 a total of 4,366,904 warrants were exercised, of which 2,902,618 warrants were exercised for 2,902,618 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $1,458 thousand, resulting in an increase in additional paid-in capital of approximately $1,458 thousand, and a total of 1,464,286 warrants were exercised for 515,391 common shares in cashless exercises, resulting in an increase in additional paid-in capital of $Nil.

F - 32

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

10.	Additional Paid-In Capital (Cont’d)

	Information with respect to warrant activity for 2011 and 2012 is as follows:

	Number of		Weighted average
	warrants		exercise price
	(All Exercisable)		$

Outstanding – January 1, 2011	21,291,223		0.66

Attached to private placements	2,748,165		0.74
Agents’ warrants exercised	(299,406	)	(0.47	)
Exercised	(4,366,904	)	(0.51	)

Outstanding - December 31, 2011	19,373,078		0.71

Agents’ warrants exercised	(219,313	)	(0.47	)
Exercised	(1,205,668	)	(0.48	)
Expired	(11,843,932	)	(0.80	)

Outstanding - December 31, 2012	6,104,165		0.59

F - 33

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

11.	Income Taxes

	Income taxes reported differ from the amount computed by applying the statutory rates to losses. The reasons are as follows:

		2012			2011
Statutory income taxes	$	(605	)	$	(694	)
Net operating losses for which no tax benefits have been recorded		368			514
Excess of depreciation over capital cost allowance		3			(2	)
Non-deductible expenses		18			4
Undeducted research and development expenses		273			231
Tax deductible portion of transaction costs		-			-
Investment tax credit		(57	)		(53	)
Modification of warrants terms		-			-


	$	-		$	-

The major components of the deferred tax assets classified by the source of temporary differences are as follows:

		2012			2011

Leasehold Improvements and equipment	$	13		$	14
Net operating losses carryforward		2,278			2,140
Undeducted research and development expenses		1,301			1,141
Non-refundable tax credits carryforward		914			807


		4,506			4,102

Valuation allowance		(4,506	)		(4,102	)

	$	-		$	-

The valuation allowance at December 31, 2011 was $4,102 thousand. The net change in the valuation allowance during the period ended December 31, 2012, was an increase of $404 thousand. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of December 31, 2012.

F - 34

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

11.	Income Taxes (Cont’d)

	There were Canadian and provincial net operating losses of approximately $8,390 thousand (2011 - $7,608 thousand) and $8,566 thousand (2011 - $7,437 thousand) respectively, that may be applied against earnings of future years. Utilization of the net operating losses is subject to significant limitations imposed by the change in control provisions. Canadian and provincial losses will be expiring between 2027 and 2032. A portion of the net operating losses may expire before they can be utilized.

	As at December 31, 2012, the Company had non-refundable tax credits of $914 thousand (2011 - $803 thousand) of which $24 thousand is expiring in 2017, $213 thousand is expiring in 2018, $193 thousand is expiring in 2019, $186 thousand is expiring in 2020, $187 thousand is expiring in 2021 and $111 thousand is expiring in 2022 and undeducted research and development expenses of $4,464 thousand (2011 - $3,656 thousand) with no expiration date.

	The deferred tax benefit of these items was not recognized in the accounts as it has been fully provided for.

	Unrecognized Tax Benefits

	The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months.

	Tax Years and Examination

	The Company files tax returns in each jurisdiction in which it is registered to do business. For each jurisdiction a statute of limitations period exists. After a statute of limitations period expires, the respective tax authorities may no longer assess additional income tax for the expired period. Similarly, the Company is no longer eligible to file claims for refund for any tax that it may have overpaid. The following table summarizes the Company’s major tax jurisdictions and the tax years that remain subject to examination by these jurisdictions as of December 31, 2012:

Tax Jurisdictions		Tax Years
Federal - Canada		2010 and onward
Provincial - Quebec		2010 and onward

F - 35

IntelGenx Technologies Corp.

Notes to Consolidated Financial Statements
December 31, 2012 and 2011
(Expressed in U.S. Funds)

12.

Statement of Cash Flows Information

In US$ thousands		2012		2011

Additional Cash Flow Information:

Interest paid	$	3	$	3

13.	Related Party Transactions

	Included in management salaries are $6 thousand (2011 - $4 thousand) for options granted to the Chief Financial Officer and $6 thousand (2011 - $4 thousand) for options granted to the Chief Executive Officer under the 2006 Stock Option Plan and $23 thousand (2011 - $10 thousand) for options granted to non-employee directors.

	Included in general and administrative expenses are director fees of $114 thousand (2011 - $87 thousand) for attendance at board meetings and audit committee meetings.

	A short term loan of $85 thousand bearing interest at 1% per annum was provided to an employee, who is also an officer of the Company, on November 9, 2011. The loan amount, together with interest accrued, was repaid to the Company on February 28, 2012.

	In the year ended December 31, 2012 the amount included in accounts payable and accrued liabilities payable to shareholders, who are also officers of the Company, is $Nil (2011 - $1 thousand).

	The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed upon by the related parties.

14.	Basic and Diluted Loss Per Common Share

	Basic and diluted loss per common share is calculated based on the weighted average number of shares outstanding during the period. The warrants and stock options have been excluded from the calculation of diluted loss per share since they are anti-dilutive.

15.	Subsequent Events

	Subsequent top the year ended December 31, 2012, 362,500 warrants were exercised for 362,500 common shares having a par value of $0 thousand for cash consideration of approximately $172 thousand, resulting in an increase in additional paid-in capital of approximately $172 thousand.

F - 36

PART II
INFORMATION NOT REQUIRED IN PROSPECTUS

Item 13. Other Expenses of Issuance and Distribution

The following table sets forth the costs and expenses payable by us in connection with the distribution of the securities being registered. All of the amounts shown are estimates, except the SEC registration fee. We have agreed to bear all expenses (other than underwriting discounts and selling commissions) in connection with the registration and sale of the securities offered by the selling security holders.

SEC registration fee	$
FINRA filing fee	$
Legal fees and expenses	$
Accountants’ fees and expenses	$
Printing expenses	$
Blue sky fees and expenses	$
Miscellaneous expenses	$
Total:	$

All amounts except the SEC registration fee and the FINRA fee are estimated. All of the expenses set forth above are being paid by us.

Item 14. Indemnification of Directors and Officers

Section 145 of the Delaware General Corporation Law (the “DGCL”), provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. Section 145 further provides that a corporation similarly may indemnify any such person serving in any such capacity who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor, against expenses (including attorneys’ fees) actually and reasonably incurred in connection with the defense or settlement of such action or suit if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Delaware Court of Chancery or such other court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

We have agreed to indemnify our officers and directors to the fullest extent permitted by law. Such indemnification is intended to supplement our officers’ and directors’ liability insurance.

Our certificate of incorporation provides that no director shall be personally liable to the corporation or its stockholders for monetary damages for any breach of fiduciary duty by such director as a director. A director shall be liable to the extent provided by applicable law, however, (a) for breach of the director’s duty of loyalty to the corporation or its stockholders, (b) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (c) pursuant to Section 174 of the DGCL, or (d) for any transaction from which the director derived an improper personal benefit.

To the extent permitted by applicable law, we are also authorized to provide indemnification of (and advancement of expenses to) such agents (and any other persons to which Delaware law permits us to provide indemnification) through provisions in our bylaws, agreements with such agents or other persons, voting of security holders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section 145 of the DGCL, subject only to limits created by applicable Delaware law (statutory or non-statutory), with respect to actions for breach of duty to us, our security holders and others.

Any repeal or modification of any of the foregoing provisions of the indemnification provisions in our certificate of incorporation or bylaws shall be prospective and shall not adversely affect any right or protection of a director, officer, agent, or other person existing at the time of, or increase the liability of any director of our company with respect to any acts or omissions of such director occurring prior to, such repeal or modification.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or controlling persons of our company, pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of our company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereunder, we will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

Recent Sales of Unregistered Securities

The following is a list of securities we have sold or issued during the past three years. There were no underwriting discounts or commissions paid in connection with the sale of these securities, except as otherwise noted.

On August 27, 2010, we completed an offering of 6,500,000 units at CAD$0.40 per unit for gross proceeds of CAD$2.6 million pursuant to the terms of subscription agreements with our investors. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder thereof to purchase one common share at an exercise price of CAD$0.50 expiring on August 27, 2013. The exercise price of the warrants is subject to adjustment for certain events, including without limitation, dividends, distributions or split of our common stock, subsequent rights offerings by us, or in the event of our consolidation, merger or reorganization. The proceeds of the private placement will be used to support our strategic development projects and for working capital purposes.

Pursuant to an agency agreement entered into on August 27, 2010, we engaged Bolder Investment Partners, Ltd. (the “Agent”) to act as placement agent for the offering on a commercially reasonable best efforts basis. We paid the Agent (a) cash compensation equal to 8% of the gross proceeds of the offering, (b) a corporate finance fee of CAD$20,000, and (c) issued 520,000 compensation options (“Placement Agent Warrants”) which was equal to 8% of the number of units sold in the offering. Each Placement Agent Warrant entitles the Agent to purchase one common share at an exercise price of CAD$0.50 expiring on August 27, 2012. The exercise price of the Placement Agent Warrants is subject to adjustment for certain events, including without limitation, dividends, distributions or split of our common stock, subsequent rights offerings by us, or in the event of our consolidation, merger or reorganization.

On June 3, 2011, we entered into a definitive securities purchase agreement with certain accredited and institutional investors for the issuance and sale in a private placement transaction of 2,582,536 shares of our common stock at a per share purchase price of $0.67, and three-year warrants to purchase up to 1,291,268 shares of common stock at an exercise price of $0.74 per share, for aggregate gross proceeds of approximately $1.7 million. The number of shares of common stock to be received upon the exercise of the warrants and the exercise price of the warrants are subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the common stock that occur after the closing date.

In connection with the U.S. private placement, on June 3, 2011, we and the investors entered into a registration rights agreement under which we are obligated to file a registration statement with the SEC registering the shares and the shares of common stock issuable upon exercise of the warrants for resale by the investors on or prior to 20 days after the closing date. In addition, we agreed to use our best efforts to cause the SEC to declare the registration statement effective by no later than 110 days following the closing date. We shall also register the shares and warrants issued pursuant to the Canadian private placement (as described below) for resale by the Canadian investors on the registration statement.

The U.S. private placement was consummated on June 21, 2011 pursuant to which we received aggregate gross proceeds of approximately $1.7 million, before deducting offering expenses. We intend to use the net proceeds from the sale of the shares and warrants pursuant to the U.S. private placement to support our strategic development projects and for working capital.

Rodman & Renshaw, LLC acted as the exclusive placement agent for the U.S. private placement. On the closing date, we paid/issued to Rodman & Renshaw, LLC or its designees: (i) cash commissions in the amount of $121,120.85, representing 7% of the aggregate gross proceeds received by us in the U.S. private placement, plus expenses in the amount of $24,982.38; and (ii) placement agent warrants to purchase 180,778 shares of common stock, representing 7% of the amount of shares sold in the U.S. private placement.

Our issuance of the shares, warrants and placement agent warrants in the U.S. private placement was made in reliance upon the exemption from registration for non-public offerings under §4(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder.

On June 21, 2011, we entered into definitive subscription agreements solely with Canadian investors for the issuance and sale in a concurrent non-brokered private placement of 2,238,806 shares and warrants to purchase up to 1,119,403 shares of common stock under the same terms and conditions as the U.S. private placement for aggregate gross proceeds of approximately $1.5 million.

The Canadian private placement was consummated on June 21, 2011 pursuant to which we received aggregate gross proceeds of approximately $1.5 million, before deducting offering expenses. We intend to use the net proceeds from the sale of the shares and warrants pursuant to the Canadian private placement to support our strategic development projects and for working capital.

On the closing date, we paid/issued to each of Haywood Securities Inc. and Raymond James Ltd. in connection with the Canadian private placement: (i) cash finder’s fee in the amount of $90,930 and $14,070 respectively, representing 7% of the aggregate gross proceeds received by us in the Canadian private placement; and (ii) warrants to purchase 135,716 and 21,000 shares of common stock respectively, representing 7% of the amount of shares sold in the Canadian private placement.

The issuances under the Canadian private placement were exempt from registration under Section 4(a)(2) of the Securities Act and/or Regulation S, promulgated pursuant to the Securities Act. None of the purchasers under the Canadian private placement are U.S. persons, no sales efforts were conducted in the U.S., and the shares, the warrants, the warrant shares, the finders warrants, and the finders warrant shares issued in connection with the Canadian private placement contain a legend restricting the sale of such securities in accordance with the Securities Act.

Except as otherwise set forth above, we believe that all of the U.S. offerings and sales were deemed to be exempt under Section 4(a)(2) of the Securities Act of 1933, as amended. No advertising or general solicitation was employed in offering the securities. The offerings and sales were made to a limited number of persons, all of whom were accredited investors, business associates of our company or executive officers of our company, and transfer was restricted by us in accordance with the requirements of the Securities Act of 1933. In addition to representations by the above-referenced persons, we have made independent determinations that all of the above-referenced persons were accredited or sophisticated investors, and that they were capable of analyzing the merits and risks of their investment, and that they understood the speculative nature of their investment. Furthermore, all of the above-referenced persons were provided with access to our Securities and Exchange Commission filings.

Except as otherwise set forth above, we believe that all of the Canadian offerings and sales were deemed to be exempt under Section 4(a)(2) of the Securities Act and/or Regulation S, promulgated pursuant to the Securities Act. None of the purchasers under the Canadian offerings are U.S. persons, no sales efforts were conducted in the U.S., and the securities issued in connection with the Canadian offerings contain a legend restricting the sale of such securities in accordance with the Securities Act.

Item 16. Exhibits and Financial Statement Schedules

The following exhibits are filed as part of this registration statement.

EXHIBIT INDEX

Exhibit	Description
No.
1.1**	Form of Placement Agent Agreement
2.1	Share exchange agreement dated April 10, 2006 (incorporated by reference to the Form 8-K/A filed on May 5, 2006)
3.1	Certificate of Incorporation (incorporated by reference to the Form SB-2 (File No. 333-90149) filed on November 16, 1999)
3.2	Amendment to the Certificate of Incorporation (incorporated by reference to amendment No. 2 to Form SB-2 (File No. 333-135591) filed on August 28, 2006)

3.3	Amendment to the Certificate of Incorporation (incorporated by reference to the Form DEF 14C filed on April 20, 2007)
3.4	By-Laws (incorporated by reference to the Form SB-2 (File No. 333-91049) filed on November 16, 1999
3.5	Amended and Restated By-Laws (incorporated by reference to the Form 8-K filed on March 31, 2011)
3.6	Amended and Restated By-Laws (incorporated by reference to the Form 8-K filed on March 21, 2012)
5.1**	Opinion of legal counsel
9.1	Voting Trust agreement (incorporated by reference to the Form 8-K/A filed on May 5, 2006)
10.1 +	Horst Zerbe employment agreement (incorporated by reference to the Form SB-2 (File No. 333-135591) filed on July 3, 2006)
10.2 +	Ingrid Zerbe employment agreement (incorporated by reference to the Form SB-2 (File No. 333-135591) filed on July 3, 2006)
10.3	Registration rights agreement (incorporated by reference to the Form SB-2 (File No. 333-135591) filed on July 3, 2006)
10.4	Principal’s registration rights agreement (incorporated by reference to the Form SB-2 (File No. 333-135591) filed on July 3, 2006)
10.5 +	2006 Stock Option Plan (incorporated by reference to the Form S-8 filed on November 21, 2006)
10.6 +	Employment Contract Paul A. Simmons (incorporated by reference to the Form 8-K filed on September 5, 2008)
10.7 +	Amended and Restated 2006 Stock Option Plan, May 29, 2008 (incorporated by reference to the Form 10-K filed on March 25, 2009)
10.8	Co-Development and Commercialization Agreement with RedHill Biopharma Ltd. (incorporated by reference to the Form 10-Q filed on November 9, 2010)
10.9 +	Amended and Restated 2006 Stock Option Plan (incorporated by reference to the Form S-8 filed on November 15, 2010)
10.10	Agency Agreement, dated as of August 27, 2010, between the Company and Bolder Investment Partners, Ltd. (incorporated by reference to the Form 8-K filed on August 30, 2010)
10.11	Registration Rights Agreement, dated as of August 27, 2010, by and among the Company and the purchasers pursuant to the offering (incorporated by reference to the Form 8-K filed on August 30, 2010)
10.12	Form of Subscription Agreement (incorporated by reference to the Form 8-K filed on August 30, 2010)
10.13	Form of Warrant (incorporated by reference to the Form 8-K filed on August 30, 2010)
10.14	Form of Compensation Option (incorporated by reference to the Form 8-K filed on August 30, 2010)
10.15	Project Transfer Agreement (incorporated by reference to the Form 10-Q filed on May 14, 2010)
10.16	Co-development and Licensing Agreement (incorporated by reference to the Form 10-Q filed on May 14, 2010)
10.17	License and Asset Transfer Agreement with Edgemont Pharmaceuticals (incorporated by reference to the Form 10Q filed on May 15, 2012)
10.18	Securities Purchase Agreement (incorporated by reference to the Form 8-K filed on June 3, 2011)
10.19	Registration Rights Agreement (incorporated by reference to the Form 8-K filed on June 3, 2011)
10.20	Form of Warrant (incorporated by reference to the Form 8-K filed on June 3, 2011)
10.21 +	Amended and Restated 2006 Stock Option Plan (incorporated by reference to the Form 8-K filed on May 9, 2013)
10.22 +	Employment Agreement Rajiv Khosla (incorporated by reference to the Form 10-Q filed on May 14, 2013)
10.23**	Form of Securities Purchase Agreement
10.24**	Form of Warrant
14.1	Code of Ethics (incorporated by reference to the Form S-1 filed on March 24, 2009)
21.1	Subsidiaries of the small business issuer (incorporated by reference to the Form SB-2 (File No. 333-135591) filed on July 3, 2006)
23.1*	Consents of Richter LLP
23.2**	Consent of legal counsel (contained in Exhibit 5.1)

+ Indicates management contract or employee compensation plan
* Filed herewith.
** To be filed by amendment

Item 17. Undertakings

The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(a) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(b) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

(c) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

(a) If the Company is relying on Rule 430B:

(i) Each prospectus filed by the Company pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

(ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or

(b) If the Company is subject to Rule 430C: Each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

(5) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

(6) For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

(7) Insofar as Indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provision, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Ville St-Laurent, Province of Quebec, on July 22, 2013.

INTELGENX TECHNOLOGIES CORP.

By:	/s/ Horst G. Zerbe
	Horst G. Zerbe
	Chief Executive Officer and President
	(Principal Executive Officer)

By:	/s/ Paul A. Simmons
	Paul A. Simmons
	Chief Financial Officer (Principal Financial and
	Accounting Officer)

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints Horst Zerbe his or her true and lawful attorney in fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any or all amendments (including post effective amendments) to the Registration Statement, and to sign any registration statement for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and all post effective amendments thereto, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, each acting alone, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

SIGNATURE	TITLE	DATE

/s/ Horst G. Zerbe	Chief Executive Officer, President and Director	July 22, 2013
Horst G. Zerbe

/s/ Paul A. Simmons	Chief Financial Officer	July 22, 2013
Paul A. Simmons

/s/ J. Bernard Boudreau	Director	July 22, 2013
J. Bernard Boudreau

/s/ Ian Troup	Director	July 22, 2013
Ian Troup

/s/ Bernd J. Melchers	Director	July22, 2013
Bernd J. Melchers

/s/ John Marinucci	Director	July 22, 2013
John Marinucci

EX-23.1 2 exhibit23-1.htm EXHIBIT 23.1 IntelGenx Technologies Corp.: Exhibit 23.1 - Filed by newsfilecorp.com

Consent of Independent Registered Public Accounting Firm

We consent to the use in this Registration Statement to Form S-1 of IntelGenx Technologies Corp. of our report dated March 15, 2013 relating to our audits of the consolidated financial statements of IntelGenx Technologies Corp. as of and for the years ended December 31, 2012 and 2011 appearing in this Registration Statement.

We also consent to the reference to our firm under the caption “Experts” in this Registration Statement.

Yours very truly,

Richter LLP (Signed) ¹

Montréal, Québec
July 22, 2013

¹CPA auditor, CA, public accountancy permit No. A110982

T. 514.934.3400
mtlinfo@richter.ca

Richter S.E.N.C.R.L./LLP
1981 McGill College
Mtl (QC) H3A 0G6
www.richter.ca

Montréal, Toronto

EX-101.INS 3 igxt-20130331.xml XBRL INSTANCE FILE --12-31 igxt IntelGenx Technologies Corp. 2013-03-31 0001098880 No Smaller Reporting Company No S-1 false Yes 2013 FY 0001098880 2012-01-01 2013-03-31 0001098880 2013-03-31 0001098880 2012-12-31 0001098880 us-gaap:CommonStockMember 2012-12-31 0001098880 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0001098880 us-gaap:RetainedEarningsMember 2012-12-31 0001098880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-12-31 0001098880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-01-01 2013-03-31 0001098880 2013-01-01 2013-03-31 0001098880 us-gaap:CommonStockMember 2013-01-01 2013-03-31 0001098880 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-03-31 0001098880 us-gaap:RetainedEarningsMember 2013-01-01 2013-03-31 0001098880 us-gaap:CommonStockMember 2013-03-31 0001098880 us-gaap:AdditionalPaidInCapitalMember 2013-03-31 0001098880 us-gaap:RetainedEarningsMember 2013-03-31 0001098880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2013-03-31 0001098880 2012-01-01 2012-03-31 0001098880 2011-12-31 0001098880 2012-03-31 0001098880 2013-01-31 2013-03-31 0001098880 us-gaap:CommonStockMember 2010-12-31 0001098880 us-gaap:AdditionalPaidInCapitalMember 2010-12-31 0001098880 us-gaap:RetainedEarningsMember 2010-12-31 0001098880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2010-12-31 0001098880 2010-12-31 0001098880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-01-01 2011-12-31 0001098880 2011-01-01 2011-12-31 0001098880 us-gaap:CommonStockMember 2011-01-01 2011-12-31 0001098880 us-gaap:AdditionalPaidInCapitalMember 2011-01-01 2011-12-31 0001098880 us-gaap:RetainedEarningsMember 2011-01-01 2011-12-31 0001098880 us-gaap:CommonStockMember 2011-12-31 0001098880 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0001098880 us-gaap:RetainedEarningsMember 2011-12-31 0001098880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-12-31 0001098880 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-01-01 2012-12-31 0001098880 2012-01-01 2012-12-31 0001098880 us-gaap:CommonStockMember 2012-01-01 2012-12-31 0001098880 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0001098880 us-gaap:RetainedEarningsMember 2012-01-01 2012-12-31 shares iso4217:USD iso4217:USD shares pure utr:M iso4217:CAD utr:Y utr:D

2168000

2059000

170000

1282000

89000

102000

243000

213000

2670000

3656000

438000

387000

106000

116000

3214000

4159000

498000

1058000

308000

806000

1366000

539000

615000

1345000

1981000

1000

16554000

16342000

-14949000

-14463000

263000

299000

1869000

2178000

3214000

4159000

49890421

16342000

-14463000

299000

-36000

362500 1000 171000 172000 50000 23000 23000

18000

-486000

50302921

1000

16554000

-14949000

263000

80000

77000

100000

157000

100000

167000

239000

456000

439000

10000

8000

10000

643000

686000

-486000

-586000

4000

-582000

91000

-522000

-491000

50236255

49324531

-0.01

20000

8000

18000

15000

-448000 -559000

-1112000

-18000

-13000

15000

30000

-249000

-560000

-270000

-77000

1000000

-458000

-982000

10000

423000

195000

233000

195000

233000

69000

189000

-69000

-189000

136000

467000

-27000

88000

3505000

4059000

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td align="left"> 1. </td> <td align="left" width="95%"> Basis of Presentation </td> </tr> <tr> <td> </td> <td align="left" width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal and recurring nature. </td> </tr> <tr> <td> </td> <td align="left" width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> These financial statements should be read in conjunction with the audited consolidated financial statements at December 31, 2012. Operating results for the three months ended March 31, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. </td> </tr> <tr> <td> </td> <td align="left" width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> The consolidated financial statements include the accounts of the Company and its subsidiary companies. On consolidation, all inter-entity transactions and balances have been eliminated. </td> </tr> <tr> <td> </td> <td align="left" width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> The financial statements are expressed in U.S. funds. </td> </tr> <tr> <td> </td> <td align="left" width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> Management has performed an evaluation of the Company’s activities through the date and time these financial statements were issued and concluded that there are no additional significant events requiring recognition or disclosure. </td> </tr> </table>

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td align="left"> 2. </td> <td align="left" width="95%"> Adoption of New Accounting Standards </td> </tr> <tr> <td> </td> <td align="left" width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> Revenue Recognition and Disclosures </td> </tr> <tr> <td> </td> <td align="left" width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> In December 2011, the FASB issued Update No. 2011-11, “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities”. The objective of this Update is to provide enhanced disclosures that will enable users of financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position. This includes the effect or potential effect of rights of setoff associated with an entity’s recognized assets and recognized liabilities within the scope of this Update. The amendments require enhanced disclosures by requiring improved information about derivatives, repurchase agreements and reverse purchase agreements, and securities borrowing and securities lending transactions that are either offset in accordance with specific criteria or subject to a master netting arrangement or similar agreement. In January 2013, the FASB also issued Update No. 2013-01, which clarifies that ordinary trade receivables and receivables are not in the scope of ASU 2011 - 11. ASU 2011 - 11 and ASU 2013 - 01 are effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. Retrospective disclosure is required for all comparative periods presented. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations. </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> In February 2013, the FASB has issued Update No. 2013-02, “Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income”. This Update has been issued to improve the transparency of reporting these reclassifications. The amendments in this Update supersede and replace the presentation requirements for reclassifications out of accumulated other comprehensive income in ASUs 2011 - 05 and 2011 - 12 for all public and private organizations. The amendments would require an entity to provide additional information about reclassifications out of accumulated other comprehensive income. Public companies are required to comply with these amendments for all reporting periods (interim and annual), effective for reporting periods beginning after December 15, 2012. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations. </td> </tr> </table>

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 3. </td> <td> Significant Accounting Policies </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Recently Issued Accounting Pronouncements </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> In December 2011, the FASB issued Update No. 2011-12, “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05”. The amendments in this Update supersede changes to those paragraphs in Update 2011 - 05 that pertain to how, when, and where reclassification adjustments are presented. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations, but may affect the presentation of Other Comprehensive Income in the Company’s financial statements. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> In February 2013, the FASB issued Update No. 2013-04, “Liabilities (Topic 405)—Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date”. The amendments in this Update provide guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this Update is fixed at the reporting date, except for obligations addressed within existing guidance in U.S. GAAP. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. The guidance in this Update also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. For public entities, the amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments shall be applied retrospectively to all prior periods presented for those obligations that exist at the beginning of the fiscal year of adoption. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> In March 2013, the FASB issued Update No. 2013-05, “Foreign Currency Matters (Topic 830)—Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity”. The amendments in this Update resolve the diversity in practice about whether Subtopic 810 - 10, Consolidation—Overall, or Subtopic 830 - 30, Foreign Currency Matters—Translation of Financial Statements, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, the amendments in this Update resolve the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. For public entities, the amendments in this ASU are effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2013. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. </td> </tr> </table>

106 116 1.00 39

1000000 39 847

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 6. </td> <td> Capital Stock </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="1%"> </td> <td align="center" nowrap="nowrap" width="12%"> March 31, </td> <td align="center" nowrap="nowrap" width="2%"> </td> <td align="center" nowrap="nowrap" width="1%"> </td> <td align="center" nowrap="nowrap" width="12%"> December 31, </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="center" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 2013 </td> <td align="center" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="center" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="center" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 2012 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> Authorized - </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left"> 100,000,000 common shares of $0.00001 par value </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> 20,000,000 preferred shares of $0.00001 par value </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left"> Issued - </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid"> 50,302,921 (December 31, 2012 - 49,890,421) common shares </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> $ </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 503 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%">$</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 499 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> </table>

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="1%"> </td> <td align="center" nowrap="nowrap" width="12%"> March 31, </td> <td align="center" nowrap="nowrap" width="2%"> </td> <td align="center" nowrap="nowrap" width="1%"> </td> <td align="center" nowrap="nowrap" width="12%"> December 31, </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="center" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 2013 </td> <td align="center" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="center" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="center" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 2012 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> Authorized - </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left"> 100,000,000 common shares of $0.00001 par value </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> 20,000,000 preferred shares of $0.00001 par value </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left"> Issued - </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid"> 50,302,921 (December 31, 2012 - 49,890,421) common shares </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> $ </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 503 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%">$</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 499 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> </table>

0 100000000 0.00001 20000000 0.00001 50302921 49890421 503 499 <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 7. </td> <td> Additional Paid-In Capital </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Stock options </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> During the three month period ended March 31, 2013 a total of 50,000 (2012 - nil) stock options were exercised for 50,000 (2012 - nil) common shares having a par value of $0 thousand in aggregate, for cash consideration of $23 thousand (2012 - $Nil), resulting in an increase in additional paid-in capital of $23 thousand (2012 - $Nil). </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Compensation expenses for stock-based compensation of $18 thousand and $15 thousand were recorded during the three-month period ended March 31, 2013 and 2012 respectively. Of the amount expensed in 2013, $13 thousand (2012 - $14 thousand) relates to stock options granted to employees and directors, and $5 thousand (2012 - $Nil) relates to options granted to independent third party consultants. In addition, $1 thousand was expensed in 2012 related to stock options granted to investor relations firms as compensation for investor relation services. As at March 31, 2013, the Company has $50 thousand (2012 - $69 thousand) of unrecognized stock- based compensation. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Warrants </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> During the three month period ended March 31, 2013 a total of 362,500 (2012 - 1,206,418) warrants were exercised for 362,500 (2012 - 726,830) common shares having a par value of $0 thousand in aggregate, for cash consideration of $172 thousand (2012 - $233 thousand), resulting in an increase in additional paid-in capital of $171 thousand (2012 - $233 thousand). </td> </tr> </table> 50000 0 50000 0 0 23 0 23 0 18 15 13 14 5 0 1 50 69 362500 1206418 362500 726830 0 172 233 171 233

2 1 3 2 4 7 22 27 54 0

680000 480000 200000 0.67 0.65 0.25 37500 995500 995500 0 472 472

263000

68000

85000

375000

4296000

149000

125000

4570000

666000

15918000

-12213000

199000

3904000

4570000

39581271

11087000

-9761000

150000

1476000

49000

4821342

2024000

685000 685000 153000 153000 3418009 1458000 1458000 299406 142000 142000 775000 318000 318000

51000

-2452000

48895028

15918000

-12213000

199000

100000

726080 233000 233000 219313 104000 104000 50000 28000 28000

59000

-2250000

1198000

433000

10000

7000

1208000

440000

1935000

1524000

-212000

-188000

716000

586000

347000

333000

582000

594000

46000

37000

-41000

-3000

3000

3458000

2892000

-2250000

-2452000

-2150000

-2403000

49637908

43736003

-0.04

-0.05

46000

37000

59000

51000

0 53000 -2145000 -2311000

1019000

38000

34000

21000

-247000

263000

390000

317000

923000

-507000

5000

-1638000

-2316000

3231000

365000

1918000

0 369000

365000

4780000

270000

34000

125000

-270000

-159000

-1543000

2305000

97000

56000

1144000

9 6 2

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td align="left"> 3. </td> <td align="left" width="95%"> Adoption of New Accounting Standards </td> </tr> <tr> <td> </td> <td width="95%"> </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> In May 2011, the FASB issued Update No. 2011-04, “Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs”. The amendments in this Update result in common fair value measurement and disclosure requirements in U.S. GAAP and IFRSs. Consequently, the amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. For many of the requirements, FASB does not intend for the amendments in this Update to result in a change in the application of the requirements in Topic 820. Some of the amendments clarify FASB’s intent about the application of existing fair value measurement requirements. Other amendments change a particular principle or requirement for measuring fair value or for disclosing information about fair value measurements. For public entities, ASU 2011-4 is effective during interim and annual periods beginning after December 15, 2011. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations. </td> </tr> <tr> <td> </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> In June 2011, the FASB issued Update No. 2011-05, “Comprehensive Income (Topic 220): Presentation of Comprehensive Income”. Under the amendments, an entity has the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both choices, an entity is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. This Update eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders’ equity. The amendments in this Update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. ASU 2011-05 should be applied retrospectively. For public entities, the amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. Early adoption is permitted. In December 2011 however, the FASB issued Update No. 2011-12, “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05”. The amendments in this Update supersede changes to those paragraphs in Update 2011-05 that pertain to how, when, and where reclassification adjustments are presented. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations. </td> </tr> </table>

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 4. </td> <td> Summary of Significant Accounting Policies </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Revenue Recognition </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The Company recognizes revenue from research and development contracts as the contracted services are performed or when milestones are achieved, in accordance with the terms of the specific agreements and when collection of the payment is reasonably assured. In addition, the performance criteria for the achievement of milestones are met if substantive effort was required to achieve the milestone and the amount of the milestone payment appears reasonably commensurate with the effort expended. Amounts received in advance of the recognition criteria being met, if any, are included in deferred income. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> IntelGenx has license agreements that specify that certain royalties are earned by the Company on sales of licensed products in the licensed territories. Licensees usually report sales and royalty information in the 45 days after the end of the quarter in which the activity takes place and typically do not provide forward estimates or current-quarter information. Because the Company is not able to reasonably estimate the amount of royalties earned during the period in which these licensees actually ship products, royalty revenue is not recognized until the royalties are reported to the Company and the collection of these royalties is reasonably assured. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> In August 2010 the Company entered into a joint development and commercialization agreement with RedHill Biopharma (“RedHill”), an Israeli company, for an anti-migraine product based upon the Company’s VersaFilm™ technology. In accordance with the terms of the agreement, RedHill made up-front and milestone payments in the aggregate amount of $600 thousand, of which $100 thousand was received by the Company in 2012 upon production of pivotal batches. RedHill is required to make additional milestone payments of up to $700,000 as follows: </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> $200 thousand upon the filing of an NDA and acceptance of the filing by the U.S. Food and Drug Administration; and </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> $500 thousand upon receipt of U.S. Food and Drug Administration marketing approval for the product. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Product Sales: </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The Company launched Forfivo XL™ in the USA in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP (“Edgemont”). Under the terms of the agreement with Edgemont, the commercial launch of Forfivo XL™ triggered launch-related milestone payments for IntelGenx of up to $4.0 million, of which $1 million was invoiced by the Company to Edgemont and recognized as revenue in the fourth quarter of 2012 and the cash received in February 2013. Additional milestones of up to a further $23.5 million are payable upon achieving certain sales and exclusivity targets and the Company expects to commence receiving royalties from sales of the product in the first quarter of 2013. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Upon entering into the licensing agreement, Edgemont paid the Company an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over the period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $923 thousand at December 31, 2012 that has not been recognized as revenue. </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Use of Estimates </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management’s judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, the investment tax credits receivable, the determination of the fair value of warrants issued as part of fundraising activities, and the resulting impact on the allocation of the proceeds between the common shares and the warrants. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Financial Instruments </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The Company estimates the fair value of its financial instruments based on current interest rates, market value and pricing of financial instruments with comparable terms. Unless otherwise indicated, the carrying value of these financial instruments approximates their fair value. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Cash and Cash Equivalents </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Cash and cash equivalents is comprised of cash on hand and term deposits with original maturity dates of less than three months that are stated at cost, which approximates fair value. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Accounts Receivable </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible. In the first quarter of 2011, the Company wrote-off a receivable in the amount of $53 thousand that was owed to the Company by Circ Pharma Limited, Ireland, which was deemed to be no longer collectible. The Company records recoveries of trade receivables previously written-off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2012 accounts receivable (2011 - $Nil). The accounts receivable balance of $1,282 thousand as at December 31, 2012 includes $1 million from Edgemont that was received by IntelGenx in February 2013. </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Investment Tax Credits </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Leasehold Improvements and Equipment </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Leasehold Improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows: </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">On the declining balance method -</td> <td align="left" bgcolor="#e6efff" width="36%"> </td> </tr> <tr> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="36%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">       Laboratory and office equipment</td> <td align="left" bgcolor="#e6efff" width="36%"> 20% </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">       Computer equipment</td> <td align="left" width="36%"> 30% </td> </tr> <tr> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> </td> <td align="left" bgcolor="#e6efff" width="36%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">On the straight-line method -</td> <td align="left" width="36%"> </td> </tr> <tr> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> </td> <td align="left" bgcolor="#e6efff" width="36%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">       Leasehold improvements</td> <td align="left" width="36%">over the lease term</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">       Manufacturing equipment</td> <td align="left" bgcolor="#e6efff" width="36%"> 5 – 10 years </td> </tr> </table> Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred. Intangible Assets Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization. Impairment of Long-lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the estimated undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value thereof. <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Foreign Currency Translation </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The Company’s reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company’s Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows: </td> </tr> </table> Assets and liabilities - at exchange rates in effect at the balance sheet date; Revenue and expenses - at average exchange rates prevailing during the year; Equity - at historical rates. Gains and losses arising from foreign currency translation are included in other comprehensive income. Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Unrecognized Tax Benefits The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 “Income Taxes”. ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision. <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> Share-Based Payments </td> </tr> <tr> <td> </td> <td width="95%"> </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation—Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company estimates its forfeiture rate in order to determine its compensation expense arising from stock-based awards. The Company uses the Black-Scholes option pricing model to determine the fair value of the options. </td> </tr> <tr> <td> </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year. </td> </tr> <tr> <td> </td> <td width="95%">   </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> Loss Per Share </td> </tr> <tr> <td> </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share. </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Fair Value Measurements </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires new disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left">Level 1:</td> <td align="left" width="90%">Quoted market prices in active markets for identical assets or liabilities.</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Level 2:</td> <td align="left" width="90%">Observable market based inputs or unobservable inputs that are corroborated by market data.</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Level 3:</td> <td align="left" width="90%">Unobservable inputs that are not corroborated by market data.</td> </tr> </table> In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. There are no assets or liabilities measured at fair value as at December 31, 2012. Fair Value of Financial Instruments The fair value represents management’s best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization. Recent Accounting Pronouncements In December 2011, the FASB issued Update No. 2011-11, “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities”. The objective of this Update is to provide enhanced disclosures that will enable users of its financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position. This includes the effect or potential effect of rights of setoff associated with an entity’s recognized assets and recognized liabilities within the scope of this Update. The amendments require enhanced disclosures by requiring improved information about financial instruments and derivative instruments that are either (1) offset in accordance with either Section 210-20-45 or Section 815-10-45 or (2) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either Section 210-20-45 or Section 815-10-45. ASU 2011-11 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. Retrospective disclosure is required for all comparative periods presented. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> In December 2011, the FASB issued Update No. 2011-12, “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05”. The amendments in this Update supersede changes to those paragraphs in Update 2011-05 that pertain to how, when, and where reclassification adjustments are presented. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations, but will affect the presentation of Other Comprehensive Income in the Company’s financial statements. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table>

Intangible Assets Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.

Impairment of Long-lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the estimated undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value thereof.

Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Unrecognized Tax Benefits The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 “Income Taxes”. ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision.

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> Share-Based Payments </td> </tr> <tr> <td> </td> <td width="95%"> </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation—Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company estimates its forfeiture rate in order to determine its compensation expense arising from stock-based awards. The Company uses the Black-Scholes option pricing model to determine the fair value of the options. </td> </tr> <tr> <td> </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year. </td> </tr> <tr> <td> </td> <td width="95%">   </td> </tr> </table>

Fair Value of Financial Instruments The fair value represents management’s best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization.

Recent Accounting Pronouncements In December 2011, the FASB issued Update No. 2011-11, “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities”. The objective of this Update is to provide enhanced disclosures that will enable users of its financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position. This includes the effect or potential effect of rights of setoff associated with an entity’s recognized assets and recognized liabilities within the scope of this Update. The amendments require enhanced disclosures by requiring improved information about financial instruments and derivative instruments that are either (1) offset in accordance with either Section 210-20-45 or Section 815-10-45 or (2) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either Section 210-20-45 or Section 815-10-45. ASU 2011-11 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. Retrospective disclosure is required for all comparative periods presented. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> In December 2011, the FASB issued Update No. 2011-12, “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05”. The amendments in this Update supersede changes to those paragraphs in Update 2011-05 that pertain to how, when, and where reclassification adjustments are presented. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations, but will affect the presentation of Other Comprehensive Income in the Company’s financial statements. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table>

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">On the declining balance method -</td> <td align="left" bgcolor="#e6efff" width="36%"> </td> </tr> <tr> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="36%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">       Laboratory and office equipment</td> <td align="left" bgcolor="#e6efff" width="36%"> 20% </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">       Computer equipment</td> <td align="left" width="36%"> 30% </td> </tr> <tr> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> </td> <td align="left" bgcolor="#e6efff" width="36%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">On the straight-line method -</td> <td align="left" width="36%"> </td> </tr> <tr> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> </td> <td align="left" bgcolor="#e6efff" width="36%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">       Leasehold improvements</td> <td align="left" width="36%">over the lease term</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">       Manufacturing equipment</td> <td align="left" bgcolor="#e6efff" width="36%"> 5 – 10 years </td> </tr> </table> 0.20 0.30 5 10 45 600000 100000 700000 200000 500000 4000000 1000000 23500000 1000000 923000 53000 0 1282000 1000000 0.50

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%"> 2012 </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%">2011</td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left"> In US$ thousands </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%">Accumulated</td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%"> Net Carrying </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%">Net Carrying</td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%">Cost</td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%">Depreciation</td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> Amount </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%">Amount</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Manufacturing equipment</td> <td align="left" bgcolor="#e6efff" width="1%">$</td> <td align="right" bgcolor="#e6efff" width="12%"> 225 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%">$</td> <td align="right" bgcolor="#e6efff" width="12%"> 0 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> $ </td> <td align="right" bgcolor="#e6efff" width="12%"> 225 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%">$</td> <td align="right" bgcolor="#e6efff" width="12%"> 0 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Laboratory and office equipment</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 418 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 265 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 153 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 138 </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Computer equipment</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 43 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 34 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 9 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 11 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid">Leasehold improvements</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 63 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 63 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 0 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 0 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td bgcolor="#e6efff"> </td> <td bgcolor="#e6efff" width="1%"> </td> <td bgcolor="#e6efff" width="12%"> </td> <td bgcolor="#e6efff" width="2%"> </td> <td bgcolor="#e6efff" width="1%"> </td> <td bgcolor="#e6efff" width="12%"> </td> <td bgcolor="#e6efff" width="2%"> </td> <td bgcolor="#e6efff" width="1%"> </td> <td bgcolor="#e6efff" width="12%"> </td> <td bgcolor="#e6efff" width="2%"> </td> <td bgcolor="#e6efff" width="1%"> </td> <td bgcolor="#e6efff" width="12%"> </td> <td bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="1%">$</td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 749 </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="1%">$</td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 362 </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $ </td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 387 </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="1%">$</td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 149 </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> </table>

225 0 225 0 418 265 153 138 43 34 9 11 63 63 0 0 749 362 387 149

116000 125000 1.00 39

1000000 39 923000

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="40%"> <tr valign="top"> <td align="left" bgcolor="#e6efff">2013</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="10%"> 15 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td align="left">2014</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="10%"> 0 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr valign="top"> <td align="left" bgcolor="#e6efff">Total</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 3px double" width="1%">$</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 3px double" width="10%"> 15 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 3px double" width="2%"> </td> </tr> </table>

15 0 15 3500 6425 6410 6420 28600 10 4500 5000 5000 2500 2500 2500 0.10

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 2012 </td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%">2011</td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Authorized -</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left"> 100,000,000 common shares of $0.00001 par value </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">   20,000,000 preferred shares of $0.00001 par value </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Issued -</td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid">   49,890,421 (December 31, 2011 - 48,895,028) common shares </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $ </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 499 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">$</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 489 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> </table>

100000000 0.00001 20000000 0.00001 49890421 48895028 499 489 4800000 2400000 3200000 0.74 36 2024000 2582536 1291268 1700000 2238806 1119403 1500000 121000 0.07 28000 180778 0.07 105000 0.07 156716 0.07 0.74 36 114000 50000 775000 50000 775000 0 0 28000 318000 28000 318000 219313 299406 219313 299406 0 104000 142000 104000 142000 1205668 491382 491382 0 233000 233000 714286 234698 0 4366904 2902618 2902618 0 1458000 1458000 1464286 515391 0 <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 10.</td> <td> Additional Paid-In Capital </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> Stock Options </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> In November 2006, the Company adopted the 2006 Stock Incentive Plan ("Plan") for the purpose of issuing both Incentive Options and Nonqualified Options to officers, employees, directors and eligible consultants of the Company. A total of 1,600,749 shares of common stock were reserved for issuance under this plan. Options may be granted under the Plan on terms and at prices as determined by the Board of Directors except that the options cannot be granted at less than 100%, of the fair market value of the common stock on the date of the grant. Each option will be exercisable after the period or periods specified in the option agreement, but no option may be exercised after the expiration of 10 years from the date of grant. All options granted to individuals other than non- employee directors will have a total vesting period of 24 months from the date of grant, with one quarter of the total options granted vesting and becoming exercisable every six months. Options granted to non-employees may vest and become 100% fully exercisable immediately upon grant. </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> At the Annual General Meeting on September 8, 2008 the shareholders of the Company approved to amend the 2006 Stock Option Plan to increase the number of shares available for issuance under the Plan from 1,600,749 to 2,074,000, or 10% of the Company’s issued and outstanding common shares as of July 28, 2008. </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td>  </td> <td width="95%">  </td> </tr> <tr valign="top"> <td align="left">  </td> <td align="left" width="95%"> A modification was made to the 2006 Stock Option Plan. The life of the options was reduced from 10 years to 5 years to comply with the regulations of the Toronto Stock Exchange. Accordingly, because the grant-date fair value of the modified options was less than the fair value of the original options measured immediately before the modification, no incremental share-based compensation expense resulted from the modification. </td> </tr> <tr> <td>  </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left">  </td> <td align="left" width="95%"> At the Annual General Meeting on June 3, 2010, the Shareholders of the Company approved an amendment to the 2006 Stock Option Plan to increase the number of shares available for issuance under the Plan from 2,074,000 to 3,308,127, or 10% of the Company’s issued and outstanding shares as of April 5, 2010. </td> </tr> <tr> <td>  </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left">  </td> <td align="left" width="95%"> On May 12, 2011 the Company granted 50,000 stock options to an employee to purchase common shares. The stock options are exercisable at $0.52 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $16 thousand, using the following assumptions: </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid"> Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 115%</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Expected life</td> <td align="center" width="14%"> 3.1 years</td> <td align="center" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.96%</td> <td align="center" bgcolor="#e6efff" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid"> Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%">  </td> </tr> </table> On November 29, 2011 the Company granted 115,000 stock options to two non-employee directors, 40,000 stock options to a director, 50,000 stock options to two officers, and 35,000 stock options to two employees, to purchase common shares. The stock options are exercisable at $0.54 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $74 thousand, using the following assumptions: <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid"> Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 101%</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Expected life</td> <td align="center" width="14%"> 3.1 years</td> <td align="center" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.40%</td> <td align="center" bgcolor="#e6efff" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid"> Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%">  </td> </tr> </table> On June 13, 2012 the Company granted 40,000 stock options to two employees to purchase common shares. The stock options are exercisable at $0.51 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $10 thousand, using the following assumptions: <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid"> Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 83%</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Expected life</td> <td align="center" width="14%"> 3.1 years</td> <td align="center" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.40%</td> <td align="center" bgcolor="#e6efff" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid"> Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%">  </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> On August 8, 2012 the Company granted 50,000 stock options to a consultant to purchase common shares. The stock options are exercisable at $0.55 per share and vest over 1 year at 25% every three months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $12 thousand, using the following assumptions: </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid"> Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 81%</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Expected life</td> <td align="center" width="14%"> 1.8 years</td> <td align="center" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.38%</td> <td align="center" bgcolor="#e6efff" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid"> Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%">  </td> </tr> </table> On December 4, 2012 the Company granted 30,000 stock options to an employee who is also a director and 25,000 stock options to an officer to purchase common shares. The stock options are exercisable at $0.60 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $15 thousand, using the following assumptions: <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid"> Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 78%</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Expected life</td> <td align="center" width="14%"> 3.1 years</td> <td align="center" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.34%</td> <td align="center" bgcolor="#e6efff" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid"> Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%">  </td> </tr> </table> On December 12, 2012 the Company granted 50,000 stock options to a consultant to purchase common shares. The stock options are exercisable at $0.62 per share and vest over 1 year at 25% every three months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $10 thousand, using the following assumptions: <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid"> Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 70%</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Expected life</td> <td align="center" width="14%"> 1.8 years</td> <td align="center" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.25%</td> <td align="center" bgcolor="#e6efff" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid"> Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%">  </td> </tr> </table> During the year ended December 31, 2012 a total of 50,000 (2011 – 775,000) stock options were exercised for 50,000 (2011 – 775,000) common shares having a par value of $0 thousand (2011 - $Nil) in aggregate, for cash consideration of $28 thousand ($318 thousand), resulting in an increase in additional paid-in capital of $28 thousand (2011 – $318 thousand). The intrinsic value of the stock options exercised, as at the date of exercise, totaled $4 thousand. <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%">  </td> <td> Information with respect to stock option activity for 2011 and 2012 is as follows: </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%">  </td> <td align="left">  </td> <td align="left" width="1%">  </td> <td align="left" width="12%">  </td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%"> Weighted average</td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%"> Number of options</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%"> exercise price</td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="12%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> $ </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> </tr> <tr> <td width="5%">  </td> <td>  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid"> Outstanding – January 1, 2011</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 1,698,088</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 0.53</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> </tr> <tr> <td width="5%">  </td> <td>  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Granted</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> 290,000</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> 0.54</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Forfeited</td> <td align="left" width="1%">  </td> <td align="right" width="12%"> (150,000</td> <td align="left" width="2%"> )</td> <td align="left" width="1%">  </td> <td align="right" width="12%"> (0.76</td> <td align="left" width="2%"> )</td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Expired</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> (65,000</td> <td align="left" bgcolor="#e6efff" width="2%"> )</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> (0.59</td> <td align="left" bgcolor="#e6efff" width="2%"> )</td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid"> Exercised</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (775,000</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> )</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (0.41</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> )</td> </tr> <tr> <td width="5%">  </td> <td bgcolor="#e6efff">  </td> <td bgcolor="#e6efff" width="1%">  </td> <td bgcolor="#e6efff" width="12%">  </td> <td bgcolor="#e6efff" width="2%">  </td> <td bgcolor="#e6efff" width="1%">  </td> <td bgcolor="#e6efff" width="12%">  </td> <td bgcolor="#e6efff" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid"> Outstanding – December 31, 2011</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 998,088</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 0.59</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> </tr> <tr> <td width="5%">  </td> <td bgcolor="#e6efff">  </td> <td bgcolor="#e6efff" width="1%">  </td> <td bgcolor="#e6efff" width="12%">  </td> <td bgcolor="#e6efff" width="2%">  </td> <td bgcolor="#e6efff" width="1%">  </td> <td bgcolor="#e6efff" width="12%">  </td> <td bgcolor="#e6efff" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Granted</td> <td align="left" width="1%">  </td> <td align="right" width="12%"> 195,000</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%"> 0.57</td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Forfeited</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> (45,000</td> <td align="left" bgcolor="#e6efff" width="2%"> )</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> (0.49</td> <td align="left" bgcolor="#e6efff" width="2%"> )</td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Expired</td> <td align="left" width="1%">  </td> <td align="right" width="12%"> (32,500</td> <td align="left" width="2%"> )</td> <td align="left" width="1%">  </td> <td align="right" width="12%"> (1.15</td> <td align="left" width="2%"> )</td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid"> Exercised</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (50,000</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> )</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (0.55</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> )</td> </tr> <tr> <td width="5%">  </td> <td>  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid"> Outstanding – December 31, 2012</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 1,065,588</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 0.58</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> </tr> </table>   <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%">  </td> <td> Details of stock options outstanding as at December 31, 2012 are as follows: </td> </tr> </table> <div align="right"> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="95%"> <tr valign="top"> <td align="center">  </td> <td align="center" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" colspan="10" style="BORDER-BOTTOM: #000000 1px solid"> Outstanding options </td> <td align="right" width="2%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" colspan="7" style="BORDER-BOTTOM: #000000 1px solid"> Exercisable options </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> </tr> <tr> <td align="center">  </td> <td align="center" width="1%">  </td> <td align="right" width="9%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="11%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%">  </td> <td width="2%">  </td> </tr> <tr valign="top"> <td align="center">  </td> <td align="center" width="1%">  </td> <td align="right" width="9%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="11%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%"> Weighted</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%"> Weighted</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%">  </td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td align="center">  </td> <td align="center" width="1%">  </td> <td align="right" width="9%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="11%"> Weighted average</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%"> average</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%"> Aggregate</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%"> average</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%"> Aggregate</td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td align="center"> Exercise</td> <td align="center" width="1%">  </td> <td align="right" width="9%"> Number of</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="11%"> remaining</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%"> exercise</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%"> intrinsic</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%"> Number of</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%"> exercise</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%"> intrinsic</td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td align="center"> prices</td> <td align="center" width="1%">  </td> <td align="right" width="9%"> options</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="11%"> contractual life</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%"> price</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%"> value</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%"> options</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%"> price</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="9%"> value</td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td align="center" style="BORDER-BOTTOM: #000000 1px solid"> $</td> <td align="center" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="11%"> (years)</td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> $</td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> $</td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> $</td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> $</td> <td align="center" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> </tr> <tr> <td align="center">  </td> <td align="center" width="1%">  </td> <td align="center" width="9%">  </td> <td align="center" width="2%">  </td> <td align="center" width="1%">  </td> <td align="center" width="11%">  </td> <td align="center" width="2%">  </td> <td align="center" width="1%">  </td> <td align="center" width="9%">  </td> <td align="center" width="2%">  </td> <td align="center" width="1%">  </td> <td align="center" width="9%">  </td> <td align="center" width="2%">  </td> <td align="center" width="1%">  </td> <td align="center" width="9%">  </td> <td align="center" width="2%">  </td> <td align="center" width="1%">  </td> <td align="center" width="9%">  </td> <td align="center" width="2%">  </td> <td align="center" width="1%">  </td> <td align="center" width="9%">  </td> <td width="2%">  </td> </tr> <tr valign="top"> <td align="center" bgcolor="#e6efff"> 0.31</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 25,000</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="11%"> 1.25</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.31</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="left" bgcolor="#e6efff" width="9%">  </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 25,000</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.31</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="left" bgcolor="#e6efff" width="9%">  </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> </tr> <tr valign="top"> <td align="center"> 0.37</td> <td align="left" width="1%">  </td> <td align="right" width="9%"> 75,000</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="11%"> 2.67</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="9%"> 0.37</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="left" width="9%">  </td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="9%"> 75,000</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="9%"> 0.37</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="left" width="9%">  </td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td align="center" bgcolor="#e6efff"> 0.45 - 0.47</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 175,000</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="11%"> 1.42</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.46</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="left" bgcolor="#e6efff" width="9%">  </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 175,000</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.46</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="left" bgcolor="#e6efff" width="9%">  </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> </tr> <tr valign="top"> <td align="center"> 0.51</td> <td align="left" width="1%">  </td> <td align="right" width="9%"> 40,000</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="11%"> 4.50</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="9%"> 0.51</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="left" width="9%">  </td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="9%"> 0</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="9%"> 0.00</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="left" width="9%">  </td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td align="center" bgcolor="#e6efff"> 0.52 - 0.54</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 270,000</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="11%"> 3.89</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.54</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="left" bgcolor="#e6efff" width="9%">  </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 147,500</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.54</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="left" bgcolor="#e6efff" width="9%">  </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> </tr> <tr valign="top"> <td align="center"> 0.55</td> <td align="left" width="1%">  </td> <td align="right" width="9%"> 50,000</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="11%"> 2.67</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="9%"> 0.55</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="left" width="9%">  </td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="9%"> 12,500</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="9%"> 0.55</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="left" width="9%">  </td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td align="center" bgcolor="#e6efff"> 0.60</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 55,000</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="11%"> 5.00</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.60</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="left" bgcolor="#e6efff" width="9%">  </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 0</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.00</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="left" bgcolor="#e6efff" width="9%">  </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> </tr> <tr valign="top"> <td align="center"> 0.61</td> <td align="left" width="1%">  </td> <td align="right" width="9%"> 125,000</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="11%"> 1.51</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="9%"> 0.61</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="left" width="9%">  </td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="9%"> 125,000</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="9%"> 0.61</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="left" width="9%">  </td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td align="center" bgcolor="#e6efff"> 0.62</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 50,000</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="11%"> 3.00</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.62</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="left" bgcolor="#e6efff" width="9%">  </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 0</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.00</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="left" bgcolor="#e6efff" width="9%">  </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> </tr> <tr valign="top"> <td align="center" style="BORDER-BOTTOM: #000000 1px solid"> 0.85</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> 200,588</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="11%"> 0.63</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> 0.85</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="9%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> 200,588</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> 0.85</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="9%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> </tr> <tr valign="top"> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 1,065,588</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="11%"> 2.60</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 0.58</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 114,050</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 760,588</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 0.59</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 86,725</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> </tr> </table> </div> Stock-based compensation expense recognized in 2012 in regards to the stock options was $59 thousand (2011 - $51 thousand). As of December 31, 2012, total unrecognized compensation expense related to unvested stock options was $72 thousand (2011 - $92 thousand), of which $17 thousand (2011 $Nil) relates to options granted to consultants. The amount of $72 thousand will be recognized as an expense over a period of two years. A change in control of the Company due to acquisition would cause the vesting of the stock options granted to employees and directors to accelerate and would result in $55 thousand being charged to stock based compensation expense. Warrants On June 21, 2011 the Company issued approximately 4.8 million stock purchase warrants exercisable into approximately 2.4 million common shares at $0.74 per share which expire on June 21, 2014. The stock purchase warrants were issued in connection with the June 21, 2011 private placements described in note 9. The stock purchase warrants were valued at $817 thousand based on their relative fair value, as determined by the Black-Scholes valuation model using the assumptions below: <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid"> Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 117%</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Expected life</td> <td align="center" width="14%"> 3 years</td> <td align="center" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.69%</td> <td align="center" bgcolor="#e6efff" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid"> Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%">  </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> On June 21, 2011 the Company issued approximately 0.3 million agents’ stock purchase warrants exercisable into approximately 0.3 million common shares at $0.74 per share which expire on June 21, 2014. The stock purchase warrants were issued in connection with the June 21, 2011 private placements described in note 9. The stock purchase warrants were valued at $153 thousand based on their relative fair value, as determined by the Black-Scholes valuation model using the assumptions below: </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid"> Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 117%</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Expected life</td> <td align="center" width="14%"> 3 years</td> <td align="center" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.69%</td> <td align="center" bgcolor="#e6efff" width="14%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid"> Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%">  </td> </tr> </table> During the year ended December 31, 2012 a total of 219,313 (2011 - 299,406) agents’ warrants were exercised for 219,313 (2011 - 299,406) common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $104 thousand (2011 - $142 thousand), resulting in an increase in additional paid-in capital of approximately $104 thousand (2011 - $142 thousand). Also in the year ended December 31, 2012 a total of 1,205,668 warrants were exercised, of which 491,382 warrants were exercised for 491,382 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $233 thousand, resulting in an increase in additional paid-in capital of approximately $233 thousand, and a total of 714,286 warrants were exercised for 234,698 common shares in cashless exercises, resulting in an increase in additional paid-in capital of $Nil. In the year ended December 31, 2011 a total of 4,366,904 warrants were exercised, of which 2,902,618 warrants were exercised for 2,902,618 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $1,458 thousand, resulting in an increase in additional paid-in capital of approximately $1,458 thousand, and a total of 1,464,286 warrants were exercised for 515,391 common shares in cashless exercises, resulting in an increase in additional paid-in capital of $Nil. <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%">  </td> <td> Information with respect to warrant activity for 2011 and 2012 is as follows: </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%">  </td> <td align="left">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%"> Number of</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%"> Weighted average</td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%"> warrants</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%"> exercise price</td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">  </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> (All Exercisable)</td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> $ </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> </tr> <tr> <td width="5%">  </td> <td>  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid"> Outstanding – January 1, 2011</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 21,291,223</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 0.66</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> </tr> <tr> <td width="5%">  </td> <td>  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Attached to private placements</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> 2,748,165</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> 0.74</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Agents’ warrants exercised</td> <td align="left" width="1%">  </td> <td align="right" width="12%"> (299,406</td> <td align="left" width="2%"> )</td> <td align="left" width="1%">  </td> <td align="right" width="12%"> (0.47</td> <td align="left" width="2%"> )</td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid"> Exercised</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> (4,366,904</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> )</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> (0.51</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> )</td> </tr> <tr> <td width="5%">  </td> <td>  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid"> Outstanding - December 31, 2011</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 19,373,078</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 0.71</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> </tr> <tr> <td width="5%">  </td> <td>  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Agents’ warrants exercised</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> (219,313</td> <td align="left" bgcolor="#e6efff" width="2%"> )</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> (0.47</td> <td align="left" bgcolor="#e6efff" width="2%"> )</td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Exercised</td> <td align="left" width="1%">  </td> <td align="right" width="12%"> (1,205,668</td> <td align="left" width="2%"> )</td> <td align="left" width="1%">  </td> <td align="right" width="12%"> (0.48</td> <td align="left" width="2%"> )</td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid"> Expired</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (11,843,932</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> )</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (0.80</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> )</td> </tr> <tr> <td width="5%">  </td> <td>  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid"> Outstanding - December 31, 2012</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 6,104,165</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 0.59</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> </tr> </table>

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid">Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 115% </td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expected life</td> <td align="center" width="14%"> 3.1 years </td> <td align="center" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.96% </td> <td align="center" bgcolor="#e6efff" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> </td> </tr> </table>

1.15 3.1 0.0096 0 <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid">Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 101% </td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expected life</td> <td align="center" width="14%"> 3.1 years </td> <td align="center" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.40% </td> <td align="center" bgcolor="#e6efff" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> </td> </tr> </table> 1.01 3.1 0.0040 0 <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid">Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 83% </td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expected life</td> <td align="center" width="14%"> 3.1 years </td> <td align="center" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.40% </td> <td align="center" bgcolor="#e6efff" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> </td> </tr> </table> 0.83 3.1 0.0040 0 <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid">Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 81% </td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expected life</td> <td align="center" width="14%"> 1.8 years </td> <td align="center" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.38% </td> <td align="center" bgcolor="#e6efff" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> </td> </tr> </table> 0.81 1.8 0.0038 0 <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid">Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 78% </td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expected life</td> <td align="center" width="14%"> 3.1 years </td> <td align="center" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.34% </td> <td align="center" bgcolor="#e6efff" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> </td> </tr> </table> 0.78 3.1 0.0034 0 <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid">Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 70% </td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expected life</td> <td align="center" width="14%"> 1.8 years </td> <td align="center" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.25% </td> <td align="center" bgcolor="#e6efff" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> </td> </tr> </table> 0.70 1.8 0.0025 0

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> Weighted average </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> Number of options </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> exercise price </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%">$ </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid">Outstanding – January 1, 2011</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 1,698,088 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 0.53 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Granted</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 290,000 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 0.54 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Forfeited</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> (150,000 </td> <td align="left" width="2%">)</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> (0.76 </td> <td align="left" width="2%">)</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Expired</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> (65,000 </td> <td align="left" bgcolor="#e6efff" width="2%">)</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> (0.59 </td> <td align="left" bgcolor="#e6efff" width="2%">)</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid">Exercised</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (775,000 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">)</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (0.41 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">)</td> </tr> <tr> <td width="5%"> </td> <td bgcolor="#e6efff"> </td> <td bgcolor="#e6efff" width="1%"> </td> <td bgcolor="#e6efff" width="12%"> </td> <td bgcolor="#e6efff" width="2%"> </td> <td bgcolor="#e6efff" width="1%"> </td> <td bgcolor="#e6efff" width="12%"> </td> <td bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid">Outstanding – December 31, 2011</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 998,088 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 0.59 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td bgcolor="#e6efff"> </td> <td bgcolor="#e6efff" width="1%"> </td> <td bgcolor="#e6efff" width="12%"> </td> <td bgcolor="#e6efff" width="2%"> </td> <td bgcolor="#e6efff" width="1%"> </td> <td bgcolor="#e6efff" width="12%"> </td> <td bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Granted</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 195,000 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 0.57 </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Forfeited</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> (45,000 </td> <td align="left" bgcolor="#e6efff" width="2%">)</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> (0.49 </td> <td align="left" bgcolor="#e6efff" width="2%">)</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expired</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> (32,500 </td> <td align="left" width="2%">)</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> (1.15 </td> <td align="left" width="2%">)</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid">Exercised</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (50,000 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%">)</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (0.55 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%">)</td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid">Outstanding – December 31, 2012</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 1,065,588 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 0.58 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> </table>

1698088 0.53 290000 0.54 -150000 -0.76 -65000 -0.59 -775000 -0.41 998088 0.59 195000 0.57 -45000 -0.49 -32500 -1.15 -50000 -0.55 1065588 0.58 <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="95%"> <tr valign="top"> <td align="center"> </td> <td align="center" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" colspan="10" style="BORDER-BOTTOM: #000000 1px solid"> Outstanding options </td> <td align="right" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" colspan="7" style="BORDER-BOTTOM: #000000 1px solid"> Exercisable options </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td align="center"> </td> <td align="center" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="11%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td align="center"> </td> <td align="center" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="11%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> Weighted </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> Weighted </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td align="center"> </td> <td align="center" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="11%"> Weighted average </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> average </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> Aggregate </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> average </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> Aggregate </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td align="center"> Exercise </td> <td align="center" width="1%"> </td> <td align="right" width="9%"> Number of </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="11%"> remaining </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> exercise </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> intrinsic </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> Number of </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> exercise </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> intrinsic </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td align="center"> prices </td> <td align="center" width="1%"> </td> <td align="right" width="9%"> options </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="11%"> contractual life </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> price </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> value </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> options </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> price </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> value </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td align="center" style="BORDER-BOTTOM: #000000 1px solid"> $ </td> <td align="center" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="11%"> (years) </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%">$</td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> $ </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%">$</td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%">$</td> <td align="center" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td align="center"> </td> <td align="center" width="1%"> </td> <td align="center" width="9%"> </td> <td align="center" width="2%"> </td> <td align="center" width="1%"> </td> <td align="center" width="11%"> </td> <td align="center" width="2%"> </td> <td align="center" width="1%"> </td> <td align="center" width="9%"> </td> <td align="center" width="2%"> </td> <td align="center" width="1%"> </td> <td align="center" width="9%"> </td> <td align="center" width="2%"> </td> <td align="center" width="1%"> </td> <td align="center" width="9%"> </td> <td align="center" width="2%"> </td> <td align="center" width="1%"> </td> <td align="center" width="9%"> </td> <td align="center" width="2%"> </td> <td align="center" width="1%"> </td> <td align="center" width="9%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td align="center" bgcolor="#e6efff"> 0.31 </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 25,000 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="11%"> 1.25 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.31 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 25,000 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.31 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td align="center"> 0.37 </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 75,000 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="11%"> 2.67 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0.37 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="9%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 75,000 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0.37 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="9%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td align="center" bgcolor="#e6efff"> 0.45 - 0.47 </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 175,000 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="11%"> 1.42 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.46 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 175,000 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.46 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td align="center"> 0.51 </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 40,000 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="11%"> 4.50 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0.51 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="9%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0.00 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="9%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td align="center" bgcolor="#e6efff"> 0.52 - 0.54 </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 270,000 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="11%"> 3.89 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.54 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 147,500 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.54 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td align="center"> 0.55 </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 50,000 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="11%"> 2.67 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0.55 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="9%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 12,500 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0.55 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="9%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td align="center" bgcolor="#e6efff"> 0.60 </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 55,000 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="11%"> 5.00 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.60 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.00 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td align="center"> 0.61 </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 125,000 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="11%"> 1.51 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0.61 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="9%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 125,000 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0.61 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="9%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td align="center" bgcolor="#e6efff"> 0.62 </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 50,000 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="11%"> 3.00 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.62 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.00 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td align="center" style="BORDER-BOTTOM: #000000 1px solid"> 0.85 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> 200,588 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="11%"> 0.63 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> 0.85 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> 200,588 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> 0.85 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr valign="top"> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 1,065,588 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="11%"> 2.60 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 0.58 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 114,050 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 760,588 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 0.59 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 86,725 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> </table> 0.31 25000 1.25 0.31 25000 0.31 0.37 75000 2.67 0.37 75000 0.37 0.45 0.47 175000 1.42 0.46 175000 0.46 0.51 40000 4.50 0.51 0 0.00 0.52 0.54 270000 3.89 0.54 147500 0.54 0.55 50000 2.67 0.55 12500 0.55 0.60 55000 5.00 0.60 0 0.00 0.61 125000 1.51 0.61 125000 0.61 0.62 50000 3.00 0.62 0 0.00 0.85 200588 0.63 0.85 200588 0.85 1065588 2.60 0.58 114050 760588 0.59 86725

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid">Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 117% </td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expected life</td> <td align="center" width="14%"> 3 years </td> <td align="center" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.69% </td> <td align="center" bgcolor="#e6efff" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> </td> </tr> </table>

1.17 3 0.0069 0 <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid">Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 117% </td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expected life</td> <td align="center" width="14%"> 3 years </td> <td align="center" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.69% </td> <td align="center" bgcolor="#e6efff" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> </td> </tr> </table> 1.17 3 0.0069 0 <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> Number of </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> Weighted average </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> warrants </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> exercise price </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> (All Exercisable) </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> $ </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid">Outstanding – January 1, 2011</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 21,291,223 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 0.66 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Attached to private placements</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 2,748,165 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 0.74 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Agents’ warrants exercised</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> (299,406 </td> <td align="left" width="2%">)</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> (0.47 </td> <td align="left" width="2%">)</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid">Exercised</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> (4,366,904 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">)</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> (0.51 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">)</td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid">Outstanding - December 31, 2011</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 19,373,078 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 0.71 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Agents’ warrants exercised</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> (219,313 </td> <td align="left" bgcolor="#e6efff" width="2%">)</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> (0.47 </td> <td align="left" bgcolor="#e6efff" width="2%">)</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Exercised</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> (1,205,668 </td> <td align="left" width="2%">)</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> (0.48 </td> <td align="left" width="2%">)</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid">Expired</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (11,843,932 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%">)</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (0.80 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%">)</td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid">Outstanding - December 31, 2012</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 6,104,165 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 0.59 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> </table> 21291223 0.66 2748165 0.74 -299406 -0.47 -4366904 -0.51 19373078 0.71 -219313 -0.47 -1205668 -0.48 -11843932 -0.80 6104165 0.59 1600749 1.00 10 24 1.00 1600749 2074000 0.10 10 5 2074000 3308127 0.10 50000 0.52 2 0.25 16000 115000 40000 50000 35000 0.54 2 0.25 74000 40000 0.51 2 0.25 10000 50000 0.55 1 0.25 12000 30000 25000 0.60 2 0.25 15000 50000 0.62 1 0.25 10000 50000 775000 50000 775000 0 0 28000 318000 28000 318000 4000 59000 51000 72000 92000 17000 0 72000 55000 4800000 2400000 0.74 817000 300000 300000 0.74 153000 219313 299406 219313 299406 0 104000 142000 104000 142000 1205668 491382 491382 0 233000 233000 714286 234698 0 4366904 2902618 2902618 0 1458000 1458000 1464286 515391 0

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 2012 </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%">2011</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Statutory income taxes</td> <td align="left" bgcolor="#e6efff" width="1%"> $ </td> <td align="right" bgcolor="#e6efff" width="12%"> (605 </td> <td align="left" bgcolor="#e6efff" width="2%"> ) </td> <td align="left" bgcolor="#e6efff" width="1%">$</td> <td align="right" bgcolor="#e6efff" width="12%"> (694 </td> <td align="left" bgcolor="#e6efff" width="2%">)</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Net operating losses for which no tax benefits have been recorded</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 368 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 514 </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Excess of depreciation over capital cost allowance</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 3 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> (2 </td> <td align="left" bgcolor="#e6efff" width="2%">)</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Non-deductible expenses</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 18 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 4 </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Undeducted research and development expenses</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 273 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 231 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Tax deductible portion of transaction costs</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> - </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> - </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Investment tax credit</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> (57 </td> <td align="left" bgcolor="#e6efff" width="2%"> ) </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> (53 </td> <td align="left" bgcolor="#e6efff" width="2%">)</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Modification of warrants terms</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> - </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> - </td> <td align="left" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid"> </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $ </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> - </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">$</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%">   - </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> </table>

-605 -694 368 514 3 -2 18 4 273 231 0 0 -57 -53 0 0 0 0

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 2012 </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%">2011</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td align="left"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%"> </td> <td align="right" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Leasehold Improvements and equipment</td> <td align="left" bgcolor="#e6efff" width="1%"> $ </td> <td align="right" bgcolor="#e6efff" width="12%"> 13 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%">$</td> <td align="right" bgcolor="#e6efff" width="12%"> 14 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Net operating losses carryforward</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 2,278 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 2,140 </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Undeducted research and development expenses</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 1,301 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 1,141 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Non-refundable tax credits carryforward</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 914 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 807 </td> <td align="left" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid"> </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 4,506 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 4,102 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td align="left"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%"> </td> <td align="right" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid">Valuation allowance</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (4,506 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> ) </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (4,102 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%">)</td> </tr> <tr> <td width="5%"> </td> <td align="left"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%"> </td> <td align="right" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $ </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> - </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">$</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%">   - </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> </table>

13 14 2278 2140 1301 1141 914 807 4506 4102 -4506 -4102 0 0 4102000 404000 8390000 7608000 8566000 7437000 914000 803000 24000 213000 193000 186000 187000 111000 4464000 3656000

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid"> In US$ thousands </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 2012 </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%">2011</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> Additional Cash Flow Information: </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid">Interest paid</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $ </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 3 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">$</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 3 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> </table>

3 3

<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td align="left"> 13.</td> <td align="left" width="95%"> Related Party Transactions</td> </tr> <tr> <td>  </td> <td width="95%">  </td> </tr> <tr valign="top"> <td align="left">  </td> <td align="left" width="95%"> Included in management salaries are $6 thousand (2011 - $4 thousand) for options granted to the Chief Financial Officer and $6 thousand (2011 - $4 thousand) for options granted to the Chief Executive Officer under the 2006 Stock Option Plan and $23 thousand (2011 - $10 thousand) for options granted to non-employee directors. </td> </tr> <tr> <td>  </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left">  </td> <td align="left" width="95%"> Included in general and administrative expenses are director fees of $114 thousand (2011 - $87 thousand) for attendance at board meetings and audit committee meetings. </td> </tr> <tr> <td>  </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left">  </td> <td align="left" width="95%"> A short term loan of $85 thousand bearing interest at 1% per annum was provided to an employee, who is also an officer of the Company, on November 9, 2011. The loan amount, together with interest accrued, was repaid to the Company on February 28, 2012. </td> </tr> <tr> <td>  </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left">  </td> <td align="left" width="95%"> In the year ended December 31, 2012 the amount included in accounts payable and accrued liabilities payable to shareholders, who are also officers of the Company, is $Nil (2011 - $1 thousand). </td> </tr> <tr> <td>  </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left">  </td> <td align="left" width="95%"> The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed upon by the related parties. </td> </tr> </table>

6000 4000 6000 4000 23000 10000 114000 87000 85000 0.01 0 1000

362500 362500 0 172000 172000 EX-101.SCH 4 igxt-20130331.xsd XBRL SCHEMA FILE 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 102 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Consolidated Statements of Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Consolidated Statement of Shareholders Equity link:calculationLink link:presentationLink link:definitionLink 106 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Nature of Business link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Adoption of New Accounting Standards link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Leasehold Improvements and Equipment link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Intangible Assets link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Deferred License Revenue link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Commitments link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Capital Stock link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Additional Paid-In Capital link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Income Tax link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Statement of Cash Flows Information link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Basic and Diluted Loss Per Common Share link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Going Concern link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Comparative Figures link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Leasehold Improvements and Equipment (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Commitments (Tables) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Capital Stock (Tables) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Additional Paid-In Capital (Tables) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Income Tax (Tables) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Statement of Cash Flows Information (Tables) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Nature of Business (Narrative) (Details) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Significant Accounting Policies (Narrative) (Details) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Intangible Assets (Narrative) (Details) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Deferred License Revenue (Narrative) (Details) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Commitments (Narrative) (Details) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Capital Stock (Narrative) (Details) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Additional Paid-In Capital (Narrative) (Details) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Income Tax (Narrative) (Details) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Related Party Transactions (Narrative) (Details) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Subsequent Events (Narrative) (Details) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Schedule of Leasehold Improvements and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Schedule of future minimum payments under operating leases (Details) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Schedule of Stock by Class (Details) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Schedule of Stock Options Valuation - May 12, 2011 (Details) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Schedule of Stock Options Valuation - November 29, 2011 (Details) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Schedule of Stock Options Valuation - June 13, 2012 (Details) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Schedule of Stock Options Valuation - August 8, 2012 (Details) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - Schedule of Stock Options Valuation - December 4, 2012 (Details) link:calculationLink link:presentationLink link:definitionLink 150 - Disclosure - Schedule of Stock Options Valuation - December 12, 2012 (Details) link:calculationLink link:presentationLink link:definitionLink 151 - Disclosure - Schedule of Stock Option Activity (Details) link:calculationLink link:presentationLink link:definitionLink 152 - Disclosure - Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity (Details) link:calculationLink link:presentationLink link:definitionLink 153 - Disclosure - Schedule of Warrants Valuation - June 21, 2011 (Details) link:calculationLink link:presentationLink link:definitionLink 154 - Disclosure - Schedule of Warrants Valuation - June 21, 2011 (Details) link:calculationLink link:presentationLink link:definitionLink 155 - Disclosure - Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) link:calculationLink link:presentationLink link:definitionLink 156 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) link:calculationLink link:presentationLink link:definitionLink 157 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 158 - Disclosure - Schedule of Cash Flow, Supplemental Disclosures (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 5 igxt-20130331_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 igxt-20130331_def.xml XBRL DEFINITION FILE EX-101.LAB 7 igxt-20130331_lab.xml XBRL LABEL FILE Document and Entity Information [Abstract] Document and Entity Information [Abstract] Statement [Table] Legal Entity [Axis] Entity [Domain] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Period End Date Trading Symbol Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Entity Current Reporting Status Entity Voluntary Filers Entity Well Known Seasoned Issuer Entity Public Float Document Fiscal Year Focus Document Fiscal Period Focus Statement of Financial Position [Abstract] Assets Current Cash and cash equivalents Accounts receivable Prepaid expenses Loan receivable Investment tax credits receivable Total Current Assets Leasehold Improvements and Equipment Intangible assets Total Assets Liabilities Current Accounts payable and accrued liabilities Deferred license revenue Total Curent Liabilities Deferred license revenue, non-current portion Total Liabilities Commitments Shareholders' Equity Capital Stock Additional Paid-in-Capital Accumulated Deficit Accumulated Other Comprehensive Income Total Stockholder Equity Total Liabilities and Stockholders Equity Statement of Operations [Abstract] Revenues Royalties License and other revenue Revenue Other Income Total Revenues Expenses Research and development Research and development tax credits Selling, general and administrative expense Management salaries General and administrative Professional fees Depreciation Amortization of intangible assets Foreign exchange loss Interest and financing fees Total Costs and Expenses Loss from Operations Other Income Interest and other income Total Other Income Loss Before Income Taxes Income taxes Net Loss Other Comprehensive Income Foreign currency translation adjustment Comprehensive Loss Basic and Diluted Weighted Average Number of Shares Outstanding Basic and Diluted Loss Per Common Share Statement of Cash Flows [Abstract] Funds Provided (Used) - Operating Activities Net loss Depreciation Stock-based compensation Accounts receivable write-off Accounts receivable write-off Total Adjustments Total adjustments Changes in assets and liabilities Accounts receivable Prepaid and other assets Other receivables Accounts payable and other accrued liabilities Deferred revenue Net change in assets and liabilities Net Cash Provided by Operating Activities Financing Activities Issuance of common stock and warrants Proceeds from exercise of warrants, agents' warrants and stock options Transaction costs Transaction Costs Net Cash Provided by Financing Activities Investing Activities Additions to leasehold improvements and equipment Additions to intangible assets Net Cash used in iInvesting Activities Increase (Decrease) in Cash and Cash Equivalents Effect of Foreign Exchange on Cash and Cash Equivalents Cash and Cash Equivalents Beginning of Year End of Year Equity Components [Axis] Equity Components [Domain] Capital Stock [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Accumulated Other Comprehensive Income [Member] Statement of Stockholders Equity [Abstract] Beginning Balance Beginning Balance (Shares) Shares Issued (Shares) Foreign currency translation adjustment Issue of common stock, net of transaction costs of $390 Issue of common stock, net of transaction costs of $390 (Shares) Warrants issued, net of transaction costs of $132 Warrants issued, net of transaction costs of $132 Agents' Warrants Agents' Warrants Agents' Warrants (Shares) Agents' Warrants (Shares) Shares Issued (Shares) (SharesIssued) Warrants exercised Warrants exercised Warrants exercised (Shares) Warrants exercised (Shares) Agents warrants exercised Agents warrants exercised Agents warrants exercised (Shares) Agents warrants exercised (Shares) Options exercised Options exercised Options exercised (Shares) Options exercised (Shares) Stock-based compensation Stock-based compensation (Shares) Net loss for the period Ending Balance Ending Balance (Shares) Notes to Financial Statements [Abstract] Notes to Financial Statements [Abstract] Basis of Presentation [Text Block] Nature of Business [Text Block] Adoption of New Accounting Standards [Text Block] Significant Accounting Policies [Text Block] Leasehold Improvements and Equipment [Text Block] Intangible Assets [Text Block] Deferred License Revenue [Text Block] Commitments [Text Block] Capital Stock [Text Block] Additional Paid-In Capital [Text Block] Additional Paid-In Capital [Text Block] Income Tax [Text Block] Statement of Cash Flows Information [Text Block] Related Party Transactions [Text Block] Basic and Diluted Loss Per Common Share [Text Block] Subsequent Events [Text Block] Going Concern [Text Block] Comparative Figures [Text Block] Revenue Recognition [Policy Text Block] Product Sales [Policy Text Block] Use of Estimates [Policy Text Block] Financial Instruments [Policy Text Block] Financial Instruments Cash and Cash Equivalents [Policy Text Block] Accounts Receivable [Policy Text Block] Investment Tax Credits [Policy Text Block] Investment Tax Credits Leasehold Improvements and Equipment [Policy Text Block] Intangible Assets [Policy Text Block] Impairment of Long-lived Assets [Policy Text Block] Foreign Currency Translation [Policy Text Block] Income Taxes [Policy Text Block] Unrecognized Tax Benefits [Policy Text Block] Unrecognized Tax Benefits Share-Based Payments [Policy Text Block] Loss Per Share [Policy Text Block] Fair Value Measurements [Policy Text Block] Fair Value of Financial Instruments [Policy Text Block] Recent Accounting Pronouncements [Policy Text Block] Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment [Table Text Block] Estimated useful lives On the declining balance method Schedule of Leasehold Improvements and Equipment [Table Text Block] Schedule of future minimum payments under operating leases [Table Text Block] Schedule of Stock by Class [Table Text Block] Schedule of Stock Options Valuation - May 12, 2011 [Table Text Block] Schedule of Stock Options Valuation - November 29, 2011 [Table Text Block] Schedule of Stock Options Valuation - November 29, 2011 Schedule of Stock Options Valuation - June 13, 2012 [Table Text Block] Schedule of Stock Options Valuation - June 13, 2012 Schedule of Stock Options Valuation - August 8, 2012 [Table Text Block] Schedule of Stock Options Valuation - August 8, 2012 Schedule of Stock Options Valuation - December 4, 2012 [Table Text Block] Schedule of Stock Options Valuation - December 4, 2012 Schedule of Stock Options Valuation - December 12, 2012 [Table Text Block] Schedule of Stock Options Valuation - December 12, 2012 Schedule of Stock Option Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity [Table Text Block] Schedule of Warrants Valuation - June 21, 2011 [Table Text Block] Schedule of Warrants Valuation - June 21, 2011 [Table Text Block] Schedule of Warrant Valuation - June 21, 2011 Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block] Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Nature Of Business 1 Nature Of Business 1 Nature Of Business 2 Nature Of Business 2 Nature Of Business 3 Nature Of Business 3 Significant Accounting Policies 1 Significant Accounting Policies 1 Significant Accounting Policies 2 Significant Accounting Policies 2 Significant Accounting Policies 3 Significant Accounting Policies 3 Significant Accounting Policies 4 Significant Accounting Policies 4 Significant Accounting Policies 5 Significant Accounting Policies 5 Significant Accounting Policies 6 Significant Accounting Policies 6 Significant Accounting Policies 7 Significant Accounting Policies 7 Significant Accounting Policies 8 Significant Accounting Policies 8 Significant Accounting Policies 9 EX-101.PRE 8 igxt-20130331_pre.xml XBRL PRESENTATION FILE GRAPHIC 9 richterlogo.jpg GRAPHIC begin 644 richterlogo.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``8$!`0%!`8%!08)!@4&"0L(!@8( M"PP*"@L*"@P0#`P,#`P,$`P.#Q`/#@P3$Q04$Q,<&QL;'"`@("`@("`@("#_ MVP!#`0<'!PT,#1@0$!@:%1$5&B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("#_P``1"``9`&8#`1$``A$!`Q$!_\0` M'````@,``P$```````````````4#!@<"!`@!_\0`-Q```0,#`P(#`PD)```` M`````@$#!`4&$0`'$A,A%#%!"%%A%B(R-T)U@9&S%1<8(R4V4H2T_\0`%0$! M`0````````````````````'_Q``5$0$!`````````````````````?_:``P# M`0`"$0,1`#\`]![A;@4:Q*"-;J[,A^*3X1T"((&YR-"5%PX;28^9[]!3_P"( MNU6%`ZK0;@H\,U05GSH'!@<^65!PR_)-!:KDW,MR@E;O51Z8U=$AN-2Y$1&W M&\O<.#A$1A\Q>HBY'.@COO=6T;*%BTN&WUI+B*N$)`R*(BJF$ MRJ9]-`HMG?>SZS7&J%+C5"@5:1A(L>KL>'ZQ%Y""H1IE?3EC/DF=`_M_<.BU MVZZY;,1F2$^@**3''1!&2Y^7343(E_$4T!7-PZ+1KPHMJ2F9)U"NH2Q'6A!6 M1X9SU%4Q)/+T%=!3*I[2%MTHOZA;-QQ@)SHMNNP6FP,^^!!3?3*KCMH&*;ZT M,:!5ZY,M^O4^'1Q8-])D-MDW/$/"P*,\GN)*A&BEE4[:#I,^T/1WV0>9M"Z7 M6710VW`IP$)"290A5'L*BIH&%Q;YV]0CHK,FC5EZ97(J3(D%B,V4@17/S'&E M=$D-,=T3.@^43?FT*A6HM'G0JI;\V<7"$-8B^&%XE7"")(;B=U7'?'?0:1H, M9]J_ZKVOO*/^F[H14MRKQW;>AP;(N6GT>C0KIX16JLA.N,BG,O<#Y$O4QI]'6_&+5>MQ4/L]/HB7?.^ MMA?+5VF.REZOA%I76X(W@L\^L(KG/NT%I]I_^V[9^_XWZ3NB0\]H_P"IBX?] M/_N8T(EA.[AM[:VA\BFJ8[*6FP_%I5>MP1OPH8X=$A7.??H,ZW+?O=O=O;UY MF-">NY*>:E&Y&,)7_P";U$0E7GPQG&5T5UYMKG0*GD0R!QY0(G49=;\C'/;RRB_!=`HJVU`5>':3-2K,B M1(M.2W):E*`\Y'2(5%'?CAM$5?7ST$M_;16]=\^+5UD2J1<$)$2-6*>YTGT% M,X%??CEV7LOQT"JA;%4R/7XU?N6N5&ZZC!7E`2I.Z>?IH.6XVWD.]Z?3X M>=$3WSM=3[HK='N!F:[2:[13Y1I\<1(B#/+IN(7TASG\U3UT%V3.._GH#0&@ 2-`:`T!H#0&@-`:`T!H#0?__9 ` end GRAPHIC 10 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``8$!`0%!`8%!08)!@4&"0L(!@8( M"PP*"@L*"@P0#`P,#`P,$`P.#Q`/#@P3$Q04$Q,<&QL;'"`@("`@("`@("#_ MVP!#`0<'!PT,#1@0$!@:%1$5&B`@("`@("`@("`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("#_P``1"`"1`&\#`1$``A$!`Q$!_\0` M'0`!``("`P$!``````````````8(!PD"`P4$`?_$`$00``$`!P$)"PH%!0`` M```````!`@,$!08'-Q$7&%56=)2RTP@2%&9UE:.EL]'D$R$T05%RD['2U!46 M,3:$(R1#@H/_Q``6`0$!`0```````````````````@'_Q``5$0$!```````` M````````````$?_:``P#`0`"$0,1`#\`M2!&8C4RGT-?FSA$)A<'5\=UMXW= MVK=15=1;V+(2GS`?/?>I?E3#=)9]X"^]2_*F&Z2S[P%]ZE^5,-TEGW@+[U+\ MJ8;I+/O`7WJ7Y4PW26?>`OO4ORIANDL^\!?>I?E3#=)9]X"^]2_*F&Z2S[P% M]ZE^5,-TEGW@+[U+\J8;I+/O`(JY3!*4(1-$-2E/Z(X0S[P)<``H=6ZUB9L\ M6U4!2#@``````````#M=O267OJ_,#9($@%#JW6L3-GBVJ@*0<``````````` M=KMZ2R]]7Y@;)`D`H=6ZUB9L\6U4!2#@`,_2AN5?S%*\+COYHX+^).S-YX/P M'RF\\HKOM[O^$*;ZY[;B`RO6P->-_5WB@4P->-_5WB@4P->-_5WB@4P->-_5 MWB@4P->-_5WB@4P->-_5WB@4P->-_5WB@5S9;CC>-%%_S==WJ4)N?AWL_E`J MR08`4.K=:Q,V>+:J`I!P`%^Z0V7RMR:[=F@)2X```````````4.K=:Q,V>+: MJ`I!P`%^Z0V7RMR:[=F@)2X```````````4.K=:Q,V>+:J`I!P`%^Z0V7RMR M:[=F@)2X```````````4.K=:Q,V>+:J`I!P`%^Z0V7RMR:[=F@)2X`!\\0?G M:'N#R_O2V]=G1DNW;K(0E-Q1FJE99-Q'G3YD`8SPFJ08T;:(\?0`PFJ08T;: M(\?0`PFJ08T;:(\?0`PFJ08T;:(\?0!R5W2](5ED*HBC:ZLFXC^U>/7_`*`9 M2``4.K=:Q,V>+:J`I!P`%^Z0V7RMR:[=F@)2X`!X<]?LF8>37SL%P->04``` M':[>DLO?5^8&R0)`*'5NM8F;/%M5`4@X`"_=(;+Y6Y-=NS0$I<``\.>OV3,/ M)KYV"X&O(*```#M=O267OJ_,#9($@%#JW6L3-GBVJ@*0<`!?ND-E\K8##6"+3;& M49^,Z_;!M,$6FV,HS\9U^V!3!%IMC*,_&=?M@4P1:;8RC/QG7[8%?JFY'IPH MNJNB)1BZJE"4?UG7U?Q@5FX,`*'5NM8F;/%M5`4@X`"_=(;+Y6Y-=NS0$I<` M``````````*'5NM8F;/%M5`4@X`"_=(;+Y6Y-=NS0$I<```````````*'5NM M8F;/%M5`4@X`"_=(;+Y6Y-=NS0$I<```````````*'5NM8F;/%M5`4@X`"[= M+:@R$Y4YEMT?)EA3L],(>[J-G=L^NZC119"B+JJRJRZ$H2CV)"4IOFTVRK@W M.#KM`%\VFV5<&YP==H`OFTVRK@W.#KM`%\VFV5<&YP==H`OFTVRK@W.#KM`% M\VFV5<&YP==H`OFTVRK@W.#KM`/U%3*<)3<1-<'2E/Z(X>Z[0"2``*'5NM8F M;/%M5`4@X```````````[7;TEE[ZOS`V2!(!0ZMUK$S9XMJH"D'````````` M``':[>DLO?5^8&R0)`,.S;N9)3F69'^//<4?V+Q$&OEFC)EY'>*I2BY<5WRB M4^H%>1@@R3CF)=!LPVF"#)..8ET&S!3!!DG',2Z#9@I@@R3CF)=!LP4P09)Q MS$N@V8*8(,DXYB70;,%,$&2< GRAPHIC 11 exhibi1.gif GRAPHIC begin 644 exhibi1.gif M1TE&.#EA=0`>`/<``"(?'RDF)C`M+37F=E M96YL;'5SH.!@8J(B)"/CY>6EIZ=G:6DI*RKJ[.RLKJYN<'`P,C'Q\[. MSM75U=S/($.*'$FRI,F3*%.J+.D!@\N7 M+CT8!$#S8`<,$"1@Z%!P0TR#/C'(S`"SJ$L.((@:?*$`50``&/`4RH(G!X%@`90ET70L!A-JU4RF`H`#7ZP*9&:76!3!``]:: M`\_2Y#JUKUBR9A&_W=MV,5RY=/<:N'I1+P."&Q305/`7P,`)4R-`!8$!`:EPN^51BY[4`,!VC:K@R[X(<```1T%MA!`,T*!3T4.)#A,-K$ MSPF^!A";X.R$M5W31)"W=T'C`/#^9@4A@68"FP1;LT8LW;MUP`BS$_0PN#OU M@J`!XI"%^#<]%$P(6FT11`E5>^9YGV.E&G(T`%!GF0!JXR.1X%DSE5T$.-/"G>FRNV6.) M`BVHI9P"Y4?`:#&6^,!V!(T'@F9\X?C!60%L``*A5!IJ):)N96G0@R",.>&= M`WWP5I2!EG(`'@`'-#`F332"ZAR/H]Z'I7XL7O@AJAIDR"M%EFEU6EB6@M#! MDUT)$*6NG[9)JF-K0<;H0),"4`"D%7&`I`4&38#DL051\``"`QR0@`1@@F`! MDDP*-"\$]7HPKD$2(.GOOQ#XI<&YOOG[YTH()ZSPP@PW[/##$$ GRAPHIC 12 exhibi2.gif GRAPHIC begin 644 exhibi2.gif M1TE&.#EA>`"<`/<``"(?'U-04%I75W5S/($.*'$FRI,F3*%.J7,FRIO5[5B7`JVK-FS5,5>)(NVK5NP:BVR?4NW[M2X%>?:W;L7+T6] M?`.[]3L1L.##90E+-(RX,5?%$1D[GIQV*^7+82UCWBP5,D3)G#%[?@@Z-.71 M#DN;=HRZH>K5B%LS?`U;L.R%M&OSO:TPMVZ[O!/Z_DTW.,+AQ`=K+KL`YTGD M3YL[+PG=J?3I(ZLWO8X]I':FW+O^?_P.(+SXCN3-G]^8?CW(]NX]PH_/<3Y] MC?;OCT6K7O]?_O[A!V"`^YW5'X&?#8A@7@HN6%B##D8&882D34BA:Q9>B%N& M&@K'88<'Y0=B;Q^.2)"()H988HH,H,CBB2NFZ.*+`LU(HXTOXB@19LN!=2!% M/!9HUH\3!;E6C!`9*1>2#RG)H($=.?D?E!Q)^2"5&UFY&),.:2DAEAIYF2"8 M&8E9(9D8F9D:EPVIB2&:%[DY&YL,R;DAG!;922*>%>GI(9]`7M;C5T3N**B0 MS$5YZ)&`%KGHDHT:2MF@7A4J(YT7ZGAII)L.2>.?GGZJ(JBFJ^ZZXQ)`:7*'&3?^S5QB(_''+)_YZ,LE4DKWQ6RRXGEM$!!=1L\\TXYZSS XML 13 R8.xml IDEA: Adoption of New Accounting Standards 2.4.0.8108 - Disclosure - Adoption of New Accounting Standardstruefalsefalse1false falsefalsecx_01_January_2013_TO_31_March_2013http://www.sec.gov/CIK0001098880duration2013-01-01T00:00:002013-03-31T00:00:002false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_NewAccountingPronouncementEarlyAdoptionTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td align="left"> 2. </td> <td align="left" width="95%"> Adoption of New Accounting Standards </td> </tr> <tr> <td> </td> <td align="left" width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> Revenue Recognition and Disclosures </td> </tr> <tr> <td> </td> <td align="left" width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> In December 2011, the FASB issued Update No. 2011-11, “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities”. The objective of this Update is to provide enhanced disclosures that will enable users of financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position. This includes the effect or potential effect of rights of setoff associated with an entity’s recognized assets and recognized liabilities within the scope of this Update. The amendments require enhanced disclosures by requiring improved information about derivatives, repurchase agreements and reverse purchase agreements, and securities borrowing and securities lending transactions that are either offset in accordance with specific criteria or subject to a master netting arrangement or similar agreement. In January 2013, the FASB also issued Update No. 2013-01, which clarifies that ordinary trade receivables and receivables are not in the scope of ASU 2011 - 11. ASU 2011 - 11 and ASU 2013 - 01 are effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. Retrospective disclosure is required for all comparative periods presented. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations. </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> In February 2013, the FASB has issued Update No. 2013-02, “Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income”. This Update has been issued to improve the transparency of reporting these reclassifications. The amendments in this Update supersede and replace the presentation requirements for reclassifications out of accumulated other comprehensive income in ASUs 2011 - 05 and 2011 - 12 for all public and private organizations. The amendments would require an entity to provide additional information about reclassifications out of accumulated other comprehensive income. Public companies are required to comply with these amendments for all reporting periods (interim and annual), effective for reporting periods beginning after December 15, 2012. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations. </td> </tr> </table>falsefalsefalse2falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td align="left"> 3. </td> <td align="left" width="95%"> Adoption of New Accounting Standards </td> </tr> <tr> <td> </td> <td width="95%"> </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> In May 2011, the FASB issued Update No. 2011-04, “Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs”. The amendments in this Update result in common fair value measurement and disclosure requirements in U.S. GAAP and IFRSs. Consequently, the amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. For many of the requirements, FASB does not intend for the amendments in this Update to result in a change in the application of the requirements in Topic 820. Some of the amendments clarify FASB’s intent about the application of existing fair value measurement requirements. Other amendments change a particular principle or requirement for measuring fair value or for disclosing information about fair value measurements. For public entities, ASU 2011-4 is effective during interim and annual periods beginning after December 15, 2011. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations. </td> </tr> <tr> <td> </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> In June 2011, the FASB issued Update No. 2011-05, “Comprehensive Income (Topic 220): Presentation of Comprehensive Income”. Under the amendments, an entity has the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both choices, an entity is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. This Update eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders’ equity. The amendments in this Update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. ASU 2011-05 should be applied retrospectively. For public entities, the amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. Early adoption is permitted. In December 2011 however, the FASB issued Update No. 2011-12, “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05”. The amendments in this Update supersede changes to those paragraphs in Update 2011-05 that pertain to how, when, and where reclassification adjustments are presented. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations. </td> </tr> </table>  falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of financial statement line items and the effect of the guidance on the financial statement line items if the entity elects early adoption of accounting guidance.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 65 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=19773497&loc=SL6892059-166502 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 605 -Section 65 -Paragraph 1 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=19773443&loc=SL6751214-165967 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 25 -Section 65 -Paragraph 1 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=19771798&loc=SL6749767-165964 false0Adoption of New Accounting Standards [Text Block]falseAdoption of New Accounting StandardsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsNewAccountingPronouncementEarlyAdoptionTableTextBlock21 XML 14 R6.xml IDEA: Basis of Presentation 2.4.0.8106 - Disclosure - Basis of Presentationtruefalsefalse1false falsefalsecx_01_January_2013_TO_31_March_2013http://www.sec.gov/CIK0001098880duration2013-01-01T00:00:002013-03-31T00:00:002false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td align="left"> 1. </td> <td align="left" width="95%"> Basis of Presentation </td> </tr> <tr> <td> </td> <td align="left" width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal and recurring nature. </td> </tr> <tr> <td> </td> <td align="left" width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> These financial statements should be read in conjunction with the audited consolidated financial statements at December 31, 2012. Operating results for the three months ended March 31, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. </td> </tr> <tr> <td> </td> <td align="left" width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> The consolidated financial statements include the accounts of the Company and its subsidiary companies. On consolidation, all inter-entity transactions and balances have been eliminated. </td> </tr> <tr> <td> </td> <td align="left" width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> The financial statements are expressed in U.S. funds. </td> </tr> <tr> <td> </td> <td align="left" width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> Management has performed an evaluation of the Company’s activities through the date and time these financial statements were issued and concluded that there are no additional significant events requiring recognition or disclosure. </td> </tr> </table>falsefalsefalse2falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 1. </td> <td> Basis of Presentation </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> IntelGenx Technologies Corp. (“IntelGenx” or the “Company”) prepares its financial statements in accordance with accounting principles generally accepted in the United States of America (“USA”). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The consolidated financial statements include the accounts of the Company and its subsidiary companies. On consolidation, all inter-entity transactions and balances have been eliminated. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The financial statements are expressed in U.S. funds. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table>  falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 46R -Paragraph 4, 14, 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2134480 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Staff Position (FSP) -Number FAS140-4/FIN46(R)-8 -Paragraph 8, C1, C7 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2122150 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 720 -SubTopic 15 -URI http://asc.fasb.org/subtopic&trid=2122524 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2197480 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 2-6 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 915 -SubTopic 235 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 852 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2209116 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 272 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 94-6 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Basis of Presentation [Text Block]falseBasis of PresentationUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock21 XML 15 R53.xml IDEA: Schedule of Warrants Valuation - June 21, 2011 (Details) 2.4.0.8154 - Disclosure - Schedule of Warrants Valuation - June 21, 2011 (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00yStandardhttp://www.xbrl.org/2009/utrYutr0pureStandardhttp://www.xbrl.org/2003/instancepure0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_ScheduleOfWarrantsValuationJuneTwoOneTwoZeroOneOneZeroOneSixTwoZeroTwoZeroEightFiveTwodThreewkZFoursqbTHigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse1.171.17falsefalsefalsenum:percentItemTypepureAdditional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 1No definition available.false0Additional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 12false 4igxt_ScheduleOfWarrantsValuationJuneTwoOneTwoZeroOneOneZeroOneSixTwoZeroTwoZeroEightFivemQBcSevenRdJWHTwoMigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse33falsefalsefalsexbrli:decimalItemTypedecimalAdditional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 2No definition available.false256Additional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 23false 4igxt_ScheduleOfWarrantsValuationJuneTwoOneTwoZeroOneOneZeroOneSixTwoZeroTwoZeroEightFivezSixmDrLLDGTwoCqigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse0.00690.0069falsefalsefalsenum:percentItemTypepureAdditional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 3No definition available.false0Additional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 34false 4igxt_ScheduleOfWarrantsValuationJuneTwoOneTwoZeroOneOneZeroOneSixTwoZeroTwoZeroEightFiveFourrBbPfWRmhPPigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00USD$falsetruefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 4No definition available.false2Additional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 4falseSchedule of Warrants Valuation - June 21, 2011 (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfWarrantValuationJuneTwoOneTwoZeroOneOneTableTextBlockDetails14 XML 16 R17.htm IDEA: XBRL DOCUMENT

Statement of Cash Flows Information

12 Months Ended

Dec. 31, 2012

Statement of Cash Flows Information [Text Block]

12.

Statement of Cash Flows Information

In US$ thousands		2012		2011

Additional Cash Flow Information:

Interest paid	$	3	$	3

XML 17 R53.htm IDEA: XBRL DOCUMENT

Schedule of Warrants Valuation - June 21, 2011 (Details) (USD $)	12 Months Ended
	Dec. 31, 2012 Y
Additional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 1	117.00%
Additional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 2	3
Additional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 3	0.69%
Additional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 4	$ 0

XML 18 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended		12 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012	Dec. 31, 2011
Funds Provided (Used) - Operating Activities
Net loss	$ (486)	$ (582)	$ (2,250)	$ (2,452)
Depreciation	20	8	46	37
Stock-based compensation	18	15	59	51
Accounts receivable write-off			0	53
Total Adjustments	(448)	(559)	(2,145)	(2,311)
Changes in assets and liabilities
Accounts receivable	1,112	18	(1,019)	(38)
Prepaid and other assets	13	(15)	(34)	(21)
Other receivables	(30)	249	247	(263)
Accounts payable and other accrued liabilities	(560)	(270)	390	317
Deferred revenue	(77)	1,000	923	0
Net change in assets and liabilities	458	982	507	(5)
Net Cash Provided by Operating Activities	10	423	(1,638)	(2,316)
Financing Activities
Issuance of common stock and warrants			0	3,231
Proceeds from exercise of warrants, agents' warrants and stock options	195	233	365	1,918
Transaction costs			0	(369)
Net Cash Provided by Financing Activities	195	233	365	4,780
Investing Activities
Additions to leasehold improvements and equipment	(69)	(189)	(270)	(34)
Additions to intangible assets			0	(125)
Net Cash used in iInvesting Activities	(69)	(189)	(270)	(159)
Increase (Decrease) in Cash and Cash Equivalents	136	467	(1,543)	2,305
Effect of Foreign Exchange on Cash and Cash Equivalents	(27)	88	97	56
Beginning of Year	2,059	3,505	3,505	1,144
End of Year	$ 2,168	$ 4,059	$ 2,059	$ 3,505

XML 19 R10.htm IDEA: XBRL DOCUMENT

Leasehold Improvements and Equipment

12 Months Ended

Dec. 31, 2012

Leasehold Improvements and Equipment [Text Block]

5.	Leasehold Improvements and Equipment

						2012		2011
In US$ thousands				Accumulated		Net Carrying		Net Carrying
		Cost		Depreciation		Amount		Amount

Manufacturing equipment	$	225	$	0	$	225	$	0
Laboratory and office equipment		418		265		153		138
Computer equipment		43		34		9		11
Leasehold improvements		63		63		0		0

	$	749	$	362	$	387	$	149

As of December 31, 2012 no depreciation has been recorded on manufacturing equipment as the equipment is not yet being utilized.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References+ Details

XML 20 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 21 R24.htm IDEA: XBRL DOCUMENT

Leasehold Improvements and Equipment (Tables)

12 Months Ended

Dec. 31, 2012

Schedule of Leasehold Improvements and Equipment [Table Text Block]

						2012		2011
In US$ thousands				Accumulated		Net Carrying		Net Carrying
		Cost		Depreciation		Amount		Amount

Manufacturing equipment	$	225	$	0	$	225	$	0
Laboratory and office equipment		418		265		153		138
Computer equipment		43		34		9		11
Leasehold improvements		63		63		0		0

	$	749	$	362	$	387	$	149

- Definition

Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.

+ References+ Details

XML 22 R29.xml IDEA: Statement of Cash Flows Information (Tables) 2.4.0.8130 - Disclosure - Statement of Cash Flows Information (Tables)truefalsefalse1false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid"> In US$ thousands </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 2012 </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%">2011</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> Additional Cash Flow Information: </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid">Interest paid</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $ </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 3 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">$</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 3 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of supplemental cash flow information for the periods presented.No definition available.false0Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]falseStatement of Cash Flows Information (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsCashFlowOperatingCapitalTableTextBlockTables11 XML 23 R56.htm IDEA: XBRL DOCUMENT

Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Income Tax Schedule Of Deferred Tax Assets And Liabilities 1	$ 13
Income Tax Schedule Of Deferred Tax Assets And Liabilities 2	14
Income Tax Schedule Of Deferred Tax Assets And Liabilities 3	2,278
Income Tax Schedule Of Deferred Tax Assets And Liabilities 4	2,140
Income Tax Schedule Of Deferred Tax Assets And Liabilities 5	1,301
Income Tax Schedule Of Deferred Tax Assets And Liabilities 6	1,141
Income Tax Schedule Of Deferred Tax Assets And Liabilities 7	914
Income Tax Schedule Of Deferred Tax Assets And Liabilities 8	807
Income Tax Schedule Of Deferred Tax Assets And Liabilities 9	4,506
Income Tax Schedule Of Deferred Tax Assets And Liabilities 10	4,102
Income Tax Schedule Of Deferred Tax Assets And Liabilities 11	(4,506)
Income Tax Schedule Of Deferred Tax Assets And Liabilities 12	(4,102)
Income Tax Schedule Of Deferred Tax Assets And Liabilities 13	0
Income Tax Schedule Of Deferred Tax Assets And Liabilities 14	$ 0

XML 24 R18.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

12 Months Ended

Mar. 31, 2013

Dec. 31, 2012

Related Party Transactions [Text Block]

8.	Related Party Transactions

	Included in management salaries are $2 thousand (2012 - $1 thousand) for options granted to the Chief Financial Officer and $3 thousand (2012 - $2 thousand) for options granted to the Chief Executive Officer under the 2006 Stock Option Plan and $4 thousand (2012 - $7 thousand) for options granted to non-employee directors.

	Also included in management salaries are director fees of $22 thousand (2012 - $27 thousand) for attendance to board meetings and audit committee meetings and $54 thousand (2012 - $Nil) for fees paid to a director under a management consultancy agreement.

	The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed to by the related parties.

13.	Related Party Transactions

	Included in management salaries are $6 thousand (2011 - $4 thousand) for options granted to the Chief Financial Officer and $6 thousand (2011 - $4 thousand) for options granted to the Chief Executive Officer under the 2006 Stock Option Plan and $23 thousand (2011 - $10 thousand) for options granted to non-employee directors.

	Included in general and administrative expenses are director fees of $114 thousand (2011 - $87 thousand) for attendance at board meetings and audit committee meetings.

	A short term loan of $85 thousand bearing interest at 1% per annum was provided to an employee, who is also an officer of the Company, on November 9, 2011. The loan amount, together with interest accrued, was repaid to the Company on February 28, 2012.

	In the year ended December 31, 2012 the amount included in accounts payable and accrued liabilities payable to shareholders, who are also officers of the Company, is $Nil (2011 - $1 thousand).

	The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed upon by the related parties.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 25 R34.xml IDEA: Commitments (Narrative) (Details) 2.4.0.8135 - Disclosure - Commitments (Narrative) (Details)truefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00yStandardhttp://www.xbrl.org/2009/utrYutr0pureStandardhttp://www.xbrl.org/2003/instancepure0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false CADfalsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00cadStandardhttp://www.xbrl.org/2003/iso4217CADiso42170CADCAD1false 4igxt_CommitmentsZeroOneSixTwoZeroTwoZeroEightFiveZOneDSldKvqNQQigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse35003500falsefalsefalse2truefalsefalse35003500falsefalsefalsexbrli:pureItemTypepureCommitments 1No definition available.false0Commitments 12false 4igxt_CommitmentsZeroOneSixTwoZeroTwoZeroEightFiveyNkfTGQcWThreehTigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse64256425falsefalsefalse2truefalsefalse64256425falsefalsefalsexbrli:pureItemTypepureCommitments 2No definition available.false0Commitments 23false 4igxt_CommitmentsZeroOneSixTwoZeroTwoZeroEightFivenSevenZeropSTwTwoSixvJqigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse64106410falsefalsefalse2truefalsefalse64106410falsefalsefalsexbrli:pureItemTypepureCommitments 3No definition available.false0Commitments 34false 4igxt_CommitmentsZeroOneSixTwoZeroTwoZeroEightFivecBxOnefOnewzDZeroOneZigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse64206420falsefalsefalse2truefalsefalse64206420falsefalsefalsexbrli:pureItemTypepureCommitments 4No definition available.false0Commitments 45false 4igxt_CommitmentsZeroOneSixTwoZeroTwoZeroEightFivepVGzSixSixSixBNcHWigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse2860028600falsefalsefalse2truefalsefalse2860028600falsefalsefalsexbrli:pureItemTypepureCommitments 5No definition available.false0Commitments 56false 4igxt_CommitmentsZeroOneSixTwoZeroTwoZeroEightFivePXzKRZQgSNSrigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1010falsefalsefalse2truefalsefalse1010falsefalsefalsexbrli:decimalItemTypedecimalCommitments 6No definition available.false256Commitments 67false 4igxt_CommitmentsZeroOneSixTwoZeroTwoZeroEightFiveEightLNwxtKTVvHfigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse45004USD$falsetruefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCommitments 7No definition available.false2Commitments 78false 4igxt_CommitmentsZeroOneSixTwoZeroTwoZeroEightFivenDxDdSCqVxKPigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse50005falsefalsefalsexbrli:monetaryItemTypemonetaryCommitments 8No definition available.false2Commitments 89false 4igxt_CommitmentsZeroOneSixTwoZeroTwoZeroEightFiveThreehEightRNTpGTSixHfigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse50005falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCommitments 9No definition available.false2Commitments 910false 4igxt_CommitmentsZeroOneSixTwoZeroTwoZeroEightFivenRTZeroFourMrKCTwoXKigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse25002falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCommitments 10No definition available.false2Commitments 1011false 4igxt_CommitmentsZeroOneSixTwoZeroTwoZeroEightFiveNhdRQrCNinemFCmigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse25002falsefalsefalsexbrli:monetaryItemTypemonetaryCommitments 11No definition available.false2Commitments 1112false 4igxt_CommitmentsZeroOneSixTwoZeroTwoZeroEightFivercFivehXbNsQbZTigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse25002USD$falsetruefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCommitments 12No definition available.false2Commitments 1213false 4igxt_CommitmentsZeroOneSixTwoZeroTwoZeroEightFiveBOneTbWkZRJxBtigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse0.100.10falsefalsefalse2truetruefalse0.100.10falsefalsefalsenum:percentItemTypepureCommitments 13No definition available.false0Commitments 13falseCommitments (Narrative) (Details)ThousandsUnKnownUnKnownUnKnowntruefalsetrueSheethttp://www.intelgenx.com/taxonomy/role/DisclosureCommitmentsAndContingenciesDisclosureTextBlockDetails213 XML 26 R44.xml IDEA: Schedule of Stock Options Valuation - May 12, 2011 (Details) 2.4.0.8145 - Disclosure - Schedule of Stock Options Valuation - May 12, 2011 (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00yStandardhttp://www.xbrl.org/2009/utrYutr0pureStandardhttp://www.xbrl.org/2003/instancepure0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_ScheduleOfStockOptionsValuationMayOneTwoTwoZeroOneOneZeroOneSixTwoZeroTwoZeroEightFivepSixVFourXSBsSixTHwigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse1.151.15falsefalsefalsenum:percentItemTypepureAdditional Paid-in Capital Schedule Of Stock Options Valuation - May 12, 2011 1No definition available.false0Additional Paid-in Capital Schedule Of Stock Options Valuation - May 12, 2011 12false 4igxt_ScheduleOfStockOptionsValuationMayOneTwoTwoZeroOneOneZeroOneSixTwoZeroTwoZeroEightFivehKywDQsZNmqEightigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse3.13.1falsefalsefalsexbrli:decimalItemTypedecimalAdditional Paid-in Capital Schedule Of Stock Options Valuation - May 12, 2011 2No definition available.false256Additional Paid-in Capital Schedule Of Stock Options Valuation - May 12, 2011 23false 4igxt_ScheduleOfStockOptionsValuationMayOneTwoTwoZeroOneOneZeroOneSixTwoZeroTwoZeroEightFivezvdXFourlXHlhqfigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse0.00960.0096falsefalsefalsenum:percentItemTypepureAdditional Paid-in Capital Schedule Of Stock Options Valuation - May 12, 2011 3No definition available.false0Additional Paid-in Capital Schedule Of Stock Options Valuation - May 12, 2011 34false 4igxt_ScheduleOfStockOptionsValuationMayOneTwoTwoZeroOneOneZeroOneSixTwoZeroTwoZeroEightFiveDdpxBcqGqlThreeQigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00USD$falsetruefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stock Options Valuation - May 12, 2011 4No definition available.false2Additional Paid-in Capital Schedule Of Stock Options Valuation - May 12, 2011 4falseSchedule of Stock Options Valuation - May 12, 2011 (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlockDetails14 XML 27 R32.xml IDEA: Intangible Assets (Narrative) (Details) 2.4.0.8133 - Disclosure - Intangible Assets (Narrative) (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2013_TO_31_March_2013http://www.sec.gov/CIK0001098880duration2013-01-01T00:00:002013-03-31T00:00:00pureStandardhttp://www.xbrl.org/2003/instancepure0mStandardhttp://www.xbrl.org/2009/utrMutr0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00mStandardhttp://www.xbrl.org/2009/utrMutr0pureStandardhttp://www.xbrl.org/2003/instancepure0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_IntangibleAssetsZeroOneFourSevenFourZerolxdtEightQSrgcXZeroigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse106106USD$falsetruefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryIntangible Assets 1No definition available.false2Intangible Assets 12false 4igxt_IntangibleAssetsZeroOneFourSevenFourZeroMVwwrStTTwonmHigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse116116falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryIntangible Assets 2No definition available.false2Intangible Assets 23false 4igxt_IntangibleAssetsZeroOneFourSevenFourZeroTThreeSevenTmgyNineSixGFourMigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse1.001.00falsefalsefalse2falsetruefalse00falsefalsefalsenum:percentItemTypepureIntangible Assets 3No definition available.false0Intangible Assets 34false 4igxt_IntangibleAssetsZeroOneFourSevenFourZeroTwoZMhGLdmrtghigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse3939falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:decimalItemTypedecimalIntangible Assets 4No definition available.false256Intangible Assets 45false 4igxt_IntangibleAssetsZeroOneSixTwoZeroTwoZeroEightFiveZEightqkWSevenZNkdFwigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse116000116000falsefalsefalsexbrli:monetaryItemTypemonetaryIntangible Assets 1No definition available.false2Intangible Assets 16false 4igxt_IntangibleAssetsZeroOneSixTwoZeroTwoZeroEightFivenTwoVTGnNlrxzPigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse125000125000USD$falsetruefalsexbrli:monetaryItemTypemonetaryIntangible Assets 2No definition available.false2Intangible Assets 27false 4igxt_IntangibleAssetsZeroOneSixTwoZeroTwoZeroEightFiveLFiveMMsgEightzSixlSkigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsetruefalse00falsefalsefalse2truetruefalse1.001.00falsefalsefalsenum:percentItemTypepureIntangible Assets 3No definition available.false0Intangible Assets 38false 4igxt_IntangibleAssetsZeroOneSixTwoZeroTwoZeroEightFiveOneGFourdSixPcSixJFourHFiveigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse3939falsefalsefalsexbrli:decimalItemTypedecimalIntangible Assets 4No definition available.false256Intangible Assets 4falseIntangible Assets (Narrative) (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureIntangibleAssetsDisclosureTextBlockDetails28 XML 28 R25.xml IDEA: Commitments (Tables) 2.4.0.8126 - Disclosure - Commitments (Tables)truefalsefalse1false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="40%"> <tr valign="top"> <td align="left" bgcolor="#e6efff">2013</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="10%"> 15 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td align="left">2014</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="10%"> 0 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr valign="top"> <td align="left" bgcolor="#e6efff">Total</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 3px double" width="1%">$</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 3px double" width="10%"> 15 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 3px double" width="2%"> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737 false0Schedule of future minimum payments under operating leases [Table Text Block]falseCommitments (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables11 XML 29 R48.htm IDEA: XBRL DOCUMENT

Schedule of Stock Options Valuation - December 4, 2012 (Details) (USD $)	12 Months Ended
	Dec. 31, 2012 Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 1	78.00%
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 2	3.1
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 3	0.34%
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 4	$ 0

XML 30 R57.htm IDEA: XBRL DOCUMENT

Schedule of Cash Flow, Supplemental Disclosures (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Statement Of Cash Flows Information Schedule Of Cash Flow, Supplemental Disclosures 1	$ 3
Statement Of Cash Flows Information Schedule Of Cash Flow, Supplemental Disclosures 2	$ 3

XML 31 R38.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2013	Dec. 31, 2012
Related Party Transactions 1	$ 2
Related Party Transactions 2	1
Related Party Transactions 3	3
Related Party Transactions 4	2
Related Party Transactions 5	4
Related Party Transactions 6	7
Related Party Transactions 7	22
Related Party Transactions 8	27
Related Party Transactions 9	54
Related Party Transactions 10	0
Related Party Transactions 1		6,000
Related Party Transactions 2		4,000
Related Party Transactions 3		6,000
Related Party Transactions 4		4,000
Related Party Transactions 5		23,000
Related Party Transactions 6		10,000
Related Party Transactions 7		114,000
Related Party Transactions 8		87,000
Related Party Transactions 9		85,000
Related Party Transactions 10		1.00%
Related Party Transactions 11		0
Related Party Transactions 12		$ 1,000

XML 32 R27.htm IDEA: XBRL DOCUMENT

Additional Paid-In Capital (Tables)

12 Months Ended

Dec. 31, 2012

Schedule of Stock Options Valuation - May 12, 2011 [Table Text Block]

	Expected volatility	115%
	Expected life	3.1 years
	Risk-free interest rate	0.96%
	Dividend yield	nil

Schedule of Stock Options Valuation - November 29, 2011 [Table Text Block]

	Expected volatility	101%
	Expected life	3.1 years
	Risk-free interest rate	0.40%
	Dividend yield	nil

Schedule of Stock Options Valuation - June 13, 2012 [Table Text Block]

	Expected volatility	83%
	Expected life	3.1 years
	Risk-free interest rate	0.40%
	Dividend yield	nil

Schedule of Stock Options Valuation - August 8, 2012 [Table Text Block]

	Expected volatility	81%
	Expected life	1.8 years
	Risk-free interest rate	0.38%
	Dividend yield	nil

Schedule of Stock Options Valuation - December 4, 2012 [Table Text Block]

	Expected volatility	78%
	Expected life	3.1 years
	Risk-free interest rate	0.34%
	Dividend yield	nil

Schedule of Stock Options Valuation - December 12, 2012 [Table Text Block]

	Expected volatility	70%
	Expected life	1.8 years
	Risk-free interest rate	0.25%
	Dividend yield	nil

Schedule of Stock Option Activity [Table Text Block]

			Weighted average
	Number of options		exercise price
			$

Outstanding – January 1, 2011	1,698,088		0.53

Granted	290,000		0.54
Forfeited	(150,000	)	(0.76	)
Expired	(65,000	)	(0.59	)
Exercised	(775,000	)	(0.41	)

Outstanding – December 31, 2011	998,088		0.59

Granted	195,000		0.57
Forfeited	(45,000	)	(0.49	)
Expired	(32,500	)	(1.15	)
Exercised	(50,000	)	(0.55	)

Outstanding – December 31, 2012	1,065,588		0.58

Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity [Table Text Block]

	Outstanding options				Exercisable options

			Weighted			Weighted
		Weighted average	average	Aggregate		average	Aggregate
Exercise	Number of	remaining	exercise	intrinsic	Number of	exercise	intrinsic
prices	options	contractual life	price	value	options	price	value
$		(years)	$	$		$	$

0.31	25,000	1.25	0.31		25,000	0.31
0.37	75,000	2.67	0.37		75,000	0.37
0.45 - 0.47	175,000	1.42	0.46		175,000	0.46
0.51	40,000	4.50	0.51		0	0.00
0.52 - 0.54	270,000	3.89	0.54		147,500	0.54
0.55	50,000	2.67	0.55		12,500	0.55
0.60	55,000	5.00	0.60		0	0.00
0.61	125,000	1.51	0.61		125,000	0.61
0.62	50,000	3.00	0.62		0	0.00
0.85	200,588	0.63	0.85		200,588	0.85
	1,065,588	2.60	0.58	114,050	760,588	0.59	86,725

Schedule of Warrants Valuation - June 21, 2011 [Table Text Block]

	Expected volatility	117%
	Expected life	3 years
	Risk-free interest rate	0.69%
	Dividend yield	nil

Schedule of Warrants Valuation - June 21, 2011 [Table Text Block]

	Expected volatility	117%
	Expected life	3 years
	Risk-free interest rate	0.69%
	Dividend yield	nil

Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block]

	Number of		Weighted average
	warrants		exercise price
	(All Exercisable)		$

Outstanding – January 1, 2011	21,291,223		0.66

Attached to private placements	2,748,165		0.74
Agents’ warrants exercised	(299,406	)	(0.47	)
Exercised	(4,366,904	)	(0.51	)

Outstanding - December 31, 2011	19,373,078		0.71

Agents’ warrants exercised	(219,313	)	(0.47	)
Exercised	(1,205,668	)	(0.48	)
Expired	(11,843,932	)	(0.80	)

Outstanding - December 31, 2012	6,104,165		0.59

XML 33 R26.htm IDEA: XBRL DOCUMENT

Capital Stock (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2013

Dec. 31, 2012

Schedule of Stock by Class [Table Text Block]

		March 31,		December 31,
		2013		2012
Authorized -
100,000,000 common shares of $0.00001 par value
20,000,000 preferred shares of $0.00001 par value
Issued -
50,302,921 (December 31, 2012 - 49,890,421) common shares	$	503	$	499

		2012		2011
Authorized -
100,000,000 common shares of $0.00001 par value
20,000,000 preferred shares of $0.00001 par value
Issued -
49,890,421 (December 31, 2011 - 48,895,028) common shares	$	499	$	489

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 150

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=14643745&loc=d3e177068-122764

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6403732&loc=d3e21300-112643

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21553-112644

+ Details

XML 34 R56.xml IDEA: Schedule of Deferred Tax Assets and Liabilities (Details) 2.4.0.8157 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_ScheduleOfDeferredTaxAssetsAndLiabilitiesZeroOneSixTwoZeroTwoZeroEightFiveSevenqqSixEightLSRrDXJigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1313USD$falsetruefalsexbrli:monetaryItemTypemonetaryIncome Tax Schedule Of Deferred Tax Assets And Liabilities 1No definition available.false2Income Tax Schedule Of Deferred Tax Assets And Liabilities 12false 4igxt_ScheduleOfDeferredTaxAssetsAndLiabilitiesZeroOneSixTwoZeroTwoZeroEightFiveLMhzJThreeRJFVFourdigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1414falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax Schedule Of Deferred Tax Assets And Liabilities 2No definition available.false2Income Tax Schedule Of Deferred Tax Assets And Liabilities 23false 4igxt_ScheduleOfDeferredTaxAssetsAndLiabilitiesZeroOneSixTwoZeroTwoZeroEightFiveMcbdQFrNsGBFiveigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse22782278falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax Schedule Of Deferred Tax Assets And Liabilities 3No definition available.false2Income Tax Schedule Of Deferred Tax Assets And Liabilities 34false 4igxt_ScheduleOfDeferredTaxAssetsAndLiabilitiesZeroOneSixTwoZeroTwoZeroEightFiveqpkNMTdbThreeVlJigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse21402140falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax Schedule Of Deferred Tax Assets And Liabilities 4No definition available.false2Income Tax Schedule Of Deferred Tax Assets And Liabilities 45false 4igxt_ScheduleOfDeferredTaxAssetsAndLiabilitiesZeroOneSixTwoZeroTwoZeroEightFiveSevenfxxLfTwowFNThreeLigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse13011301falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax Schedule Of Deferred Tax Assets And Liabilities 5No definition available.false2Income Tax Schedule Of Deferred Tax Assets And Liabilities 56false 4igxt_ScheduleOfDeferredTaxAssetsAndLiabilitiesZeroOneSixTwoZeroTwoZeroEightFiveqThreetTwozNEightfdtKgigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse11411141falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax Schedule Of Deferred Tax Assets And Liabilities 6No definition available.false2Income Tax Schedule Of Deferred Tax Assets And Liabilities 67false 4igxt_ScheduleOfDeferredTaxAssetsAndLiabilitiesZeroOneSixTwoZeroTwoZeroEightFiveJHWJrvPplhsZeroigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse914914falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax Schedule Of Deferred Tax Assets And Liabilities 7No definition available.false2Income Tax Schedule Of Deferred Tax Assets And Liabilities 78false 4igxt_ScheduleOfDeferredTaxAssetsAndLiabilitiesZeroOneSixTwoZeroTwoZeroEightFiveCBMsTlHkMmlFigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse807807falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax Schedule Of Deferred Tax Assets And Liabilities 8No definition available.false2Income Tax Schedule Of Deferred Tax Assets And Liabilities 89false 4igxt_ScheduleOfDeferredTaxAssetsAndLiabilitiesZeroOneSixTwoZeroTwoZeroEightFivecBwdpkNineHSixRBEightigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse45064506falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax Schedule Of Deferred Tax Assets And Liabilities 9No definition available.false2Income Tax Schedule Of Deferred Tax Assets And Liabilities 910false 4igxt_ScheduleOfDeferredTaxAssetsAndLiabilitiesZeroOneSixTwoZeroTwoZeroEightFiverThreeBLMFiveBgXZeroNSevenigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse41024102falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax Schedule Of Deferred Tax Assets And Liabilities 10No definition available.false2Income Tax Schedule Of Deferred Tax Assets And Liabilities 1011false 4igxt_ScheduleOfDeferredTaxAssetsAndLiabilitiesZeroOneSixTwoZeroTwoZeroEightFiveThreeVfLZeroTdSNyHpigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-4506-4506falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax Schedule Of Deferred Tax Assets And Liabilities 11No definition available.false2Income Tax Schedule Of Deferred Tax Assets And Liabilities 1112false 4igxt_ScheduleOfDeferredTaxAssetsAndLiabilitiesZeroOneSixTwoZeroTwoZeroEightFiveZvcvdNinefNineMKHTwoigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-4102-4102falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax Schedule Of Deferred Tax Assets And Liabilities 12No definition available.false2Income Tax Schedule Of Deferred Tax Assets And Liabilities 1213false 4igxt_ScheduleOfDeferredTaxAssetsAndLiabilitiesZeroOneSixTwoZeroTwoZeroEightFiveEightSevenTwoPGHRPvnWvigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax Schedule Of Deferred Tax Assets And Liabilities 13No definition available.false2Income Tax Schedule Of Deferred Tax Assets And Liabilities 1314false 4igxt_ScheduleOfDeferredTaxAssetsAndLiabilitiesZeroOneSixTwoZeroTwoZeroEightFivexWNGSixmXncSLrigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00USD$falsetruefalsexbrli:monetaryItemTypemonetaryIncome Tax Schedule Of Deferred Tax Assets And Liabilities 14No definition available.false2Income Tax Schedule Of Deferred Tax Assets And Liabilities 14falseSchedule of Deferred Tax Assets and Liabilities (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlockDetails114 XML 35 R46.htm IDEA: XBRL DOCUMENT

Schedule of Stock Options Valuation - June 13, 2012 (Details) (USD $)	12 Months Ended
	Dec. 31, 2012 Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - June 13, 2012 1	83.00%
Additional Paid-in Capital Schedule Of Stock Options Valuation - June 13, 2012 2	3.1
Additional Paid-in Capital Schedule Of Stock Options Valuation - June 13, 2012 3	0.40%
Additional Paid-in Capital Schedule Of Stock Options Valuation - June 13, 2012 4	$ 0

XML 36 R34.htm IDEA: XBRL DOCUMENT

Commitments (Narrative) (Details) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2012 USD ($) Y	Dec. 31, 2012 CAD
Commitments 1	3,500	3,500
Commitments 2	6,425	6,425
Commitments 3	6,410	6,410
Commitments 4	6,420	6,420
Commitments 5	28,600	28,600
Commitments 6	10	10
Commitments 7	$ 4
Commitments 8		5
Commitments 9	5
Commitments 10	2
Commitments 11		2
Commitments 12	$ 2
Commitments 13	10.00%	10.00%

XML 37 R57.xml IDEA: Schedule of Cash Flow, Supplemental Disclosures (Details) 2.4.0.8158 - Disclosure - Schedule of Cash Flow, Supplemental Disclosures (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_ScheduleOfCashFlowSupplementalDisclosuresZeroOneSixTwoZeroTwoZeroEightFivecpHFiveSwNqFourxnZigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse33USD$falsetruefalsexbrli:monetaryItemTypemonetaryStatement Of Cash Flows Information Schedule Of Cash Flow, Supplemental Disclosures 1No definition available.false2Statement Of Cash Flows Information Schedule Of Cash Flow, Supplemental Disclosures 12false 4igxt_ScheduleOfCashFlowSupplementalDisclosuresZeroOneSixTwoZeroTwoZeroEightFivefMZzKKbZrKmhigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse33USD$falsetruefalsexbrli:monetaryItemTypemonetaryStatement Of Cash Flows Information Schedule Of Cash Flow, Supplemental Disclosures 2No definition available.false2Statement Of Cash Flows Information Schedule Of Cash Flow, Supplemental Disclosures 2falseSchedule of Cash Flow, Supplemental Disclosures (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfCashFlowSupplementalDisclosuresTableTextBlockDetails12 XML 38 R19.xml IDEA: Basic and Diluted Loss Per Common Share 2.4.0.8119 - Disclosure - Basic and Diluted Loss Per Common Sharetruefalsefalse1false falsefalsecx_31_January_2013_TO_31_March_2013http://www.sec.gov/CIK0001098880duration2013-01-31T00:00:002013-03-31T00:00:002false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_EarningsPerShareTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 9. </td> <td> Basic and Diluted Loss Per Common Share </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Basic and diluted loss per common share is calculated based on the weighted average number of shares outstanding during the period. The warrants, share-based compensation and convertible notes have been excluded from the calculation of diluted loss per share since they are anti-dilutive. </td> </tr> </table>falsefalsefalse2falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td align="left"> 14.</td> <td align="left" width="95%"> Basic and Diluted Loss Per Common Share </td> </tr> <tr> <td>  </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left">  </td> <td align="left" width="95%"> Basic and diluted loss per common share is calculated based on the weighted average number of shares outstanding during the period. The warrants and stock options have been excluded from the calculation of diluted loss per share since they are anti-dilutive. </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for earnings per share.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.21) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256 false0Basic and Diluted Loss Per Common Share [Text Block]falseBasic and Diluted Loss Per Common ShareUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock21 XML 39 R40.htm IDEA: XBRL DOCUMENT

Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2012 Y
Provisions for depreciation 1	20.00%
Provisions for depreciation 2	30.00%
Provisions for depreciation 3	$ 5
Provisions for depreciation 4	10

XML 40 R49.htm IDEA: XBRL DOCUMENT

Schedule of Stock Options Valuation - December 12, 2012 (Details) (USD $)	12 Months Ended
	Dec. 31, 2012 Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 1	70.00%
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 2	1.8
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 3	0.25%
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 4	$ 0

XML 41 R31.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2012 D
Significant Accounting Policies 1	45
Significant Accounting Policies 2	$ 600,000
Significant Accounting Policies 3	100,000
Significant Accounting Policies 4	700,000
Significant Accounting Policies 5	200,000
Significant Accounting Policies 6	500,000
Significant Accounting Policies 7	4,000,000
Significant Accounting Policies 8	1,000,000
Significant Accounting Policies 9	23,500,000
Significant Accounting Policies 10	1,000,000
Significant Accounting Policies 11	923,000
Significant Accounting Policies 12	53,000
Significant Accounting Policies 13	0
Significant Accounting Policies 14	1,282,000
Significant Accounting Policies 15	$ 1,000,000
Significant Accounting Policies 16	50.00%

XML 42 R49.xml IDEA: Schedule of Stock Options Valuation - December 12, 2012 (Details) 2.4.0.8150 - Disclosure - Schedule of Stock Options Valuation - December 12, 2012 (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00yStandardhttp://www.xbrl.org/2009/utrYutr0pureStandardhttp://www.xbrl.org/2003/instancepure0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_ScheduleOfStockOptionsValuationDecemberOneTwoTwoZeroOneTwoZeroOneSixTwoZeroTwoZeroEightFiveTwoysJPNineJzFXpligxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse0.700.70falsefalsefalsenum:percentItemTypepureAdditional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 1No definition available.false0Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 12false 4igxt_ScheduleOfStockOptionsValuationDecemberOneTwoTwoZeroOneTwoZeroOneSixTwoZeroTwoZeroEightFiveBWFivedLmLSevenSixhwEightigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1.81.8falsefalsefalsexbrli:decimalItemTypedecimalAdditional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 2No definition available.false256Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 23false 4igxt_ScheduleOfStockOptionsValuationDecemberOneTwoTwoZeroOneTwoZeroOneSixTwoZeroTwoZeroEightFiveNineEightLKxpSixMmGGLigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse0.00250.0025falsefalsefalsenum:percentItemTypepureAdditional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 3No definition available.false0Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 34false 4igxt_ScheduleOfStockOptionsValuationDecemberOneTwoTwoZeroOneTwoZeroOneSixTwoZeroTwoZeroEightFivefSevenwSdyHFourkTwoTwoQigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00USD$falsetruefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 4No definition available.false2Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 4falseSchedule of Stock Options Valuation - December 12, 2012 (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfStockOptionsValuationDecemberOneTwoTwoZeroOneTwoTableTextBlockDetails14 XML 43 R51.xml IDEA: Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity (Details) 2.4.0.8152 - Disclosure - Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00pureStandardhttp://www.xbrl.org/2003/instancepure0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveZsdSZLDGQWWPigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.310.31falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 1No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 12false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveyNshMkmDkRxzigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse2500025000USD$falsetruefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 2No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 23false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveFyFivehScnFourWSevenTwoFiveigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1.251.25falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 3No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 34false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivexrNinehThreeRtwZeroEightEightsigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.310.31falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 4No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 45false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveEightBrMTFivemSygSevenFourigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse2500025000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 5No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 56false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveSixbNineMbcRvtPQkigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.310.31falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 6No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 67false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivepctpylSevenThreehvZsigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.370.37falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 7No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 78false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveOneGFrCNineSJThreeVThreezigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse7500075000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 8No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 89false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveSixCmfbcCDhxJrigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse2.672.67falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 9No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 910false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveGnSevenKsbxRWwtrigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.370.37falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 10No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 1011false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveXZSixsThreeKSevenLDZeroygigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse7500075000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 11No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 1112false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveFVMNineZeroySevendTHhCigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.370.37falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 12No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 1213false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivetKGGHxShFiveTwoOnebigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.450.45falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 13No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 1314false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivemxbPOnecZtKfsrigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.470.47falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 14No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 1415false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivevblFourTZerosFiveSixGTfigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse175000175000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 15No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 1516false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveKfTEightNinelOneqPFourwnigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1.421.42falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 16No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 1617false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveZZerocBNSNLfFiveltigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.460.46falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 17No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 1718false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveyxZNinesCqZerodwFNigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse175000175000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 18No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 1819false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveqlSixMFourbFourFdThreeTThreeigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.460.46falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 19No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 1920false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivercXMwNinegVSixMlRigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.510.51falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 20No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 2021false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveRpnZerosTwoTVqZZeroNigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse4000040000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 21No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 2122false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivetszJDxfHEightOnerTwoigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse4.504.50falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 22No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 2223false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveSixRHKdlvZeroZWvFiveigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.510.51falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 23No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 2324false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivexLZFourqPmrZXTwoGigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 24No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 2425false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivekMZEightHZLKSDpOneigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.000.00falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 25No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 2526false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivevEightqWFourVVBNinepvZeroigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.520.52falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 26No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 2627false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivepJyhVWNineCzHNinedigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.540.54falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 27No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 2728false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveDmHNtGdSixNstNineigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse270000270000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 28No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 2829false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveZvCZWvxfktpSixigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse3.893.89falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 29No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 2930false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveVEightyTzdVEightOnesSixMigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.540.54falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 30No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 3031false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveLSevenDZeroQEightwTlKgNineigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse147500147500falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 31No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 3132false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveSixnRCSwkyMgZerohigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.540.54falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 32No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 3233false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveQcHBnOnedMRVSevenzigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.550.55falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 33No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 3334false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveEightQCFourbZTswlQDigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse5000050000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 34No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 3435false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveZerogFourTPZeroTwryJWigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse2.672.67falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 35No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 3536false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveBOnebfSixwWklXqNigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.550.55falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 36No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 3637false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveBkNMzkGZpZeroBqigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1250012500falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 37No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 3738false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveDbbVkXMWFourmJBigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.550.55falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 38No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 3839false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveqhhqpRFourJMFkTwoigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.600.60falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 39No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 3940false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveQNzSTzTHtnpGigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse5500055000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 40No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 4041false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveThreeLGdMgfHlSevenOneligxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse5.005.00falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 41No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 4142false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveSixvNpybFiveBBNinesrigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.600.60falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 42No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 4243false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveSixgSsEightSixFourSixFiveVNineJigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 43No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 4344false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveBTLfKxOneyckHCigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.000.00falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 44No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 4445false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveSixyLRlgNzXLTQigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.610.61falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 45No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 4546false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveEightBEightThreeJkSixThreeGWLdigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse125000125000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 46No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 4647false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveCsqKZZerolyxBkSigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1.511.51falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 47No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 4748false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveOnePDMhTTwoyBXXGigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.610.61falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 48No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 4849false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivedrwhcNccSixhkhigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse125000125000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 49No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 4950false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveFivemZEightJFiveJxmbdnigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.610.61falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 50No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 5051false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveqtpgptfdzmNineThreeigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.620.62falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 51No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 5152false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveNFiveSevensFTFourrknPqigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse5000050000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 52No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 5253false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveFourxplFourPThreedTbygigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse3.003.00falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 53No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 5354false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveFourTJKvWThZerobOneMigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.620.62falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 54No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 5455false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivetsRTVhbOneKNineJPigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 55No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 5556false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveFiveGxfmtcbHKDmigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.000.00falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 56No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 5657false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivehmTOnebpThreeDOnemTwoSixigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.850.85falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 57No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 5758false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveBHWWThreeSgnFivectdigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse200588200588falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 58No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 5859false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivefzvhmBFourkXDsbigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.630.63falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 59No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 5960false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivegsSOneTQNineqbEightNineTigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.850.85falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 60No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 6061false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveTwotvFourlnvdrvEightFiveigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse200588200588falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 61No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 6162false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveqlZsThreegFivemxlqTigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.850.85falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 62No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 6263false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivebTJyRSvqvRkxigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse10655881065588falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 63No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 6364false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveTTwoNineFQFiveSDDTZeroHigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse2.602.60falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 64No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 6465false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivezFiveTPRzGxxfEightvigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.580.58falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 65No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 6566false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveDNineQrVsgZeroqSevenlGigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse114050114050falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 66No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 6667false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveHbRmnzfXDwTwoThreeigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse760588760588falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 67No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 6768false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveFourgOnedsvySQBDRigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.590.59falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 68No definition available.false0Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 6869false 4igxt_ScheduleOfSharebasedCompensationStockOptionsAndWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivecVJWPwfZTMCNigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse8672586725USD$falsetruefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 69No definition available.false2Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 69falseSchedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfShareBasedCompensationStockOptionsActivityAndWarrantsOrRightsActivityTableTextBlockDetails169 XML 44 R9.xml IDEA: Significant Accounting Policies 2.4.0.8109 - Disclosure - Significant Accounting Policiestruefalsefalse1false falsefalsecx_01_January_2013_TO_31_March_2013http://www.sec.gov/CIK0001098880duration2013-01-01T00:00:002013-03-31T00:00:002false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_SignificantAccountingPoliciesTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 3. </td> <td> Significant Accounting Policies </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Recently Issued Accounting Pronouncements </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> In December 2011, the FASB issued Update No. 2011-12, “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05”. The amendments in this Update supersede changes to those paragraphs in Update 2011 - 05 that pertain to how, when, and where reclassification adjustments are presented. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations, but may affect the presentation of Other Comprehensive Income in the Company’s financial statements. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> In February 2013, the FASB issued Update No. 2013-04, “Liabilities (Topic 405)—Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date”. The amendments in this Update provide guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this Update is fixed at the reporting date, except for obligations addressed within existing guidance in U.S. GAAP. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. The guidance in this Update also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. For public entities, the amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments shall be applied retrospectively to all prior periods presented for those obligations that exist at the beginning of the fiscal year of adoption. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> In March 2013, the FASB issued Update No. 2013-05, “Foreign Currency Matters (Topic 830)—Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity”. The amendments in this Update resolve the diversity in practice about whether Subtopic 810 - 10, Consolidation—Overall, or Subtopic 830 - 30, Foreign Currency Matters—Translation of Financial Statements, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, the amendments in this Update resolve the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. For public entities, the amendments in this ASU are effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2013. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. </td> </tr> </table>falsefalsefalse2falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 4. </td> <td> Summary of Significant Accounting Policies </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Revenue Recognition </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The Company recognizes revenue from research and development contracts as the contracted services are performed or when milestones are achieved, in accordance with the terms of the specific agreements and when collection of the payment is reasonably assured. In addition, the performance criteria for the achievement of milestones are met if substantive effort was required to achieve the milestone and the amount of the milestone payment appears reasonably commensurate with the effort expended. Amounts received in advance of the recognition criteria being met, if any, are included in deferred income. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> IntelGenx has license agreements that specify that certain royalties are earned by the Company on sales of licensed products in the licensed territories. Licensees usually report sales and royalty information in the 45 days after the end of the quarter in which the activity takes place and typically do not provide forward estimates or current-quarter information. Because the Company is not able to reasonably estimate the amount of royalties earned during the period in which these licensees actually ship products, royalty revenue is not recognized until the royalties are reported to the Company and the collection of these royalties is reasonably assured. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> In August 2010 the Company entered into a joint development and commercialization agreement with RedHill Biopharma (“RedHill”), an Israeli company, for an anti-migraine product based upon the Company’s VersaFilm™ technology. In accordance with the terms of the agreement, RedHill made up-front and milestone payments in the aggregate amount of $600 thousand, of which $100 thousand was received by the Company in 2012 upon production of pivotal batches. RedHill is required to make additional milestone payments of up to $700,000 as follows: </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> $200 thousand upon the filing of an NDA and acceptance of the filing by the U.S. Food and Drug Administration; and </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> $500 thousand upon receipt of U.S. Food and Drug Administration marketing approval for the product. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Product Sales: </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The Company launched Forfivo XL™ in the USA in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP (“Edgemont”). Under the terms of the agreement with Edgemont, the commercial launch of Forfivo XL™ triggered launch-related milestone payments for IntelGenx of up to $4.0 million, of which $1 million was invoiced by the Company to Edgemont and recognized as revenue in the fourth quarter of 2012 and the cash received in February 2013. Additional milestones of up to a further $23.5 million are payable upon achieving certain sales and exclusivity targets and the Company expects to commence receiving royalties from sales of the product in the first quarter of 2013. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Upon entering into the licensing agreement, Edgemont paid the Company an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over the period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $923 thousand at December 31, 2012 that has not been recognized as revenue. </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Use of Estimates </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management’s judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, the investment tax credits receivable, the determination of the fair value of warrants issued as part of fundraising activities, and the resulting impact on the allocation of the proceeds between the common shares and the warrants. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Financial Instruments </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The Company estimates the fair value of its financial instruments based on current interest rates, market value and pricing of financial instruments with comparable terms. Unless otherwise indicated, the carrying value of these financial instruments approximates their fair value. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Cash and Cash Equivalents </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Cash and cash equivalents is comprised of cash on hand and term deposits with original maturity dates of less than three months that are stated at cost, which approximates fair value. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Accounts Receivable </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible. In the first quarter of 2011, the Company wrote-off a receivable in the amount of $53 thousand that was owed to the Company by Circ Pharma Limited, Ireland, which was deemed to be no longer collectible. The Company records recoveries of trade receivables previously written-off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2012 accounts receivable (2011 - $Nil). The accounts receivable balance of $1,282 thousand as at December 31, 2012 includes $1 million from Edgemont that was received by IntelGenx in February 2013. </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Investment Tax Credits </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Leasehold Improvements and Equipment </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Leasehold Improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows: </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">On the declining balance method -</td> <td align="left" bgcolor="#e6efff" width="36%"> </td> </tr> <tr> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="36%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">       Laboratory and office equipment</td> <td align="left" bgcolor="#e6efff" width="36%"> 20% </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">       Computer equipment</td> <td align="left" width="36%"> 30% </td> </tr> <tr> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> </td> <td align="left" bgcolor="#e6efff" width="36%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">On the straight-line method -</td> <td align="left" width="36%"> </td> </tr> <tr> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> </td> <td align="left" bgcolor="#e6efff" width="36%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">       Leasehold improvements</td> <td align="left" width="36%">over the lease term</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">       Manufacturing equipment</td> <td align="left" bgcolor="#e6efff" width="36%"> 5 – 10 years </td> </tr> </table> Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred. Intangible Assets Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization. Impairment of Long-lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the estimated undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value thereof. <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Foreign Currency Translation </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The Company’s reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company’s Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows: </td> </tr> </table> Assets and liabilities - at exchange rates in effect at the balance sheet date; Revenue and expenses - at average exchange rates prevailing during the year; Equity - at historical rates. Gains and losses arising from foreign currency translation are included in other comprehensive income. Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Unrecognized Tax Benefits The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 “Income Taxes”. ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision. <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> Share-Based Payments </td> </tr> <tr> <td> </td> <td width="95%"> </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation—Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company estimates its forfeiture rate in order to determine its compensation expense arising from stock-based awards. The Company uses the Black-Scholes option pricing model to determine the fair value of the options. </td> </tr> <tr> <td> </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year. </td> </tr> <tr> <td> </td> <td width="95%">   </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> Loss Per Share </td> </tr> <tr> <td> </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share. </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Fair Value Measurements </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires new disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left">Level 1:</td> <td align="left" width="90%">Quoted market prices in active markets for identical assets or liabilities.</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Level 2:</td> <td align="left" width="90%">Observable market based inputs or unobservable inputs that are corroborated by market data.</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Level 3:</td> <td align="left" width="90%">Unobservable inputs that are not corroborated by market data.</td> </tr> </table> In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. There are no assets or liabilities measured at fair value as at December 31, 2012. Fair Value of Financial Instruments The fair value represents management’s best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization. Recent Accounting Pronouncements In December 2011, the FASB issued Update No. 2011-11, “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities”. The objective of this Update is to provide enhanced disclosures that will enable users of its financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position. This includes the effect or potential effect of rights of setoff associated with an entity’s recognized assets and recognized liabilities within the scope of this Update. The amendments require enhanced disclosures by requiring improved information about financial instruments and derivative instruments that are either (1) offset in accordance with either Section 210-20-45 or Section 815-10-45 or (2) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either Section 210-20-45 or Section 815-10-45. ASU 2011-11 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. Retrospective disclosure is required for all comparative periods presented. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> In December 2011, the FASB issued Update No. 2011-12, “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05”. The amendments in this Update supersede changes to those paragraphs in Update 2011-05 that pertain to how, when, and where reclassification adjustments are presented. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations, but will affect the presentation of Other Comprehensive Income in the Company’s financial statements. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for all significant accounting policies of the reporting entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 22 -Paragraph 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790 false0Significant Accounting Policies [Text Block]falseSignificant Accounting PoliciesUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock21 XML 45 R43.htm IDEA: XBRL DOCUMENT

Schedule of Stock by Class (Details) (USD $)	3 Months Ended	12 Months Ended
Schedule of Stock by Class (Details) (USD $)	Mar. 31, 2013	Dec. 31, 2012
Capital Stock Schedule Of Stock By Class 1	$ 0
Capital Stock Schedule Of Stock By Class 2	100,000,000
Capital Stock Schedule Of Stock By Class 3	0.00001
Capital Stock Schedule Of Stock By Class 4	20,000,000
Capital Stock Schedule Of Stock By Class 5	0.00001
Capital Stock Schedule Of Stock By Class 7	50,302,921
Capital Stock Schedule Of Stock By Class 8	49,890,421
Capital Stock Schedule Of Stock By Class 9	503
Capital Stock Schedule Of Stock By Class 10	499
Capital Stock Schedule Of Stock By Class 1		100,000,000
Capital Stock Schedule Of Stock By Class 2		0.00001
Capital Stock Schedule Of Stock By Class 3		20,000,000
Capital Stock Schedule Of Stock By Class 4		0.00001
Capital Stock Schedule Of Stock By Class 5		49,890,421
Capital Stock Schedule Of Stock By Class 6		48,895,028
Capital Stock Schedule Of Stock By Class 7		499
Capital Stock Schedule Of Stock By Class 8		$ 489

XML 46 R12.xml IDEA: Deferred License Revenue 2.4.0.8112 - Disclosure - Deferred License Revenuetruefalsefalse1false falsefalsecx_01_January_2013_TO_31_March_2013http://www.sec.gov/CIK0001098880duration2013-01-01T00:00:002013-03-31T00:00:002false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_DeferredRevenueDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 5. </td> <td> Deferred License Revenue </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Deferred license revenue represents upfront payments received for the granting of licenses to the Company’s patents, intellectual property, and proprietary technology, for commercialization. Deferred license revenue is recognized in income over the period where sales of the licensed products will occur. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Upon entering into the licensing agreement with Edgemont Pharmaceuticals the Company received an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over a period of 39 months, which is the minimum period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $847 thousand at March 31, 2013 that has not been recognized as revenue. </td> </tr> </table>falsefalsefalse2falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 7.</td> <td> Deferred License Revenue </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> Deferred license revenue represents upfront payments received for the granting of licenses to the Company’s patents, intellectual property, and proprietary technology, for commercialization. Deferred license revenue is recognized in income over the period where sales of the licensed products will occur. </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> Upon entering into the licensing agreement with Edgemont Pharmaceuticals the Company received an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over a period of 39 months, which is the minimum period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $923 thousand at December 31, 2012 that has not been recognized as revenue. </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.3(b).Q1(c),(b).Q2,(c).Q3) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Concepts (CON) -Number 5 -Paragraph 83, 84 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Deferred License Revenue [Text Block]falseDeferred License RevenueUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsDeferredRevenueDisclosureTextBlock21 XML 47 R46.xml IDEA: Schedule of Stock Options Valuation - June 13, 2012 (Details) 2.4.0.8147 - Disclosure - Schedule of Stock Options Valuation - June 13, 2012 (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00yStandardhttp://www.xbrl.org/2009/utrYutr0pureStandardhttp://www.xbrl.org/2003/instancepure0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_ScheduleOfStockOptionsValuationJuneOneThreeTwoZeroOneTwoZeroOneSixTwoZeroTwoZeroEightFivevmTwoyTKbHnZerolTwoigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse0.830.83falsefalsefalsenum:percentItemTypepureAdditional Paid-in Capital Schedule Of Stock Options Valuation - June 13, 2012 1No definition available.false0Additional Paid-in Capital Schedule Of Stock Options Valuation - June 13, 2012 12false 4igxt_ScheduleOfStockOptionsValuationJuneOneThreeTwoZeroOneTwoZeroOneSixTwoZeroTwoZeroEightFiveSevenFourWtOnelDkPXZeroFourigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse3.13.1falsefalsefalsexbrli:decimalItemTypedecimalAdditional Paid-in Capital Schedule Of Stock Options Valuation - June 13, 2012 2No definition available.false256Additional Paid-in Capital Schedule Of Stock Options Valuation - June 13, 2012 23false 4igxt_ScheduleOfStockOptionsValuationJuneOneThreeTwoZeroOneTwoZeroOneSixTwoZeroTwoZeroEightFivelZeroTwoFiveVZTJHJSevenPigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse0.00400.0040falsefalsefalsenum:percentItemTypepureAdditional Paid-in Capital Schedule Of Stock Options Valuation - June 13, 2012 3No definition available.false0Additional Paid-in Capital Schedule Of Stock Options Valuation - June 13, 2012 34false 4igxt_ScheduleOfStockOptionsValuationJuneOneThreeTwoZeroOneTwoZeroOneSixTwoZeroTwoZeroEightFivepnFourJBSevenmZeroqNineSnigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00USD$falsetruefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stock Options Valuation - June 13, 2012 4No definition available.false2Additional Paid-in Capital Schedule Of Stock Options Valuation - June 13, 2012 4falseSchedule of Stock Options Valuation - June 13, 2012 (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfStockOptionsValuationJuneOneThreeTwoZeroOneTwoTableTextBlockDetails14 XML 48 R25.htm IDEA: XBRL DOCUMENT

Commitments (Tables)

12 Months Ended

Dec. 31, 2012

Schedule of future minimum payments under operating leases [Table Text Block]

2013		15
2014		0
Total	$	15

XML 49 R6.htm IDEA: XBRL DOCUMENT

Basis of Presentation

3 Months Ended

12 Months Ended

Mar. 31, 2013

Dec. 31, 2012

Basis of Presentation [Text Block]

1.	Basis of Presentation

	The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal and recurring nature.

	These financial statements should be read in conjunction with the audited consolidated financial statements at December 31, 2012. Operating results for the three months ended March 31, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.

	The consolidated financial statements include the accounts of the Company and its subsidiary companies. On consolidation, all inter-entity transactions and balances have been eliminated.

	The financial statements are expressed in U.S. funds.

	Management has performed an evaluation of the Company’s activities through the date and time these financial statements were issued and concluded that there are no additional significant events requiring recognition or disclosure.

1.	Basis of Presentation

	IntelGenx Technologies Corp. (“IntelGenx” or the “Company”) prepares its financial statements in accordance with accounting principles generally accepted in the United States of America (“USA”). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.

	The consolidated financial statements include the accounts of the Company and its subsidiary companies. On consolidation, all inter-entity transactions and balances have been eliminated.

	The financial statements are expressed in U.S. funds.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 50 R40.xml IDEA: Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment (Details) 2.4.0.8141 - Disclosure - Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00yStandardhttp://www.xbrl.org/2009/utrYutr0pureStandardhttp://www.xbrl.org/2003/instancepure0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_ScheduleOfLeaseholdImprovementsAndEquipmentZeroOneSixTwoZeroTwoZeroEightFiveFiveThreeGnNEightKSevenTwoCKCigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse0.200.20falsefalsefalsenum:percentItemTypepureProvisions for depreciation 1No definition available.false0Provisions for depreciation 12false 4igxt_ScheduleOfLeaseholdImprovementsAndEquipmentZeroOneSixTwoZeroTwoZeroEightFiveyhtJGHTdcwNFourigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse0.300.30falsefalsefalsenum:percentItemTypepureProvisions for depreciation 2No definition available.false0Provisions for depreciation 23false 4igxt_ScheduleOfLeaseholdImprovementsAndEquipmentZeroOneSixTwoZeroTwoZeroEightFiveTQQkBpqSevenCVFSevenigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse55USD$falsetruefalsexbrli:monetaryItemTypemonetaryProvisions for depreciation 3No definition available.false2Provisions for depreciation 34false 4igxt_ScheduleOfLeaseholdImprovementsAndEquipmentZeroOneSixTwoZeroTwoZeroEightFivegCSixSevensvtwqTThreeyigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1010falsefalsefalsexbrli:decimalItemTypedecimalProvisions for depreciation 4No definition available.false256Provisions for depreciation 4falseSchedule of Estimated Useful Lives of Leasehold Improvements and Equipment (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureEstimatedUsefulLivesOnTheDecliningBalanceMethodTableTextBlockDetails14 XML 51 R52.xml IDEA: Schedule of Warrants Valuation - June 21, 2011 (Details) 2.4.0.8153 - Disclosure - Schedule of Warrants Valuation - June 21, 2011 (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00yStandardhttp://www.xbrl.org/2009/utrYutr0pureStandardhttp://www.xbrl.org/2003/instancepure0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_ScheduleOfWarrantsValuationJuneTwoOneTwoZeroOneOneZeroOneSixTwoZeroTwoZeroEightFivePRMqxFvSevenfTwoGgigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse1.171.17falsefalsefalsenum:percentItemTypepureAdditional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 1No definition available.false0Additional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 12false 4igxt_ScheduleOfWarrantsValuationJuneTwoOneTwoZeroOneOneZeroOneSixTwoZeroTwoZeroEightFiveqRWEightcvXOneZgvVigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse33falsefalsefalsexbrli:decimalItemTypedecimalAdditional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 2No definition available.false256Additional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 23false 4igxt_ScheduleOfWarrantsValuationJuneTwoOneTwoZeroOneOneZeroOneSixTwoZeroTwoZeroEightFivebTCttZrKCEightfHigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse0.00690.0069falsefalsefalsenum:percentItemTypepureAdditional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 3No definition available.false0Additional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 34false 4igxt_ScheduleOfWarrantsValuationJuneTwoOneTwoZeroOneOneZeroOneSixTwoZeroTwoZeroEightFivefyRvgsGyvqWSevenigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00USD$falsetruefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 4No definition available.false2Additional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 4falseSchedule of Warrants Valuation - June 21, 2011 (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlockDetails14 XML 52 R8.htm IDEA: XBRL DOCUMENT

Adoption of New Accounting Standards

3 Months Ended

12 Months Ended

Mar. 31, 2013

Dec. 31, 2012

Adoption of New Accounting Standards [Text Block]

2.	Adoption of New Accounting Standards

	Revenue Recognition and Disclosures

	In December 2011, the FASB issued Update No. 2011-11, “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities”. The objective of this Update is to provide enhanced disclosures that will enable users of financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position. This includes the effect or potential effect of rights of setoff associated with an entity’s recognized assets and recognized liabilities within the scope of this Update. The amendments require enhanced disclosures by requiring improved information about derivatives, repurchase agreements and reverse purchase agreements, and securities borrowing and securities lending transactions that are either offset in accordance with specific criteria or subject to a master netting arrangement or similar agreement. In January 2013, the FASB also issued Update No. 2013-01, which clarifies that ordinary trade receivables and receivables are not in the scope of ASU 2011 - 11. ASU 2011 - 11 and ASU 2013 - 01 are effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. Retrospective disclosure is required for all comparative periods presented. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations.

In February 2013, the FASB has issued Update No. 2013-02, “Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income”. This Update has been issued to improve the transparency of reporting these reclassifications. The amendments in this Update supersede and replace the presentation requirements for reclassifications out of accumulated other comprehensive income in ASUs 2011 - 05 and 2011 - 12 for all public and private organizations. The amendments would require an entity to provide additional information about reclassifications out of accumulated other comprehensive income. Public companies are required to comply with these amendments for all reporting periods (interim and annual), effective for reporting periods beginning after December 15, 2012. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations.

3.	Adoption of New Accounting Standards

	In May 2011, the FASB issued Update No. 2011-04, “Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs”. The amendments in this Update result in common fair value measurement and disclosure requirements in U.S. GAAP and IFRSs. Consequently, the amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. For many of the requirements, FASB does not intend for the amendments in this Update to result in a change in the application of the requirements in Topic 820. Some of the amendments clarify FASB’s intent about the application of existing fair value measurement requirements. Other amendments change a particular principle or requirement for measuring fair value or for disclosing information about fair value measurements. For public entities, ASU 2011-4 is effective during interim and annual periods beginning after December 15, 2011. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations.

	In June 2011, the FASB issued Update No. 2011-05, “Comprehensive Income (Topic 220): Presentation of Comprehensive Income”. Under the amendments, an entity has the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both choices, an entity is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. This Update eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders’ equity. The amendments in this Update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. ASU 2011-05 should be applied retrospectively. For public entities, the amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. Early adoption is permitted. In December 2011 however, the FASB issued Update No. 2011-12, “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05”. The amendments in this Update supersede changes to those paragraphs in Update 2011-05 that pertain to how, when, and where reclassification adjustments are presented. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations.

XML 53 R11.xml IDEA: Intangible Assets 2.4.0.8111 - Disclosure - Intangible Assetstruefalsefalse1false falsefalsecx_01_January_2013_TO_31_March_2013http://www.sec.gov/CIK0001098880duration2013-01-01T00:00:002013-03-31T00:00:002false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_IntangibleAssetsDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 4. </td> <td> Intangible Assets </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> As of March 31, 2013 NDA acquisition costs of $106 thousand (December 31, 2012 - $116 thousand) were recorded as intangible assets on the Company’s balance sheet and represent the net book value of the final progress payment related to the acquisition of 100% ownership of Forfivo XL™. The asset will be amortized over its estimated useful life of 39 months. The Company commenced amortization upon commercial launch of the product in October 2012. </td> </tr> </table>falsefalsefalse2falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 6.</td> <td> Intangible Assets </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> As of December 31, 2012 NDA acquisition costs of $116 thousand (December 31, 2011 - $125 thousand) were recorded as intangible assets on the Company’s balance sheet and represent the net book value of the final progress payment related to the acquisition of 100% ownership of Forfivo XL™. The asset will be amortized over its estimated useful life of 39 months and the Company commenced amortization upon commercial launch of the product in October 2012. </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for all or part of the information related to intangible assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16373-109275 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16265-109275 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 44, 45, 46 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Intangible Assets [Text Block]falseIntangible AssetsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock21 XML 54 R11.htm IDEA: XBRL DOCUMENT

Intangible Assets

3 Months Ended

12 Months Ended

Mar. 31, 2013

Dec. 31, 2012

Intangible Assets [Text Block]

4.	Intangible Assets

	As of March 31, 2013 NDA acquisition costs of $106 thousand (December 31, 2012 - $116 thousand) were recorded as intangible assets on the Company’s balance sheet and represent the net book value of the final progress payment related to the acquisition of 100% ownership of Forfivo XL™. The asset will be amortized over its estimated useful life of 39 months. The Company commenced amortization upon commercial launch of the product in October 2012.

6.	Intangible Assets

	As of December 31, 2012 NDA acquisition costs of $116 thousand (December 31, 2011 - $125 thousand) were recorded as intangible assets on the Company’s balance sheet and represent the net book value of the final progress payment related to the acquisition of 100% ownership of Forfivo XL™. The asset will be amortized over its estimated useful life of 39 months and the Company commenced amortization upon commercial launch of the product in October 2012.

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References+ Details

XML 55 R14.xml IDEA: Capital Stock 2.4.0.8114 - Disclosure - Capital Stocktruefalsefalse1false falsefalsecx_01_January_2013_TO_31_March_2013http://www.sec.gov/CIK0001098880duration2013-01-01T00:00:002013-03-31T00:00:002false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_StockholdersEquityNoteDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 6. </td> <td> Capital Stock </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="1%"> </td> <td align="center" nowrap="nowrap" width="12%"> March 31, </td> <td align="center" nowrap="nowrap" width="2%"> </td> <td align="center" nowrap="nowrap" width="1%"> </td> <td align="center" nowrap="nowrap" width="12%"> December 31, </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="center" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 2013 </td> <td align="center" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="center" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="center" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 2012 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> Authorized - </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left"> 100,000,000 common shares of $0.00001 par value </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> 20,000,000 preferred shares of $0.00001 par value </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left"> Issued - </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid"> 50,302,921 (December 31, 2012 - 49,890,421) common shares </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> $ </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 503 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%">$</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 499 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> </table>falsefalsefalse2falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 9.</td> <td> Capital Stock </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">  </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 2012</td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 2011</td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Authorized -</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="left" bgcolor="#e6efff" width="12%">  </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="left" bgcolor="#e6efff" width="12%">  </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> 100,000,000 common shares of $0.00001 par value</td> <td align="left" width="1%">  </td> <td align="left" width="12%">  </td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="left" width="12%">  </td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff">   20,000,000 preferred shares of $0.00001 par value</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="left" bgcolor="#e6efff" width="12%">  </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="left" bgcolor="#e6efff" width="12%">  </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Issued -</td> <td align="left" width="1%">  </td> <td align="left" width="12%">  </td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="left" width="12%">  </td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid">   49,890,421 (December 31, 2011 - 48,895,028) common shares</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 499 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 489</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> </tr> </table> On June 21, 2011, as part of two concurrent private placement offerings, the Company issued approximately 4.8 million shares of common stock, and three-year warrants to purchase up to approximately 2.4 million shares of common stock, for aggregate gross proceeds of approximately US$3.2 million. Each warrant entitles the holder to purchase one half of one common share at an exercise price of $0.74 per common share and expires 36 months after the date of issuance. Proceeds were allocated between the common shares and the warrants based on their relative fair value. The common shares were recorded at a value of $2,024 thousand. (See note 10 for the portion allocated to the warrants). The private placements consisted of a definitive securities purchase agreement with certain accredited and institutional investors for the issuance and sale in a private placement transaction (the "US Private Offering") of 2,582,536 shares and warrants to purchase up to 1,291,268 shares of common stock, for aggregate gross proceeds of approximately $1.7 million, and a definitive subscription agreement solely with Canadian investors for the issuance and sale in a concurrent non-brokered private placement transaction (the "Canadian Private Offering") of 2,238,806 shares and warrants to purchase up to 1,119,403 shares of common stock, for aggregate gross proceeds of approximately $1.5 million. The Company paid an agent cash commissions in the amount of approximately $121 thousand, representing 7% of the aggregate gross proceeds received by the Company in the US Private Offering, plus expenses in the amount of approximately $28 thousand, and issued warrants to the agent to purchase 180,778 shares of common stock, representing 7% of the amount of shares sold in the US Private Offering. The Company also paid cash finder’s fees in the amount of approximately $105 thousand, representing 7% of the aggregate gross proceeds received by the Company in the Canadian Private Offering; and issued warrants to purchase 156,716 shares of common stock, representing 7% of the amount of shares sold in the Canadian Private Offering. Each warrant entitles the holder to purchase one half of one common share at an exercise price of $0.74 per common share and expires 36 months after the date of issuance. In addition, the Company paid approximately $114 thousand in cash consideration for other transaction costs, which have been reflected as a reduction of the common shares and the warrants based on their relative fair values. All of the above transaction costs have been reflected as a reduction to the common shares and the warrants based on their relative fair values. <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%">  </td> <td> In the year ended December 31, 2012 a total of 50,000 (2011 – 775,000) stock options were exercised for 50,000 (2011 – 775,000) common shares having a par value of $0 thousand (2011 - $Nil) in aggregate, for cash consideration of $28 thousand ($318 thousand), resulting in an increase in additional paid-in capital of $28 thousand (2011 – $318 thousand). </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> During the year ended December 31, 2012 a total of 219,313 (2011 - 299,406) agents’ warrants were exercised for 219,313 (2011 - 299,406) common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $104 thousand (2011 - $142 thousand), resulting in an increase in additional paid- in capital of approximately $104 thousand (2011 - $142 thousand). </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> Also in the year ended December 31, 2012 a total of 1,205,668 warrants were exercised, of which 491,382 warrants were exercised for 491,382 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $233 thousand, resulting in an increase in additional paid-in capital of approximately $233 thousand, and a total of 714,286 warrants were exercised for 234,698 common shares in cashless exercises, resulting in an increase in additional paid-in capital of $Nil. </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> In the year ended December 31, 2011 a total of 4,366,904 warrants were exercised, of which 2,902,618 warrants were exercised for 2,902,618 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $1,458 thousand, resulting in an increase in additional paid-in capital of approximately $1,458 thousand, and a total of 1,464,286 warrants were exercised for 515,391 common shares in cashless exercises, resulting in an increase in additional paid-in capital of $Nil. </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Article 4 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section B -Paragraph 7, 11A -Chapter 1 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Preferred Stock -URI http://asc.fasb.org/extlink&oid=6521494 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(d),(e)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 17: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 18: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 19: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644 Reference 20: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 21: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644 Reference 22: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644 Reference 23: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph d -Article 4 false0Capital Stock [Text Block]falseCapital StockUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock21 XML 56 R2.xml IDEA: Consolidated Balance Sheets 2.4.0.8102 - Statement - Consolidated Balance SheetstruefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$cx_31_March_2013http://www.sec.gov/CIK0001098880instant2013-03-31T00:00:000001-01-01T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$cx_31_December_2012http://www.sec.gov/CIK0001098880instant2012-12-31T00:00:000001-01-01T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$cx_31_December_2011http://www.sec.gov/CIK0001098880instant2011-12-31T00:00:000001-01-01T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 5us-gaap_AssetsCurrentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Current2false 6us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse21680002168USD$falsetruefalse2truefalsefalse20590002059USD$falsetruefalse3truefalsefalse35050003505USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Cash and cash equivalents3false 6us-gaap_AccountsReceivableNetCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse170000170falsefalsefalse2truefalsefalse12820001282falsefalsefalse3truefalsefalse263000263falsefalsefalsexbrli:monetaryItemTypemonetaryAmount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3-4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a(1) -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 false2Accounts receivable4false 6us-gaap_PrepaidExpenseCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse8900089falsefalsefalse2truefalsefalse102000102falsefalsefalse3truefalsefalse6800068falsefalsefalsexbrli:monetaryItemTypemonetarySum of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section A -Paragraph 4 -Chapter 3 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Assets -URI http://asc.fasb.org/extlink&oid=6509628 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6787-107765 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section 05 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6386993&loc=d3e5879-108316 false2Prepaid expenses5false 6us-gaap_LoansAndLeasesReceivableRelatedPartiesus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2truefalsefalse00falsefalsefalse3truefalsefalse8500085falsefalsefalsexbrli:monetaryItemTypemonetaryFor an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 57 -Paragraph 2 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.7(e)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher OTS -Name Federal Regulation (FR) -Number Title 12 -Section 563c.102 -Paragraph 8 -Subparagraph j -Chapter V -Subsection I -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy. It will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 7 -Subparagraph e -Article 9 false2Loan receivable6false 6us-gaap_TaxCreditCarryforwardAmountus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse243000243falsefalsefalse2truefalsefalse213000213falsefalsefalse3truefalsefalse375000375falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Carryforwards -URI http://asc.fasb.org/extlink&oid=6506874 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 48 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 17 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Investment tax credits receivable7false 6us-gaap_AssetsCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse26700002670falsefalsefalse2truefalsefalse36560003656falsefalsefalse3truefalsefalse42960004296falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 9 -Article 5 true2Total Current Assets8false 5us-gaap_PropertyPlantAndEquipmentNetus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse438000438falsefalsefalse2truefalsefalse387000387falsefalsefalse3truefalsefalse149000149falsefalsefalsexbrli:monetaryItemTypemonetaryAmount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 12 -Paragraph 5 -Subparagraph b, c -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Leasehold Improvements and Equipment9false 5us-gaap_IntangibleAssetsNetExcludingGoodwillus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse106000106falsefalsefalse2truefalsefalse116000116falsefalsefalse3truefalsefalse125000125falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 42, 45 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Intangible assets10false 5us-gaap_Assetsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse32140003214falsefalsefalse2truefalsefalse41590004159falsefalsefalse3truefalsefalse45700004570falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.18) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Concepts (CON) -Number 6 -Paragraph 25 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. true2Total Assets11true 5us-gaap_LiabilitiesCurrentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Current12false 6us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse498000498falsefalsefalse2truefalsefalse10580001058falsefalsefalse3truefalsefalse666000666falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Article 5 false2Accounts payable and accrued liabilities13false 6us-gaap_DeferredRevenueCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse308000308falsefalsefalse2truefalsefalse308000308falsefalsefalse3truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section A -Paragraph 7, 8 -Chapter 3 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Deferred license revenue14false 6us-gaap_LiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse806000806falsefalsefalse2truefalsefalse13660001366falsefalsefalse3truefalsefalse666000666falsefalsefalsexbrli:monetaryItemTypemonetaryTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 21 -Article 5 true2Total Curent Liabilities15false 5us-gaap_DeferredRevenueNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse539000539falsefalsefalse2truefalsefalse615000615falsefalsefalse3truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section A -Paragraph 7, 8 -Chapter 3 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 48 -Paragraph 6 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Deferred license revenue, non-current portion16false 5us-gaap_Liabilitiesus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse13450001345falsefalsefalse2truefalsefalse19810001981falsefalsefalse3truefalsefalse666000666falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 true2Total Liabilities17false 4us-gaap_CommitmentsAndContingenciesus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2truefalsefalse00falsefalsefalse3truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 25 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 7 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 17 -Article 9 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.(a),19) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 8, 9 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Commitments18true 4us-gaap_StockholdersEquityAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Shareholders' Equity19false 5us-gaap_CommonStockValueus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse10001falsefalsefalse2truefalsefalse00falsefalsefalse3truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false2Capital Stock20false 5us-gaap_AdditionalPaidInCapitalus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse1655400016554falsefalsefalse2truefalsefalse1634200016342falsefalsefalse3truefalsefalse1591800015918falsefalsefalsexbrli:monetaryItemTypemonetaryExcess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.30(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Additional Paid-in-Capital21false 5us-gaap_RetainedEarningsAccumulatedDeficitus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-14949000-14949falsefalsefalse2truefalsefalse-14463000-14463falsefalsefalse3truefalsefalse-12213000-12213falsefalsefalsexbrli:monetaryItemTypemonetaryThe cumulative amount of the reporting entity's undistributed earnings or deficit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Accumulated Deficit22false 5us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse263000263falsefalsefalse2truefalsefalse299000299falsefalsefalse3truefalsefalse199000199falsefalsefalsexbrli:monetaryItemTypemonetaryAccumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e681-108580 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669686-108580 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Staff Position (FSP) -Number FAS115-1/124-1 -Paragraph 15D -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 14, 17, 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 false2Accumulated Other Comprehensive Income23false 5us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse18690001869falsefalsefalse2truefalsefalse21780002178falsefalsefalse3truefalsefalse39040003904falsefalsefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 true2Total Stockholder Equity24false 4us-gaap_LiabilitiesAndStockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse32140003214USD$falsetruefalse2truefalsefalse41590004159USD$falsetruefalse3truefalsefalse45700004570USD$falsetruefalsexbrli:monetaryItemTypemonetaryTotal of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.32) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 32 -Article 5 true2Total Liabilities and Stockholders EquityfalseConsolidated Balance Sheets (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/BalanceSheet324 XML 57 R9.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

3 Months Ended

12 Months Ended

Mar. 31, 2013

Dec. 31, 2012

Significant Accounting Policies [Text Block]

3.	Significant Accounting Policies

	Recently Issued Accounting Pronouncements

	In December 2011, the FASB issued Update No. 2011-12, “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05”. The amendments in this Update supersede changes to those paragraphs in Update 2011 - 05 that pertain to how, when, and where reclassification adjustments are presented. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations, but may affect the presentation of Other Comprehensive Income in the Company’s financial statements.

	In February 2013, the FASB issued Update No. 2013-04, “Liabilities (Topic 405)—Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date”. The amendments in this Update provide guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this Update is fixed at the reporting date, except for obligations addressed within existing guidance in U.S. GAAP. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. The guidance in this Update also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. For public entities, the amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments shall be applied retrospectively to all prior periods presented for those obligations that exist at the beginning of the fiscal year of adoption. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.

In March 2013, the FASB issued Update No. 2013-05, “Foreign Currency Matters (Topic 830)—Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity”. The amendments in this Update resolve the diversity in practice about whether Subtopic 810 - 10, Consolidation—Overall, or Subtopic 830 - 30, Foreign Currency Matters—Translation of Financial Statements, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, the amendments in this Update resolve the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. For public entities, the amendments in this ASU are effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2013. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.

4.	Summary of Significant Accounting Policies

	Revenue Recognition

	The Company recognizes revenue from research and development contracts as the contracted services are performed or when milestones are achieved, in accordance with the terms of the specific agreements and when collection of the payment is reasonably assured. In addition, the performance criteria for the achievement of milestones are met if substantive effort was required to achieve the milestone and the amount of the milestone payment appears reasonably commensurate with the effort expended. Amounts received in advance of the recognition criteria being met, if any, are included in deferred income.

	IntelGenx has license agreements that specify that certain royalties are earned by the Company on sales of licensed products in the licensed territories. Licensees usually report sales and royalty information in the 45 days after the end of the quarter in which the activity takes place and typically do not provide forward estimates or current-quarter information. Because the Company is not able to reasonably estimate the amount of royalties earned during the period in which these licensees actually ship products, royalty revenue is not recognized until the royalties are reported to the Company and the collection of these royalties is reasonably assured.

	In August 2010 the Company entered into a joint development and commercialization agreement with RedHill Biopharma (“RedHill”), an Israeli company, for an anti-migraine product based upon the Company’s VersaFilm™ technology. In accordance with the terms of the agreement, RedHill made up-front and milestone payments in the aggregate amount of $600 thousand, of which $100 thousand was received by the Company in 2012 upon production of pivotal batches. RedHill is required to make additional milestone payments of up to $700,000 as follows:

	$200 thousand upon the filing of an NDA and acceptance of the filing by the U.S. Food and Drug Administration; and

	$500 thousand upon receipt of U.S. Food and Drug Administration marketing approval for the product.

	Product Sales:

	The Company launched Forfivo XL™ in the USA in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP (“Edgemont”). Under the terms of the agreement with Edgemont, the commercial launch of Forfivo XL™ triggered launch-related milestone payments for IntelGenx of up to $4.0 million, of which $1 million was invoiced by the Company to Edgemont and recognized as revenue in the fourth quarter of 2012 and the cash received in February 2013. Additional milestones of up to a further $23.5 million are payable upon achieving certain sales and exclusivity targets and the Company expects to commence receiving royalties from sales of the product in the first quarter of 2013.

	Upon entering into the licensing agreement, Edgemont paid the Company an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over the period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $923 thousand at December 31, 2012 that has not been recognized as revenue.

	Use of Estimates

	The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management’s judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, the investment tax credits receivable, the determination of the fair value of warrants issued as part of fundraising activities, and the resulting impact on the allocation of the proceeds between the common shares and the warrants.

	Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions.

	Financial Instruments

	The Company estimates the fair value of its financial instruments based on current interest rates, market value and pricing of financial instruments with comparable terms. Unless otherwise indicated, the carrying value of these financial instruments approximates their fair value.

	Cash and Cash Equivalents

	Cash and cash equivalents is comprised of cash on hand and term deposits with original maturity dates of less than three months that are stated at cost, which approximates fair value.

	Accounts Receivable

	The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible. In the first quarter of 2011, the Company wrote-off a receivable in the amount of $53 thousand that was owed to the Company by Circ Pharma Limited, Ireland, which was deemed to be no longer collectible. The Company records recoveries of trade receivables previously written-off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2012 accounts receivable (2011 - $Nil). The accounts receivable balance of $1,282 thousand as at December 31, 2012 includes $1 million from Edgemont that was received by IntelGenx in February 2013.

	Investment Tax Credits

	Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed.

	Leasehold Improvements and Equipment

	Leasehold Improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows:

	On the declining balance method -

	Laboratory and office equipment	20%
	Computer equipment	30%

	On the straight-line method -

	Leasehold improvements	over the lease term
	Manufacturing equipment	5 – 10 years

Intangible Assets

Impairment of Long-lived Assets

	Foreign Currency Translation

	The Company’s reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company’s Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows:

Assets and liabilities - at exchange rates in effect at the balance sheet date;

Revenue and expenses - at average exchange rates prevailing during the year;

Equity - at historical rates.

Gains and losses arising from foreign currency translation are included in other comprehensive income.

Income Taxes

Unrecognized Tax Benefits

	Share-Based Payments

	The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation—Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company estimates its forfeiture rate in order to determine its compensation expense arising from stock-based awards. The Company uses the Black-Scholes option pricing model to determine the fair value of the options.

	The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year.

	Loss Per Share

	Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share.

	Fair Value Measurements

	ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires new disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

	Level 1:	Quoted market prices in active markets for identical assets or liabilities.
	Level 2:	Observable market based inputs or unobservable inputs that are corroborated by market data.
	Level 3:	Unobservable inputs that are not corroborated by market data.

Fair Value of Financial Instruments

Recent Accounting Pronouncements

In December 2011, the FASB issued Update No. 2011-12, “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05”. The amendments in this Update supersede changes to those paragraphs in Update 2011-05 that pertain to how, when, and where reclassification adjustments are presented. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations, but will affect the presentation of Other Comprehensive Income in the Company’s financial statements.

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

XML 58 R41.htm IDEA: XBRL DOCUMENT

Schedule of Leasehold Improvements and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 1	$ 225
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 2	0
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 3	225
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 4	0
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 5	418
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 6	265
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 7	153
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 8	138
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 9	43
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 10	34
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 11	9
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 12	11
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 13	63
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 14	63
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 15	0
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 16	0
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 17	749
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 18	362
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 19	387
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 20	$ 149

XML 59 R28.htm IDEA: XBRL DOCUMENT

Income Tax (Tables)

12 Months Ended

Dec. 31, 2012

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

		2012			2011
Statutory income taxes	$	(605	)	$	(694	)
Net operating losses for which no tax benefits have been recorded		368			514
Excess of depreciation over capital cost allowance		3			(2	)
Non-deductible expenses		18			4
Undeducted research and development expenses		273			231
Tax deductible portion of transaction costs		-			-
Investment tax credit		(57	)		(53	)
Modification of warrants terms		-			-


	$	-		$	-

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

		2012			2011

Leasehold Improvements and equipment	$	13		$	14
Net operating losses carryforward		2,278			2,140
Undeducted research and development expenses		1,301			1,141
Non-refundable tax credits carryforward		914			807


		4,506			4,102

Valuation allowance		(4,506	)		(4,102	)

	$	-		$	-

XML 60 R32.htm IDEA: XBRL DOCUMENT

Intangible Assets (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended
Intangible Assets (Narrative) (Details) (USD $)	Mar. 31, 2013 M	Dec. 31, 2012 M
Intangible Assets 1	$ 106
Intangible Assets 2	116
Intangible Assets 3	100.00%
Intangible Assets 4	39
Intangible Assets 1		116,000
Intangible Assets 2		$ 125,000
Intangible Assets 3		100.00%
Intangible Assets 4		39

XML 61 R24.xml IDEA: Leasehold Improvements and Equipment (Tables) 2.4.0.8125 - Disclosure - Leasehold Improvements and Equipment (Tables)truefalsefalse1false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_PropertyPlantAndEquipmentTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%"> 2012 </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%">2011</td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left"> In US$ thousands </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%">Accumulated</td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%"> Net Carrying </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="12%">Net Carrying</td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%">Cost</td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%">Depreciation</td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> Amount </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%">Amount</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Manufacturing equipment</td> <td align="left" bgcolor="#e6efff" width="1%">$</td> <td align="right" bgcolor="#e6efff" width="12%"> 225 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%">$</td> <td align="right" bgcolor="#e6efff" width="12%"> 0 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> $ </td> <td align="right" bgcolor="#e6efff" width="12%"> 225 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%">$</td> <td align="right" bgcolor="#e6efff" width="12%"> 0 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Laboratory and office equipment</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 418 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 265 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 153 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 138 </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Computer equipment</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 43 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 34 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 9 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 11 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid">Leasehold improvements</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 63 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 63 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 0 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 0 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td bgcolor="#e6efff"> </td> <td bgcolor="#e6efff" width="1%"> </td> <td bgcolor="#e6efff" width="12%"> </td> <td bgcolor="#e6efff" width="2%"> </td> <td bgcolor="#e6efff" width="1%"> </td> <td bgcolor="#e6efff" width="12%"> </td> <td bgcolor="#e6efff" width="2%"> </td> <td bgcolor="#e6efff" width="1%"> </td> <td bgcolor="#e6efff" width="12%"> </td> <td bgcolor="#e6efff" width="2%"> </td> <td bgcolor="#e6efff" width="1%"> </td> <td bgcolor="#e6efff" width="12%"> </td> <td bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="1%">$</td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 749 </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="1%">$</td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 362 </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $ </td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 387 </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="1%">$</td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 149 </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 5 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph b -Article 5 false0Schedule of Leasehold Improvements and Equipment [Table Text Block]falseLeasehold Improvements and Equipment (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables11 XML 62 R10.xml IDEA: Leasehold Improvements and Equipment 2.4.0.8110 - Disclosure - Leasehold Improvements and Equipmenttruefalsefalse1false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_PropertyPlantAndEquipmentDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 5.</td> <td> Leasehold Improvements and Equipment </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%">  </td> <td align="left">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="12%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="12%"> 2012</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="12%"> 2011</td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> In US$ thousands</td> <td align="left" width="1%">  </td> <td align="right" width="12%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="12%"> Accumulated</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="12%"> Net Carrying</td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="12%"> Net Carrying</td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> Cost</td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> Depreciation</td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> Amount</td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> Amount</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> </tr> <tr> <td width="5%">  </td> <td>  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Manufacturing equipment</td> <td align="left" bgcolor="#e6efff" width="1%"> $</td> <td align="right" bgcolor="#e6efff" width="12%"> 225</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%"> $</td> <td align="right" bgcolor="#e6efff" width="12%"> 0</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%"> $</td> <td align="right" bgcolor="#e6efff" width="12%"> 225 </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%"> $</td> <td align="right" bgcolor="#e6efff" width="12%"> 0</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Laboratory and office equipment</td> <td align="left" width="1%">  </td> <td align="right" width="12%"> 418</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%"> 265</td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%"> 153 </td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%"> 138</td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Computer equipment</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> 43</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> 34</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> 9 </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> 11</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid"> Leasehold improvements</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 63</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 63</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 0 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 0</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> </tr> <tr> <td width="5%">  </td> <td bgcolor="#e6efff">  </td> <td bgcolor="#e6efff" width="1%">  </td> <td bgcolor="#e6efff" width="12%">  </td> <td bgcolor="#e6efff" width="2%">  </td> <td bgcolor="#e6efff" width="1%">  </td> <td bgcolor="#e6efff" width="12%">  </td> <td bgcolor="#e6efff" width="2%">  </td> <td bgcolor="#e6efff" width="1%">  </td> <td bgcolor="#e6efff" width="12%">  </td> <td bgcolor="#e6efff" width="2%">  </td> <td bgcolor="#e6efff" width="1%">  </td> <td bgcolor="#e6efff" width="12%">  </td> <td bgcolor="#e6efff" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">  </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $</td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 749</td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $</td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 362</td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $</td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 387 </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $</td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 149</td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%">  </td> <td> As of December 31, 2012 no depreciation has been recorded on manufacturing equipment as the equipment is not yet being utilized. </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 5 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13-14) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false0Leasehold Improvements and Equipment [Text Block]falseLeasehold Improvements and EquipmentUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock11 XML 63 R37.htm IDEA: XBRL DOCUMENT

Income Tax (Narrative) (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2012
Income Tax 1	$ 4,102
Income Tax 2	404
Income Tax 3	8,390
Income Tax 4	7,608
Income Tax 5	8,566
Income Tax 6	7,437
Income Tax 7	914
Income Tax 8	803
Income Tax 9	24
Income Tax 10	213
Income Tax 11	193
Income Tax 12	186
Income Tax 13	187
Income Tax 14	111
Income Tax 15	4,464
Income Tax 16	$ 3,656

XML 64 R5.xml IDEA: Consolidated Statement of Shareholders Equity 2.4.0.8105 - Statement - Consolidated Statement of Shareholders EquitytruefalseIn Thousands, except Share datafalse1falseColumnus-gaap_StatementEquityComponentsAxisAxis*ColumnunitUnit*falsefalseCapital Stock [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CommonStockMemberus-gaap_StatementEquityComponentsAxisexplicitMemberCapital Stock [Member]sharesStandardhttp://www.xbrl.org/2003/instanceshares0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDtruefalse$na0001-01-01T00:00:000001-01-01T00:00:00falsefalseCapital Stock [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_CommonStockMemberus-gaap_StatementEquityComponentsAxisexplicitMemberUSDUSD$2falseColumnus-gaap_StatementEquityComponentsAxisAxis*ColumnunitUnit*falsefalseAdditional Paid-In Capital [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AdditionalPaidInCapitalMemberus-gaap_StatementEquityComponentsAxisexplicitMemberAdditional Paid-In Capital [Member]usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDtruefalse$na0001-01-01T00:00:000001-01-01T00:00:00falsefalseAdditional Paid-In Capital [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AdditionalPaidInCapitalMemberus-gaap_StatementEquityComponentsAxisexplicitMemberUSDUSD$3falseColumnus-gaap_StatementEquityComponentsAxisAxis*ColumnunitUnit*falsefalseAccumulated Deficit [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_RetainedEarningsMemberus-gaap_StatementEquityComponentsAxisexplicitMemberAccumulated Deficit [Member]usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDtruefalse$na0001-01-01T00:00:000001-01-01T00:00:00falsefalseAccumulated Deficit [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_RetainedEarningsMemberus-gaap_StatementEquityComponentsAxisexplicitMemberUSDUSD$4falseColumnus-gaap_StatementEquityComponentsAxisAxis*ColumnunitUnit*falsefalseAccumulated Other Comprehensive Income [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AccumulatedOtherComprehensiveIncomeMemberus-gaap_StatementEquityComponentsAxisexplicitMemberAccumulated Other Comprehensive Income [Member]usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDtruefalse$na0001-01-01T00:00:000001-01-01T00:00:00falsefalseAccumulated Other Comprehensive Income [Member]us-gaap_StatementEquityComponentsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AccumulatedOtherComprehensiveIncomeMemberus-gaap_StatementEquityComponentsAxisexplicitMemberUSDUSD$5falseColumnus-gaap_StatementEquityComponentsAxisAxis*ColumnunitUnit*truefalseEquity Components [Domain]us-gaap_StatementEquityComponentsAxisus-gaap_EquityComponentDomainus-gaap_StatementEquityComponentsAxisexplicitMemberEquity Components [Domain]usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170 USDfalsefalse$na0001-01-01T00:00:000001-01-01T00:00:00USDUSD$1falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*2false 4us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabelxbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Beginning Balanceduration2011-01-01T00:00:002011-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsetruefalsefalsetruefalsefalseperiodStartLabel1truefalsefalse00USD$falsetruefalse2truefalsefalse1108700011087USD$falsetruefalse3truefalsefalse-9761000-9761USD$falsetruefalse4truefalsefalse150000150USD$falsetruefalse5truefalsefalse14760001476USD$falsetruefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 falseinstant2010-12-31T00:00:000001-01-01T00:00:002Beginning Balance at Dec. 31, 20102falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*3false 4us-gaap_SharesIssuedus-gaap_truenainstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabelxbrli:sharesItemTypesharesNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 false1Beginning Balance (Shares)duration2011-01-01T00:00:002011-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_SharesIssuedus-gaap_truenainstantfalsefalsetruefalsefalsetruefalsefalseperiodStartLabel1truefalsefalse3958127139581271falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 falseinstant2010-12-31T00:00:000001-01-01T00:00:001Beginning Balance (Shares) at Dec. 31, 20103falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*4false 4us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParentus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabelxbrli:monetaryItemTypemonetaryAmount after tax and reclassification adjustments, resulting from the process of expressing in the reporting currency of the reporting entity those amounts that are denominated or measured in a different currency, and from transactions whose terms are denominated in a currency other than the entity's functional currency, which is attributable to the parent entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(3) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684 false2Foreign currency translation adjustmentduration2011-01-01T00:00:002011-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParentus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse4900049falsefalsefalse5truefalsefalse4900049falsefalsefalsexbrli:monetaryItemTypemonetaryAmount after tax and reclassification adjustments, resulting from the process of expressing in the reporting currency of the reporting entity those amounts that are denominated or measured in a different currency, and from transactions whose terms are denominated in a currency other than the entity's functional currency, which is attributable to the parent entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(3) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684 false2Foreign currency translation adjustment4falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*5false 4us-gaap_StockIssuedDuringPeriodValueNewIssuesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:monetaryItemTypemonetaryEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Issue of common stock, net of transaction costs of $390duration2011-01-01T00:00:002011-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_StockIssuedDuringPeriodValueNewIssuesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2truefalsefalse20240002024falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse20240002024falsefalsefalsexbrli:monetaryItemTypemonetaryEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Issue of common stock, net of transaction costs of $3905falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*6false 4us-gaap_StockIssuedDuringPeriodSharesNewIssuesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsexbrli:sharesItemTypesharesNumber of new stock issued during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Issue of common stock, net of transaction costs of $390 (Shares)duration2011-01-01T00:00:002011-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_StockIssuedDuringPeriodSharesNewIssuesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse48213424821342falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of new stock issued during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 false1Issue of common stock, net of transaction costs of $390 (Shares)6falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*7false 4igxt_WarrantsIssuedNetOfTransactionCostsOfOneEightSixEightOneEightigxt_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:monetaryItemTypemonetaryWarrants issued, net of transaction costs of $132No definition available.false2Warrants issued, net of transaction costs of $132duration2011-01-01T00:00:002011-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_WarrantsIssuedNetOfTransactionCostsOfOneEightSixEightOneEightigxt_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse685000685falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse685000685falsefalsefalsexbrli:monetaryItemTypemonetaryWarrants issued, net of transaction costs of $132No definition available.false2Warrants issued, net of transaction costs of $1327falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*8false 4igxt_AgentsWarrantsigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:monetaryItemTypemonetaryAgents' WarrantsNo definition available.false2Agents' Warrantsduration2011-01-01T00:00:002011-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_AgentsWarrantsigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse153000153falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse153000153falsefalsefalsexbrli:monetaryItemTypemonetaryAgents' WarrantsNo definition available.false2Agents' Warrants8falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*9false 4igxt_WarrantsExercisedigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:monetaryItemTypemonetaryWarrants exercisedNo definition available.false2Warrants exercisedduration2011-01-01T00:00:002011-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_WarrantsExercisedigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse14580001458falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse14580001458falsefalsefalsexbrli:monetaryItemTypemonetaryWarrants exercisedNo definition available.false2Warrants exercised9falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*10false 4igxt_WarrantsExercisedSharesigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:sharesItemTypesharesWarrants exercised (Shares)No definition available.false1Warrants exercised (Shares)duration2011-01-01T00:00:002011-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_WarrantsExercisedSharesigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse34180093418009falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesWarrants exercised (Shares)No definition available.false1Warrants exercised (Shares)10falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*11false 4igxt_AgentsWarrantsExercisedigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:monetaryItemTypemonetaryAgents warrants exercisedNo definition available.false2Agents warrants exercisedduration2011-01-01T00:00:002011-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_AgentsWarrantsExercisedigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse142000142falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse142000142falsefalsefalsexbrli:monetaryItemTypemonetaryAgents warrants exercisedNo definition available.false2Agents warrants exercised11falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*12false 4igxt_AgentsWarrantsExercisedSharesigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:sharesItemTypesharesAgents warrants exercised (Shares)No definition available.false1Agents warrants exercised (Shares)duration2011-01-01T00:00:002011-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_AgentsWarrantsExercisedSharesigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse299406299406falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesAgents warrants exercised (Shares)No definition available.false1Agents warrants exercised (Shares)12falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*13false 4igxt_OptionsExercisedigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:monetaryItemTypemonetaryOptions exercisedNo definition available.false2Options exercisedduration2011-01-01T00:00:002011-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_OptionsExercisedigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse318000318falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse318000318falsefalsefalsexbrli:monetaryItemTypemonetaryOptions exercisedNo definition available.false2Options exercised13falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*14false 4igxt_OptionsExercisedSharesigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:sharesItemTypesharesOptions exercised (Shares)No definition available.false1Options exercised (Shares)duration2011-01-01T00:00:002011-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_OptionsExercisedSharesigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse775000775000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesOptions exercised (Shares)No definition available.false1Options exercised (Shares)14falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*15false 4us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabelxbrli:monetaryItemTypemonetaryValue of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph 64 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Stock-based compensationduration2011-01-01T00:00:002011-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse5100051falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse5100051falsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph 64 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Stock-based compensation15falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*16false 4us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabelxbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Net loss for the periodduration2011-01-01T00:00:002011-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-2452000-2452falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse-2452000-2452falsefalsefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Net loss for the period16falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*17false 4us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Ending Balanceduration2011-01-01T00:00:002011-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse00falsefalsefalse2truefalsefalse1591800015918falsefalsefalse3truefalsefalse-12213000-12213falsefalsefalse4truefalsefalse199000199falsefalsefalse5truefalsefalse39040003904falsefalsefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 falseinstant2011-12-31T00:00:000001-01-01T00:00:002Ending Balance at Dec. 31, 201117falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*18false 4us-gaap_SharesIssuedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:sharesItemTypesharesNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 false1Ending Balance (Shares)duration2011-01-01T00:00:002011-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_SharesIssuedus-gaap_truenainstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse4889502848895028falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 falseinstant2011-12-31T00:00:000001-01-01T00:00:001Ending Balance (Shares) at Dec. 31, 201118falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*4false 4us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParentus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabelxbrli:monetaryItemTypemonetaryAmount after tax and reclassification adjustments, resulting from the process of expressing in the reporting currency of the reporting entity those amounts that are denominated or measured in a different currency, and from transactions whose terms are denominated in a currency other than the entity's functional currency, which is attributable to the parent entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(3) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684 false2Foreign currency translation adjustmentduration2012-01-01T00:00:002012-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParentus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse100000100falsefalsefalse5truefalsefalse100000100falsefalsefalsexbrli:monetaryItemTypemonetaryAmount after tax and reclassification adjustments, resulting from the process of expressing in the reporting currency of the reporting entity those amounts that are denominated or measured in a different currency, and from transactions whose terms are denominated in a currency other than the entity's functional currency, which is attributable to the parent entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(3) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684 false2Foreign currency translation adjustment19falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*9false 4igxt_WarrantsExercisedigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:monetaryItemTypemonetaryWarrants exercisedNo definition available.false2Warrants exercisedduration2012-01-01T00:00:002012-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_WarrantsExercisedigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse233000233falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse233000233falsefalsefalsexbrli:monetaryItemTypemonetaryWarrants exercisedNo definition available.false2Warrants exercised20falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*10false 4igxt_WarrantsExercisedSharesigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:sharesItemTypesharesWarrants exercised (Shares)No definition available.false1Warrants exercised (Shares)duration2012-01-01T00:00:002012-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_WarrantsExercisedSharesigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse726080726080falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesWarrants exercised (Shares)No definition available.false1Warrants exercised (Shares)21falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*11false 4igxt_AgentsWarrantsExercisedigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:monetaryItemTypemonetaryAgents warrants exercisedNo definition available.false2Agents warrants exercisedduration2012-01-01T00:00:002012-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_AgentsWarrantsExercisedigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse104000104falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse104000104falsefalsefalsexbrli:monetaryItemTypemonetaryAgents warrants exercisedNo definition available.false2Agents warrants exercised22falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*12false 4igxt_AgentsWarrantsExercisedSharesigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:sharesItemTypesharesAgents warrants exercised (Shares)No definition available.false1Agents warrants exercised (Shares)duration2012-01-01T00:00:002012-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_AgentsWarrantsExercisedSharesigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse219313219313falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesAgents warrants exercised (Shares)No definition available.false1Agents warrants exercised (Shares)23falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*13false 4igxt_OptionsExercisedigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:monetaryItemTypemonetaryOptions exercisedNo definition available.false2Options exercisedduration2012-01-01T00:00:002012-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_OptionsExercisedigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse2800028falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse2800028falsefalsefalsexbrli:monetaryItemTypemonetaryOptions exercisedNo definition available.false2Options exercised24falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*14false 4igxt_OptionsExercisedSharesigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:sharesItemTypesharesOptions exercised (Shares)No definition available.false1Options exercised (Shares)duration2012-01-01T00:00:002012-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_OptionsExercisedSharesigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse5000050000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesOptions exercised (Shares)No definition available.false1Options exercised (Shares)25falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*15false 4us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabelxbrli:monetaryItemTypemonetaryValue of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph 64 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Stock-based compensationduration2012-01-01T00:00:002012-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse5900059falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse5900059falsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph 64 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Stock-based compensation26falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*16false 4us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabelxbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Net loss for the periodduration2012-01-01T00:00:002012-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-2250000-2250falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse-2250000-2250falsefalsefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Net loss for the period27falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*17false 4us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Ending Balanceduration2012-01-01T00:00:002012-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse00falsefalsefalse2truefalsefalse1634200016342falsefalsefalse3truefalsefalse-14463000-14463falsefalsefalse4truefalsefalse299000299falsefalsefalse5truefalsefalse21780002178falsefalsefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 falseinstant2012-12-31T00:00:000001-01-01T00:00:002Ending Balance at Dec. 31, 201228falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*18false 4us-gaap_SharesIssuedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:sharesItemTypesharesNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 false1Ending Balance (Shares)duration2012-01-01T00:00:002012-12-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_SharesIssuedus-gaap_truenainstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse4989042149890421falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 falseinstant2012-12-31T00:00:000001-01-01T00:00:001Ending Balance (Shares) at Dec. 31, 201229falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*4false 4us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParentus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabelxbrli:monetaryItemTypemonetaryAmount after tax and reclassification adjustments, resulting from the process of expressing in the reporting currency of the reporting entity those amounts that are denominated or measured in a different currency, and from transactions whose terms are denominated in a currency other than the entity's functional currency, which is attributable to the parent entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(3) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684 false2Foreign currency translation adjustmentduration2013-01-01T00:00:002013-03-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParentus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse-36000-36falsefalsefalse5truefalsefalse-36000-36falsefalsefalsexbrli:monetaryItemTypemonetaryAmount after tax and reclassification adjustments, resulting from the process of expressing in the reporting currency of the reporting entity those amounts that are denominated or measured in a different currency, and from transactions whose terms are denominated in a currency other than the entity's functional currency, which is attributable to the parent entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(3) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684 false2Foreign currency translation adjustment30falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*9false 4igxt_WarrantsExercisedigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:monetaryItemTypemonetaryWarrants exercisedNo definition available.false2Warrants exercisedduration2013-01-01T00:00:002013-03-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_WarrantsExercisedigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse10001falsefalsefalse2truefalsefalse171000171falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse172000172falsefalsefalsexbrli:monetaryItemTypemonetaryWarrants exercisedNo definition available.false2Warrants exercised31falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*10false 4igxt_WarrantsExercisedSharesigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:sharesItemTypesharesWarrants exercised (Shares)No definition available.false1Warrants exercised (Shares)duration2013-01-01T00:00:002013-03-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_WarrantsExercisedSharesigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse362500362500falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesWarrants exercised (Shares)No definition available.false1Warrants exercised (Shares)32falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*13false 4igxt_OptionsExercisedigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:monetaryItemTypemonetaryOptions exercisedNo definition available.false2Options exercisedduration2013-01-01T00:00:002013-03-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_OptionsExercisedigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse2300023falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse2300023falsefalsefalsexbrli:monetaryItemTypemonetaryOptions exercisedNo definition available.false2Options exercised33falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*14false 4igxt_OptionsExercisedSharesigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabelxbrli:sharesItemTypesharesOptions exercised (Shares)No definition available.false1Options exercised (Shares)duration2013-01-01T00:00:002013-03-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0igxt_OptionsExercisedSharesigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse5000050000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesOptions exercised (Shares)No definition available.false1Options exercised (Shares)34falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*15false 4us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabelxbrli:monetaryItemTypemonetaryValue of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph 64 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Stock-based compensationduration2013-01-01T00:00:002013-03-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse1800018falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse1800018falsefalsefalsexbrli:monetaryItemTypemonetaryValue of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph 64 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Stock-based compensation35falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*16false 4us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabelxbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Net loss for the periodduration2013-01-01T00:00:002013-03-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-486000-486falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse-486000-486falsefalsefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Net loss for the period36falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*17false 4us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 false2Ending Balanceduration2013-01-01T00:00:002013-03-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse10001USD$falsetruefalse2truefalsefalse1655400016554USD$falsetruefalse3truefalsefalse-14949000-14949USD$falsetruefalse4truefalsefalse263000263USD$falsetruefalse5truefalsefalse18690001869USD$falsetruefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 falseinstant2013-03-31T00:00:000001-01-01T00:00:002Ending Balance at Mar. 31, 201337falseRowperiodPeriod*RowprimaryElement*Rowdei_LegalEntityAxisAxis*18false 4us-gaap_SharesIssuedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabelxbrli:sharesItemTypesharesNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 false1Ending Balance (Shares)duration2013-01-01T00:00:002013-03-31T00:00:00truefalseEntity [Domain]dei_LegalEntityAxisdei_EntityDomaindei_LegalEntityAxisexplicitMemberEntity [Domain] 0us-gaap_SharesIssuedus-gaap_truenainstantfalsefalsetruefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse5030292150302921falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 falseinstant2013-03-31T00:00:000001-01-01T00:00:001Ending Balance (Shares) at Mar. 31, 2013trueConsolidated Statement of Shareholders Equity (USD $)ThousandsNoRoundingUnKnownUnKnownfalsefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/StockholdersEquity537 XML 65 R55.htm IDEA: XBRL DOCUMENT

Schedule of Effective Income Tax Rate Reconciliation (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 1	$ (605)
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 2	(694)
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 3	368
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 4	514
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 5	3
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 6	(2)
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 7	18
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 8	4
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 9	273
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 10	231
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 11	0
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 12	0
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 13	(57)
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 14	(53)
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 15	0
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 16	0
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 17	0
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 18	$ 0

EXCEL 66 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\U9C8Q,S`U,U]F9C'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O M#I7;W)K#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#PO>#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E-T871E;65N=%]O9E]#87-H7T9L;W=S7TEN M9F]R;3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)E M;&%T961?4&%R='E?5')A;G-A8W1I;VYS/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]! M8V-O=6YT/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DQE87-E:&]L9%]);7!R;W9E;65N M='-?86YD7T5Q=3$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K M#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%D9&ET:6]N86Q?4&%I M9$EN7T-A<&ET86Q?5&%B;#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN8V]M95]487A?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z M5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DYA='5R95]O9E]"=7-I;F5S#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-I9VYI9FEC86YT7T%C8V]U;G1I M;F=?4&]L:6-I93(\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-A<&ET86Q?4W1O8VM? M3F%R#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%D9&ET:6]N86Q?4&%I9$EN7T-A<&ET86Q?3F%R#I. M86UE/@T*("`@(#QX.E=O#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K M#I7;W)K5]#;&%S#I7 M;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E-C:&5D=6QE7V]F7U-T;V-K7T]P=&EO;G-?5F%L=3,\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-C:&5D=6QE7V]F7U-H87)E8F%S961?0V]M<&5N#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-C:&5D=6QE7V]F7U=A#I7;W)K#I7 M;W)K#I7;W)K#I7;W)K#I7;W)K#I3='EL M97-H965T($A2968],T0B5V]R:W-H965T3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U9C8Q,S`U,U]F9C'0O:'1M M;#L@8VAA'0^4RTQ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^9F%L'0^36%R(#,Q+`T*"0DR,#$S/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^:6=X=#QS M<&%N/CPO'0^26YT96Q'96YX(%1E8VAN;VQO9VEE2!#=7)R96YT M(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA2!&:6QE'0^,C`Q,SQS<&%N/CPO'0^1ED\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S"!C'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N(&]F M(&EN=&%N9VEB;&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XQ,#QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6%B;&4@86YD(&]T:&5R(&%C8W)U960@;&EA8FEL M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA&5R8VES92!O9B!W87)R86YT'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&-H86YG92!O;B!#87-H(&%N9"!#87-H M($5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R M-RD\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S&5R8VES960\+W1D/@T* M("`@("`@("`\=&0@8VQA&5R8VES960\+W1D/@T*("`@ M("`@("`\=&0@8VQA&5R8VES M960@*%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S2!T'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5R8VES960@*%-H87)E&5R8VES960\ M+W1D/@T*("`@("`@("`\=&0@8VQA&5R8VES960\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S2!T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S&5R M8VES960@*%-H87)E'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^ M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U9C8Q M,S`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`F(S@R M,C`[0V]M<&%N>28C.#(R,3LI('!R97!A2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E2!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S M+'-EF4Z(#$P<'0[;6%R9VEN.FEN:&5R:70[)SY4:&4@ M8V]N2!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M+'1I;65S+'-EF4Z(#$P<'0[;6%R9VEN.FEN:&5R:70[ M)SY4:&4@9FEN86YC:6%L('-T871E;65N=',@87)E(&5X<')E6QE/3-$)V9O;G0M9F%M M:6QY.B!T:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO8VM=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\=&%B;&4@8F]R9&5R/3-$ M,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O M2!S<&5C:6%L:7IE2!H87,@9&5V96QO<&5D('1H2!S='EL93TS1"=F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N+'1I;65S+'-EF4Z(#$P<'0[ M;6%R9VEN.FEN:&5R:70[)SX-"@D)"0D)"51H92!T:')E92!T96-H;F]L;V=Y M('!L871F;W)M2!E;F-O=6YT97)E9"!I;B!O6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE2!S='EL M93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-EF4Z(#$P<'0[;6%R9VEN.FEN:&5R:70[)SX-"@D)"0D)"4EN M=&5L1V5N>"8C.#(Q-SL@<')O9'5C="!P:7!E;&EN92!C=7)R96YT;'D@8V]N MF4@=&AE(#QI/E9EF5S('1H M92`\:3Y!9%9E2X\+W`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`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M=&%B;&4@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<] M,T0P('-T>6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.B!T M:6UE2!S M='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-E MF4Z(#$P<'0[;6%R9VEN.FEN:&5R:70[)SXF(S$V,#L\ M+W`^#0H@("`@("`@(#PO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R('9A M;&EG;CTS1'1O<#X-"B`@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF(S$V,#L\ M+W1D/@T*("`@("`@("`\=&0@86QI9VX],T1L969T('=I9'1H/3-$.34E/@T* M("`@("`@("`@(#QP(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-EF4Z M(#$P<'0[;6%R9VEN.FEN:&5R:70[)SX-"B`@("`@("`@("`@(#QB/E)E=F5N M=64@4F5C;V=N:71I;VX@86YD($1I2!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I M;65S+'-EF4Z(#$P<'0[;6%R9VEN.FEN:&5R:70[)SXF M(S$V,#L\+W`^#0H@("`@("`@(#PO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R('9A;&EG;CTS1'1O<#X-"B`@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF M(S$V,#L\+W1D/@T*("`@("`@("`\=&0@86QI9VX],T1L969T('=I9'1H/3-$ M.34E/@T*("`@("`@("`@(#QP(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-EF4Z(#$P<'0[;6%R9VEN.FEN:&5R:70[)SX-"B`@("`@("`@("`@($EN M($1E8V5M8F5R(#(P,3$L('1H92!&05-"(&ES2!T2`Q+"`R,#$S+"!A;F0@:6YT M97)I;2!P97)I;V1S('=I=&AI;B!T:&]S92!A;FYU86P@<&5R:6]D6QE/3-$)V)O6QE M/3-$)V9O;G0M9F%M:6QY.B!T:6UEF%T:6]N6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE2`R,#$Q+"!T:&4@1D%30B!I2!&05-")B,X,C$W.W,@ M:6YT96YT(&%B;W5T('1H92!A<'!L:6-A=&EO;B!O9B!E>&ES=&EN9R!F86ER M('9A;'5E(&UE87-U6QE/3-$)V9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE M65A7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA2!S='EL93TS1"=F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-EF4Z(#$P<'0[;6%R9VEN.FEN:&5R:70[)SX-"B`@("`@("`@("`@("`@/&(^ M4F5C96YT;'D@27-S=65D($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+V(^ M#0H@("`@("`@("`@("`\+W`^#0H@("`@("`@("`@/"]T9#X-"B`@("`@("`@ M/"]T3H@=&EM M97,@;F5W(')O;6%N+'1I;65S+'-EF4Z(#$P<'0[;6%R M9VEN.FEN:&5R:70[)SX-"B`@("`@("`@("`@("`@26X@1&5C96UB97(@,C`Q M,2P@=&AE($9!4T(@:7-S=65D(%5P9&%T92!.;RX@,C`Q,2TQ,BP@)B,X,C(P M.T-O;7!R96AE;G-I=F4@26YC;VUE("A4;W!I8R`R,C`I.B!$969E28C.#(Q-SMS(&9I;F%N8VEA;"!P;W-I=&EO;B!O6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE&5D(&%T('1H92!297!O2!A&ES=&EN9R!G=6ED86YC92!I;B!5+E,N($=! M05`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`@("`@ M("`@("`@("`@/&(^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG M(%!O;&EC:65S/"]B/@T*("`@("`@("`@("`@/"]P/@T*("`@("`@("`@(#PO M=&0^#0H@("`@("`@(#PO='(^#0H@("`@("`@(#QT6QE/3-$)V9O M;G0M9F%M:6QY.B!T:6UE2!C;VUM96YS=7)A=&4@=VET:"!T:&4@969F;W)T(&5X<&5N9&5D+B!! M;6]U;G1S(')E8V5I=F5D(&EN(&%D=F%N8V4@;V8@=&AE(')E8V]G;FET:6]N M(&-R:71E2!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N+'1I;65S+'-EF4Z(#$P<'0[;6%R9VEN M.FEN:&5R:70[)SX-"B`@("`@("`@("`@("`@("`@($EN=&5L1V5N>"!H87,@ M;&EC96YS92!A9W)E96UE;G1S('1H870@2!T:&%T(&-E2!R97!O6%L M='D@:6YF;W)M871I;VX@:6X@=&AE#0H@("`@("`@("`@("`@("`@("`T-0T* M("`@("`@("`@("`@("`@("`@9&%Y2!T86ME2!R979E;G5E(&ES(&YO="!R96-O9VYI>F5D('5N=&EL('1H M92!R;WEA;'1I97,@87)E(')E<&]R=&5D('1O('1H92!#;VUP86YY(&%N9"!T M:&4@8V]L;&5C=&EO;B!O9B!T:&5S92!R;WEA;'1I97,@:7,@2!A2!S='EL93TS1"=F;VYT+69A M;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-EF4Z M(#$P<'0[;6%R9VEN.FEN:&5R:70[)SX-"B`@("`@("`@("`@("`@("`@($EN M($%U9W5S="`R,#$P('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(&IO:6YT M(&1E=F5L;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!A9W)E96UE;G0@ M=VET:"!2961(:6QL($)I;W!H87)M82`H)B,X,C(P.U)E9$AI;&PF(S@R,C$[ M*2P@86X@27-R865L:2!C;VUP86YY+"!F;W(@86X@86YT:2UM:6=R86EN92!P M2!T:&4@0V]M<&%N>2!I;B`R,#$R('5P;VX@<')O9'5C=&EO;B!O M9B!P:79O=&%L(&)A=&-H97,N(%)E9$AI;&P@:7,@6QE M/3-$)V9O;G0M9F%M:6QY.B!T:6UEF4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE2!L875N8VAE9"!& M;W)F:79O(%A,)B,X-#@R.R!I;B!T:&4@55-!(&EN($]C=&]B97(@,C`Q,B!U M;F1E2!T:&4@0V]M<&%N>2!T;R!%9&=E;6]N="!A M;F0@2`R M,#$S+B!!9&1I=&EO;F%L(&UI;&5S=&]N97,@;V8@=7`@=&\@82!F=7)T:&5R M("0R,RXU#0H@("`@("`@("`@("`@("`@("!M:6QL:6]N(&%R92!P87EA8FQE M('5P;VX@86-H:65V:6YG(&-E6%L=&EE6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE2!R96-O9VYI>F5D(&%S(&1E9F5R'!E8W1E9"!T M;R!B92!E>&-L=7-I=F4N($%S(&$@2!H87,@82!D969E6QE/3-$ M)V9O;G0M9F%M:6QY.B!T:6UE'!E;G-E M6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V)O2!S M='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-E MF4Z(#$P<'0[;6%R9VEN.FEN:&5R:70[)SX-"B`@("`@ M("`@("`@("`@("`@(#QB/D%C8V]U;G1S(%)E8V5I=F%B;&4\+V(^#0H@("`@ M("`@("`@("`@("`@/"]P/@T*("`@("`@("`@("`@("`\+W1D/@T*("`@("`@ M("`@("`@/"]T6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE2!R96=U;&%R;'D@979A;'5A=&EN9R!I;F1I=FED=6%L(&-U2!W2!R96-O2!W2!C;W9E'!O"!I;B!&96)R=6%R>2`R,#$S+@T*("`@("`@ M("`@("`@("`@(#PO<#X-"B`@("`@("`@("`@("`@/"]T9#X-"B`@("`@("`@ M("`@(#PO='(^#0H@("`@("`@(#PO=&%B;&4^#0H@("`@("`@("`@("`@(#QT M86)L92!B;W)D97(],T0P(&-E;&QP861D:6YG/3-$,"!C96QL6QE/3-$)V9O;G0M9F%M:6QY M.B!T:6UE"!CF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V)O2!A;F0@;V9F M:6-E(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@("`@("`@("`@("`\=&0@86QI M9VX],T1L969T(&)G8V]L;W(],T0C939E9F9F('=I9'1H/3-$,S8E/@T*("`@ M("`@("`@("`@("`@("`@("`R,"4-"B`@("`@("`@("`@("`@("`@(#PO=&0^ M#0H@("`@("`@("`@("`@("`@/"]TF4Z(#$P<'0[)SY5<&]N(')E=&ER96UE M;G0@;W(@9&ES<&]S86PL('1H92!C;W-T(&]F('1H92!A3H@=&EM97,@ M;F5W(')O;6%N+'1I;65S+'-EF4Z(#$P<'0[)SX-"B`@ M("`@("`@("`\8CY);G1A;F=I8FQE($%S3H@=&EM97,@;F5W(')O;6%N+'1I;65S M+'-EF4Z(#$P<'0[)SY087EM96YTF5D(&]V97(@=&AE(')E;6%I M;FEN9R!UF5D(&9O6UE;G1S(&%R92!I;F-L=61E M9"!I;B!O=&AE2!S='EL93TS1"=M87)G:6XM;&5F=#H@-24[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)VUA2!N;W0@8F4@ M'!E8W1E9"!T;R!B92!G M96YE2!T:&4@86UO=6YT(&)Y('=H:6-H M('1H92!C87)R>6EN9R!A;6]U;G0@;V8@=&AE(&%S6QE/3-$)V9O;G0M9F%M:6QY.B!T M:6UE2!43H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-EF4Z(#$P M<'0[)SY!6QE/3-$)VUA2`M(&%T(&AI3H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-EF4Z M(#$P<'0[)SY'86EN2!S='EL93TS1"=M87)G:6XM;&5F=#H@-24[(&9O;G0M M9F%M:6QY.B!T:6UE3H@=&EM97,@;F5W(')O M;6%N+'1I;65S+'-EF4Z(#$P<'0[)SY4:&4@0V]M<&%N M>2!A8V-O=6YT&5S(&EN(&%C8V]R9&%N8V4@=VET M:"!&05-"($%30R`W-#`@(DEN8V]M92!487AE&5S M(&%R92!P"!AF5D(&9O2!D:69F97)E;F-E"!AF5D+B!$969E2!S='EL93TS M1"=M87)G:6XM;&5F=#H@-24[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)VUA&5S)B,X,C(Q.RX@05-#(#"!P;W-I=&EO;G,N(%1H92!F M:7)S="!S=&5P(&ES('1O(&5V86QU871E('1H92!T87@@<&]S:71I;VX@9F]R M(')E8V]G;FET:6]N(&)Y(&1E=&5R;6EN:6YG(&EF('1H92!W96EG:'0@;V8@ M879A:6QA8FQE(&5V:61E;F-E(&EN9&EC871E2P@:6YC;'5D:6YG(')EF5D('5P;VX@=6QT:6UA=&4@ M3H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-EF4Z(#$P M<'0[)SY!9&1I=&EO;F%L;'DL($%30R`W-#`@"!P;W-I=&EO;G,@9F]R('=H:6-H M(')E6UE;G1S/"]B/@T*("`@("`@("`@("`@("`\+W1D/@T* M("`@("`@("`@("`@/"]T6UE;G1S('1O(&5M<&QO>65E'!E;G-E(&)A65E MF5D(&]N(&$@2!R96-O2!U2!S='EL93TS1"=F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-EF4Z(#$P M<'0[;6%R9VEN.FEN:&5R:70[)SXF(S$V,#L\+W`^#0H@("`@("`@("`@("`@ M(#PO=&0^#0H@("`@("`@("`@("`\+W1R/@T*("`@("`@("`@("`@/'1R('9A M;&EG;CTS1'1O<#X-"B`@("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F=#XF M(S$V,#L\+W1D/@T*("`@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('=I M9'1H/3-$.34E/@T*("`@("`@("`@("`@("`@(#QP(&%L:6=N/3-$:G5S=&EF M>2!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S M+'-EF4Z(#$P<'0[;6%R9VEN.FEN:&5R:70[)SY4:&4@ M0V]M<&%N>2!M96%S=7)E2!);G-T M65E M2!V97-T960@86YD(&%R92!F;W(@9G5T=7)E('!E M2!IF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE M65A6QE/3-$ M)V)O2!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N+'1I;65S+'-EF4Z(#$P<'0[;6%R9VEN.FEN M:&5R:70[)SX-"B`@("`@("`@("`@("`@("`@(#QB/D9A:7(@5F%L=64@365A M2!S='EL93TS1"=F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-EF4Z(#$P<'0[;6%R9VEN.FEN:&5R:70[)SY!4T,@.#(P(&%P<&QI97,@=&\@ M86QL(&%S2!O9B!T:&4@:6YF;W)M871I;VX@=7-E9"!T M;R!D971E6QE/3-$)V)O M3H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-EF4Z M(#$P<'0[)SY);B!D971E2!P97)F;W)M3H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-EF4Z(#$P<'0[)SX-"B`@("`@("`@("`\8CY&86ER(%9A;'5E M(&]F($9I;F%N8VEA;"!);G-T3H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-E MF4Z(#$P<'0[)SY4:&4@9F%I6%B;&5S M(&%R:7-I;F<@:6X@=&AE(&]R9&EN87)Y(&-O=7)S92!O9B!B=7-I;F5S3H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-EF4Z(#$P<'0[)SX-"B`@("`@("`@("`\8CY296-E;G0@06-C;W5N M=&EN9R!03H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-EF4Z(#$P<'0[)SY);B!$96-E;6)E28C.#(Q-SMS(')E8V]G;FEZ M960@87-S971S(&%N9"!R96-O9VYI>F5D(&QI86)I;&ET:65S('=I=&AI;B!T M:&4@2!I6QE/3-$)V)O2!S='EL93TS M1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S+'-EF4Z(#$P<'0[;6%R9VEN.FEN:&5R:70[)SY);B!$96-E;6)E28C.#(Q-SMS(&9I M;F%N8VEA;"!P;W-I=&EO;B!O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N+'1I;65S+'-EF4Z(#$P<'0[;6%R M9VEN.FEN:&5R:70[)SX-"@D)"0D)"3QB/DQE87-E:&]L9"!);7!R;W9E;65N M=',@86YD($5Q=6EP;65N=#PO8CX\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^ M#0H)"3PO=&%B;&4^#0H)"3QB"!S;VQI9"<^#0H)"0D)"0D))FYB6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!W:61T:#TS M1#$R)3X-"@D)"0D)"0E#;W-T/"]T9#X-"@D)"0D)"3QT9"!A;&EG;CTS1')I M9VAT('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M)R!W:61T:#TS1#(E/@T*"0D)"0D)"29N8G-P.SPO=&0^#0H)"0D)"0D\=&0@ M86QI9VX],T1R:6=H="!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P>"!S;VQI9"<@=VED=&@],T0Q)3X-"@D)"0D)"0DF;F)S<#L\+W1D/@T* M"0D)"0D)/'1D(&%L:6=N/3-$6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!X('-O;&ED)R!W:61T:#TS1#$R)3X-"@D)"0D)"0D\8CY!;6]U;G0\ M+V(^/"]T9#X-"@D)"0D)"3QT9"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!W:61T:#TS1#(E/@T* M"0D)"0D)"29N8G-P.SPO=&0^#0H)"0D)"0D\=&0@86QI9VX],T1R:6=H="!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=VED M=&@],T0Q)3X-"@D)"0D)"0DF;F)S<#L\+W1D/@T*"0D)"0D)/'1D(&%L:6=N M/3-$6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED)R!W:61T:#TS1#(E/@T*"0D)"0D)"29N8G-P.SPO M=&0^#0H)"0D)"3PO='(^#0H)"0D)"3QT6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!X('-O;&ED)SX-"@D)"0D)"0E,96%S96AO;&0@:6UP M6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED M)R!W:61T:#TS1#$R)3X-"@D)"0D)"0DV,SPO=&0^#0H)"0D)"0D\=&0@86QI M9VX],T1L969T('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X M('-O;&ED)R!W:61T:#TS1#(E/@T*"0D)"0D)"29N8G-P.SPO=&0^#0H)"0D) M"0D\=&0@86QI9VX],T1L969T('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!X('-O;&ED)R!W:61T:#TS1#$E/@T*"0D)"0D)"29N8G-P.SPO M=&0^#0H)"0D)"0D\=&0@86QI9VX],T1R:6=H="!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=VED=&@],T0Q,B4^#0H)"0D) M"0D)-C,\+W1D/@T*"0D)"0D)/'1D(&%L:6=N/3-$;&5F="!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=VED=&@],T0R)3X- M"@D)"0D)"0DF;F)S<#L\+W1D/@T*"0D)"0D)/'1D(&%L:6=N/3-$;&5F="!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=VED M=&@],T0Q)3X-"@D)"0D)"0DF;F)S<#L\+W1D/@T*"0D)"0D)/'1D(&%L:6=N M/3-$6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!X('-O;&ED)R!W:61T:#TS1#(E/@T*"0D)"0D)"29N8G-P M.SPO=&0^#0H)"0D)"0D\=&0@86QI9VX],T1L969T('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!W:61T:#TS1#$E/@T*"0D) M"0D)"29N8G-P.SPO=&0^#0H)"0D)"0D\=&0@86QI9VX],T1R:6=H="!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9"<@=VED=&@] M,T0Q,B4^#0H)"0D)"0D),#PO=&0^#0H)"0D)"0D\=&0@86QI9VX],T1L969T M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED)R!W M:61T:#TS1#(E/@T*"0D)"0D)"29N8G-P.SPO=&0^#0H)"0D)"3PO='(^#0H) M"0D)"3QT"!S;VQI9"<@=VED=&@],T0Q,B4^#0H)"0D)"0D),S8R/"]T M9#X-"@D)"0D)"3QT9"!A;&EG;CTS1&QE9G0@"!S;VQI9"<@=VED=&@],T0Q,B4^#0H) M"0D)"0D),30Y/"]T9#X-"@D)"0D)"3QT9"!A;&EG;CTS1&QE9G0@F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE65T(&)E:6YG('5T M:6QI>F5D+CPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T'0O:F%V87-C XML 67 R39.xml IDEA: Subsequent Events (Narrative) (Details) 2.4.0.8140 - Disclosure - Subsequent Events (Narrative) (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2013_TO_31_March_2013http://www.sec.gov/CIK0001098880duration2013-01-01T00:00:002013-03-31T00:00:00pureStandardhttp://www.xbrl.org/2003/instancepure0sharesStandardhttp://www.xbrl.org/2003/instanceshares0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false CADfalsefalsecx_01_January_2013_TO_31_March_2013http://www.sec.gov/CIK0001098880duration2013-01-01T00:00:002013-03-31T00:00:00cadStandardhttp://www.xbrl.org/2003/iso4217CADiso42170CADCAD3false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_SubsequentEventsZeroOneFourSevenFourZerofszThreeWfTFCTcBigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse680000680000falsefalsefalse2truefalsefalse680000680000falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesSubsequent Events 1No definition available.false1Subsequent Events 12false 4igxt_SubsequentEventsZeroOneFourSevenFourZerodpZbrEightwQfWrEightigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse480000480000falsefalsefalse2truefalsefalse480000480000falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:pureItemTypepureSubsequent Events 2No definition available.false0Subsequent Events 23false 4igxt_SubsequentEventsZeroOneFourSevenFourZeropEightThreeDTwoNineWpOneZerowwigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse200000200000falsefalsefalse2truefalsefalse200000200000falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:pureItemTypepureSubsequent Events 3No definition available.false0Subsequent Events 34false 4igxt_SubsequentEventsZeroOneFourSevenFourZerotThreezqDbRHsZeroEightFourigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse0.670.67CADfalsetruefalse3falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetarySubsequent Events 4No definition available.false2Subsequent Events 45false 4igxt_SubsequentEventsZeroOneFourSevenFourZeroNNineTBzrcQdFourKTigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.650.65falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetarySubsequent Events 5No definition available.false2Subsequent Events 56false 4igxt_SubsequentEventsZeroOneFourSevenFourZerodWxmhSixTLZeroDtOneigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse0.250.25falsefalsefalse2truetruefalse0.250.25falsefalsefalse3falsetruefalse00falsefalsefalsenum:percentItemTypepureSubsequent Events 6No definition available.false0Subsequent Events 67false 4igxt_SubsequentEventsZeroOneFourSevenFourZerolFGCnFourpyFiveQZWigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse3750037500falsefalsefalse2truefalsefalse3750037500falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesSubsequent Events 7No definition available.false1Subsequent Events 78false 4igxt_SubsequentEventsZeroOneFourSevenFourZeroFivekvvCTsSevenhKcTigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse995500995500falsefalsefalse2truefalsefalse995500995500falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesSubsequent Events 8No definition available.false1Subsequent Events 89false 4igxt_SubsequentEventsZeroOneFourSevenFourZeronTwoFEighttgzFourTwolFourDigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse995500995500falsefalsefalse2truefalsefalse995500995500falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesSubsequent Events 9No definition available.false1Subsequent Events 910false 4igxt_SubsequentEventsZeroOneFourSevenFourZeroqSixkTZZRSevenKzrJigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetarySubsequent Events 10No definition available.false2Subsequent Events 1011false 4igxt_SubsequentEventsZeroOneFourSevenFourZeroBxHhBMSgRRdWigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse472472falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetarySubsequent Events 11No definition available.false2Subsequent Events 1112false 4igxt_SubsequentEventsZeroOneFourSevenFourZeroSevennRNGHZFouryWwZeroigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse472472falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetarySubsequent Events 12No definition available.false2Subsequent Events 1213false 4igxt_SubsequentEventsZeroOneSixTwoZeroTwoZeroEightFiveSevenTworSXhTOneNGXSixigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse362500362500falsefalsefalsexbrli:sharesItemTypesharesSubsequent Events 1No definition available.false1Subsequent Events 114false 4igxt_SubsequentEventsZeroOneSixTwoZeroTwoZeroEightFivesQNineTworNineEightTLSixNineNineigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse362500362500falsefalsefalsexbrli:sharesItemTypesharesSubsequent Events 2No definition available.false1Subsequent Events 215false 4igxt_SubsequentEventsZeroOneSixTwoZeroTwoZeroEightFiveFsThreeSixPFiveQJsFnsigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetarySubsequent Events 3No definition available.false2Subsequent Events 316false 4igxt_SubsequentEventsZeroOneSixTwoZeroTwoZeroEightFiveZSevenzygZKSevenvZxNineigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse172000172000falsefalsefalsexbrli:monetaryItemTypemonetarySubsequent Events 4No definition available.false2Subsequent Events 417false 4igxt_SubsequentEventsZeroOneSixTwoZeroTwoZeroEightFivemNTFourFVDyTpSixkigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse172000172000USD$falsetruefalsexbrli:monetaryItemTypemonetarySubsequent Events 5No definition available.false2Subsequent Events 5falseSubsequent Events (Narrative) (Details)NoRoundingNoRoundingUnKnownUnKnowntruefalsetrueSheethttp://www.intelgenx.com/taxonomy/role/DisclosureSubsequentEventsTextBlockDetails317 XML 68 R4.xml IDEA: Consolidated Statements of Cash Flows 2.4.0.8104 - Statement - Consolidated Statements of Cash FlowstruefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$cx_01_January_2013_TO_31_March_2013http://www.sec.gov/CIK0001098880duration2013-01-01T00:00:002013-03-31T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$cx_01_January_2012_TO_31_March_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-03-31T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$cx_01_January_2011_TO_31_December_2011http://www.sec.gov/CIK0001098880duration2011-01-01T00:00:002011-12-31T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 4us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Funds Provided (Used) - Operating Activities2false 5us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse-486000-486USD$falsetruefalse2truefalsefalse-582000-582USD$falsetruefalse3truefalsefalse-2250000-2250USD$falsetruefalse4truefalsefalse-2452000-2452USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Net loss3false 5us-gaap_DepreciationAndAmortizationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse2000020falsefalsefalse2truefalsefalse80008falsefalsefalse3truefalsefalse4600046falsefalsefalse4truefalsefalse3700037falsefalsefalsexbrli:monetaryItemTypemonetaryThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 5 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false2Depreciation4false 5us-gaap_ShareBasedCompensationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse1800018falsefalsefalse2truefalsefalse1500015falsefalsefalse3truefalsefalse5900059falsefalsefalse4truefalsefalse5100051falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false2Stock-based compensation5false 5igxt_AccountsReceivableWriteOffigxt_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse00falsefalsefalse4truefalsefalse5300053falsefalsefalsexbrli:monetaryItemTypemonetaryAccounts receivable write-offNo definition available.false2Accounts receivable write-off6false 5igxt_TotalAdjustmentsigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-448000-448falsefalsefalse2truefalsefalse-559000-559falsefalsefalse3truefalsefalse-2145000-2145falsefalsefalse4truefalsefalse-2311000-2311falsefalsefalsexbrli:monetaryItemTypemonetaryTotal adjustmentsNo definition available.true2Total Adjustments7true 5us-gaap_IncreaseDecreaseInOperatingCapitalAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Changes in assets and liabilities8false 6us-gaap_IncreaseDecreaseInAccountsReceivableus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse11120001112falsefalsefalse2truefalsefalse1800018falsefalsefalse3truefalsefalse-1019000-1019falsefalsefalse4truefalsefalse-38000-38falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false2Accounts receivable9false 6us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse1300013falsefalsefalse2truefalsefalse-15000-15falsefalsefalse3truefalsefalse-34000-34falsefalsefalse4truefalsefalse-21000-21falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false2Prepaid and other assets10false 6us-gaap_IncreaseDecreaseInOtherReceivablesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-30000-30falsefalsefalse2truefalsefalse249000249falsefalsefalse3truefalsefalse247000247falsefalsefalse4truefalsefalse-263000-263falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false2Other receivables11false 6us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-560000-560falsefalsefalse2truefalsefalse-270000-270falsefalsefalse3truefalsefalse390000390falsefalsefalse4truefalsefalse317000317falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false2Accounts payable and other accrued liabilities12false 6us-gaap_IncreaseDecreaseInDeferredRevenueus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-77000-77falsefalsefalse2truefalsefalse10000001000falsefalsefalse3truefalsefalse923000923falsefalsefalse4truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false2Deferred revenue13false 6us-gaap_IncreaseDecreaseInOperatingCapitalus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedTotalLabel1truefalsefalse458000458falsefalsefalse2truefalsefalse982000982falsefalsefalse3truefalsefalse507000507falsefalsefalse4truefalsefalse-5000-5falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period of all assets and liabilities used in operating activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 true2Net change in assets and liabilities14false 5us-gaap_NetCashProvidedByUsedInOperatingActivitiesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse1000010falsefalsefalse2truefalsefalse423000423falsefalsefalse3truefalsefalse-1638000-1638falsefalsefalse4truefalsefalse-2316000-2316falsefalsefalsexbrli:monetaryItemTypemonetaryThe net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585 true2Net Cash Provided by Operating Activities15true 4us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Financing Activities16false 5us-gaap_ProceedsFromIssuanceOfCommonStockus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse00falsefalsefalse4truefalsefalse32310003231falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow from the additional capital contribution to the entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 19 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Issuance of common stock and warrants17false 5us-gaap_ProceedsFromWarrantExercisesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse195000195falsefalsefalse2truefalsefalse233000233falsefalsefalse3truefalsefalse365000365falsefalsefalse4truefalsefalse19180001918falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow associated with the amount received from holders exercising their stock warrants.No definition available.false2Proceeds from exercise of warrants, agents' warrants and stock options18false 5igxt_TransactionCostsigxt_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse00falsefalsefalse4truefalsefalse-369000-369falsefalsefalsexbrli:monetaryItemTypemonetaryTransaction CostsNo definition available.false2Transaction costs19false 5us-gaap_NetCashProvidedByUsedInFinancingActivitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse195000195falsefalsefalse2truefalsefalse233000233falsefalsefalse3truefalsefalse365000365falsefalsefalse4truefalsefalse47800004780falsefalsefalsexbrli:monetaryItemTypemonetaryThe net cash inflow or outflow from financing activity for the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. true2Net Cash Provided by Financing Activities20true 4us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Investing Activities21false 5us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-69000-69falsefalsefalse2truefalsefalse-189000-189falsefalsefalse3truefalsefalse-270000-270falsefalsefalse4truefalsefalse-34000-34falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 17 -Subparagraph c -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Additions to leasehold improvements and equipment22false 5us-gaap_PaymentsToAcquireIntangibleAssetsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse00falsefalsefalse4truefalsefalse-125000-125falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 17 -Subparagraph c -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Additions to intangible assets23false 5us-gaap_NetCashProvidedByUsedInInvestingActivitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-69000-69falsefalsefalse2truefalsefalse-189000-189falsefalsefalse3truefalsefalse-270000-270falsefalsefalse4truefalsefalse-159000-159falsefalsefalsexbrli:monetaryItemTypemonetaryThe net cash inflow or outflow from investing activity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. true2Net Cash used in iInvesting Activities24false 4us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse136000136falsefalsefalse2truefalsefalse467000467falsefalsefalse3truefalsefalse-1543000-1543falsefalsefalse4truefalsefalse23050002305falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. true2Increase (Decrease) in Cash and Cash Equivalents25false 4us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-27000-27falsefalsefalse2truefalsefalse8800088falsefalsefalse3truefalsefalse9700097falsefalsefalse4truefalsefalse5600056falsefalsefalsexbrli:monetaryItemTypemonetaryThe effect of exchange rate changes on cash balances held in foreign currencies.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 25 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Effect of Foreign Exchange on Cash and Cash Equivalents26false 4us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabel1truefalsefalse20590002059falsefalsefalse2truefalsefalse35050003505falsefalsefalse3truefalsefalse35050003505falsefalsefalse4truefalsefalse11440001144falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Beginning of Year27false 4us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse21680002168USD$falsetruefalse2truefalsefalse40590004059USD$falsetruefalse3truefalsefalse20590002059USD$falsetruefalse4truefalsefalse35050003505USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2End of YearfalseConsolidated Statements of Cash Flows (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/CashFlows427 XML 69 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 HtmlAndXml 39 653 1 false 4 0 false 8 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.intelgenx.com/taxonomy/role/DocumentAndEntityInformation Document and Entity Information R1.xml true false R2.htm 102 - Statement - Consolidated Balance Sheets Sheet http://www.intelgenx.com/taxonomy/role/BalanceSheet Consolidated Balance Sheets R2.xml false false R3.htm 103 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.intelgenx.com/taxonomy/role/IncomeStatement Consolidated Statements of Comprehensive Loss R3.xml false false R4.htm 104 - Statement - Consolidated Statements of Cash Flows Sheet http://www.intelgenx.com/taxonomy/role/CashFlows Consolidated Statements of Cash Flows R4.xml false false R5.htm 105 - Statement - Consolidated Statement of Shareholders Equity Sheet http://www.intelgenx.com/taxonomy/role/StockholdersEquity Consolidated Statement of Shareholders Equity R5.xml false false R6.htm 106 - Disclosure - Basis of Presentation Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Basis of Presentation R6.xml false false R7.htm 107 - Disclosure - Nature of Business Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperationsTextBlock Nature of Business R7.xml false false R8.htm 108 - Disclosure - Adoption of New Accounting Standards Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsNewAccountingPronouncementEarlyAdoptionTableTextBlock Adoption of New Accounting Standards R8.xml false false R9.htm 109 - Disclosure - Significant Accounting Policies Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Significant Accounting Policies R9.xml false false R10.htm 110 - Disclosure - Leasehold Improvements and Equipment Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock Leasehold Improvements and Equipment R10.xml false false R11.htm 111 - Disclosure - Intangible Assets Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsIntangibleAssetsDisclosureTextBlock Intangible Assets R11.xml false false R12.htm 112 - Disclosure - Deferred License Revenue Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsDeferredRevenueDisclosureTextBlock Deferred License Revenue R12.xml false false R13.htm 113 - Disclosure - Commitments Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments R13.xml false false R14.htm 114 - Disclosure - Capital Stock Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Capital Stock R14.xml false false R15.htm 115 - Disclosure - Additional Paid-In Capital Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsAdditionalPaidInCapitalTextBlock Additional Paid-In Capital R15.xml false false R16.htm 116 - Disclosure - Income Tax Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Tax R16.xml false false R17.htm 117 - Disclosure - Statement of Cash Flows Information Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsCashFlowOperatingCapitalTableTextBlock Statement of Cash Flows Information R17.xml false false R18.htm 118 - Disclosure - Related Party Transactions Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transactions R18.xml false false R19.htm 119 - Disclosure - Basic and Diluted Loss Per Common Share Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Basic and Diluted Loss Per Common Share R19.xml false false R20.htm 120 - Disclosure - Subsequent Events Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock Subsequent Events R20.xml false false R21.htm 122 - Disclosure - Comparative Figures Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsReclassificationsTextBlock Comparative Figures R21.xml false false R22.htm 123 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Summary of Significant Accounting Policies (Policies) R22.xml false false R23.htm 124 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables Significant Accounting Policies (Tables) R23.xml false false R24.htm 125 - Disclosure - Leasehold Improvements and Equipment (Tables) Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables Leasehold Improvements and Equipment (Tables) R24.xml false false R25.htm 126 - Disclosure - Commitments (Tables) Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables Commitments (Tables) R25.xml false false R26.htm 127 - Disclosure - Capital Stock (Tables) Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Capital Stock (Tables) R26.xml false false R27.htm 128 - Disclosure - Additional Paid-In Capital (Tables) Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsAdditionalPaidInCapitalTextBlockTables Additional Paid-In Capital (Tables) R27.xml false false R28.htm 129 - Disclosure - Income Tax (Tables) Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables Income Tax (Tables) R28.xml false false R29.htm 130 - Disclosure - Statement of Cash Flows Information (Tables) Sheet http://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsCashFlowOperatingCapitalTableTextBlockTables Statement of Cash Flows Information (Tables) R29.xml false false R30.htm 131 - Disclosure - Nature of Business (Narrative) (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureNatureOfOperationsDetails Nature of Business (Narrative) (Details) R30.xml false false R31.htm 132 - Disclosure - Significant Accounting Policies (Narrative) (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureSignificantAccountingPoliciesTextBlockDetails Significant Accounting Policies (Narrative) (Details) R31.xml false false R32.htm 133 - Disclosure - Intangible Assets (Narrative) (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureIntangibleAssetsDisclosureTextBlockDetails Intangible Assets (Narrative) (Details) R32.xml false false R33.htm 134 - Disclosure - Deferred License Revenue (Narrative) (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureDeferredRevenueDisclosureTextBlockDetails Deferred License Revenue (Narrative) (Details) R33.xml false false R34.htm 135 - Disclosure - Commitments (Narrative) (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureCommitmentsAndContingenciesDisclosureTextBlockDetails Commitments (Narrative) (Details) R34.xml false false R35.htm 136 - Disclosure - Capital Stock (Narrative) (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureStockholdersEquityNoteDisclosureTextBlockDetails Capital Stock (Narrative) (Details) R35.xml false false R36.htm 137 - Disclosure - Additional Paid-In Capital (Narrative) (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureAdditionalPaidInCapitalTextBlockDetails Additional Paid-In Capital (Narrative) (Details) R36.xml false false R37.htm 138 - Disclosure - Income Tax (Narrative) (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureIncomeTaxDisclosureTextBlockDetails Income Tax (Narrative) (Details) R37.xml false false R38.htm 139 - Disclosure - Related Party Transactions (Narrative) (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureRelatedPartyTransactionsDisclosureTextBlockDetails Related Party Transactions (Narrative) (Details) R38.xml false false R39.htm 140 - Disclosure - Subsequent Events (Narrative) (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureSubsequentEventsTextBlockDetails Subsequent Events (Narrative) (Details) R39.xml false false R40.htm 141 - Disclosure - Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureEstimatedUsefulLivesOnTheDecliningBalanceMethodTableTextBlockDetails Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment (Details) R40.xml false false R41.htm 142 - Disclosure - Schedule of Leasehold Improvements and Equipment (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentTextBlockDetails Schedule of Leasehold Improvements and Equipment (Details) R41.xml false false R42.htm 143 - Disclosure - Schedule of future minimum payments under operating leases (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlockDetails Schedule of future minimum payments under operating leases (Details) R42.xml false false R43.htm 144 - Disclosure - Schedule of Stock by Class (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfStockByClassTextBlockDetails Schedule of Stock by Class (Details) R43.xml false false R44.htm 145 - Disclosure - Schedule of Stock Options Valuation - May 12, 2011 (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlockDetails Schedule of Stock Options Valuation - May 12, 2011 (Details) R44.xml false false R45.htm 146 - Disclosure - Schedule of Stock Options Valuation - November 29, 2011 (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfStockOptionsValuationNovemberTwoNineTwoZeroOneOneTableTextBlockDetails Schedule of Stock Options Valuation - November 29, 2011 (Details) R45.xml false false R46.htm 147 - Disclosure - Schedule of Stock Options Valuation - June 13, 2012 (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfStockOptionsValuationJuneOneThreeTwoZeroOneTwoTableTextBlockDetails Schedule of Stock Options Valuation - June 13, 2012 (Details) R46.xml false false R47.htm 148 - Disclosure - Schedule of Stock Options Valuation - August 8, 2012 (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfStockOptionsValuationAugustEightTwoZeroOneTwoTableTextBlockDetails Schedule of Stock Options Valuation - August 8, 2012 (Details) R47.xml false false R48.htm 149 - Disclosure - Schedule of Stock Options Valuation - December 4, 2012 (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfStockOptionsValuationDecemberFourTwoZeroOneTwoTableTextBlockDetails Schedule of Stock Options Valuation - December 4, 2012 (Details) R48.xml false false R49.htm 150 - Disclosure - Schedule of Stock Options Valuation - December 12, 2012 (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfStockOptionsValuationDecemberOneTwoTwoZeroOneTwoTableTextBlockDetails Schedule of Stock Options Valuation - December 12, 2012 (Details) R49.xml false false R50.htm 151 - Disclosure - Schedule of Stock Option Activity (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlockDetails Schedule of Stock Option Activity (Details) R50.xml false false R51.htm 152 - Disclosure - Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfShareBasedCompensationStockOptionsActivityAndWarrantsOrRightsActivityTableTextBlockDetails Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity (Details) R51.xml false false R52.htm 153 - Disclosure - Schedule of Warrants Valuation - June 21, 2011 (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlockDetails Schedule of Warrants Valuation - June 21, 2011 (Details) R52.xml false false R53.htm 154 - Disclosure - Schedule of Warrants Valuation - June 21, 2011 (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfWarrantValuationJuneTwoOneTwoZeroOneOneTableTextBlockDetails Schedule of Warrants Valuation - June 21, 2011 (Details) R53.xml false false R54.htm 155 - Disclosure - Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfStockholdersEquityNoteWarrantsOrRightsActivityTextBlockDetails Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) R54.xml false false R55.htm 156 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlockDetails Schedule of Effective Income Tax Rate Reconciliation (Details) R55.xml false false R56.htm 157 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlockDetails Schedule of Deferred Tax Assets and Liabilities (Details) R56.xml false false R57.htm 158 - Disclosure - Schedule of Cash Flow, Supplemental Disclosures (Details) Sheet http://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfCashFlowSupplementalDisclosuresTableTextBlockDetails Schedule of Cash Flow, Supplemental Disclosures (Details) R57.xml false false All Reports Book All Reports 'Monetary' elements on report '132 - Disclosure - Significant Accounting Policies (Narrative) (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '134 - Disclosure - Deferred License Revenue (Narrative) (Details)' had a mix of different decimal attribute values. 'Shares' elements on report '136 - Disclosure - Capital Stock (Narrative) (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '136 - Disclosure - Capital Stock (Narrative) (Details)' had a mix of different decimal attribute values. Process Flow-Through: 102 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2012' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 103 - Statement - Consolidated Statements of Comprehensive Loss Process Flow-Through: 104 - Statement - Consolidated Statements of Cash Flows igxt-20130331.xml igxt-20130331.xsd igxt-20130331_cal.xml igxt-20130331_def.xml igxt-20130331_lab.xml igxt-20130331_pre.xml true true XML 70 R48.xml IDEA: Schedule of Stock Options Valuation - December 4, 2012 (Details) 2.4.0.8149 - Disclosure - Schedule of Stock Options Valuation - December 4, 2012 (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00yStandardhttp://www.xbrl.org/2009/utrYutr0pureStandardhttp://www.xbrl.org/2003/instancepure0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_ScheduleOfStockOptionsValuationDecemberFourTwoZeroOneTwoZeroOneSixTwoZeroTwoZeroEightFiveTPQqBgxzSixrbLigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse0.780.78falsefalsefalsenum:percentItemTypepureAdditional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 1No definition available.false0Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 12false 4igxt_ScheduleOfStockOptionsValuationDecemberFourTwoZeroOneTwoZeroOneSixTwoZeroTwoZeroEightFivencTZkWFiveFmRqpigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse3.13.1falsefalsefalsexbrli:decimalItemTypedecimalAdditional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 2No definition available.false256Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 23false 4igxt_ScheduleOfStockOptionsValuationDecemberFourTwoZeroOneTwoZeroOneSixTwoZeroTwoZeroEightFivefSrThreeFourgtXNineFourzZigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse0.00340.0034falsefalsefalsenum:percentItemTypepureAdditional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 3No definition available.false0Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 34false 4igxt_ScheduleOfStockOptionsValuationDecemberFourTwoZeroOneTwoZeroOneSixTwoZeroTwoZeroEightFivesFourRnSixLFiveQmNqyigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00USD$falsetruefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 4No definition available.false2Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 4falseSchedule of Stock Options Valuation - December 4, 2012 (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfStockOptionsValuationDecemberFourTwoZeroOneTwoTableTextBlockDetails14 XML 71 R50.htm IDEA: XBRL DOCUMENT

Schedule of Stock Option Activity (Details) (USD $)	12 Months Ended
Schedule of Stock Option Activity (Details) (USD $)	Dec. 31, 2012
Additional Paid-in Capital Schedule Of Stock Option Activity 1	$ 1,698,088
Additional Paid-in Capital Schedule Of Stock Option Activity 2	0.53
Additional Paid-in Capital Schedule Of Stock Option Activity 3	290,000
Additional Paid-in Capital Schedule Of Stock Option Activity 4	0.54
Additional Paid-in Capital Schedule Of Stock Option Activity 5	(150,000)
Additional Paid-in Capital Schedule Of Stock Option Activity 6	(0.76)
Additional Paid-in Capital Schedule Of Stock Option Activity 7	(65,000)
Additional Paid-in Capital Schedule Of Stock Option Activity 8	(0.59)
Additional Paid-in Capital Schedule Of Stock Option Activity 9	(775,000)
Additional Paid-in Capital Schedule Of Stock Option Activity 10	(0.41)
Additional Paid-in Capital Schedule Of Stock Option Activity 11	998,088
Additional Paid-in Capital Schedule Of Stock Option Activity 12	0.59
Additional Paid-in Capital Schedule Of Stock Option Activity 13	195,000
Additional Paid-in Capital Schedule Of Stock Option Activity 14	0.57
Additional Paid-in Capital Schedule Of Stock Option Activity 15	(45,000)
Additional Paid-in Capital Schedule Of Stock Option Activity 16	(0.49)
Additional Paid-in Capital Schedule Of Stock Option Activity 17	(32,500)
Additional Paid-in Capital Schedule Of Stock Option Activity 18	(1.15)
Additional Paid-in Capital Schedule Of Stock Option Activity 19	(50,000)
Additional Paid-in Capital Schedule Of Stock Option Activity 20	(0.55)
Additional Paid-in Capital Schedule Of Stock Option Activity 21	$ 1,065,588
Additional Paid-in Capital Schedule Of Stock Option Activity 22	0.58

XML 72 R45.htm IDEA: XBRL DOCUMENT

Schedule of Stock Options Valuation - November 29, 2011 (Details) (USD $)	12 Months Ended
	Dec. 31, 2012 Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - November 29, 2011 1	101.00%
Additional Paid-in Capital Schedule Of Stock Options Valuation - November 29, 2011 2	3.1
Additional Paid-in Capital Schedule Of Stock Options Valuation - November 29, 2011 3	0.40%
Additional Paid-in Capital Schedule Of Stock Options Valuation - November 29, 2011 4	$ 0

XML 73 R3.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Loss (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		12 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012	Dec. 31, 2011
Revenues
Royalties	$ 80	$ 0
License and other revenue	77	100
Revenue			1,198	433
Other Income			10	7
Total Revenues	157	100	1,208	440
Expenses
Research and development	167	239	1,935	1,524
Research and development tax credits			(212)	(188)
Selling, general and administrative expense	456	439
Management salaries			716	586
General and administrative			347	333
Professional fees			582	594
Depreciation	10	8	46	37
Amortization of intangible assets	10	0
Foreign exchange loss			41	3
Interest and financing fees			3	3
Total Costs and Expenses	643	686	3,458	2,892
Loss from Operations	(486)	(586)
Other Income
Interest and other income	0	4
Total Other Income	0	4
Loss Before Income Taxes			(2,250)	(2,452)
Income taxes			0	0
Net Loss	(486)	(582)	(2,250)	(2,452)
Other Comprehensive Income
Foreign currency translation adjustment	(36)	91	100	49
Comprehensive Loss	$ (522)	$ (491)	$ (2,150)	$ (2,403)
Basic and Diluted Weighted Average Number of Shares Outstanding	50,236,255	49,324,531	49,637,908	43,736,003
Basic and Diluted Loss Per Common Share	$ (0.01)	$ (0.01)	$ (0.04)	$ (0.05)

XML 74 R14.htm IDEA: XBRL DOCUMENT

Capital Stock

3 Months Ended

12 Months Ended

Mar. 31, 2013

Dec. 31, 2012

Capital Stock [Text Block]

6.	Capital Stock

		March 31,		December 31,
		2013		2012
Authorized -
100,000,000 common shares of $0.00001 par value
20,000,000 preferred shares of $0.00001 par value
Issued -
50,302,921 (December 31, 2012 - 49,890,421) common shares	$	503	$	499

9.	Capital Stock

		2012		2011
Authorized -
100,000,000 common shares of $0.00001 par value
20,000,000 preferred shares of $0.00001 par value
Issued -
49,890,421 (December 31, 2011 - 48,895,028) common shares	$	499	$	489

	In the year ended December 31, 2012 a total of 50,000 (2011 – 775,000) stock options were exercised for 50,000 (2011 – 775,000) common shares having a par value of $0 thousand (2011 - $Nil) in aggregate, for cash consideration of $28 thousand ($318 thousand), resulting in an increase in additional paid-in capital of $28 thousand (2011 – $318 thousand).

	During the year ended December 31, 2012 a total of 219,313 (2011 - 299,406) agents’ warrants were exercised for 219,313 (2011 - 299,406) common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $104 thousand (2011 - $142 thousand), resulting in an increase in additional paid- in capital of approximately $104 thousand (2011 - $142 thousand).

	Also in the year ended December 31, 2012 a total of 1,205,668 warrants were exercised, of which 491,382 warrants were exercised for 491,382 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $233 thousand, resulting in an increase in additional paid-in capital of approximately $233 thousand, and a total of 714,286 warrants were exercised for 234,698 common shares in cashless exercises, resulting in an increase in additional paid-in capital of $Nil.

	In the year ended December 31, 2011 a total of 4,366,904 warrants were exercised, of which 2,902,618 warrants were exercised for 2,902,618 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $1,458 thousand, resulting in an increase in additional paid-in capital of approximately $1,458 thousand, and a total of 1,464,286 warrants were exercised for 515,391 common shares in cashless exercises, resulting in an increase in additional paid-in capital of $Nil.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7, 11A

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

+ Details

XML 75 R20.xml IDEA: Subsequent Events 2.4.0.8120 - Disclosure - Subsequent Eventstruefalsefalse1false falsefalsecx_01_January_2013_TO_31_March_2013http://www.sec.gov/CIK0001098880duration2013-01-01T00:00:002013-03-31T00:00:002false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_SubsequentEventsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 10. </td> <td> Subsequent Events </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Subsequent to the end of the quarter, the Company's board of directors granted options to acquire 680,000 common shares under the 2006 Stock Option Plan, as amended. Of the total stock options granted, 480,000 were granted to the Chief Operating Officer and Chief Scientific Officer, Dr. Rajiv Khosla, and 200,000 were granted to the Chief Financial Officer, Mr. Paul A. Simmons. The options have an exercise price of CAD$0.67 (US$0.65) and expire on April 23, 2018. All of the options granted to Dr. Khosla vest on December 31, 2015. The options granted to Mr. Simmons vest over a period of two years at the rate of 25% every six months. In addition, 37,500 unvested options that were granted to Dr. Khosla in November 2011 expired upon issuance of the above options. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Subsequent to the end of the quarter, 995,500 warrants were exercised for 995,500 common shares having a par value of $0 thousand for cash consideration of approximately $472 thousand, resulting in an increase in additional paid-in capital of approximately $472 thousand. </td> </tr> </table>falsefalsefalse2falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td align="left"> 15.</td> <td align="left" width="95%"> Subsequent Events </td> </tr> <tr> <td>  </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left">  </td> <td align="left" width="95%"> Subsequent top the year ended December 31, 2012, 362,500 warrants were exercised for 362,500 common shares having a par value of $0 thousand for cash consideration of approximately $172 thousand, resulting in an increase in additional paid-in capital of approximately $172 thousand . </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.No definition available.false0Subsequent Events [Text Block]falseSubsequent EventsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock21 XML 76 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statement of Shareholders Equity (USD $) In Thousands, except Share data	Capital Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Total
Beginning Balance at Dec. 31, 2010	$ 0	$ 11,087	$ (9,761)	$ 150	$ 1,476
Beginning Balance (Shares) at Dec. 31, 2010	39,581,271
Foreign currency translation adjustment				49	49
Issue of common stock, net of transaction costs of $390		2,024			2,024
Issue of common stock, net of transaction costs of $390 (Shares)	4,821,342
Warrants issued, net of transaction costs of $132		685			685
Agents' Warrants		153			153
Warrants exercised		1,458			1,458
Warrants exercised (Shares)	3,418,009
Agents warrants exercised		142			142
Agents warrants exercised (Shares)	299,406
Options exercised		318			318
Options exercised (Shares)	775,000
Stock-based compensation		51			51
Net loss for the period			(2,452)		(2,452)
Ending Balance at Dec. 31, 2011	0	15,918	(12,213)	199	3,904
Ending Balance (Shares) at Dec. 31, 2011	48,895,028
Foreign currency translation adjustment				100	100
Warrants exercised		233			233
Warrants exercised (Shares)	726,080
Agents warrants exercised		104			104
Agents warrants exercised (Shares)	219,313
Options exercised		28			28
Options exercised (Shares)	50,000
Stock-based compensation		59			59
Net loss for the period			(2,250)		(2,250)
Ending Balance at Dec. 31, 2012	0	16,342	(14,463)	299	2,178
Ending Balance (Shares) at Dec. 31, 2012	49,890,421
Foreign currency translation adjustment				(36)	(36)
Warrants exercised	1	171			172
Warrants exercised (Shares)	362,500
Options exercised		23			23
Options exercised (Shares)	50,000
Stock-based compensation		18			18
Net loss for the period			(486)		(486)
Ending Balance at Mar. 31, 2013	$ 1	$ 16,554	$ (14,949)	$ 263	$ 1,869
Ending Balance (Shares) at Mar. 31, 2013	50,302,921

XML 77 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current
Cash and cash equivalents	$ 2,168	$ 2,059	$ 3,505
Accounts receivable	170	1,282	263
Prepaid expenses	89	102	68
Loan receivable		0	85
Investment tax credits receivable	243	213	375
Total Current Assets	2,670	3,656	4,296
Leasehold Improvements and Equipment	438	387	149
Intangible assets	106	116	125
Total Assets	3,214	4,159	4,570
Current
Accounts payable and accrued liabilities	498	1,058	666
Deferred license revenue	308	308	0
Total Curent Liabilities	806	1,366	666
Deferred license revenue, non-current portion	539	615	0
Total Liabilities	1,345	1,981	666
Commitments		0	0
Shareholders' Equity
Capital Stock	1	0	0
Additional Paid-in-Capital	16,554	16,342	15,918
Accumulated Deficit	(14,949)	(14,463)	(12,213)
Accumulated Other Comprehensive Income	263	299	199
Total Stockholder Equity	1,869	2,178	3,904
Total Liabilities and Stockholders Equity	$ 3,214	$ 4,159	$ 4,570

XML 78 R47.xml IDEA: Schedule of Stock Options Valuation - August 8, 2012 (Details) 2.4.0.8148 - Disclosure - Schedule of Stock Options Valuation - August 8, 2012 (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00yStandardhttp://www.xbrl.org/2009/utrYutr0pureStandardhttp://www.xbrl.org/2003/instancepure0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_ScheduleOfStockOptionsValuationAugustEightTwoZeroOneTwoZeroOneSixTwoZeroTwoZeroEightFiveyTCvQbbkpEightdNigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse0.810.81falsefalsefalsenum:percentItemTypepureAdditional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 1No definition available.false0Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 12false 4igxt_ScheduleOfStockOptionsValuationAugustEightTwoZeroOneTwoZeroOneSixTwoZeroTwoZeroEightFiveFMNineZerorrzDFiveTwotWigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1.81.8falsefalsefalsexbrli:decimalItemTypedecimalAdditional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 2No definition available.false256Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 23false 4igxt_ScheduleOfStockOptionsValuationAugustEightTwoZeroOneTwoZeroOneSixTwoZeroTwoZeroEightFivevmFiveyNvWZFiveTwoxNigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse0.00380.0038falsefalsefalsenum:percentItemTypepureAdditional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 3No definition available.false0Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 34false 4igxt_ScheduleOfStockOptionsValuationAugustEightTwoZeroOneTwoZeroOneSixTwoZeroTwoZeroEightFiveNineyNBzRCwqFiveCFourigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00USD$falsetruefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 4No definition available.false2Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 4falseSchedule of Stock Options Valuation - August 8, 2012 (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfStockOptionsValuationAugustEightTwoZeroOneTwoTableTextBlockDetails14 XML 79 R7.xml IDEA: Nature of Business 2.4.0.8107 - Disclosure - Nature of Businesstruefalsefalse1false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_NatureOfOperationsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 2.</td> <td> Nature of Business </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> The Company specializes in the development of pharmaceutical products in co-operation with various pharmaceutical companies. </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> Technologies </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> The Company has developed three proprietary delivery platforms; including an immediate release oral film “ VersaFilm™ ”, a mucoadhesive tablet “ AdVersa™ ” and a multilayer controlled release tablet “ VersaTab™ ”. </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> The three technology platforms have been designed to address the challenges commonly encountered in oral drug delivery, such as first-pass metabolism, gastrointestinal (“GI”) side effects, or incomplete absorption of the drug in the GI tract. IntelGenx’ technologies are broadly applicable and have the ability to improve the performance of a wide variety of existing pharmaceutical compounds. </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> Product Pipeline </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> IntelGenx’ product pipeline currently consists of 9 products in various stages of development, including products for the treatment of hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, idiopathic pulmonary fibrosis, allergies and pain management. Of the products currently under development, 6 utilize the VersaFilm™ technology, 2 utilize the VersaTab™ technology, and one utilizes the AdVersa™ technology. </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> Approved and Commercialized Products </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> The Company’s first FDA-approved product, Forfivo XL™, was launched in the USA in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP. Forfivo XL™ is indicated for the treatment of Major Depressive Disorder (MDD) and is the only extended-release bupropion HCl product to provide a once-daily, 450mg dose in a single tablet. The active ingredient in Forfivo XL is bupropion, the same active ingredient used in Wellbutrin XL®. </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> Sales of the Company’s first commercialized product, a pre-natal multivitamin supplement, marketed in the USA as Gesticare®, were discontinued in the third quarter of 2011. The Company received final royalties from the sale of the product in the fourth quarter of 2011 from Azur Pharma, now part of Jazz Pharmaceuticals plc. </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 94-6 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Nature of Business [Text Block]falseNature of BusinessUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperationsTextBlock11 XML 80 R17.xml IDEA: Statement of Cash Flows Information 2.4.0.8117 - Disclosure - Statement of Cash Flows Informationtruefalsefalse1false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_CashFlowOperatingCapitalTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 12. </td> <td> Statement of Cash Flows Information </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid"> In US$ thousands </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 2012 </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%">2011</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> Additional Cash Flow Information: </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="12%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid">Interest paid</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $ </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 3 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%">$</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 3 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the net increase (decrease) in operating capital in the operating section of the statement of cash flows, represents the entire footnote disclosure that provides details regarding the net change during the reporting period of all assets and liabilities used in operating activities.No definition available.false0Statement of Cash Flows Information [Text Block]falseStatement of Cash Flows InformationUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsCashFlowOperatingCapitalTableTextBlock11 XML 81 R51.htm IDEA: XBRL DOCUMENT

Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 1	0.31
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 2	$ 25,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 3	1.25
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 4	0.31
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 5	25,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 6	0.31
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 7	0.37
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 8	75,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 9	2.67
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 10	0.37
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 11	75,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 12	0.37
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 13	0.45
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 14	0.47
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 15	175,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 16	1.42
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 17	0.46
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 18	175,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 19	0.46
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 20	0.51
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 21	40,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 22	4.50
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 23	0.51
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 24	0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 25	0.00
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 26	0.52
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 27	0.54
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 28	270,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 29	3.89
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 30	0.54
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 31	147,500
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 32	0.54
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 33	0.55
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 34	50,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 35	2.67
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 36	0.55
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 37	12,500
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 38	0.55
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 39	0.60
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 40	55,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 41	5.00
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 42	0.60
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 43	0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 44	0.00
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 45	0.61
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 46	125,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 47	1.51
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 48	0.61
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 49	125,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 50	0.61
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 51	0.62
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 52	50,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 53	3.00
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 54	0.62
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 55	0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 56	0.00
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 57	0.85
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 58	200,588
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 59	0.63
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 60	0.85
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 61	200,588
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 62	0.85
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 63	1,065,588
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 64	2.60
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 65	0.58
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 66	114,050
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 67	760,588
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 68	0.59
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 69	$ 86,725

XML 82 R45.xml IDEA: Schedule of Stock Options Valuation - November 29, 2011 (Details) 2.4.0.8146 - Disclosure - Schedule of Stock Options Valuation - November 29, 2011 (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00yStandardhttp://www.xbrl.org/2009/utrYutr0pureStandardhttp://www.xbrl.org/2003/instancepure0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_ScheduleOfStockOptionsValuationNovemberTwoNineTwoZeroOneOneZeroOneSixTwoZeroTwoZeroEightFivePTRnSevenXGMMSixMpigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse1.011.01falsefalsefalsenum:percentItemTypepureAdditional Paid-in Capital Schedule Of Stock Options Valuation - November 29, 2011 1No definition available.false0Additional Paid-in Capital Schedule Of Stock Options Valuation - November 29, 2011 12false 4igxt_ScheduleOfStockOptionsValuationNovemberTwoNineTwoZeroOneOneZeroOneSixTwoZeroTwoZeroEightFiveNineQThreeSlFFourrwRTMigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse3.13.1falsefalsefalsexbrli:decimalItemTypedecimalAdditional Paid-in Capital Schedule Of Stock Options Valuation - November 29, 2011 2No definition available.false256Additional Paid-in Capital Schedule Of Stock Options Valuation - November 29, 2011 23false 4igxt_ScheduleOfStockOptionsValuationNovemberTwoNineTwoZeroOneOneZeroOneSixTwoZeroTwoZeroEightFiveJNgpTThreeQVbCqSixigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse0.00400.0040falsefalsefalsenum:percentItemTypepureAdditional Paid-in Capital Schedule Of Stock Options Valuation - November 29, 2011 3No definition available.false0Additional Paid-in Capital Schedule Of Stock Options Valuation - November 29, 2011 34false 4igxt_ScheduleOfStockOptionsValuationNovemberTwoNineTwoZeroOneOneZeroOneSixTwoZeroTwoZeroEightFiveGdgZPKsldXWpigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00USD$falsetruefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stock Options Valuation - November 29, 2011 4No definition available.false2Additional Paid-in Capital Schedule Of Stock Options Valuation - November 29, 2011 4falseSchedule of Stock Options Valuation - November 29, 2011 (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfStockOptionsValuationNovemberTwoNineTwoZeroOneOneTableTextBlockDetails14 XML 83 R16.xml IDEA: Income Tax 2.4.0.8116 - Disclosure - Income Taxtruefalsefalse1false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_IncomeTaxDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 11.</td> <td> Income Taxes </td> </tr> <tr> <td width="5%">  </td> <td>  </td> </tr> <tr> <td width="5%">  </td> <td> Income taxes reported differ from the amount computed by applying the statutory rates to losses. The reasons are as follows: </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 2012</td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 2011</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Statutory income taxes</td> <td align="left" bgcolor="#e6efff" width="1%"> $</td> <td align="right" bgcolor="#e6efff" width="12%"> (605 </td> <td align="left" bgcolor="#e6efff" width="2%"> )</td> <td align="left" bgcolor="#e6efff" width="1%"> $</td> <td align="right" bgcolor="#e6efff" width="12%"> (694</td> <td align="left" bgcolor="#e6efff" width="2%"> )</td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Net operating losses for which no tax benefits have been recorded</td> <td align="left" width="1%">  </td> <td align="right" width="12%"> 368 </td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%"> 514</td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Excess of depreciation over capital cost allowance</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> 3 </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> (2</td> <td align="left" bgcolor="#e6efff" width="2%"> )</td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Non-deductible expenses</td> <td align="left" width="1%">  </td> <td align="right" width="12%"> 18 </td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%"> 4</td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Undeducted research and development expenses</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> 273 </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> 231</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Tax deductible portion of transaction costs</td> <td align="left" width="1%">  </td> <td align="right" width="12%"> - </td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%"> -</td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Investment tax credit</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> (57 </td> <td align="left" bgcolor="#e6efff" width="2%"> )</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> (53</td> <td align="left" bgcolor="#e6efff" width="2%"> )</td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Modification of warrants terms</td> <td align="left" width="1%">  </td> <td align="right" width="12%"> - </td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%"> -</td> <td align="left" width="2%">  </td> </tr> <tr> <td width="5%">  </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid">  </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%">  </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%">  </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> </tr> <tr> <td width="5%">  </td> <td>  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> - </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%">   -</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> </tr> </table> The major components of the deferred tax assets classified by the source of temporary differences are as follows: <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid">  </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 2012</td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 2011</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> </tr> <tr> <td width="5%">  </td> <td align="left">  </td> <td align="right" width="1%">  </td> <td align="right" width="12%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="12%">  </td> <td align="right" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Leasehold Improvements and equipment</td> <td align="left" bgcolor="#e6efff" width="1%"> $</td> <td align="right" bgcolor="#e6efff" width="12%"> 13 </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%"> $</td> <td align="right" bgcolor="#e6efff" width="12%"> 14</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Net operating losses carryforward</td> <td align="left" width="1%">  </td> <td align="right" width="12%"> 2,278 </td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%"> 2,140</td> <td align="left" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff"> Undeducted research and development expenses</td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> 1,301 </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> 1,141</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left"> Non-refundable tax credits carryforward</td> <td align="left" width="1%">  </td> <td align="right" width="12%"> 914 </td> <td align="left" width="2%">  </td> <td align="left" width="1%">  </td> <td align="right" width="12%"> 807</td> <td align="left" width="2%">  </td> </tr> <tr> <td width="5%">  </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid">  </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%">  </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%">  </td> <td bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%">  </td> </tr> <tr> <td width="5%">  </td> <td>  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> <td width="1%">  </td> <td width="12%">  </td> <td width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> 4,506 </td> <td align="left" bgcolor="#e6efff" width="2%">  </td> <td align="left" bgcolor="#e6efff" width="1%">  </td> <td align="right" bgcolor="#e6efff" width="12%"> 4,102</td> <td align="left" bgcolor="#e6efff" width="2%">  </td> </tr> <tr> <td width="5%">  </td> <td align="left">  </td> <td align="right" width="1%">  </td> <td align="right" width="12%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="12%">  </td> <td align="right" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid"> Valuation allowance</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (4,506 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> )</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%">  </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (4,102</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> )</td> </tr> <tr> <td width="5%">  </td> <td align="left">  </td> <td align="right" width="1%">  </td> <td align="right" width="12%">  </td> <td align="right" width="2%">  </td> <td align="right" width="1%">  </td> <td align="right" width="12%">  </td> <td align="right" width="2%">  </td> </tr> <tr valign="top"> <td width="5%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> - </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> $</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%">   -</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">  </td> </tr> </table> The valuation allowance at December 31, 2011 was $4,102 thousand. The net change in the valuation allowance during the period ended December 31, 2012, was an increase of $404 thousand. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of December 31, 2012. <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td height="45" width="5%">  </td> <td height="45"> There were Canadian and provincial net operating losses of approximately $8,390 thousand (2011 - $7,608 thousand) and $8,566 thousand (2011 - $7,437 thousand) respectively, that may be applied against earnings of future years. Utilization of the net operating losses is subject to significant limitations imposed by the change in control provisions. Canadian and provincial losses will be expiring between 2027 and 2032. A portion of the net operating losses may expire before they can be utilized. </td> </tr> <tr> <td height="15" width="5%">  </td> <td height="15">  </td> </tr> <tr> <td height="45" width="5%">  </td> <td height="45"> As at December 31, 2012, the Company had non-refundable tax credits of $914 thousand (2011 - $803 thousand) of which $24 thousand is expiring in 2017, $213 thousand is expiring in 2018, $193 thousand is expiring in 2019, $186 thousand is expiring in 2020, $187 thousand is expiring in 2021 and $111 thousand is expiring in 2022 and undeducted research and development expenses of $4,464 thousand (2011 - $3,656 thousand) with no expiration date. </td> </tr> <tr> <td height="15" width="5%">  </td> <td height="15">  </td> </tr> <tr> <td height="15" width="5%">  </td> <td height="15"> The deferred tax benefit of these items was not recognized in the accounts as it has been fully provided for. </td> </tr> <tr> <td height="15" width="5%">  </td> <td height="15">  </td> </tr> <tr> <td height="15" width="5%">  </td> <td height="15"> Unrecognized Tax Benefits </td> </tr> <tr> <td height="15" width="5%">  </td> <td height="15">  </td> </tr> <tr> <td height="15" width="5%">  </td> <td height="15"> The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. </td> </tr> <tr> <td height="15" width="5%">  </td> <td height="15">  </td> </tr> <tr> <td height="15" width="5%">  </td> <td height="15"> Tax Years and Examination </td> </tr> <tr> <td height="15" width="5%">  </td> <td height="15">  </td> </tr> <tr> <td height="45" width="5%">  </td> <td height="45"> The Company files tax returns in each jurisdiction in which it is registered to do business. For each jurisdiction a statute of limitations period exists. After a statute of limitations period expires, the respective tax authorities may no longer assess additional income tax for the expired period. Similarly, the Company is no longer eligible to file claims for refund for any tax that it may have overpaid. The following table summarizes the Company’s major tax jurisdictions and the tax years that remain subject to examination by these jurisdictions as of December 31, 2012: </td> </tr> </table> <div align="center"> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="90%"> <tr valign="top"> <td align="center" style="BORDER-BOTTOM: #000000 2px solid"> Tax Jurisdictions</td> <td align="center" width="6%">  </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="46%">       Tax Years</td> </tr> <tr valign="top"> <td align="center"> Federal - Canada</td> <td align="center" width="6%">  </td> <td align="center" width="46%"> 2010 and onward</td> </tr> <tr valign="top"> <td align="center"> Provincial - Quebec</td> <td align="center" width="6%">  </td> <td align="center" width="46%"> 2010 and onward</td> </tr> </table> </div>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 136, 172 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 43, 44, 45, 46, 47, 48, 49 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Income Tax [Text Block]falseIncome TaxUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock11 XML 84 R27.xml IDEA: Additional Paid-In Capital (Tables) 2.4.0.8128 - Disclosure - Additional Paid-In Capital (Tables)truefalsefalse1false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid">Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 115% </td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expected life</td> <td align="center" width="14%"> 3.1 years </td> <td align="center" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.96% </td> <td align="center" bgcolor="#e6efff" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false0Schedule of Stock Options Valuation - May 12, 2011 [Table Text Block]2false 4igxt_ScheduleOfStockOptionsValuationNovemberTwoNineTwoZeroOneOneTableTextBlockigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid">Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 101% </td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expected life</td> <td align="center" width="14%"> 3.1 years </td> <td align="center" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.40% </td> <td align="center" bgcolor="#e6efff" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaSchedule of Stock Options Valuation - November 29, 2011No definition available.false0Schedule of Stock Options Valuation - November 29, 2011 [Table Text Block]3false 4igxt_ScheduleOfStockOptionsValuationJuneOneThreeTwoZeroOneTwoTableTextBlockigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid">Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 83% </td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expected life</td> <td align="center" width="14%"> 3.1 years </td> <td align="center" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.40% </td> <td align="center" bgcolor="#e6efff" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaSchedule of Stock Options Valuation - June 13, 2012No definition available.false0Schedule of Stock Options Valuation - June 13, 2012 [Table Text Block]4false 4igxt_ScheduleOfStockOptionsValuationAugustEightTwoZeroOneTwoTableTextBlockigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid">Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 81% </td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expected life</td> <td align="center" width="14%"> 1.8 years </td> <td align="center" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.38% </td> <td align="center" bgcolor="#e6efff" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaSchedule of Stock Options Valuation - August 8, 2012No definition available.false0Schedule of Stock Options Valuation - August 8, 2012 [Table Text Block]5false 4igxt_ScheduleOfStockOptionsValuationDecemberFourTwoZeroOneTwoTableTextBlockigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid">Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 78% </td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expected life</td> <td align="center" width="14%"> 3.1 years </td> <td align="center" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.34% </td> <td align="center" bgcolor="#e6efff" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaSchedule of Stock Options Valuation - December 4, 2012No definition available.false0Schedule of Stock Options Valuation - December 4, 2012 [Table Text Block]6false 4igxt_ScheduleOfStockOptionsValuationDecemberOneTwoTwoZeroOneTwoTableTextBlockigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid">Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 70% </td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expected life</td> <td align="center" width="14%"> 1.8 years </td> <td align="center" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.25% </td> <td align="center" bgcolor="#e6efff" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaSchedule of Stock Options Valuation - December 12, 2012No definition available.false0Schedule of Stock Options Valuation - December 12, 2012 [Table Text Block]7false 4us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="1%"> </td> <td align="left" width="12%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> Weighted average </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> Number of options </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> exercise price </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%">$ </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid">Outstanding – January 1, 2011</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 1,698,088 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 0.53 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Granted</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 290,000 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 0.54 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Forfeited</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> (150,000 </td> <td align="left" width="2%">)</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> (0.76 </td> <td align="left" width="2%">)</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Expired</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> (65,000 </td> <td align="left" bgcolor="#e6efff" width="2%">)</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> (0.59 </td> <td align="left" bgcolor="#e6efff" width="2%">)</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid">Exercised</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (775,000 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">)</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (0.41 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%">)</td> </tr> <tr> <td width="5%"> </td> <td bgcolor="#e6efff"> </td> <td bgcolor="#e6efff" width="1%"> </td> <td bgcolor="#e6efff" width="12%"> </td> <td bgcolor="#e6efff" width="2%"> </td> <td bgcolor="#e6efff" width="1%"> </td> <td bgcolor="#e6efff" width="12%"> </td> <td bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid">Outstanding – December 31, 2011</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 998,088 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 0.59 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td bgcolor="#e6efff"> </td> <td bgcolor="#e6efff" width="1%"> </td> <td bgcolor="#e6efff" width="12%"> </td> <td bgcolor="#e6efff" width="2%"> </td> <td bgcolor="#e6efff" width="1%"> </td> <td bgcolor="#e6efff" width="12%"> </td> <td bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Granted</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 195,000 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> 0.57 </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Forfeited</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> (45,000 </td> <td align="left" bgcolor="#e6efff" width="2%">)</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> (0.49 </td> <td align="left" bgcolor="#e6efff" width="2%">)</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expired</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> (32,500 </td> <td align="left" width="2%">)</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> (1.15 </td> <td align="left" width="2%">)</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid">Exercised</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (50,000 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%">)</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (0.55 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%">)</td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid">Outstanding – December 31, 2012</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 1,065,588 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 0.58 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 false0Schedule of Stock Option Activity [Table Text Block]8false 4igxt_ScheduleOfShareBasedCompensationStockOptionsActivityAndWarrantsOrRightsActivityTableTextBlockigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="95%"> <tr valign="top"> <td align="center"> </td> <td align="center" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" colspan="10" style="BORDER-BOTTOM: #000000 1px solid"> Outstanding options </td> <td align="right" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" colspan="7" style="BORDER-BOTTOM: #000000 1px solid"> Exercisable options </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td align="center"> </td> <td align="center" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="11%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td align="center"> </td> <td align="center" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="11%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> Weighted </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> Weighted </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td align="center"> </td> <td align="center" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="11%"> Weighted average </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> average </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> Aggregate </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> average </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> Aggregate </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td align="center"> Exercise </td> <td align="center" width="1%"> </td> <td align="right" width="9%"> Number of </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="11%"> remaining </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> exercise </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> intrinsic </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> Number of </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> exercise </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> intrinsic </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td align="center"> prices </td> <td align="center" width="1%"> </td> <td align="right" width="9%"> options </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="11%"> contractual life </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> price </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> value </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> options </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> price </td> <td align="right" width="2%"> </td> <td align="right" width="1%"> </td> <td align="right" width="9%"> value </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td align="center" style="BORDER-BOTTOM: #000000 1px solid"> $ </td> <td align="center" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="11%"> (years) </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%">$</td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> $ </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%">$</td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%">$</td> <td align="center" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td align="center"> </td> <td align="center" width="1%"> </td> <td align="center" width="9%"> </td> <td align="center" width="2%"> </td> <td align="center" width="1%"> </td> <td align="center" width="11%"> </td> <td align="center" width="2%"> </td> <td align="center" width="1%"> </td> <td align="center" width="9%"> </td> <td align="center" width="2%"> </td> <td align="center" width="1%"> </td> <td align="center" width="9%"> </td> <td align="center" width="2%"> </td> <td align="center" width="1%"> </td> <td align="center" width="9%"> </td> <td align="center" width="2%"> </td> <td align="center" width="1%"> </td> <td align="center" width="9%"> </td> <td align="center" width="2%"> </td> <td align="center" width="1%"> </td> <td align="center" width="9%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td align="center" bgcolor="#e6efff"> 0.31 </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 25,000 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="11%"> 1.25 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.31 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 25,000 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.31 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td align="center"> 0.37 </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 75,000 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="11%"> 2.67 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0.37 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="9%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 75,000 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0.37 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="9%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td align="center" bgcolor="#e6efff"> 0.45 - 0.47 </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 175,000 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="11%"> 1.42 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.46 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 175,000 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.46 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td align="center"> 0.51 </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 40,000 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="11%"> 4.50 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0.51 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="9%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0.00 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="9%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td align="center" bgcolor="#e6efff"> 0.52 - 0.54 </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 270,000 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="11%"> 3.89 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.54 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 147,500 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.54 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td align="center"> 0.55 </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 50,000 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="11%"> 2.67 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0.55 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="9%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 12,500 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0.55 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="9%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td align="center" bgcolor="#e6efff"> 0.60 </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 55,000 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="11%"> 5.00 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.60 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.00 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td align="center"> 0.61 </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 125,000 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="11%"> 1.51 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0.61 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="9%"> </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 125,000 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="9%"> 0.61 </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="left" width="9%"> </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td align="center" bgcolor="#e6efff"> 0.62 </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 50,000 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="11%"> 3.00 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.62 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="9%"> 0.00 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="left" bgcolor="#e6efff" width="9%"> </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td align="center" style="BORDER-BOTTOM: #000000 1px solid"> 0.85 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> 200,588 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="11%"> 0.63 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> 0.85 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> 200,588 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> 0.85 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="9%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr valign="top"> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 1,065,588 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="11%"> 2.60 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 0.58 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 114,050 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 760,588 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 0.59 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="9%"> 86,725 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaSchedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity [Table Text Block]No definition available.false0Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity [Table Text Block]9false 4us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid">Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 117% </td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expected life</td> <td align="center" width="14%"> 3 years </td> <td align="center" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.69% </td> <td align="center" bgcolor="#e6efff" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph i -Article 4 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 28 -Article 5 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number D-98 -Paragraph 2 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Schedule of Warrants Valuation - June 21, 2011 [Table Text Block]10false 4igxt_ScheduleOfWarrantValuationJuneTwoOneTwoZeroOneOneTableTextBlockigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid">Expected volatility</td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> 117% </td> <td align="center" bgcolor="#e6efff" style="BORDER-TOP: #000000 2px solid" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Expected life</td> <td align="center" width="14%"> 3 years </td> <td align="center" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Risk-free interest rate</td> <td align="center" bgcolor="#e6efff" width="14%"> 0.69% </td> <td align="center" bgcolor="#e6efff" width="14%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid">Dividend yield</td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> nil </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="14%"> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaSchedule of Warrant Valuation - June 21, 2011No definition available.false0Schedule of Warrants Valuation - June 21, 2011 [Table Text Block]11false 4igxt_ScheduleOfStockholdersEquityNoteWarrantsOrRightsActivityTextBlockigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> Number of </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> Weighted average </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> warrants </td> <td align="left" width="2%"> </td> <td align="left" width="1%"> </td> <td align="right" width="12%"> exercise price </td> <td align="left" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid"> </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> (All Exercisable) </td> <td align="left" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> $ </td> <td align="center" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid">Outstanding – January 1, 2011</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 21,291,223 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 0.66 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Attached to private placements</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 2,748,165 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> 0.74 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Agents’ warrants exercised</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> (299,406 </td> <td align="left" width="2%">)</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> (0.47 </td> <td align="left" width="2%">)</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid">Exercised</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> (4,366,904 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">)</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> (0.51 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%">)</td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid">Outstanding - December 31, 2011</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 19,373,078 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> 0.71 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">Agents’ warrants exercised</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> (219,313 </td> <td align="left" bgcolor="#e6efff" width="2%">)</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="12%"> (0.47 </td> <td align="left" bgcolor="#e6efff" width="2%">)</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Exercised</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> (1,205,668 </td> <td align="left" width="2%">)</td> <td align="left" width="1%"> </td> <td align="right" width="12%"> (0.48 </td> <td align="left" width="2%">)</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid">Expired</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (11,843,932 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%">)</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="12%"> (0.80 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 1px solid" width="2%">)</td> </tr> <tr> <td width="5%"> </td> <td> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> <td width="1%"> </td> <td width="12%"> </td> <td width="2%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid">Outstanding - December 31, 2012</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 6,104,165 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="1%"> </td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="12%"> 0.59 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 2px solid" width="2%"> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaSchedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block]No definition available.false0Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block]falseAdditional Paid-In Capital (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsAdditionalPaidInCapitalTextBlockTables111 XML 85 R18.xml IDEA: Related Party Transactions 2.4.0.8118 - Disclosure - Related Party Transactionstruefalsefalse1false falsefalsecx_01_January_2013_TO_31_March_2013http://www.sec.gov/CIK0001098880duration2013-01-01T00:00:002013-03-31T00:00:002false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_RelatedPartyTransactionsDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 8. </td> <td> Related Party Transactions </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Included in management salaries are $2 thousand (2012 - $1 thousand) for options granted to the Chief Financial Officer and $3 thousand (2012 - $2 thousand) for options granted to the Chief Executive Officer under the 2006 Stock Option Plan and $4 thousand (2012 - $7 thousand) for options granted to non-employee directors. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Also included in management salaries are director fees of $22 thousand (2012 - $27 thousand) for attendance to board meetings and audit committee meetings and $54 thousand (2012 - $Nil) for fees paid to a director under a management consultancy agreement. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed to by the related parties. </td> </tr> </table>falsefalsefalse2falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td align="left"> 13.</td> <td align="left" width="95%"> Related Party Transactions</td> </tr> <tr> <td>  </td> <td width="95%">  </td> </tr> <tr valign="top"> <td align="left">  </td> <td align="left" width="95%"> Included in management salaries are $6 thousand (2011 - $4 thousand) for options granted to the Chief Financial Officer and $6 thousand (2011 - $4 thousand) for options granted to the Chief Executive Officer under the 2006 Stock Option Plan and $23 thousand (2011 - $10 thousand) for options granted to non-employee directors. </td> </tr> <tr> <td>  </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left">  </td> <td align="left" width="95%"> Included in general and administrative expenses are director fees of $114 thousand (2011 - $87 thousand) for attendance at board meetings and audit committee meetings. </td> </tr> <tr> <td>  </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left">  </td> <td align="left" width="95%"> A short term loan of $85 thousand bearing interest at 1% per annum was provided to an employee, who is also an officer of the Company, on November 9, 2011. The loan amount, together with interest accrued, was repaid to the Company on February 28, 2012. </td> </tr> <tr> <td>  </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left">  </td> <td align="left" width="95%"> In the year ended December 31, 2012 the amount included in accounts payable and accrued liabilities payable to shareholders, who are also officers of the Company, is $Nil (2011 - $1 thousand). </td> </tr> <tr> <td>  </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left">  </td> <td align="left" width="95%"> The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed upon by the related parties. </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph b -Article 3A Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Article 4 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 57 -Paragraph 1-4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Related Party Transactions [Text Block]falseRelated Party TransactionsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock21 XML 86 R3.xml IDEA: Consolidated Statements of Comprehensive Loss 2.4.0.8103 - Statement - Consolidated Statements of Comprehensive LosstruefalseIn Thousands, except Share data, unless otherwise specifiedfalse1false USDfalsefalse$cx_01_January_2013_TO_31_March_2013http://www.sec.gov/CIK0001098880duration2013-01-01T00:00:002013-03-31T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0usd_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$cx_01_January_2012_TO_31_March_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-03-31T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0usd_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0usd_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$cx_01_January_2011_TO_31_December_2011http://www.sec.gov/CIK0001098880duration2011-01-01T00:00:002011-12-31T00:00:00sharesStandardhttp://www.xbrl.org/2003/instanceshares0usd_sharesDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instanceshares0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 4us-gaap_RevenuesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Revenues2false 5us-gaap_RoyaltyRevenueus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse8000080USD$falsetruefalse2truefalsefalse00USD$falsetruefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRevenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false2Royalties3false 5us-gaap_LicenseAndServicesRevenueus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse7700077falsefalsefalse2truefalsefalse100000100falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRevenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(d),(e)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 false2License and other revenue4false 4us-gaap_OtherSalesRevenueNetus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse11980001198falsefalsefalse4truefalsefalse433000433falsefalsefalsexbrli:monetaryItemTypemonetaryRevenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a),(d)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false2Revenue5false 4us-gaap_OtherIncomeus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse1000010falsefalsefalse4truefalsefalse70007falsefalsefalsexbrli:monetaryItemTypemonetaryReflects the sum of all other revenue and income recognized by the entity in the period not otherwise specified in the income statement.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.4) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 4 -Article 7 false2Other Income6false 4us-gaap_Revenuesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse157000157falsefalsefalse2truefalsefalse100000100falsefalsefalse3truefalsefalse12080001208falsefalsefalse4truefalsefalse440000440falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 true2Total Revenues7true 4us-gaap_OperatingExpensesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Expenses8false 5us-gaap_ResearchAndDevelopmentExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse167000167falsefalsefalse2truefalsefalse239000239falsefalsefalse3truefalsefalse19350001935falsefalsefalse4truefalsefalse15240001524falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 2 -Paragraph 12, 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph g -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 86 -Paragraph 11, 12 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Research and development9false 5us-gaap_IncomeTaxCreditsAndAdjustmentsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-212000-212falsefalsefalse4truefalsefalse-188000-188falsefalsefalsexbrli:monetaryItemTypemonetaryA credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Research and development tax credits10false 5us-gaap_SellingGeneralAndAdministrativeExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse456000456falsefalsefalse2truefalsefalse439000439falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 4 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6386349&loc=d3e3636-108311 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Paragraph 5A -Chapter 4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Selling, general and administrative expense11false 5us-gaap_LaborAndRelatedExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse716000716falsefalsefalse4truefalsefalse586000586falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of expenditures for salaries, wages, profit sharing and incentive compensation, and other employee benefits, including equity-based compensation, and pension and other postretirement benefit expense.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 false2Management salaries12false 5us-gaap_GeneralAndAdministrativeExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse347000347falsefalsefalse4truefalsefalse333000333falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 false2General and administrative13false 5us-gaap_ProfessionalFeesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse582000582falsefalsefalse4truefalsefalse594000594falsefalsefalsexbrli:monetaryItemTypemonetaryA fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07.2(a),(b),(c),(d)) -URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 225 -Section 45 -Paragraph 3 -Subparagraph (k) -URI http://asc.fasb.org/extlink&oid=6488370&loc=d3e13550-115849 false2Professional fees14false 5us-gaap_Depreciationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse1000010falsefalsefalse2truefalsefalse80008falsefalsefalse3truefalsefalse4600046falsefalsefalse4truefalsefalse3700037falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 5 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false2Depreciation15false 5us-gaap_AmortizationOfIntangibleAssetsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse1000010falsefalsefalse2truefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=7658586&loc=d3e16323-109275 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 45 -Subparagraph a(2) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Amortization of intangible assets16false 5us-gaap_ForeignCurrencyTransactionGainLossBeforeTaxus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse4100041falsefalsefalse4truefalsefalse30003falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate foreign currency transaction gain (loss) (both realized and unrealized) included in determining net income for the reporting period. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements. For certain enterprises, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 20 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30690-110894 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 20 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6450189&loc=d3e30700-110894 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 52 -Paragraph 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Foreign exchange loss17false 5us-gaap_InterestExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse30003falsefalsefalse4truefalsefalse30003falsefalsefalsexbrli:monetaryItemTypemonetaryThe cost of borrowed funds accounted for as interest that was charged against earnings during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 34 -Paragraph 21 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 9 -Article 9 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher OTS -Name Federal Regulation (FR) -Number Title 12 -Section 563c.102 -Paragraph 9 -Chapter V -Subsection II -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy. It will be removed from future versions of this taxonomy. false2Interest and financing fees18false 5us-gaap_OperatingExpensesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse643000643falsefalsefalse2truefalsefalse686000686falsefalsefalse3truefalsefalse34580003458falsefalsefalse4truefalsefalse28920002892falsefalsefalsexbrli:monetaryItemTypemonetaryGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.No definition available.true2Total Costs and Expenses19false 4us-gaap_OperatingIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-486000-486falsefalsefalse2truefalsefalse-586000-586falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe net result for the period of deducting operating expenses from operating revenues.No definition available.true2Loss from Operations20true 4us-gaap_NonoperatingIncomeExpenseAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Other Income21false 5us-gaap_InvestmentIncomeInterestus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse00falsefalsefalse2truefalsefalse40004falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryIncome derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 115 -Paragraph 14 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 7 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(b)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 false2Interest and other income22false 5us-gaap_NonoperatingIncomeExpenseus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse00falsefalsefalse2truefalsefalse40004falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 7 -Article 5 true2Total Other Income23false 4us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse-2250000-2250falsefalsefalse4truefalsefalse-2452000-2452falsefalsefalsexbrli:monetaryItemTypemonetarySum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)(1)(i)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Subparagraph 1(i) -Article 4 false2Loss Before Income Taxes24false 4us-gaap_IncomeTaxExpenseBenefitus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse00falsefalsefalse4truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Income Tax Expense (or Benefit) -URI http://asc.fasb.org/extlink&oid=6515339 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a),(b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 45 -Subparagraph a, b -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Income taxes25false 4us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-486000-486falsefalsefalse2truefalsefalse-582000-582falsefalsefalse3truefalsefalse-2250000-2250falsefalsefalse4truefalsefalse-2452000-2452falsefalsefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. true2Net Loss26true 4us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Other Comprehensive Income27false 5us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParentus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-36000-36falsefalsefalse2truefalsefalse9100091falsefalsefalse3truefalsefalse100000100falsefalsefalse4truefalsefalse4900049falsefalsefalsexbrli:monetaryItemTypemonetaryAmount after tax and reclassification adjustments, resulting from the process of expressing in the reporting currency of the reporting entity those amounts that are denominated or measured in a different currency, and from transactions whose terms are denominated in a currency other than the entity's functional currency, which is attributable to the parent entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(3) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 29 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684 false2Foreign currency translation adjustment28false 5us-gaap_ComprehensiveIncomeNetOfTaxus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-522000-522USD$falsetruefalse2truefalsefalse-491000-491USD$falsetruefalse3truefalsefalse-2150000-2150USD$falsetruefalse4truefalsefalse-2403000-2403USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Comprehensive Income -URI http://asc.fasb.org/extlink&oid=16317811 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e557-108580 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph c(3) -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A5 -Appendix A true2Comprehensive Loss29false 4us-gaap_WeightedAverageNumberOfSharesOutstandingBasicus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse5023625550236255falsefalsefalse2truefalsefalse4932453149324531falsefalsefalse3truefalsefalse4963790849637908falsefalsefalse4truefalsefalse4373600343736003falsefalsefalsexbrli:sharesItemTypesharesNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 07-4 -Paragraph 4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 171 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Weighted-Average Number of Common Shares Outstanding -URI http://asc.fasb.org/extlink&oid=6528421 false1Basic and Diluted Weighted Average Number of Shares Outstanding30false 4us-gaap_EarningsPerShareDilutedus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-0.01-0.01USD$falsetruefalse2truefalsefalse-0.01-0.01USD$falsetruefalse3truefalsefalse-0.04-0.04USD$falsetruefalse4truefalsefalse-0.05-0.05USD$falsetruefalsenum:perShareItemTypedecimalThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 07-4 -Paragraph 4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.21) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 18 -Article 7 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 11, 12, 36 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 20 -Article 5 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 21 -Article 9 false3Basic and Diluted Loss Per Common SharefalseConsolidated Statements of Comprehensive Loss (USD $)ThousandsNoRoundingNoRoundingUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/IncomeStatement430 XML 87 R29.htm IDEA: XBRL DOCUMENT

Statement of Cash Flows Information (Tables)

12 Months Ended

Dec. 31, 2012

Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]

In US$ thousands		2012		2011

Additional Cash Flow Information:

Interest paid	$	3	$	3

XML 88 R23.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2012

Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment [Table Text Block]

	On the declining balance method -

	Laboratory and office equipment	20%
	Computer equipment	30%

	On the straight-line method -

	Leasehold improvements	over the lease term
	Manufacturing equipment	5 – 10 years

XML 89 R44.htm IDEA: XBRL DOCUMENT

Schedule of Stock Options Valuation - May 12, 2011 (Details) (USD $)	12 Months Ended
	Dec. 31, 2012 Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - May 12, 2011 1	115.00%
Additional Paid-in Capital Schedule Of Stock Options Valuation - May 12, 2011 2	3.1
Additional Paid-in Capital Schedule Of Stock Options Valuation - May 12, 2011 3	0.96%
Additional Paid-in Capital Schedule Of Stock Options Valuation - May 12, 2011 4	$ 0

XML 90 R50.xml IDEA: Schedule of Stock Option Activity (Details) 2.4.0.8151 - Disclosure - Schedule of Stock Option Activity (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00pureStandardhttp://www.xbrl.org/2003/instancepure0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFiveFDMEightkLJHOnebcFiveigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse16980881698088USD$falsetruefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stock Option Activity 1No definition available.false2Additional Paid-in Capital Schedule Of Stock Option Activity 12false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFivevwQSixFiveHDfLFourGPigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.530.53falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stock Option Activity 2No definition available.false0Additional Paid-in Capital Schedule Of Stock Option Activity 23false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFiveZZHNinegbXhbZerocpigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse290000290000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stock Option Activity 3No definition available.false2Additional Paid-in Capital Schedule Of Stock Option Activity 34false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFiveRMJZeroXFiveOnekGZSLigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.540.54falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stock Option Activity 4No definition available.false0Additional Paid-in Capital Schedule Of Stock Option Activity 45false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFiveSixnwWckwCynqfigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-150000-150000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stock Option Activity 5No definition available.false2Additional Paid-in Capital Schedule Of Stock Option Activity 56false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFiveFivedJJyZlcNmJEightigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-0.76-0.76falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stock Option Activity 6No definition available.false0Additional Paid-in Capital Schedule Of Stock Option Activity 67false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFivehDnRhSixsXnfNineligxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-65000-65000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stock Option Activity 7No definition available.false2Additional Paid-in Capital Schedule Of Stock Option Activity 78false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFiveFiveZeroTwokhdmKyFFivexigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-0.59-0.59falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stock Option Activity 8No definition available.false0Additional Paid-in Capital Schedule Of Stock Option Activity 89false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFivefThreeZTwoOneXOnemTbyBigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-775000-775000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stock Option Activity 9No definition available.false2Additional Paid-in Capital Schedule Of Stock Option Activity 910false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFivesFourySevenVzVJWcrGigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-0.41-0.41falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stock Option Activity 10No definition available.false0Additional Paid-in Capital Schedule Of Stock Option Activity 1011false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFiveFourthWQThreeGgSixnFourwigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse998088998088falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stock Option Activity 11No definition available.false2Additional Paid-in Capital Schedule Of Stock Option Activity 1112false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFiveQBdThreerThreeSixsDGvmigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.590.59falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stock Option Activity 12No definition available.false0Additional Paid-in Capital Schedule Of Stock Option Activity 1213false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFiveWxTzCFourPDxTThreeSigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse195000195000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stock Option Activity 13No definition available.false2Additional Paid-in Capital Schedule Of Stock Option Activity 1314false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFiveEightKwHTwoVOneTrPWQigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.570.57falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stock Option Activity 14No definition available.false0Additional Paid-in Capital Schedule Of Stock Option Activity 1415false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFivefZerosMTsNineTbfSevendigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-45000-45000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stock Option Activity 15No definition available.false2Additional Paid-in Capital Schedule Of Stock Option Activity 1516false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFiveFivehThreecHlKsSfrEightigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-0.49-0.49falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stock Option Activity 16No definition available.false0Additional Paid-in Capital Schedule Of Stock Option Activity 1617false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFivepkFiveCXZeroThreegZeroThreegTwoigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-32500-32500falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stock Option Activity 17No definition available.false2Additional Paid-in Capital Schedule Of Stock Option Activity 1718false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFiveEightWHbSevenSevenbxFZlpigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-1.15-1.15falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stock Option Activity 18No definition available.false0Additional Paid-in Capital Schedule Of Stock Option Activity 1819false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFiveSevenNXzTmzFSevenSevenFiveSixigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-50000-50000falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stock Option Activity 19No definition available.false2Additional Paid-in Capital Schedule Of Stock Option Activity 1920false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFivetSevenmKZOneTwoFourSSixlgigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-0.55-0.55falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stock Option Activity 20No definition available.false0Additional Paid-in Capital Schedule Of Stock Option Activity 2021false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFiveTGZeroEightcEightZerocbCvligxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse10655881065588USD$falsetruefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stock Option Activity 21No definition available.false2Additional Paid-in Capital Schedule Of Stock Option Activity 2122false 4igxt_ScheduleOfStockOptionActivityZeroOneSixTwoZeroTwoZeroEightFiveThreelycSixTTJbqrLigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.580.58falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stock Option Activity 22No definition available.false0Additional Paid-in Capital Schedule Of Stock Option Activity 22falseSchedule of Stock Option Activity (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlockDetails122 XML 91 R54.htm IDEA: XBRL DOCUMENT

Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1	$ 21,291,223
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 2	0.66
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 3	2,748,165
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 4	0.74
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 5	(299,406)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 6	(0.47)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 7	(4,366,904)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 8	(0.51)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 9	19,373,078
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 10	0.71
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 11	(219,313)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 12	(0.47)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 13	(1,205,668)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 14	(0.48)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 15	(11,843,932)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 16	(0.80)
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 17	$ 6,104,165
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 18	0.59

XML 92 R39.htm IDEA: XBRL DOCUMENT

Subsequent Events (Narrative) (Details)	3 Months Ended		12 Months Ended
Subsequent Events (Narrative) (Details)	Mar. 31, 2013 USD ($)	Mar. 31, 2013 CAD	Dec. 31, 2012 USD ($)
Subsequent Events 1	680,000	680,000
Subsequent Events 2	480,000	480,000
Subsequent Events 3	200,000	200,000
Subsequent Events 4		0.67
Subsequent Events 5	0.65
Subsequent Events 6	25.00%	25.00%
Subsequent Events 7	37,500	37,500
Subsequent Events 8	995,500	995,500
Subsequent Events 9	995,500	995,500
Subsequent Events 10	0
Subsequent Events 11	472
Subsequent Events 12	472
Subsequent Events 1			362,500
Subsequent Events 2			362,500
Subsequent Events 3			0
Subsequent Events 4			172,000
Subsequent Events 5			$ 172,000

XML 93 R42.xml IDEA: Schedule of future minimum payments under operating leases (Details) 2.4.0.8143 - Disclosure - Schedule of future minimum payments under operating leases (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesZeroOneSixTwoZeroTwoZeroEightFiveLryThreeKShZdxZeroTwoigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1515USD$falsetruefalsexbrli:monetaryItemTypemonetaryCommitments Schedule Of Future Minimum Payments Under Operating Leases 1No definition available.false2Commitments Schedule Of Future Minimum Payments Under Operating Leases 12false 4igxt_ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesZeroOneSixTwoZeroTwoZeroEightFiveyNbsMRzTwoTwokrzigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCommitments Schedule Of Future Minimum Payments Under Operating Leases 2No definition available.false2Commitments Schedule Of Future Minimum Payments Under Operating Leases 23false 4igxt_ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesZeroOneSixTwoZeroTwoZeroEightFiveFiveEightnyThreeNQmJFourlNineigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1515USD$falsetruefalsexbrli:monetaryItemTypemonetaryCommitments Schedule Of Future Minimum Payments Under Operating Leases 3No definition available.false2Commitments Schedule Of Future Minimum Payments Under Operating Leases 3falseSchedule of future minimum payments under operating leases (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlockDetails13 XML 94 R31.xml IDEA: Significant Accounting Policies (Narrative) (Details) 2.4.0.8132 - Disclosure - Significant Accounting Policies (Narrative) (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00pureStandardhttp://www.xbrl.org/2003/instancepure0dStandardhttp://www.xbrl.org/2009/utrDutr0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_SignificantAccountingPoliciesZeroOneSixTwoZeroTwoZeroEightFivePDVSHNinedgrMnfigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse4545falsefalsefalsexbrli:decimalItemTypedecimalSignificant Accounting Policies 1No definition available.false256Significant Accounting Policies 12false 4igxt_SignificantAccountingPoliciesZeroOneSixTwoZeroTwoZeroEightFiveDSQHFourhDsRLGEightigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse600000600000USD$falsetruefalsexbrli:monetaryItemTypemonetarySignificant Accounting Policies 2No definition available.false2Significant Accounting Policies 23false 4igxt_SignificantAccountingPoliciesZeroOneSixTwoZeroTwoZeroEightFiveqlPKdnMFtNVqigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse100000100000falsefalsefalsexbrli:monetaryItemTypemonetarySignificant Accounting Policies 3No definition available.false2Significant Accounting Policies 34false 4igxt_SignificantAccountingPoliciesZeroOneSixTwoZeroTwoZeroEightFivebLKglTwoSmThreeWBxigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse700000700000falsefalsefalsexbrli:monetaryItemTypemonetarySignificant Accounting Policies 4No definition available.false2Significant Accounting Policies 45false 4igxt_SignificantAccountingPoliciesZeroOneSixTwoZeroTwoZeroEightFiveRcMTVRlZeroCZeroRZigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse200000200000falsefalsefalsexbrli:monetaryItemTypemonetarySignificant Accounting Policies 5No definition available.false2Significant Accounting Policies 56false 4igxt_SignificantAccountingPoliciesZeroOneSixTwoZeroTwoZeroEightFivepZftQJBQJblQigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse500000500000falsefalsefalsexbrli:monetaryItemTypemonetarySignificant Accounting Policies 6No definition available.false2Significant Accounting Policies 67false 4igxt_SignificantAccountingPoliciesZeroOneSixTwoZeroTwoZeroEightFiveFourcXThreedEightThreeFourSixZeroFourHigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse40000004000000falsefalsefalsexbrli:monetaryItemTypemonetarySignificant Accounting Policies 7No definition available.false2Significant Accounting Policies 78false 4igxt_SignificantAccountingPoliciesZeroOneSixTwoZeroTwoZeroEightFivefTFourNinewXcpBSevenMFiveigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse10000001000000falsefalsefalsexbrli:monetaryItemTypemonetarySignificant Accounting Policies 8No definition available.false2Significant Accounting Policies 89false 4igxt_SignificantAccountingPoliciesZeroOneSixTwoZeroTwoZeroEightFivetPtFDsfyOneTtpigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse2350000023500000falsefalsefalsexbrli:monetaryItemTypemonetarySignificant Accounting Policies 9No definition available.false2Significant Accounting Policies 910false 4igxt_SignificantAccountingPoliciesZeroOneSixTwoZeroTwoZeroEightFiveCOnevTwozPLwCbytigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse10000001000000falsefalsefalsexbrli:monetaryItemTypemonetarySignificant Accounting Policies 10No definition available.false2Significant Accounting Policies 1011false 4igxt_SignificantAccountingPoliciesZeroOneSixTwoZeroTwoZeroEightFivekSevenFsFourqOnevEightGNineKigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse923000923000falsefalsefalsexbrli:monetaryItemTypemonetarySignificant Accounting Policies 11No definition available.false2Significant Accounting Policies 1112false 4igxt_SignificantAccountingPoliciesZeroOneSixTwoZeroTwoZeroEightFiveLFivegvzgSTwVTkigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse5300053000falsefalsefalsexbrli:monetaryItemTypemonetarySignificant Accounting Policies 12No definition available.false2Significant Accounting Policies 1213false 4igxt_SignificantAccountingPoliciesZeroOneSixTwoZeroTwoZeroEightFivepJvHOneNHDRThreecmigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetarySignificant Accounting Policies 13No definition available.false2Significant Accounting Policies 1314false 4igxt_SignificantAccountingPoliciesZeroOneSixTwoZeroTwoZeroEightFiveSevenQkZerofNinefcdXlVigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse12820001282000falsefalsefalsexbrli:monetaryItemTypemonetarySignificant Accounting Policies 14No definition available.false2Significant Accounting Policies 1415false 4igxt_SignificantAccountingPoliciesZeroOneSixTwoZeroTwoZeroEightFiveqpqGVKnZeroJSixGThreeigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse10000001000000USD$falsetruefalsexbrli:monetaryItemTypemonetarySignificant Accounting Policies 15No definition available.false2Significant Accounting Policies 1516false 4igxt_SignificantAccountingPoliciesZeroOneSixTwoZeroTwoZeroEightFiveffdthLZWNineNineRDigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truetruefalse0.500.50falsefalsefalsenum:percentItemTypepureSignificant Accounting Policies 16No definition available.false0Significant Accounting Policies 16falseSignificant Accounting Policies (Narrative) (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureSignificantAccountingPoliciesTextBlockDetails116 XML 95 R35.htm IDEA: XBRL DOCUMENT

Capital Stock (Narrative) (Details) (USD $)	12 Months Ended
Capital Stock (Narrative) (Details) (USD $)	Dec. 31, 2012 M
Capital Stock 1	4,800,000
Capital Stock 2	2,400,000
Capital Stock 3	$ 3,200,000
Capital Stock 4	0.74
Capital Stock 5	36
Capital Stock 6	2,024,000
Capital Stock 7	2,582,536
Capital Stock 8	1,291,268
Capital Stock 9	1,700,000
Capital Stock 10	2,238,806
Capital Stock 11	1,119,403
Capital Stock 12	1,500,000
Capital Stock 13	121,000
Capital Stock 14	7.00%
Capital Stock 15	28,000
Capital Stock 16	180,778
Capital Stock 17	7.00%
Capital Stock 18	105,000
Capital Stock 19	7.00%
Capital Stock 20	156,716
Capital Stock 21	7.00%
Capital Stock 22	0.74
Capital Stock 23	36
Capital Stock 24	114,000
Capital Stock 25	50,000
Capital Stock 26	775,000
Capital Stock 27	50,000
Capital Stock 28	775,000
Capital Stock 29	0
Capital Stock 30	0
Capital Stock 31	28,000
Capital Stock 32	318,000
Capital Stock 33	28,000
Capital Stock 34	318,000
Capital Stock 35	219,313
Capital Stock 36	299,406
Capital Stock 37	219,313
Capital Stock 38	299,406
Capital Stock 39	0
Capital Stock 40	104,000
Capital Stock 41	142,000
Capital Stock 42	104,000
Capital Stock 43	142,000
Capital Stock 44	1,205,668
Capital Stock 45	491,382
Capital Stock 46	491,382
Capital Stock 47	0
Capital Stock 48	233,000
Capital Stock 49	233,000
Capital Stock 50	714,286
Capital Stock 51	234,698
Capital Stock 52	0
Capital Stock 53	4,366,904
Capital Stock 54	2,902,618
Capital Stock 55	2,902,618
Capital Stock 56	0
Capital Stock 57	1,458,000
Capital Stock 58	1,458,000
Capital Stock 59	1,464,286
Capital Stock 60	515,391
Capital Stock 61	$ 0

XML 96 R36.htm IDEA: XBRL DOCUMENT

Additional Paid-In Capital (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2013	Dec. 31, 2012 Y M
Additional Paid-in Capital 1	50,000
Additional Paid-in Capital 2	0
Additional Paid-in Capital 3	50,000
Additional Paid-in Capital 4	0
Additional Paid-in Capital 5	$ 0
Additional Paid-in Capital 6	23
Additional Paid-in Capital 7	0
Additional Paid-in Capital 8	23
Additional Paid-in Capital 9	0
Additional Paid-in Capital 10	18
Additional Paid-in Capital 11	15
Additional Paid-in Capital 12	13
Additional Paid-in Capital 13	14
Additional Paid-in Capital 14	5
Additional Paid-in Capital 15	0
Additional Paid-in Capital 16	1
Additional Paid-in Capital 17	50
Additional Paid-in Capital 18	69
Additional Paid-in Capital 19	362,500
Additional Paid-in Capital 20	1,206,418
Additional Paid-in Capital 21	362,500
Additional Paid-in Capital 22	726,830
Additional Paid-in Capital 23	0
Additional Paid-in Capital 24	172
Additional Paid-in Capital 25	233
Additional Paid-in Capital 26	171
Additional Paid-in Capital 27	233
Additional Paid-in Capital 1		1,600,749
Additional Paid-in Capital 2		100.00%
Additional Paid-in Capital 3		10
Additional Paid-in Capital 4		24
Additional Paid-in Capital 5		100.00%
Additional Paid-in Capital 6		1,600,749
Additional Paid-in Capital 7		2,074,000
Additional Paid-in Capital 8		10.00%
Additional Paid-in Capital 9		10
Additional Paid-in Capital 10		5
Additional Paid-in Capital 11		2,074,000
Additional Paid-in Capital 12		3,308,127
Additional Paid-in Capital 13		10.00%
Additional Paid-in Capital 14		50,000
Additional Paid-in Capital 15		$ 0.52
Additional Paid-in Capital 16		2
Additional Paid-in Capital 17		25.00%
Additional Paid-in Capital 18		16,000
Additional Paid-in Capital 19		115,000
Additional Paid-in Capital 20		40,000
Additional Paid-in Capital 21		50,000
Additional Paid-in Capital 22		35,000
Additional Paid-in Capital 23		$ 0.54
Additional Paid-in Capital 24		2
Additional Paid-in Capital 25		25.00%
Additional Paid-in Capital 26		74,000
Additional Paid-in Capital 27		40,000
Additional Paid-in Capital 28		$ 0.51
Additional Paid-in Capital 29		2
Additional Paid-in Capital 30		25.00%
Additional Paid-in Capital 31		10,000
Additional Paid-in Capital 32		50,000
Additional Paid-in Capital 33		$ 0.55
Additional Paid-in Capital 34		1
Additional Paid-in Capital 35		25.00%
Additional Paid-in Capital 36		12,000
Additional Paid-in Capital 37		30,000
Additional Paid-in Capital 38		25,000
Additional Paid-in Capital 39		$ 0.60
Additional Paid-in Capital 40		2
Additional Paid-in Capital 41		25.00%
Additional Paid-in Capital 42		15,000
Additional Paid-in Capital 43		50,000
Additional Paid-in Capital 44		$ 0.62
Additional Paid-in Capital 45		1
Additional Paid-in Capital 46		25.00%
Additional Paid-in Capital 47		10,000
Additional Paid-in Capital 48		50,000
Additional Paid-in Capital 49		775,000
Additional Paid-in Capital 50		50,000
Additional Paid-in Capital 51		775,000
Additional Paid-in Capital 52		0
Additional Paid-in Capital 53		0
Additional Paid-in Capital 54		28,000
Additional Paid-in Capital 55		318,000
Additional Paid-in Capital 56		28,000
Additional Paid-in Capital 57		318,000
Additional Paid-in Capital 58		4,000
Additional Paid-in Capital 59		59,000
Additional Paid-in Capital 60		51,000
Additional Paid-in Capital 61		72,000
Additional Paid-in Capital 62		92,000
Additional Paid-in Capital 63		17,000
Additional Paid-in Capital 64		0
Additional Paid-in Capital 65		72,000
Additional Paid-in Capital 66		55,000
Additional Paid-in Capital 67		4,800,000
Additional Paid-in Capital 68		2,400,000
Additional Paid-in Capital 69		$ 0.74
Additional Paid-in Capital 70		817,000
Additional Paid-in Capital 71		300,000
Additional Paid-in Capital 72		300,000
Additional Paid-in Capital 73		$ 0.74
Additional Paid-in Capital 74		153,000
Additional Paid-in Capital 75		219,313
Additional Paid-in Capital 76		299,406
Additional Paid-in Capital 77		219,313
Additional Paid-in Capital 78		299,406
Additional Paid-in Capital 79		0
Additional Paid-in Capital 80		104,000
Additional Paid-in Capital 81		142,000
Additional Paid-in Capital 82		104,000
Additional Paid-in Capital 83		142,000
Additional Paid-in Capital 84		1,205,668
Additional Paid-in Capital 85		491,382
Additional Paid-in Capital 86		491,382
Additional Paid-in Capital 87		0
Additional Paid-in Capital 88		233,000
Additional Paid-in Capital 89		233,000
Additional Paid-in Capital 90		714,286
Additional Paid-in Capital 91		234,698
Additional Paid-in Capital 92		0
Additional Paid-in Capital 93		4,366,904
Additional Paid-in Capital 94		2,902,618
Additional Paid-in Capital 95		2,902,618
Additional Paid-in Capital 96		0
Additional Paid-in Capital 97		1,458,000
Additional Paid-in Capital 98		1,458,000
Additional Paid-in Capital 99		1,464,286
Additional Paid-in Capital 100		515,391
Additional Paid-in Capital 101		$ 0

XML 97 R30.xml IDEA: Nature of Business (Narrative) (Details) 2.4.0.8131 - Disclosure - Nature of Business (Narrative) (Details)truefalsefalse1false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00pureStandardhttp://www.xbrl.org/2003/instancepure01false 4igxt_NatureOfBusinessZeroOneSixTwoZeroTwoZeroEightFiveRgLVkrnMxnwXigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse99falsefalsefalsexbrli:pureItemTypepureNature Of Business 1No definition available.false0Nature Of Business 12false 4igxt_NatureOfBusinessZeroOneSixTwoZeroTwoZeroEightFiveNQZOneEightPZNFourMkZeroigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse66falsefalsefalsexbrli:pureItemTypepureNature Of Business 2No definition available.false0Nature Of Business 23false 4igxt_NatureOfBusinessZeroOneSixTwoZeroTwoZeroEightFiveWWGrNineFivermxKDhigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse22falsefalsefalsexbrli:pureItemTypepureNature Of Business 3No definition available.false0Nature Of Business 3falseNature of Business (Narrative) (Details)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureNatureOfOperationsDetails13 XML 98 R13.htm IDEA: XBRL DOCUMENT

Commitments

12 Months Ended

Dec. 31, 2012

Commitments [Text Block]

8.	Commitments

	The Company currently operates out of a 3,500 square feet leasehold facility consisting of laboratories and office space at 6425 Abrams, Saint-Laurent, Quebec. The original lease agreement expired in August 2009, since when it has been extended for varying periods whilst the Company sought alternative premises. The most recent extension is defined as the day immediately preceding the fulfillment of certain conditions relating to the occupation of new leased premises at 6410 - 6420 Abrams. In the first half of 2013, the Company plans to enter into an addendum to its existing lease to include the relocation of the Company’s operations to larger premises consisting of approximately 28,600 of rentable square feet. The term of the amended lease is 10 years following relocation, which is expected to commence in the autumn of 2013 upon completion of certain leasehold improvements.

	As of December 31, 2012 future minimum payments under operating leases for facilities were as follows (in thousands):

2013		15
2014		0
Total	$	15

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 99 R21.xml IDEA: Comparative Figures 2.4.0.8122 - Disclosure - Comparative Figurestruefalsefalse1false falsefalsecx_01_January_2013_TO_31_March_2013http://www.sec.gov/CIK0001098880duration2013-01-01T00:00:002013-03-31T00:00:001false 4us-gaap_Reclassificationsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; font-size: 10pt; border-collapse: collapse; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 11. </td> <td> Comparative Figures </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Certain reclassifications of March 31, 2012 amounts have been made to facilitate comparison with the current period. </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section A -Paragraph 2 -Chapter 2 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Comparative Figures [Text Block]falseComparative FiguresUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsReclassificationsTextBlock11 XML 100 R30.htm IDEA: XBRL DOCUMENT

Nature of Business (Narrative) (Details)	12 Months Ended
Nature of Business (Narrative) (Details)	Dec. 31, 2012
Nature Of Business 1	9
Nature Of Business 2	6
Nature Of Business 3	2

XML 101 R42.htm IDEA: XBRL DOCUMENT

Schedule of future minimum payments under operating leases (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Commitments Schedule Of Future Minimum Payments Under Operating Leases 1	$ 15
Commitments Schedule Of Future Minimum Payments Under Operating Leases 2	0
Commitments Schedule Of Future Minimum Payments Under Operating Leases 3	$ 15

XML 102 R16.htm IDEA: XBRL DOCUMENT

Income Tax

12 Months Ended

Dec. 31, 2012

Income Tax [Text Block]

11.	Income Taxes

	Income taxes reported differ from the amount computed by applying the statutory rates to losses. The reasons are as follows:

		2012			2011
Statutory income taxes	$	(605	)	$	(694	)
Net operating losses for which no tax benefits have been recorded		368			514
Excess of depreciation over capital cost allowance		3			(2	)
Non-deductible expenses		18			4
Undeducted research and development expenses		273			231
Tax deductible portion of transaction costs		-			-
Investment tax credit		(57	)		(53	)
Modification of warrants terms		-			-


	$	-		$	-

The major components of the deferred tax assets classified by the source of temporary differences are as follows:

		2012			2011

Leasehold Improvements and equipment	$	13		$	14
Net operating losses carryforward		2,278			2,140
Undeducted research and development expenses		1,301			1,141
Non-refundable tax credits carryforward		914			807


		4,506			4,102

Valuation allowance		(4,506	)		(4,102	)

	$	-		$	-

	There were Canadian and provincial net operating losses of approximately $8,390 thousand (2011 - $7,608 thousand) and $8,566 thousand (2011 - $7,437 thousand) respectively, that may be applied against earnings of future years. Utilization of the net operating losses is subject to significant limitations imposed by the change in control provisions. Canadian and provincial losses will be expiring between 2027 and 2032. A portion of the net operating losses may expire before they can be utilized.

	As at December 31, 2012, the Company had non-refundable tax credits of $914 thousand (2011 - $803 thousand) of which $24 thousand is expiring in 2017, $213 thousand is expiring in 2018, $193 thousand is expiring in 2019, $186 thousand is expiring in 2020, $187 thousand is expiring in 2021 and $111 thousand is expiring in 2022 and undeducted research and development expenses of $4,464 thousand (2011 - $3,656 thousand) with no expiration date.

	The deferred tax benefit of these items was not recognized in the accounts as it has been fully provided for.

	Unrecognized Tax Benefits

	The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months.

	Tax Years and Examination

	The Company files tax returns in each jurisdiction in which it is registered to do business. For each jurisdiction a statute of limitations period exists. After a statute of limitations period expires, the respective tax authorities may no longer assess additional income tax for the expired period. Similarly, the Company is no longer eligible to file claims for refund for any tax that it may have overpaid. The following table summarizes the Company’s major tax jurisdictions and the tax years that remain subject to examination by these jurisdictions as of December 31, 2012:

Tax Jurisdictions		Tax Years
Federal - Canada		2010 and onward
Provincial - Quebec		2010 and onward

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 136, 172

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 43, 44, 45, 46, 47, 48, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 103 R22.xml IDEA: Summary of Significant Accounting Policies (Policies) 2.4.0.8123 - Disclosure - Summary of Significant Accounting Policies (Policies)truefalsefalse1false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_RevenueRecognitionPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Revenue Recognition </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The Company recognizes revenue from research and development contracts as the contracted services are performed or when milestones are achieved, in accordance with the terms of the specific agreements and when collection of the payment is reasonably assured. In addition, the performance criteria for the achievement of milestones are met if substantive effort was required to achieve the milestone and the amount of the milestone payment appears reasonably commensurate with the effort expended. Amounts received in advance of the recognition criteria being met, if any, are included in deferred income. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> IntelGenx has license agreements that specify that certain royalties are earned by the Company on sales of licensed products in the licensed territories. Licensees usually report sales and royalty information in the 45 days after the end of the quarter in which the activity takes place and typically do not provide forward estimates or current-quarter information. Because the Company is not able to reasonably estimate the amount of royalties earned during the period in which these licensees actually ship products, royalty revenue is not recognized until the royalties are reported to the Company and the collection of these royalties is reasonably assured. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> In August 2010 the Company entered into a joint development and commercialization agreement with RedHill Biopharma (“RedHill”), an Israeli company, for an anti-migraine product based upon the Company’s VersaFilm™ technology. In accordance with the terms of the agreement, RedHill made up-front and milestone payments in the aggregate amount of $600 thousand, of which $100 thousand was received by the Company in 2012 upon production of pivotal batches. RedHill is required to make additional milestone payments of up to $700,000 as follows: </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> $200 thousand upon the filing of an NDA and acceptance of the filing by the U.S. Food and Drug Administration; and </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> $500 thousand upon receipt of U.S. Food and Drug Administration marketing approval for the product. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section B -Paragraph Question 1 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.B.Q1) -URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 22 -Paragraph 8, 12, 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790 false0Revenue Recognition [Policy Text Block]2false 4us-gaap_CostOfSalesPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Product Sales: </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The Company launched Forfivo XL™ in the USA in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP (“Edgemont”). Under the terms of the agreement with Edgemont, the commercial launch of Forfivo XL™ triggered launch-related milestone payments for IntelGenx of up to $4.0 million, of which $1 million was invoiced by the Company to Edgemont and recognized as revenue in the fourth quarter of 2012 and the cash received in February 2013. Additional milestones of up to a further $23.5 million are payable upon achieving certain sales and exclusivity targets and the Company expects to commence receiving royalties from sales of the product in the first quarter of 2013. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Upon entering into the licensing agreement, Edgemont paid the Company an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over the period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $923 thousand at December 31, 2012 that has not been recognized as revenue. </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 2 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2197414 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 50 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6408645&loc=d3e63676-111659 false0Product Sales [Policy Text Block]3false 4us-gaap_UseOfEstimatesus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Use of Estimates </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management’s judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, the investment tax credits receivable, the determination of the fair value of warrants issued as part of fundraising activities, and the resulting impact on the allocation of the proceeds between the common shares and the warrants. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 94-6 -Paragraph 11, 14 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Use of Estimates [Policy Text Block]4false 4igxt_FinancialInstrumentsPolicyTextBlockigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Financial Instruments </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The Company estimates the fair value of its financial instruments based on current interest rates, market value and pricing of financial instruments with comparable terms. Unless otherwise indicated, the carrying value of these financial instruments approximates their fair value. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaFinancial InstrumentsNo definition available.false0Financial Instruments [Policy Text Block]5false 4us-gaap_CashAndCashEquivalentsPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Cash and Cash Equivalents </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Cash and cash equivalents is comprised of cash on hand and term deposits with original maturity dates of less than three months that are stated at cost, which approximates fair value. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 305 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2122427 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Financial Reporting Release (FRR) -Number 203 -Paragraph 02-03 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Technical Practice Aid (TPA) -Number 2110 -Paragraph 6 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 8, 9, 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Cash and Cash Equivalents [Policy Text Block]6false 4us-gaap_TradeAndOtherAccountsReceivablePolicyus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Accounts Receivable </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible. In the first quarter of 2011, the Company wrote-off a receivable in the amount of $53 thousand that was owed to the Company by Circ Pharma Limited, Ireland, which was deemed to be no longer collectible. The Company records recoveries of trade receivables previously written-off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2012 accounts receivable (2011 - $Nil). The accounts receivable balance of $1,282 thousand as at December 31, 2012 includes $1 million from Edgemont that was received by IntelGenx in February 2013. </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables. If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3, 4 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Statement of Position (SOP) -Number 01-6 -Paragraph 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=7512638&loc=d3e5093-111524 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6378556&loc=d3e10133-111534 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 50 -Paragraph 15 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=7512638&loc=d3e5212-111524 false0Accounts Receivable [Policy Text Block]7false 4igxt_InvestmentTaxCreditsPolicyTextBlockigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Investment Tax Credits </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaInvestment Tax CreditsNo definition available.false0Investment Tax Credits [Policy Text Block]8false 4us-gaap_PropertyPlantAndEquipmentPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Leasehold Improvements and Equipment </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> Leasehold Improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows: </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">On the declining balance method -</td> <td align="left" bgcolor="#e6efff" width="36%"> </td> </tr> <tr> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="36%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">       Laboratory and office equipment</td> <td align="left" bgcolor="#e6efff" width="36%"> 20% </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">       Computer equipment</td> <td align="left" width="36%"> 30% </td> </tr> <tr> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> </td> <td align="left" bgcolor="#e6efff" width="36%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">On the straight-line method -</td> <td align="left" width="36%"> </td> </tr> <tr> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> </td> <td align="left" bgcolor="#e6efff" width="36%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">       Leasehold improvements</td> <td align="left" width="36%">over the lease term</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">       Manufacturing equipment</td> <td align="left" bgcolor="#e6efff" width="36%"> 5 – 10 years </td> </tr> </table> Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred.falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for property, plant and equipment which may include the basis of such assets, depreciation methods used and estimated useful lives, the entity's capitalization policy, including its accounting treatment for costs incurred for repairs and maintenance activities, whether such asset balances include capitalized interest and the method by which such is calculated, how disposals of such assets are accounted for and how impairment of such assets is assessed and recognized.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2155824 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 22 -Paragraph 12, 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section C -Paragraph 5 -Chapter 9 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 5 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 7 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 34 -Paragraph 8, 9 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Leasehold Improvements and Equipment [Policy Text Block]9false 4us-gaap_IntangibleAssetsFiniteLivedPolicyus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00 Intangible Assets Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -URI http://asc.fasb.org/subtopic&trid=2144471 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 144 -Paragraph 7-18, 22 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 142 -Paragraph 11-15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Intangible Assets [Policy Text Block]10false 4us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00 Impairment of Long-lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the estimated undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value thereof.falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.No definition available.false0Impairment of Long-lived Assets [Policy Text Block]11false 4us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Foreign Currency Translation </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The Company’s reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company’s Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows: </td> </tr> </table> Assets and liabilities - at exchange rates in effect at the balance sheet date; Revenue and expenses - at average exchange rates prevailing during the year; Equity - at historical rates. Gains and losses arising from foreign currency translation are included in other comprehensive income.falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 20 -URI http://asc.fasb.org/subtopic&trid=2175856 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2175826 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -URI http://asc.fasb.org/subtopic&trid=2175892 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 52 -Paragraph 5, 7-20, 80 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Foreign Currency Translation [Policy Text Block]12false 4us-gaap_IncomeTaxPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00 Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 4 -Paragraph 11 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 48 -Paragraph 20 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32247-109318 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 30 -URI http://asc.fasb.org/subtopic&trid=2144749 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 740 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2144681 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 17 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32280-109318 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 6-34, 43, 47, 49 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Income Taxes [Policy Text Block]13false 4igxt_UnrecognizedTaxBenefitsPolicyTextBlockigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00 Unrecognized Tax Benefits The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 “Income Taxes”. ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision.falsefalsefalsenonnum:textBlockItemTypenaUnrecognized Tax BenefitsNo definition available.false0Unrecognized Tax Benefits [Policy Text Block]14false 4us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicyus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> Share-Based Payments </td> </tr> <tr> <td> </td> <td width="95%"> </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation—Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company estimates its forfeiture rate in order to determine its compensation expense arising from stock-based awards. The Company uses the Black-Scholes option pricing model to determine the fair value of the options. </td> </tr> <tr> <td> </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year. </td> </tr> <tr> <td> </td> <td width="95%">   </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 123R -Paragraph A240 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b),(f) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2228939 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 06-11 -Paragraph 7 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Share-Based Payments [Policy Text Block]15false 4us-gaap_EarningsPerSharePolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> Loss Per Share </td> </tr> <tr> <td> </td> <td width="95%">   </td> </tr> <tr valign="top"> <td align="left"> </td> <td align="left" width="95%"> Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share. </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2144384 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 6, 8-16, 60 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Loss Per Share [Policy Text Block]16false 4us-gaap_FairValueMeasurementPolicyPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> Fair Value Measurements </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires new disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left">Level 1:</td> <td align="left" width="90%">Quoted market prices in active markets for identical assets or liabilities.</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Level 2:</td> <td align="left" width="90%">Observable market based inputs or unobservable inputs that are corroborated by market data.</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">Level 3:</td> <td align="left" width="90%">Unobservable inputs that are not corroborated by market data.</td> </tr> </table> In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. There are no assets or liabilities measured at fair value as at December 31, 2012.falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for fair value measurements, which may include, but is not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 35 -Paragraph 18G -URI http://asc.fasb.org/extlink&oid=15229074&loc=SL7494712-110257 false0Fair Value Measurements [Policy Text Block]17false 4us-gaap_FairValueOfFinancialInstrumentsPolicyus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00 Fair Value of Financial Instruments The fair value represents management’s best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization.falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for determining the fair value of financial instruments.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -URI http://asc.fasb.org/subtopic&trid=2155942 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 107 -Paragraph 8, 10, 12, 13, 14 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Fair Value of Financial Instruments [Policy Text Block]18false 4us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00 Recent Accounting Pronouncements In December 2011, the FASB issued Update No. 2011-11, “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities”. The objective of this Update is to provide enhanced disclosures that will enable users of its financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position. This includes the effect or potential effect of rights of setoff associated with an entity’s recognized assets and recognized liabilities within the scope of this Update. The amendments require enhanced disclosures by requiring improved information about financial instruments and derivative instruments that are either (1) offset in accordance with either Section 210-20-45 or Section 815-10-45 or (2) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either Section 210-20-45 or Section 815-10-45. ASU 2011-11 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. Retrospective disclosure is required for all comparative periods presented. The Company is currently evaluating the impact of this Statement on its consolidated financial statements. <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td width="5%"> </td> <td> In December 2011, the FASB issued Update No. 2011-12, “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05”. The amendments in this Update supersede changes to those paragraphs in Update 2011-05 that pertain to how, when, and where reclassification adjustments are presented. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations, but will affect the presentation of Other Comprehensive Income in the Company’s financial statements. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of the adoption of new accounting pronouncements that may impact the entity's financial reporting.No definition available.false0Recent Accounting Pronouncements [Policy Text Block]falseSummary of Significant Accounting Policies (Policies)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies118 XML 104 R12.htm IDEA: XBRL DOCUMENT

Deferred License Revenue

3 Months Ended

12 Months Ended

Mar. 31, 2013

Dec. 31, 2012

Deferred License Revenue [Text Block]

5.	Deferred License Revenue

	Deferred license revenue represents upfront payments received for the granting of licenses to the Company’s patents, intellectual property, and proprietary technology, for commercialization. Deferred license revenue is recognized in income over the period where sales of the licensed products will occur.

	Upon entering into the licensing agreement with Edgemont Pharmaceuticals the Company received an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over a period of 39 months, which is the minimum period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $847 thousand at March 31, 2013 that has not been recognized as revenue.

7.	Deferred License Revenue

	Deferred license revenue represents upfront payments received for the granting of licenses to the Company’s patents, intellectual property, and proprietary technology, for commercialization. Deferred license revenue is recognized in income over the period where sales of the licensed products will occur.

	Upon entering into the licensing agreement with Edgemont Pharmaceuticals the Company received an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over a period of 39 months, which is the minimum period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $923 thousand at December 31, 2012 that has not been recognized as revenue.

- Definition

The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References+ Details

XML 105 R7.htm IDEA: XBRL DOCUMENT

Nature of Business

12 Months Ended

Dec. 31, 2012

Nature of Business [Text Block]

2.	Nature of Business

	The Company specializes in the development of pharmaceutical products in co-operation with various pharmaceutical companies.

	Technologies

	The Company has developed three proprietary delivery platforms; including an immediate release oral film “ VersaFilm™ ”, a mucoadhesive tablet “ AdVersa™ ” and a multilayer controlled release tablet “ VersaTab™ ”.

	The three technology platforms have been designed to address the challenges commonly encountered in oral drug delivery, such as first-pass metabolism, gastrointestinal (“GI”) side effects, or incomplete absorption of the drug in the GI tract. IntelGenx’ technologies are broadly applicable and have the ability to improve the performance of a wide variety of existing pharmaceutical compounds.

	Product Pipeline

	IntelGenx’ product pipeline currently consists of 9 products in various stages of development, including products for the treatment of hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, idiopathic pulmonary fibrosis, allergies and pain management. Of the products currently under development, 6 utilize the VersaFilm™ technology, 2 utilize the VersaTab™ technology, and one utilizes the AdVersa™ technology.

	Approved and Commercialized Products

	The Company’s first FDA-approved product, Forfivo XL™, was launched in the USA in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP. Forfivo XL™ is indicated for the treatment of Major Depressive Disorder (MDD) and is the only extended-release bupropion HCl product to provide a once-daily, 450mg dose in a single tablet. The active ingredient in Forfivo XL is bupropion, the same active ingredient used in Wellbutrin XL®.

	Sales of the Company’s first commercialized product, a pre-natal multivitamin supplement, marketed in the USA as Gesticare®, were discontinued in the third quarter of 2011. The Company received final royalties from the sale of the product in the fourth quarter of 2011 from Azur Pharma, now part of Jazz Pharmaceuticals plc.

XML 106 R54.xml IDEA: Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) 2.4.0.8155 - Disclosure - Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00pureStandardhttp://www.xbrl.org/2003/instancepure0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveblHfOneBSFiveRBykigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse2129122321291223USD$falsetruefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1No definition available.false2Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 12false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivehMcvNNLxPcRsigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.660.66falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 2No definition available.false0Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 23false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveThvOneBypcFOneBLigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse27481652748165falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 3No definition available.false2Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 34false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivehpLSixSevenlrDBOneEightTwoigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.740.74falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 4No definition available.false0Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 45false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveLFourNxVVMLCMtnigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-299406-299406falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 5No definition available.false2Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 56false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivelTwohTwoWSevengMTGZNineigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-0.47-0.47falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 6No definition available.false0Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 67false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveXGMWBbmNwmDcigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-4366904-4366904falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 7No definition available.false2Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 78false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivexOneSevenZeroVXTGPyxhigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-0.51-0.51falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 8No definition available.false0Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 89false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivecJVnDGZGDpTXigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1937307819373078falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 9No definition available.false2Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 910false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivenHmhZerofRSEightSixVFiveigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.710.71falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 10No definition available.false0Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1011false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveSgSevenSevenmEightThcCWNineigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-219313-219313falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 11No definition available.false2Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1112false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveOnehBNZKtFourOneSyEightigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-0.47-0.47falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 12No definition available.false0Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1213false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveSevenZFiveQpVZRWWPNigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-1205668-1205668falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 13No definition available.false2Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1314false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveBqThkZSqvFourMZeroigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-0.48-0.48falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 14No definition available.false0Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1415false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivemlZFNHJTwoJEightKqigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-11843932-11843932falsefalsefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 15No definition available.false2Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1516false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveOnebCcBkFourrOneLOneQigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-0.80-0.80falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 16No definition available.false0Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1617false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFivegSevenOneQgyFqThreeFourrbigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse61041656104165USD$falsetruefalsexbrli:monetaryItemTypemonetaryAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 17No definition available.false2Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1718false 4igxt_ScheduleOfStockholdersaposEquityNoteWarrantsOrRightsActivityZeroOneSixTwoZeroTwoZeroEightFiveZbZxFourNzcsZcFigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse0.590.59falsefalsefalsexbrli:pureItemTypepureAdditional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 18No definition available.false0Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 18falseSchedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureScheduleOfStockholdersEquityNoteWarrantsOrRightsActivityTextBlockDetails118 XML 107 R52.htm IDEA: XBRL DOCUMENT

Schedule of Warrants Valuation - June 21, 2011 (Details) (USD $)	12 Months Ended
	Dec. 31, 2012 Y
Additional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 1	117.00%
Additional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 2	3
Additional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 3	0.69%
Additional Paid-in Capital Schedule Of Warrants Valuation - June 21, 2011 4	$ 0

XML 108 R37.xml IDEA: Income Tax (Narrative) (Details) 2.4.0.8138 - Disclosure - Income Tax (Narrative) (Details)truefalseIn Thousands, unless otherwise specifiedfalse1false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_IncomeTaxZeroOneSixTwoZeroTwoZeroEightFivevMhbFourKBRkTEightCigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse41020004102USD$falsetruefalsexbrli:monetaryItemTypemonetaryIncome Tax 1No definition available.false2Income Tax 12false 4igxt_IncomeTaxZeroOneSixTwoZeroTwoZeroEightFiveZLMwEightMWqblfGigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse404000404falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax 2No definition available.false2Income Tax 23false 4igxt_IncomeTaxZeroOneSixTwoZeroTwoZeroEightFiveSevenEightgxSTXNineThreexqJigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse83900008390falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax 3No definition available.false2Income Tax 34false 4igxt_IncomeTaxZeroOneSixTwoZeroTwoZeroEightFiveHdcxxFourtKFivegFNineigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse76080007608falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax 4No definition available.false2Income Tax 45false 4igxt_IncomeTaxZeroOneSixTwoZeroTwoZeroEightFivelVPFPcXFivebKwcigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse85660008566falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax 5No definition available.false2Income Tax 56false 4igxt_IncomeTaxZeroOneSixTwoZeroTwoZeroEightFiveKfDFiveTzcJczpTigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse74370007437falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax 6No definition available.false2Income Tax 67false 4igxt_IncomeTaxZeroOneSixTwoZeroTwoZeroEightFivewrBFiveBBSZeroGtmFigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse914000914falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax 7No definition available.false2Income Tax 78false 4igxt_IncomeTaxZeroOneSixTwoZeroTwoZeroEightFiveSixdVkNineFKhFHwbigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse803000803falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax 8No definition available.false2Income Tax 89false 4igxt_IncomeTaxZeroOneSixTwoZeroTwoZeroEightFivehTKStFsWJZFiveFourigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse2400024falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax 9No definition available.false2Income Tax 910false 4igxt_IncomeTaxZeroOneSixTwoZeroTwoZeroEightFiveqtvmFournLThreeJFourDSevenigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse213000213falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax 10No definition available.false2Income Tax 1011false 4igxt_IncomeTaxZeroOneSixTwoZeroTwoZeroEightFivesKwCJSTLEightBVfigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse193000193falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax 11No definition available.false2Income Tax 1112false 4igxt_IncomeTaxZeroOneSixTwoZeroTwoZeroEightFiveFiveEightTFpWSevenJLVRxigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse186000186falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax 12No definition available.false2Income Tax 1213false 4igxt_IncomeTaxZeroOneSixTwoZeroTwoZeroEightFiveXTMySevenDEightFiveCFourpMigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse187000187falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax 13No definition available.false2Income Tax 1314false 4igxt_IncomeTaxZeroOneSixTwoZeroTwoZeroEightFiveBVHqSevenZDOnezxwZeroigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse111000111falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax 14No definition available.false2Income Tax 1415false 4igxt_IncomeTaxZeroOneSixTwoZeroTwoZeroEightFivewOneLOnenrnrhSDFourigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse44640004464falsefalsefalsexbrli:monetaryItemTypemonetaryIncome Tax 15No definition available.false2Income Tax 1516false 4igxt_IncomeTaxZeroOneSixTwoZeroTwoZeroEightFiveDmvNinekCgtThreeTZdigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse36560003656USD$falsetruefalsexbrli:monetaryItemTypemonetaryIncome Tax 16No definition available.false2Income Tax 16falseIncome Tax (Narrative) (Details) (USD $)ThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureIncomeTaxDisclosureTextBlockDetails116 XML 109 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 110 R47.htm IDEA: XBRL DOCUMENT

Schedule of Stock Options Valuation - August 8, 2012 (Details) (USD $)	12 Months Ended
	Dec. 31, 2012 Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 1	81.00%
Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 2	1.8
Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 3	0.38%
Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 4	$ 0

XML 111 R13.xml IDEA: Commitments 2.4.0.8113 - Disclosure - Commitmentstruefalsefalse1false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4us-gaap_CommitmentsAndContingenciesDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr> <td valign="top" width="5%"> 8. </td> <td> Commitments </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> The Company currently operates out of a 3,500 square feet leasehold facility consisting of laboratories and office space at 6425 Abrams, Saint-Laurent, Quebec. The original lease agreement expired in August 2009, since when it has been extended for varying periods whilst the Company sought alternative premises. The most recent extension is defined as the day immediately preceding the fulfillment of certain conditions relating to the occupation of new leased premises at 6410 - 6420 Abrams. In the first half of 2013, the Company plans to enter into an addendum to its existing lease to include the relocation of the Company’s operations to larger premises consisting of approximately 28,600 of rentable square feet. The term of the amended lease is 10 years following relocation, which is expected to commence in the autumn of 2013 upon completion of certain leasehold improvements. </td> </tr> <tr> <td width="5%"> </td> <td> </td> </tr> <tr> <td width="5%"> </td> <td> As of December 31, 2012 future minimum payments under operating leases for facilities were as follows (in thousands): </td> </tr> </table> <div align="center"> <table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="40%"> <tr valign="top"> <td align="left" bgcolor="#e6efff">2013</td> <td align="left" bgcolor="#e6efff" width="1%"> </td> <td align="right" bgcolor="#e6efff" width="10%"> 15 </td> <td align="left" bgcolor="#e6efff" width="2%"> </td> </tr> <tr valign="top"> <td align="left">2014</td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="1%"> </td> <td align="right" style="BORDER-BOTTOM: #000000 1px solid" width="10%"> 0 </td> <td align="left" style="BORDER-BOTTOM: #000000 1px solid" width="2%"> </td> </tr> <tr valign="top"> <td align="left" bgcolor="#e6efff">Total</td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 3px double" width="1%">$</td> <td align="right" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 3px double" width="10%"> 15 </td> <td align="left" bgcolor="#e6efff" style="BORDER-BOTTOM: #000000 3px double" width="2%"> </td> </tr> </table> </div> On October 1, 2009, the Company signed new agreements with each of Little Gem Life Science Partners and SectorSpeak Inc. for investor relation services in the USA and in Canada, respectively. Under the terms of these agreements, the Company was required to pay $4.5 thousand a month to Little Gem Life Science Partners and CDN$5.0 thousand (US$5.0 thousand) monthly to Sector Speak Inc. The Company renegotiated these agreements in May 2012 and reduced payments to $2.5 thousand and CDN$2.5 thousand (US$2.5 thousand) respectively. The agreements automatically renew unless specifically terminated. On May 7, 2010, the Company executed a Project Transfer Agreement with one of its former development partners whereby the Company acquired full rights to, and ownership of, Forfivo XL™, a novel, high strength formulation of Bupropion hydrochloride, the active ingredient in Wellbutrin XL®. In accordance with the Project Transfer Agreement, and following commercial launch of Forfivo XL™ in October 2012, the Company is required to pay to its former development partner 10% of net sales royalties received under the commercialization agreement that was executed with Edgemont Pharmaceuticals in February 2012. falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for commitments and contingencies.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 14 -Paragraph 3 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 9, 10, 11, 12 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0Commitments [Text Block]falseCommitmentsUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock11 XML 112 R38.xml IDEA: Related Party Transactions (Narrative) (Details) 2.4.0.8139 - Disclosure - Related Party Transactions (Narrative) (Details)truefalsefalse1false USDfalsefalse$cx_01_January_2013_TO_31_March_2013http://www.sec.gov/CIK0001098880duration2013-01-01T00:00:002013-03-31T00:00:00usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$cx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:00pureStandardhttp://www.xbrl.org/2003/instancepure0usdStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4igxt_RelatedPartyTransactionsZeroOneFourSevenFourZerobFnhlwSixHNZJThreeigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse22USD$falsetruefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 1No definition available.false2Related Party Transactions 12false 4igxt_RelatedPartyTransactionsZeroOneFourSevenFourZeroVmKzZZeroDSevenWvMMigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse11falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 2No definition available.false2Related Party Transactions 23false 4igxt_RelatedPartyTransactionsZeroOneFourSevenFourZeroJwmkpJTdwcqkigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse33falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 3No definition available.false2Related Party Transactions 34false 4igxt_RelatedPartyTransactionsZeroOneFourSevenFourZerodHSSvTZwgTwoNinekigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse22falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 4No definition available.false2Related Party Transactions 45false 4igxt_RelatedPartyTransactionsZeroOneFourSevenFourZeroyPcnEightLPLsxSevenDigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse44falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 5No definition available.false2Related Party Transactions 56false 4igxt_RelatedPartyTransactionsZeroOneFourSevenFourZerolGyTwosWrSixGSevenThreeThreeigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse77falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 6No definition available.false2Related Party Transactions 67false 4igxt_RelatedPartyTransactionsZeroOneFourSevenFourZeroSpRqpSixpThreeLydpigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse2222falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 7No definition available.false2Related Party Transactions 78false 4igxt_RelatedPartyTransactionsZeroOneFourSevenFourZeroTXNineqPVNineWtCkLigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse2727falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 8No definition available.false2Related Party Transactions 89false 4igxt_RelatedPartyTransactionsZeroOneFourSevenFourZeroJgSvMTBWThreegszigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse5454falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 9No definition available.false2Related Party Transactions 910false 4igxt_RelatedPartyTransactionsZeroOneFourSevenFourZeroRhVdJQFrTQnEightigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 10No definition available.false2Related Party Transactions 1011false 4igxt_RelatedPartyTransactionsZeroOneSixTwoZeroTwoZeroEightFivenKTTFourQTwoTwofrOneyigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse60006000falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 1No definition available.false2Related Party Transactions 112false 4igxt_RelatedPartyTransactionsZeroOneSixTwoZeroTwoZeroEightFiveDfgWpSixSixbWyDOneigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse40004000falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 2No definition available.false2Related Party Transactions 213false 4igxt_RelatedPartyTransactionsZeroOneSixTwoZeroTwoZeroEightFiveHvKFiveTwoSevengqSixFiveBtigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse60006000falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 3No definition available.false2Related Party Transactions 314false 4igxt_RelatedPartyTransactionsZeroOneSixTwoZeroTwoZeroEightFiveFtBwZeroZeroXGnTJKigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse40004000falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 4No definition available.false2Related Party Transactions 415false 4igxt_RelatedPartyTransactionsZeroOneSixTwoZeroTwoZeroEightFivenTPThreeTXzSNinePTfigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse2300023000falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 5No definition available.false2Related Party Transactions 516false 4igxt_RelatedPartyTransactionsZeroOneSixTwoZeroTwoZeroEightFivezDSevenOneJQVFEightWhKigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse1000010000falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 6No definition available.false2Related Party Transactions 617false 4igxt_RelatedPartyTransactionsZeroOneSixTwoZeroTwoZeroEightFivekFivekDSDFiveHxGTcigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse114000114000falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 7No definition available.false2Related Party Transactions 718false 4igxt_RelatedPartyTransactionsZeroOneSixTwoZeroTwoZeroEightFivezlJGFivebglSSevenlNigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse8700087000falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 8No definition available.false2Related Party Transactions 819false 4igxt_RelatedPartyTransactionsZeroOneSixTwoZeroTwoZeroEightFiveOnexPOneFivemmHLEightZeronigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse8500085000falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 9No definition available.false2Related Party Transactions 920false 4igxt_RelatedPartyTransactionsZeroOneSixTwoZeroTwoZeroEightFiveQRThreeXcFgLrBNinegigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsetruefalse00falsefalsefalse2truetruefalse0.010.01falsefalsefalsenum:percentItemTypepureRelated Party Transactions 10No definition available.false0Related Party Transactions 1021false 4igxt_RelatedPartyTransactionsZeroOneSixTwoZeroTwoZeroEightFiveGSevenEightvNhXsNDysigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 11No definition available.false2Related Party Transactions 1122false 4igxt_RelatedPartyTransactionsZeroOneSixTwoZeroTwoZeroEightFiveFiveLPwMnNpxHxqigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse10001000USD$falsetruefalsexbrli:monetaryItemTypemonetaryRelated Party Transactions 12No definition available.false2Related Party Transactions 12falseRelated Party Transactions (Narrative) (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/DisclosureRelatedPartyTransactionsDisclosureTextBlockDetails222 XML 113 R23.xml IDEA: Significant Accounting Policies (Tables) 2.4.0.8124 - Disclosure - Significant Accounting Policies (Tables)truefalsefalse1false falsefalsecx_01_January_2012_TO_31_December_2012http://www.sec.gov/CIK0001098880duration2012-01-01T00:00:002012-12-31T00:00:001false 4igxt_EstimatedUsefulLivesOnTheDecliningBalanceMethodTableTextBlockigxt_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00<table border="0" cellpadding="0" cellspacing="0" style="border-color: black; border-collapse: collapse; font-size: 10pt; font-family: times new roman,times,serif;" width="100%"> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">On the declining balance method -</td> <td align="left" bgcolor="#e6efff" width="36%"> </td> </tr> <tr> <td width="5%"> </td> <td align="left"> </td> <td align="left" width="36%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">       Laboratory and office equipment</td> <td align="left" bgcolor="#e6efff" width="36%"> 20% </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">       Computer equipment</td> <td align="left" width="36%"> 30% </td> </tr> <tr> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> </td> <td align="left" bgcolor="#e6efff" width="36%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">On the straight-line method -</td> <td align="left" width="36%"> </td> </tr> <tr> <td width="5%"> </td> <td align="left" bgcolor="#e6efff"> </td> <td align="left" bgcolor="#e6efff" width="36%"> </td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left">       Leasehold improvements</td> <td align="left" width="36%">over the lease term</td> </tr> <tr valign="top"> <td width="5%"> </td> <td align="left" bgcolor="#e6efff">       Manufacturing equipment</td> <td align="left" bgcolor="#e6efff" width="36%"> 5 – 10 years </td> </tr> </table>falsefalsefalsenonnum:textBlockItemTypenaEstimated useful lives On the declining balance methodNo definition available.false0Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment [Table Text Block]falseSignificant Accounting Policies (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.intelgenx.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables11 XML 114 R33.htm IDEA: XBRL DOCUMENT

Deferred License Revenue (Narrative) (Details) (USD $)	3 Months Ended	12 Months Ended
Deferred License Revenue (Narrative) (Details) (USD $)	Mar. 31, 2013 M	Dec. 31, 2012 M
Deferred License Revenue 1	$ 1,000,000
Deferred License Revenue 2	39
Deferred License Revenue 3	847
Deferred License Revenue 1		1,000,000
Deferred License Revenue 2		39
Deferred License Revenue 3		$ 923,000

ZIP 115 0001062993-13-003530-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001062993-13-003530-xbrl.zip M4$L#!!0````(`)UV]D)L4AD`WN,``%C'"0`1`!P`:6=X="TR,#$S,#,S,2YX M;6Q55`D``XI_[5&*?^U1=7@+``$$)0X```0Y`0``[%UM<]LXDOY^5?^P.KW3D@S+-]AWOC]P=1.&J='A`9 M4L^AKN^Q]P[_VFUR(4_#5Q./9N1?P6"2?E$!2/7'CX`URY] M.YHR+R23,`S.CXZ>GI[:=O+(<_($7CPBI-6*^_VGQG-.`$^[@S) M0T-V;IV<]]^<6V?DIU\?6IWC3B?3P84?S`0?3T+RO?U#.'5";-G^?:/_54:^OL[.Q(W8V;A[,`M%IRT!`<%'6-"EOX+JLVC.J)B6"C]P<(O!7#:S]+Y^!(4P:! MGU]$0L!DQL']A[#N^P!_OY2\?Z\@_J153,OJ!HOCS< M?.E97WX%3!.\T#OXL=4"B?6L=T?+NDT)/PB*L_E^-AWZ;GUJR)0FE>LH[?^C M%_)P=L?&7(:">N$G.EV#J6L>[_ICSB1,71&T-?DR.BF*V-;< M,L%]9VW9XK^M3B\1;VFW1=XOH(&@[K7GL.>?V:P^U4ZG8W7.3D]/.UE6"]T6 MJ?[3=R,OA%ZON`OVLC[53WZ66J&[(C5U]0*8'_MB#0[OI]2%#L#&!KX(08N4 M4:;>+`LA1Z,(X#?FNC][_I-WSZ@$5^1<2QE!CQNRO:#;><5Z`$.Q!M^M@B)A M-VGG`[CDX.4KEX[K]SZBKF2Z_UQ/UV7G2I M<;J"*VO0Q7_S8BQTN8BFGK9K4KWZO8QFIDM-U?1+N%.Q7WP*GF-*AN87_.8. M7AEQT&GEI/+^)_;=%]<_Y^U%^EC<\5&NYW>!`IS2@7A%A,J,Q:ZW`SJ:7DT: M,F/MLC:192P@DLIT_N[(2*)4+"]+!CIJ"W.LQ=?68>V2V6PZ9$(-^4OBKAO' M"HUQ]P5G._=A[[]YZ_JH:U+`U6:C1%0 M<@$NZ8#U'+(,E]L\U%B(PZ&=3G5,_'F^E)V#'^-FF37'F3`[)L:T,VFDM+FWTB^C9K+S MP=Q;VE<]?/OLL*KPB1=C'NJ]EZ"./ZW&7$RJ83(9HRJB,!/M17WYW%/_67>!3A><6VGZ(I$S3T17:,5U+4US_N%W1QGLI>P&T,V';!F9C0#5$)?5/>VN">I6L`"\^\?G`'P$VUP\ MI_EQ*^U^/01UY-'IUD7Q0)\O!(.`1VG4R!=/5#B#*4IQD^EVW,L!64)E$SAU M9I:U)J*!E"R4FRM(]Z0X@;(=UZ-9@^_>2?^D*ME;X4,8$J%8'70X@08 MT,`DVH#SX]YI02L7D]D(4!VQG+Y9$].U%U)OS,&T:$E"@X_/MAOAX7`_^;[S MQ-VY<^;JF-E.?KBJD&L$8!TS8VV*4;?;0$R]KG5.120L;M MW-(9^AS0'[@B(N;\PNF0NY!-L@8LR/'9::FSJT"U2;BU_%&_("O>YT\LG(":X*H8XC6P-&H5IT6#,ZJD6A<1WHG]0`4)/3)]^R-A=#O MG2T;A93&^E!JB.3$ZJ^#)B.X31Q0[[B_:#SJT*NC`F>G5C62F;KLIAEAGF*Q MX]ID:[!;F>R"0N0F3)_T^P6_64YC72!U1OVD=]RMCZ58F\NL9L$\P;+`_AJB`T@'I_T-H)880'P%U]B&'9,Y?'J2AS;?^QK4:Z72;TYK`J!NU<%:74BL[,*2.UUVA2X*Q#4D]1&M8!YKGZYZML=`^>/2(:FKJ0'@XWPE#P811B5OS@W]*R)&)G MIRPN'_U>/EW;J4A>T6B\>"GBIRW.?Z,"OR8A/SXS87/)'&WD&U:]-=Q/[Z3; M1P$M0[F,CQURL#"Y+$>V0]2;^*8WN^)A%8YN-1PW`7+Z\A2YWTGQEV-AZF4D(++1'ZY0118E]0\4GD'Q@+75G]5Z,:*V2K*K M6JSL6A0[90?\6YIN-SQH:T7#QZ=Y5YX#V"#VYF"L2"RW:PU[G>Y9@UGE=CUX MH_G-3FS'7(%WM]#7S">+1=<=R[NA9+)F4GSGSZB+WW13JSK-FH/3_%Z3/*GU M892U,+,,PB_VI57#T#SNNF(^+HAY'=R7 M#-R+S;<1:^>G3I;0NA#J"JBXG641@L$4"U3_47=N1L4M9%L5RW+2S<'UBK(/OF>GQ?J5IQD-IU?1+$1 M8)O)K"JVZM6/-52^6[7Z\8)6C>JR>9:O2GS%I;<2JHOVW6QH7_O=_,@NH=P0 MQ-K*=WPVMYFP&L3?8)@F(7,&CS![QNQ3A$6&FY$NB=U$(1Z)@9OH/U#)[0WD MNK`8U\5EMGZ*O!:@K?&R=``6;E?I=8_[/:L17N+JU2T3JODE=Z-PT\6,+_/( MNZ`\G78G`WH!Y0;@K=+JYN!E8WY,B#*A;,/+08NSG0+=A@`VEPLMQ?'!_?)JN.!9IK0VC?G1C]A$N@9'&K[9@ M(+!+IO^_]N;?B6U82)9E=0LQ]&H,3:.N+=/"!&@"LWG=-GY=PP3!,-55H+:- MPD:K\%;K>IBVS]>&9F`[;*FFZ>@V/#2]S@H6BN2;A5M[/G0+2W";`Z[RLE_3 MR<+)*JE7`;5]QNJ/SIM=,%9XT:SAP2DLOZTDWRC:]5:AFH2;5.$6O#VU::C2 M7^70B@":!5Q;I<].5T4-RP'CR1Y43FZ%CZ?P.!]FGR%,S#PTL$/^N`4C4UA, MJ`YC._!KE^ZZO4;PPP,V8XZ\$O[4[,N,]^(U+?"S?#2PC')3&.NOOO;6Q+A` M_E?Q'?QKY*_-,%!^PIC>E%MTR0U;H,([ M,'60;(N'VMZTL#=H?1X^CD;,#F]&'Y_M"?7&[(Z&[,8K[Z_AJ=#-\U`'R;9X MJ%UI/6V(A28.^;-65`;ZG7X%I=G*6835%W@W/XCP1HRI9PK<%[XG?9<[H?I]*,$NC-X>D"?N MA)/W!Y!9_.W@NW'X5I^A28C"+P@(FX^]]P>A'^1NFP8.,?==-@H+#723(5ZT MVOCGT7"^AZ/06=EMC/&L_[=2$D'<&NO2?#1+Y%A9#'/"G5(QYMXY]R9P/WP[ M1S;#&Z[A2>*/2%:ORM@U#`LMI>X,[[``>Z.ZQH?T`L&AWP#KP"-?P/,A@)MF MZ'$/KD_U$AWU'-UG"+#Q2QLB4MM!)`E]<@7-@-'6_ZEF`Q%R&PRFU<'I=,?& MD=XK0NY;_VJ3@<((]-W9(78V(XY//#^$3O&\/Y")Z^)SFDX>P,CW0V@*@`53 M&8)#AK-Z7**\71:RU3)NDVM/H?`#[B$"``4#37 M$KR*(DG)B'*!`Y78ELMAS.!&,D2EP,9&$>3!?B(K2XH=[:J*@&8GG'L@$ M<#K<5IOH8XL2]QM.`,&4SI`E]AQ`I(](#;$9HP*)()`BREZ;H.&^T&8[MKZ2 M<`1;QFF)62ZW3B5FC&L#]-E34E61K23?:P4[[78[;S^W[]ODI\'@-KEFO?T! M$4(H,XP#F@PY[CWZ+F3S>K0"_`:!MD>ZF8C0PJ3-T=C@6(*Q!5[08(OX?1V\ M-:;@")3@P2+Y8PC4`>73!(P:"-!CSJ%JQ>)-W/@#XG'U9\DS7!])Z.RMV=Z: M-11>K;9#<=`1FF`,ES]C6Q'/<=1;G-XR&H*#Y^C6==3&&00)-UZ&#$PE'1BH M8*K%U,<[2)CNGM6S8$A=M`;9,(ZY7'T;8J__>_UO3/_+7:]0+@^0Y]5K0&B_)ED2&#A)(*C#-`[3,K!S((8HB3DR9C:.8*PW;T%'TR4/ MB/S\:*SC2S3DRH`B)+RR*%Y]@C2,<'TZA0EB=):E`S_M3S:@PIT-'%\=B_.@WMS8%TX;*9QVO^'"::PP.)]!MTBJ7)BQ>`X5 MCMS74??>9L=J&6_IN\N8;70%J7W<:^5>*W>DE==>6DC"U5U5^297@_L/<93R M.5#!S2>_K1JTL$VFT/-!9XSD?L)82+Y_\`-NDZ[5^>$\J]"$#OTH)#>CD62A MLL!F9STJ?F83;Z9:I,M9_O`/9J=U,BYC/%S5]P.](X0P;X(HG$SP8TIIZHM` MS%/^/@(QJ22Z-#2#[DP,J+-NIM;9,:(*_!`39F@>7QO!"&@^U/ZWL>E"S62B MD^M/1H1*Z>,K5\PL@)23SE2S:"KS MS%4WL[$;^S&U/6G[05'J>DPH,.M,,T'H`OD/9YD@E4]QK%1>EUDZ45H!L1)_ M5,50B76\(()8#3>ST+%@<6JH(#_"\#%2P*0Z6C)22H@)1,J42;I2IAVK* M8193D4)7:SDF8%55W,P$I*[TRV=AK]6!6?@TX?:$V-`??D76L*&6L+`SX-!1 MM2."\SU]IY7]:5GNMI_*_U1)=22^]I;UTBKV( M>"*AU5#+7)Z'Y6/0+'PI$6O;:LL2:`D#ZXCO?!*=.=$1#ET\&J:LKG4K7H., M'TTFBH^*J`F8>VWP[*'P4544A'1*H-%*U@<5,O6U,L@R]8$Z2>]F10[7WM2$ MRP2R:C8F215T[J@Q5/4ZU#ZEE:G9\!9FLO,F"440+T,`)7/L`4R0=A-12#ZG M3*^]_E2LU/.;1XROKQ0MK&Q8*[);%\%+"4NNV%"4644LW"PRBMU<:)([JH#H MLPJ2"*6+$ MI)O_'=O6(!JZ,-@HA$#%&.#?,B6L>3D^J=7D.*I)`JILJ)FIRLV',AL*L$UN M->)D&<Q`T-9:'_UPV'!3RYSD-HU)JF" MU8]7QK]1_Y3=>[Y&5;)PN$!:OXK<6#9G+S@S1:45GJE MU;,\NQ@9ZW-?LA?^Y"O46NK&]#JU[9ILD_U8^+@+[%C]/*#-%R` M<`(;95?N],;8N2!F1*[!HA+T*$[8D M#U^4@Q_G3%;VU!!CJ8X[_1\2!>F^O8&$9VSLS)U23306(P!,_N%#UJ+FUSW6 M?D&#XNYF9)"MNZ-=^TU50Q&>.D3*I/.Q(4RI@)\E5_P9R^%:R],B`-K(&I8H MS@C'$=N7HW-Q5/ MO*,+MP5KV2:W3(8K\RFW$9VQ[CEJ>L%$1M.80\-O'K'I2E7;E0T-P,`9@YGL M0N;*.*=E>N@)URO4BQ,M1=07TN3-LVSZOXRD-MPR0W/()M0=Q00S71=$45`R MM0A0+AZC2+JPHU^XT#`7#3W%_4?X54)392$@ M*N:+[6;^%G5-N7ZES?&4R*P;:!EG&%3%'N/7VT25"%(_S]6>LRD/DQ`@WLH+ M=\QW[Z%]O!5-%P"Q5$CML*2X@CV:]WN6OS"TB7_]%NOV^XAAETF/?A^F8OC0 MSX4/YK1G$A_W#'W!W!%)+'':ZV1C"7V:;H]!#?3YD_"C0+D2LZG!6#-*8O@?MXN`WN1)MUR$^4P0?H(0JN.$JG5F=E M4F1U#DENTV*&>A>(DD"??6ZV"D@TBOBI!L$1[/)^X$)P`7?ST%M+%FK'PU6=::F55[@US3^C=@Y!VQ,-XE[-J3R$SE-R#V(Y\KZ,& M>$)U2UTE3:"!%$(3R&%FJEP/42^U@A!FZ@[&NMPUKV=),N7JI3*SJ^6'A2+2 MGS8WCN0*H.CG?A'W/S#Z5,>MBI`]VFU7GS,1 M7LIV>2LO:MO77R8HBI(XIDB9I"3+O_X!R.0J4@N9U.+2Q'2WQ24)()%(`(G% M2_,#Q!A;`!X>08`OFI@;PW12I:NI+,(%]U[T3'RU@7&82.5Z'*NJ1XH(Z"N. M"E(92PHQZ]S^QO/@2.F90"R;(M8/:4+3U;+)DZ"4"MJ:Z#_BO`U)IT3S'?%$ MJQ*&.]]LRX)X-!=X)E3]/&="/L-P36-[)+#AVO$AJ8V1A/&;D\/@K@#KRV;N MVB^E8GW2,6T.;)3=7R?2UJ4=>*.4^,8WEHR$2J[5HNA0E/\N@W'M8(IWF>>* M@M6-D;\\T(39TLPC`5>;IOF*:W:@^J8RNDY@,^J@NPB=(R3*03N3N9^;9;SZ MZ)OM24VT^)=DCD"!L+L:Z3*P-;:UH2D]7W$0J_ME5WE&1%@8<)/<1-B8`*,P MAN@``12QA%R//CZPU?8`O6QM->:KE8/H%9;U'][(0"4`A#`45@ZV7B"+@NY9 MM#GI\L"`.>=$`7*T!@JI:[\4Q^0'1.4E[%MS[$&!5@#1IU]4R_QEJ*?FP$(/ MK8%_X#7]O>7\0,7N[L'J*,]X25Q9MR*6J:WSA@$9($J!U_7C:&0].(W&R#1Z MYV)1*BV*4AB8%-@T&EB[@BXU>IWQ#>BT#]K[&=Z^SH!;'Y@GTFFEM.MU>!`! M7!I<1^;+=??LJM6SG$XW`W:]R+Q5#A9%+`1)M'E+J.KV5B%,T``64P8]_:FV M:++CVL3#>BBX'"+Q%LH29Y4I.J[@C+%M9/.",^E-FJ\=4E&]2#M@5# MN>J0S?,T`J5_.EAFFQ\Y\($\UU:<=M:7'>8&0YM>U\'P'S"]BPH7%WA,K-FW M--6A=!%5Z1JPSCMPCY3(/H']5B5W$14M8ES()M&<@6YF4TL1/E' MJZ.BFBS==F6K)ROJP-$4V#M#=6P\9I<-;R6T5969/.'O`U(Z.?;\\^[`*'ZB M&VS2\9HP9"U#Q@QH$+J,8PQO;9O4$O84'$6C%N610O M#H@*@RGZ`,-O=M&"E'G@@.+KVO$(:GWJWMA%#S; M4G:B-BIYC7%,C%*BU(8P^5UJB]B-DFR7V=I20%%T'^;[)G\G24D[:9'ZJ9_2 M504OO=ZUQ=HQ._5`)Q:A,*9&&S3LXS-4M9N7([IQ0I]XNLE#818$6FID'_LG MI["$R+3`W^VCQY?%]>MI-ATLJ%2XQD(622EP@+WQ$$BU;*Q9[8QO3&=K,,S8 M>1C\>OZN_0_3%N22OUWB4Y\E_&) MO%ABX>_/XAW/F-.PGI<*:,'XTFI,--J^9+38*-5!"*"S MS,OH#9RO2MS3F>W/[,B(WA52SOJ7=9G$ZL'!1LQ'K%QC%V/2(^8]KHJ<PK\OQ`A-=5Y'2+V&<\OD@Z,U@B?")7UV>: ME]CS@=PX=-T7]$P/4_P9P$X*TF7TB^3A$\G!'_*[8KY")HZR;((_?RY??HP; M=!E:6AH_2F8?RN;CL-:2,]XO/Z]//@LC_@[RYO?%?(TD[:1_/8UBL%DRYS/@ ML%9R,[6_/-Y7/LM//H>/?`FX3/&->\9*K%]\#MAR=:5ZT(5]IA$_>"8;:UF^ MUEQG--[OO<2)"OF[UXSV$_*'78CQ;T]W5`=R5.*?3,H$<9YM^_W.;L"]D['P M,@INWE%&F%)C]]&ZIB2>7N?ZXO%!>V^]94"/"<>)0A'\?ZDPG80O-:KV*V;T MZ+U'*D)Q;^.OHY&XV:S!;#+E/!6F\>"EQO;5>;D^;8S,\?GX^/Q)]*26L\QI M&+34&([:]XT7S,\B@CW=P#./5VLSG;'0I<9U2(N@B3QQ_G+V=OEV`6M!J""" M7;E8!OTH%;*QX*5&]KPY?&)4^[!@G'NZ^2*:A:L'H-M54R(<#V)JC+N]TY-. M_\/1V]TL>,;.:BK\@@"EQJIQRK-&6SU8[1V\W,?GL!2B2"1!?4F%Y!3X`C@? M>M7&;V6M]=/@V7R__0EXK(*X:';GWN9G=_K\(2&#[/PT),XB<:AQY+85-=9R M+DEJ2*Q2ZA([P&^G+]/TG0PLMTZM@WH(J_OA%OA0#:RL&*F=(?,6'=$*(K68 MX/BO<0&4AJ9_`]P"[,)*.:KO6+''9E6#LHP=/H+JRKP@L>?K9X]8B%8 M<[K3L=0.M0NA6D*R3277;*W%^PW1`.5*P@A?W>J5-QIVJ?3;HFC47UTS%(M* M>6M&L!U''P4@7%)XQOO\GQ!2I62[QG);8UC#1C5LQCE8"H>*7R%GT2+8: M+M3F4K)*A7*Q7JB6]K^!G&,,,U.#FW_TO7*]@(UQEJ3&E?;*"4-X$K!<2=C: MLFEWI;VDW6..+^=2FFXNITVB?T=S'TUR&EG]Q@A]1A_G\-_[R\=K0V"=9O+8 M^6[US*"E1W/TB]4]!_"D.C(%HI>N9(.ORA0Z=$[UI4/YUYY/WI0+M=A MYH+PI,?JQ6E0!X3'3N/\M"'Z,"_MK$U`E6':>G=/;X[2?GY'027P7#;#S(5! M2H_;]=')T>GHN6E_W&79_6,Z4.RGPRP(4'JTE.:8?C=9WX>F,+YK'?;&HIER-08#2H\7.IL?GUTU8SZA#W`P_/L3B M5TV'7RQDZ1']&'X8^%\ZEW_3G?>S1[%GZ>FPC`$KPQ(=O2EPO?%!U8D?.KUU MD*L30*7'[[$]^G@_,9S&N=T0RZ/I4`O"DQZKKL(##3K/)V?*U84B.,8C'6X3 M4&40G:C.=CL=,E,Z;2-+[Z))!.L'*>5G%*KT"(XM:]AHW!K*".B519F),0DK M]7(MK4T8ABL]?K>CL_'IHVME-E_@F2Q[1'P@:+E8KZ;5<.(`3(_NT.H"O<;- MQMV#WD;WRO7]2DI4$T#,8%$U M>[VW\]&-]%CUD=W;YSWUO MG))^=-$Z)S6>]B?!)G%*+3P9O@Q.Y//VY5%C-+I^>3L3/*$I%9T@1.GQ0L?S MZ["!/X_.&@8SSM9C&F-!"Y^J\(:?./PU%'[189`L,)W=8RS1;UF5+PP`=2Y6^S#Q633C] M_$:GM3&A,12[TM74MG2J&;)!C8A_M=N:@GW-,`9H9@!2`DAS?/''NZH,,!3* M^^+`:/'V@.5BLB^80]W&T*[9J\:=46P@R(I6E&>')TSE(=EQ5*-%7?*P^YXI6RVIIZH8LL`B MZ>0!*`,4;*'!HVKXYI?:3`ZFP+JV"S(&.N"'9!\5ME+D(,Y>1)TR]ELN;IEX MW9B8&M`WS:'JA2ZR@$@GL&EC8([*>BCV5!DU/6JXB()1?5>ZLM'Q@D9#O23Y M-=Y(-1R7H]JH[FEV5V71KL0BK'ODF!X/@@-+)W6KU6@`3`IU-J#Q)[V5I%$*`,>+7.'QZ&C9=1!RQ`=#&)12XM@TY`E0'# M\:UBD'OBZO;*?F>M.<5F6*9$,@ZP#'CJ9V.@EOV$*;=GD8-?H?CNI<1W&H`9 M\'[HW[_U8<@^#70U;HD]GRZGY>%)N#(@V7C&9?!V^XC_>7*.7\6Z.LMIYW02 MKBPRMO,PO&X,J1Z.2K;)U\\SOY#C;?R7OS6UO;S9[#%9U#'&>Q3+)N?F('FG"+KRH`99"SW"VZBE39246*@ M#3<$RP[L0&-`%>/`YG.K<@X<,/4,7-_!5$66OK(KH?WI9I@4V#MQV9((),@; M^(BCH0`Q3$<-VJ5@AS+'2QMHP$F9Z(HC?24M]6V@&LX/D-+.[]Q-(GZQ+2IU`T*K5(P5O`FB-VF-KE#\ M!LLQ>'PB,4:)QRQ>V$[9;&)[IB3.P8*MG^84NTN%9&VF-C"C_&A"!;G'_6=O ML-`=U0HE^/Z_-G?WDH3C)P7>68)[MH"^6N5M`/>C'ZSOS]&L<]8Q2`$3E^4> M92)Z2>0L`3$V![H0_5PU'@K*-XP]JOG5)SZE_^K#:7+KFGK,B641S]7CF_]F`S%Q!%50;J&#]W*`UTZW)4>-"2BS;8X MEP2T8\F&ET8I]2UX$Z?O^/#D2W&WOA?]_M=_'O!Z[1OAJ+[W81IQ]SV$-W6I M7*&4S_U=Z5#774Z).5-""C#<)&Z5$GTD^!QK6_)#`]K#%LO.\LD362;Q]]H[(WF5,J`4LB'$$6 M[\*'HU,50%HSI!N`FO`%7$N<5IM&7 M#@YJ,[MI/5E9O4TPD;S4-9G%@I<"N3R\2C4[X"<%3G^?#CK(4K8W!LUQ,@>=T M`%-@S,;Z>#MIWI_;7L(,WLV`K2*'?(AEK.E:WUL0U63(4J!Y@Y1J''U8RET+ MKUT*S'-AZ-461&\2HC2K\>F]A['KC2LZCW1^98HVCS(I(59>%+$8F%)@II^> M'=./_AA#@>]>A!=3KNS5%EY^DU"E0(U"FX?#XX9-E[N72A9FC,4-E(7%D8N! M*P5V!I:&H*7J=#[P(J;7EA*Y>6'=9%/E?K4 MX*3`Z>C]O'MT_="YOV]E67(QI]E>UD,:4%)@0C^,^YNS\Q>\-'X:X=45XQ0/ M5#0B7L$"RNAKX'7FR%E&'BD)PPV.J-L37;U3GF(,T>8#O^@11.I62)>H.2*YR MO4)FT3Q?"L-T:ZGH8?C!:F<*`8:L;!^6V"^$@;@R9<,^-%I7Z/\(`!T(GL"` M[>E0E:=#%8!HOL_E`.(,PNW70H1+`V9#?C^VU);F',N6-6Z;UDBV6H&3.`(<'?M!1.>@29Z;9&FFZGA&V%N,.*K78V7C'!\.0WS" M6YS>HS8Z$",K`W#%#Q^10CG39D$2W)B&DB\5_"\D$B(W"H2_>$P).[BN428? MPS=A#:F&(G)CFO(-4<#,/Q,+`6,:=!+]2*1CT="L)`!NJ8.EK.-FRNK M$)]!E3DH5D/037X@4=C`2A`-SL1N.>MS$>J0EX^U+)X!2/$_#V@9X9)F(^$T MF`:M\'?-W@FLMVMZ::HS\>?-*=*RME\J8R6'.'@RSF,6>*=+EIE$%0UJ@A29 M!^Q2J;B_MQ"_"H<^*FOF`7OG8*]>6BW88;SM MKX%CTW;L7^U?O,?N@_9._W5_K]4DUKD?,CM:*R3/"E`\["#UW='6:DI+M4J@ MET,(3I$(B`#"O?3#C>MD(G(MI'JEBLZ!@PC?1""=ALMZ,46UMC^Y"CQ8!>,A M"I8PXZPCEY0/#JK%>BR?)[-*PG-KQC#EI`6\P$SEP#L+@<629=:2<_;V`MM2 M/)Q3$%DK7JF4]I-1$8M$9D#F4?F(^D>8"QMJ+[I.)*_%N%L6PF8%U%@J1J#: M^;YF\5.7RDM6KM;*(21#0(J%7R`H"WB=<[&N]P]JQ?)^+E[G+/`NV>NB]$< MU\@3D&+J!&.T@"6=9NK2>0+*D3@3,9Z`%,1>"!32"Q]D'3,46,CN9(!]=JE> M.MB?U$8C7\T*5YK8B$HE#5B,EOFH[!%@V*=2PI""(GOS@<#)(YYW2^5BF%/< M+Z7Y?AJ.J!;G^KRM8DH;F$@G\(!N4L((3Y$23Y.#2BT"U)3/"X,TU1%Q)`IC M`4@9FWEY21@[Z]N<>0C)4MA;.OW[XF!-X]HM[>^GAO5*;IH6/,#3SO)BTKU2 M)!$C]K/904MS#+&_.&AGJJ%:LDZ$[6F&9CLL$SDO\E6J8W-"D>R:/`/U'%79([4-S\2DNV3?'JKAL\L%8,D)B33[1D4,#C\! M+$NU2$`?P-'_--#C+>0J-:E]KAFF!3>[2'G:5\"C,9+]6G:X)=[!V:5X: M8M2,7B(V:TI&(7$)*R8C#,B9]0CTEO9D;F=FSHG3U,.?%`!7BJE8%*Z8X\*D M_%(1]EADM4WYNB`PTW%SL9(.S"?>WN&0=7>XH>8.O]KL+."7W]F!=9+(1-^D MN)N#>F7OH!B(NUD(IMS0F34/2>A4]BJ@T5:$H!/M)^'V8C<$>1@A\+-V6B7Q:$(QB+9VI,*[H4&:> MHZ35!(Y.@8P=%$_4RWH";4']U6[GL;?/^*0`N-*0+)B<,P]L#6PJD;.'M1J( MAX]^+S4HJ7;M2JDT"Y2`:D2%W&%\^N]/8Y*>.9S]E`ZB2O),*$3#G4;$33BF M,T/-"\ZYE82X@@H"DTZCX@M<"3"U9^`Q#U3Y8Y;&9"\M`3-ZU)_B/(1)Q$$^ M&P:Q,*>A?#WJ3.E0<;1A/K)FIU2/:!3S`Y,/$BFUS;H0).`%155;Y.'\R?MJ_6H' M@E'S=%W._+A06--(;Z!S]&@U+<0\R-B-)\UA%ZW7$F&-?EP4F&DB>*)I8[/A M9"95I.)&;G9W]$.I84C#S4?#*)EK7/=Q69]7"BL M:21NI.;W@@`GK`QV!IJSLA9E\?EAR0>'5*&5$2]X6ASP):RS#/_!93"4=9Q$ MEM<05/=EM5G%_M'^]*%]:/>B\[ZB\C M?CSQ)GG89%P$EKRP2&-&U@5A$?_,(6L^`8MJGKKCLZJLEJK5.3@G\LU(_)35 MD0U^(G=L&K:I:RWWM.[64FT8@'[^:GOMJKU$(OM$LQ7=M`>6VE!Y"]4T;"6^ MB]6LIE7!!E<"NEC-Z(4\9R>K8"^KV%96"D:L-@ZJ)H*@M&^/`0]^D/A[*8"JS!G*][4H;P,<5-]1F6E%@;5.S=6J1)3-G-?:D[EL: MO-''8XT.B\[7QWA?[6/("+R+,/P#\A1^D0PCMCSL`9:*'$+BGX?#(&38V!YX MN.ER-&VMI<%V"P/C+5BE MN](O(_`9X$[@(UV'<1W8(^$36#_(\5T[C+&:LHZK+-BQ3M6U'@#H;%EJO5DJ MEHM00H#D`/EJ,VGXS^[#KM0>&"W[D\QFN,6A?ZV?G=)QH/?#C11%*](1=X'L MP,U?;3]>_#=3M/_XXX\@E_WA_IZA7?_A/DC*9CF@5H=XRA\N\MK2M.<_PI"R M^48I?S2P-0,6;03R?ACP(":AA9%,MWA2(8\;3;L_#WT2GUT:!,N?H49@T[7[ M&-JJPXNVJUZV_(QOG+Q^5[9ZLJ(.'-`+==!0S=9`88JL8NZ8[F)FJNQ0MC1S M8$=?\O?Q[<2OP](,&D#;1;D6C0D1+&A^AC237(GE0M9A,0I[>L0<=;)@4P*96N)*-' MQK*=G;X,H_5@*35!P;5[!:DCV\!L:$OB61&\'G2DG/T,>7C`-`4CA%SJ=@&] M0AKFCO6!,\&R;=JFU7=])[27(AQ\7SW[B1:JXNQ*$PZFTM[?/D4T[@MI6K#( MT/W#7#*H\>(R(2*1'4V!C&,DD=8#\<`OPX:,U"3W$GIPD%%4VIA5>!BNJ.^: MS9Q-DYNT.6%+;=?(JC;I6Z9I2;=:'QC94+<;]5K,3^SBY5JQU.=S)?'VR3I5 MM;8UF[F[#D+JLZLLVX[<88[<@.I=".SHWDMM[H5V+%5V7`6].\9H#DQD1:\8 MB$$%-E$0/6.[/3`4YBMKJ@:0"`="=XJFL)=`\MJ:7)!Z6L?"RGGX3=OL&7A- M:VEF7W:Z\&Q_H(.D1<6CK8%0`FS(^:9:3%2!3.K#VQ)0%?!`J':E7TS\>8#[ MY``!`]M["-&Z!!((31#F89]3)_%WD()4GC)"HE80'`"1,&':^#!V>)RI:HP_ MS%9NKH7Z#`*O&S@H>SC$/W\ICMD$H8/^0RY_9`E4 M*A29*%UERS%@?7>U/G-B_&B!&`,LI-N0@F1+5U>WN_'?ES24Z"T\.<,CD#@Q M?2W_%RY3,K%-AM.)9I/G4?IZ?7+RC1U_,,'#U-IWD.DMM;7CVC_-`=J`J%R> M'WM^&-3^^BSH"9`R0>G;:Z,`FO(EGCA+BJKM6%!X'XDD,EON" MVQVL1X=PPI,^?@B.]]$"06;+O;C7!MP?_Z3J>G/@6/"G2Y[27G5K=*UTD5%A MU,AA6\QJ4\*2TEMO,AYJ[Q@R)KR0@3[4'`#1`*,*#!.5;>'P_5?5":\\6)!G M:%`I8,SXO``K%504J:79"JL@X[\$RH;5DMX&L!YA50#`&.K$.-7UC%B4=,=/ M&76@S%C6*<"P#43B'*JK+K+N&N'CM\V!!V^,3/S!_T,] M,4^!,/>=J\=7R[A^-T;/V:+C^O#A8+!6\<]_NQT8,T&5!;N;NQ>W`>CMR\TI M3.?U*SX@'--Z6DR3(,R"]=/3F74#C^+?5N_]\J0K'-]R6GPG88N&"(\.O=`1 M4+X,^%-A%;QE2Q\?MDQRES2H"\DV_@ZVG-!98/@![SB:/Z&K;6=:!%XE301> M:'`7VH/IH7[N-**\A!F7_"G'("6C)5LM>P%00I)SGO-YTN/G.Y2/8I0^W"+- M1,T+Y&)SL+3X.=!AQ[1G,F7P]/#A"'1$:D;W3Q^C?Z0;V"E6"T%/_:FL M61(+%[X&91:$#*G%7QN@6RK2?KGX[3M&L1DM%N@!2NVATM74(>W\H(M+"0.@ MTNP''DCW*J5>>)%V%!]R=GAX2P_^/+U_L(-G`4P)]C]+>@(HO1P94-1!WV$' MG01$&X$8$A"]"!`M'PAK-A"[TG$H@LX)P\'BM.GJ"*00KB/2L($L+=56+*VI MHK=E[.HYR5]$2X2!BH,$X$=0\":'F\4!DM^8%K+<-`=.`KXVV4")`!087[1, MY#;3H1`MP[>)DLD-V/D4EUTB<-TM$I<8A[7'2[O2`];8YX\%Z:K+P.UC`C"D M`1.,#LRSR!`X*@[$I4'B)F/F52*C5E`ÙYXAA!X/WG*X'JV&>L/ MFH"41-%RH#,7I,.'?]AJK:*IQPXUT+)KL6]3<)W68X=SAH%QH'W*X`"S4`7Q M8-!I8QMU:7@X0P9NPF_!%Q@48,E.,5?< MT+`^D($-;W'6(3O'BTG(-RHLPZZS,AD>%_^5A3*_XR9X,3#4>7?!6B$:,>[5 MG)1X*Q"^!Y9I#PQ&V2$KQ[T1VL'^(7=66,ZA.UOB,;$82D`N);8.R5M$GV`6 M-U;4PN\HH>_0D:;*T%.\'COXG*$ZWET4"Y-/F"3\XL:35(WN!;U1W`?`3T&X M:$B`AQVV2L[(E&R,LD=*-P<."T97!B2Y_&!1/&4%'1[L?:5K:HH:H@I((BYR M6T&2J++2]=$)XPOL98*X(P`<;$P"`ST/,'!TW!MK6V MQOC#G^E=?\\LUB2[:P[T%KY!^@+%JCB6B3%UR(WZ.&'?C:@E%-;L;;XXKVW8 MXV&FQZILV6SRW;W8W8"1>XANZ-_ES\VQ*9/5[6_+0'08L*'/R'A_X)#HPT")L#^%!4.-Y[TZ3P>&*X^)-X MY=>`>#+0W99K9;&@`2'C3-88<;Z`]6`/@+2@M:O>RB`T<+Y0>'4LN=]EVCI[ MWF4J8G,\T<4S57@%)J%`3,P8`?ZR@AS*E50Y4(81^8DO;YS6C5?$PJ[390?% MIW)A1)0_2RYJW/J/C+O1*R"9TNFI/8VW5\S?[N>)7]U:A?8.S\23['XRN";*7,$#G,9`0Q#-/.8]L-B8.&R:P``^"J8)09_0&;>Y58A+A^;+&,5`Y)=.P>39$#Z M2J"UJ6XNHL%3E%$ZJ$K0,=EGI8"8E2G;I@'2"91N&]UQ3,V6>9/APD3$KH(5 MOT'_\OVE#%+7RHK@T4/+I$TILZ"UD@(->AM81A0/$[1Q^3@TIC>(9\-SFY(C MX-]W40'[!FV,(#X4+V``3JB\>G3C7Z?\[A9B>]ACR;[>R3T2O#5TPY.9(]=; M^S[^314W.,"O@`@"NQ0(89Y(3,.T>,E1US;;"H<-%PYQ.X5?M0%=62QJ2PTN M1+*7V`H=LQ\*-Y[\Z!"RL*G\@-05L-SZ&#]X*!>GBP]X-8$T`UK0H M(_V*785W!_:`"C4PIP0?$)<6@V`<-0K=;BKK;DLEI@&*G*UHT; MR`(CCKJ:TN7R@B)T`$OY5<5(%5GARWS4G\3O!I.4R-7]T[9D5==X[BULGZA1R.@*=;0= M-^+?"Y%K8IL6:="?XNZ)B\4.O-]!8>(+DB_U8C%N7IRN.;!AN`(^Q.3(E]+T1[G6Q#65R%8!(+`(8B02 MIQN7!WUM2*[YINPH7=P;7-PB!PT]D,F>\H?QE).(PFB#/C[[9:]8+!3CX<54 M-A!(YLC^OA4ROX60^5*>P;G>TFUK.FZCF/IG2#^SUXK38/KY&8[),$GLD]/#Z0:" MM']+;6GKV?QTB\?S;+KINY1^\7WKU/S-^"#HZ/3RTA)RQW++5@L9"NZ#04LA M&$`4KZ>'/^+%!'&+A:.&;\7CYEA:IT,V$'L2L]GH.#Y&]<4=P7?W^(IP=3=V M.X(1=/*A!M3[*<^1;H^U+H&4$[H]?,:C(SEN?(^!['NGI^41E7U7@6QW0^[. M4[5IX3$N/E;9A:UQ4O\/Z/VRU,;A8>`OYVZQNR.BIW8H?LU7<,7:%(!>;>552."8X9R;:R@WEET50K2BD+ M4ZCR6V[Q^4.V=J+O'V1%Q5!7N;FRJWMK$^#)8E6XE5&!2C#SH.#@Z3JD63ZPLS'$M;Y7B3R<1/*7X'YM8\X=[ MU+!5BS\Q)S1(+V"AVMQ1FE0273'I?`EU$](W_WE@^4O<>6H'BLMX?E3_O(J$ MF6T/>GT6!DHR3&;QB^R`F1_NR#VO\K3,V@)1_7&_)V@AF,AEMGE\>H=<];$O MH!"E0E_HD_9<:Y-(^N'R<<"$*JA[M=$#!V+L)=+_::=A>];44ML^>9AO'P_7 MO2H\\E#6=)*BH1PB]+U[A`XY__\[:'78B847CFL.'(7G6;4'5.H5J,546X:( MHEG*H&>3V]'>#<6P^<`QA=&>@0Q^;V"K[0%8'-J0$TJ#G5"SW,@(#*K?T4GG M9E-58''H.PQ])=SXWG9X'+9&'8(88\GODH(E+;QP!:00>ZREHGF$D?2!0(]@ M"Y;%$M25K3/GQ.A$%>0+W>]*6`"<_ZE;6=3.<]-;G??U@ M:W9&N#N[]A@>9'>I]8`[J`O/-BYBTP7IL9]:X:9=#$ANN%9>FX*B\-@^N.2` M+S`]P4^J]&*[0Q'I05'A%G)Q)D5WDF3CYPMX(._%?K,/MS00P99?FB-18/\& M'+I5:C=Z!4Y5:KUB^-)/PW:L`2V+K6;[B=DAZ-SUI=JD2A#N`J3YW#&AD[$$ M+QA+PGA*VZVH%,C6[UN:P@]VXX1AI5`^-U MRK@SES=6\Z&.ZF/!C]#QW;N/,&#KH[R5XULYOMX+=ZH6(64_\_/LA6ROQDS!)5HKR<@1859&!'L>^#(R>H)5GZ$[P8`DU3% MRAYNE@&%$U.A)'/0=-!C&!S)T[OQD&VH`4;H"]9U]&:BVX1U4'$]L_@8/\36 MQZQYYJYT[;NB7:^@VSP30W+I^"WT?0^Y)AY)=K#\$Z9%H!R7>0?.EC;46NA! M46`:S)YJA='G+3>U%CM2E;W'$O+Q/4=L@3LTI:X&+U@LG\$U.51XS.QI2L!O M&ZZV.L)D+-R[VC%S0LEO@/68-J\6'NAB>H6;*`'/4$1X4C1`*7R<.;),1]W! M+\F!KWAAWWZP=VWZF2;MIACI88XFDSF`_L>:I?!(&>E*ZVED!OW$H!0,%&=; M[H@.BPD?=CQKF.1=IK(A`>RBN8Q8,@+_.U0Q08@LJ0FJ]9'K`%:=4==1#4+: M)R8/',$?O1"OL:9`G-\XH@#8+)[#%!@8TK8Q`(7:HU"\#[95`5T'%@RE\N$Y MMOK>9^<>CDDM6>F<&T:8/"/V!@_,U%>J&+(C?;G1]&]N>>G)QX+GTZ5">;\\ M_83:CC^DYL<"]HR('_(\>A$&'FL$`_S]>*.)0)WM"?=6LUE[I/HL/ZUW0HV<.E/W0JNL&T'EL&3 M?K+^;/YY*3H7*0-TNS%\8NZ8P@"JRP#>%F"U?.??+C8J&FHVR5C2Z[%M#)AV MCAOV[=FQ3(2[$KH5CI(9V*Y4[JF@5+?L8.9HWMKL%+D6FJ>-EV\^%T\MAYN= MK0-OAXKC-CM$A?_[\W_4NMINMVG$7VXW9T5GF[-K>C%6D'9$?,C%HE)?"(U$ M8>"3]XFL]U&=YT:VO$$LUV\?"D7_TKZ MPN9-RX*3@'ZI`7K;LM!]+BI7\J'RVO#[>HO)U3'C+S<8T9*Q&]`.M3W-L+=L M_DZRY:3F7?O:]D88#@QRSU8P:X=F_$J M>>7%2Z6$]TJQ2<(2*XXN;H>:9NTDFI7,.-Q!NGR7:G\M8'O$5ZS^AQ7@<-R> M,:PM3-^T9=W-T+:]:HZ4#<'OLT`6/^V`>1'E0)GT"4L3/D$-6+TP;M\[26$P M8ZDCT[D2/S1";V-;9]F-7J;DKO0CZ!9L4YUPS-[@.2?4@(>L$S<[DNKM4<8V MGI^&(QO,T7E(N2=Q;ITX!)8*^JV;:$].73H;Q8:;U)0( MAL(BHJPE%2O@AP?53(MW2[;@W"AR7W-XCU!B`"\MUI.AP#$R,SD]9T0[4.R3 M\9E;]L4K$!H<&/G#'BA=OS9`M/8GZ^*@>72W"]2E`9D[P,P<..;:7FL&"J4R M7?FI3&O,3E?1A"NIJ^J,*2B-)%)B@_8&Y?.-`4B`[]0]C M`W*-=]0BS&0>::W9?G9,#`R>_)W(M<%8"6J".\`N#2RVL(U^N6AN>`Y=1UHWT#M"9W0Z>/(71"P1=P"__W&D:BIC% M3JEID3AX.H4RVS/6W^:[`3^Q(WOJ,<>I::D`@W1,847*6&I8LF'K\K:6>_Z0 MK90K`O%/H3@T/UE9<5F"-[:G0G$M7(L6#Y^2#;FE@:1F%]WGV@-#X25RO"&F M-##W1O$;SKBQ7#@@9T<_'NP?`^.^6`\ M$PN!,G/()Y_[O)>;RA]Z776 MG8Q*S[L'V)XT&;L.9"JD!)IG*_!N4-,-:*[L>)R*,;.LQQ[L/AC$R=+/L889 MK[00&BQ4PV-R1'A$3AP.]JZXRVP?P#/7P+5@G8;YZY"X+AJ-(*'3?CM,R3`U M`'W7+N%AY;ALO-!@UCZ.1Y>9?3#.F=7B%_N`N]2P!`QFG(Y7#`NF7"4TG%B+ M!9Q3VMA9GS<*FF_S,^9)N-RR62RX##N!Q$(?11M[LU`K.]5O&;%S[@XLK#YSZ&''6O+S M,6S)J$=?K-=Z'-L<\BZ4`?K9;NDA3.F@T33R;?!T%B8`0P1GSEY_>DBL^S&C M&I,A(Q5/$4DB>K6)5"0N4M5U]?!LR5FBBJJ7N)]W!9$-*T.FU`DJE8GU=BA? M".20HP=*G1*[$#4&L!5A"F>!*Q^,.6Q3'[@U43P'.K9'TLE=A8*LP^0OU>I! M5<=M8<1(9V/>32M(.\XA'NGXRY#/-?6"XV\"3X^+@''"VO?@Y\;J5&'**EBYRAF31_9L9_=G<;;-/&/-$N\UY=@X MO@U]:%M_P&)<.T<4IND>O"1[P\3[E19%,X)9=I?7>L[-"@K$A%0CJM'&2])Y MAUNX??;ZNCE6X\TK7OC-#0C&RK*>TE3:E_X\#M2V\QQCY;\?L/R=%+SYI]L, M!(:'I:V'>C#R=+]892<6;+;3ABO`3'8W]#(\<1_V/C=#M7*],:$X9ZF#]>R8 M>A^NLT.%_GAS>YL]Q@2H1U8FC=U1?>/$DZR4ZQL.9J)\7_]8$Y-7_`J,WB&Z MV6[C3DKN3I9K&QS=:KDM#[VBWUCI>`=/L]B!YRZOE_R.%=59>52.B'N4SPYU MN$Y!99+-CDHN$(\[N&H0R"[U0\KM*1^/HX3LG<4RND8V,K]R(V/IMDJ'^LQ; M&DPP]9)5Z(<+,UM[+B2 M+;G(*>L=@9M$K5C;J14+0>LZT$0<1^6NXT#].K\NS4]6SA26U"\2.@VTM7YX M^Q6^?JB@>@Z#%23R%@(^QG_Y&0X34@^@4-+],Q/34."I!]ZP]T]N4"8L4+>: MJL:+4T;-);1\985M-V0O:;9G'($FK3$O'JNZ$_<5KV^PFQ4^`4[P:)P;EZ$1 MXDZDW(JL;%\*N*4\^Q2?T%@R)`5#!'H`\_-W%AI@87@.*_?.J['+U$J$^\:" M#X4@"`[("QGI(!&3B*TR!O!+O=%+7;0\L9`G$`?+!K.^$#%R'+6**3OO46%CM9[NL2N+)=IUL^GB#L M$1BF"@NWA@V%&>>T7\NZPB-?0W8S\ZWC+LJC&HP!U=-!RYG5C`]6OXH$-L!. M1]UX'*VEH>>;SMH#!6$MWKZF%8P1=R'A?G)Z4VU%0!:VX?T^XOM3QI%-CRY$ M5?615-5K_R!M6U#G,S,$VJS[Y2([LV$V`I[7),0,>`8#.^WR;34Z"^(1%^3> M"Y@]O):?^R7O?`FA#ARN,D7=._S!4]2V)??4D6DQE=X_+@U:C(;;P*;@6ACP M'SMT:ML$D1M\)W!*3'XO$.>>1Q0C&:AZ'`LBD5M,=B?Z3Y%>>.YH\_.A/DAW MSWKF[>>QR)H=_BP:GAZNK,Y@5X,-PU*Z8W:**QNO[M9`%8VJ;_ZQZ><$YU%CAM^AA\(S M&2I8BA?/ECLF5NU;356,S[1%S:N9I19/$SK=%7*T5/J>4J/CN-P-3.I+RNKN MHSO9/8PAG8==Y^%P+>!4BJWD_$GG_AY[[N:MU(HF73DCZ7XUT3E"_,O)Q]1/ M+GDH(LCTG^&7/;FMF)9E4LT(%L/&QVC)CKQQI*QD).4_TPB%`2[BB#5-0BTM MW./G9`$YBDZ"]8?N4AV)&G'Q<<\F:W_IR)I.PE[6QW1:%\JY2E05[$'SO]0= MSG15`'+HH6]UHM=:89KRX4>-1-S+@8T533//'K,#7=#B5@4MB,`N9DN,B`XH_'GC/VV,G#J6E(A/QKUN83VWSM-O8UGI- M#`&*Z=8GH[[5(>Q95#3L\!TW-CC8/8LTJ,DV+M$*TKQ3M!]X[\8#8RP`AC(K MYL!B!]!-3(9AA;5;7)V;T24OV*<@K),I\L`.9__"=JJ/);L+J\QUB.-M]*0' MHJ5A"%[SV^M-Z&5&!BM6KC,/8W5[(%G@L.W6,@T3(RO7EX%!)'N2PB_431$G M_&#CGSZ=9=V8N_3`#CX3.%L\XJD^#Y3J\[5A]C5%*I>*W[Y+)YX%9',3Z)N!K<5',=M/JB8 M_2CE>;EO0+;%$.9&7/P<4!5\?E[LEG%IA?N0,N,XO@$5)7)8('4F7)'>[JYJ M=%#]M?2-1^?$!57QAQY4=DH-_+E3+NY4:^QLFEW<+]5V2N[%K^5O0;V!R`HP M*RI7?&TLMQ4S__BNK<%JE*U@YW/-`F+T?4X>=5E,C^.6U!<$.CHY_G'7*:X1 MQCKX53J3-`S6N3&L]."V!%*%E#*>[]%&_"YD@RJD,PVBPOP;D?!TGUU,.ANF M#_![F'7O6*:'>,`E$@S,;_,$$][.C!YU1^?[J7M2[Q^Z!OK;!IHKN)GOBM]/ M_<'S-I@&#TXR;%/76K1HXJ1`8OK<9[':/Z4?,<5.5@[M9,>A%$.>D>)N:&7: MT"BI2?92H7YXB^N$-"$,CO'E(@_IOF4<[!V/@)H02@LA:?X36,^6?@V(;0\# M14U8%$XL:+#H`KK&`Y[H8!S=!)K%VL2N&I#>M'3];=4>P,H#G50-MXW%M8UK MLV/)_2Z]Q)_G7V#BN.^FD)A2UQP5>"8:"@U*\<,-)X0ZS_[RSY8BJUUN\;`@ M=RU[<%.G"],)E<^@`'[9[WOK[II&8N#.Y(XL4?H*ZVM+L9E^BGESP)6)0*_Q M?F1NI\_6;#!FR*"`SKA&IP=B"J3_[[\&]DY'EOO?`ZW#??Z^!8FM@';24-^= M(]U47O^-`_VO^P[/[;[W,X_HA;'W.*5&P8][M?U_?RKO_RF6_L-WM_^@!FPOEML?8("D0\/XA16+7",G*)C>HWP4R%2P^M11N@/(6CZBX94"'6[0?X/*VJ#$Z#\]S+\#> MX$5]RBR0$&T/%E1)G9@`?-5V3,/-2%:Z&@S<*B0E9U"K72^B%/8?%%:^LF^[ M&Y[A-9#RJT;Q=(I0FXXQ:].!F]Y$/D4PL%/!!EVPLWFITAQ2MY!8!(\>FA-M M*O3F8$#'D&Q+=,.PMDA^5BP?A\;T!O&\0>'B3_Y]%Q5*A[1"^&`L).Q^`\H2 M\.C&O\Y:AB"V;C$XKT43I4X,`_U*0JFD'O[NT:_CIEH6)HI&>$GJ4RM%K'JI M;1?]A$3W6W1AG"ULX2SDV%]V]SLIL5BM-PUX+;2@Y'\PP$=^Q5(UH%_P)3ONXV$E@-Y+O2$7?GAJ.=:5`6:&\&%[W7DS$L-/Q9 MX3,2B#CC_N`@8K9'?J2IXC!*VUVM[TU3P:.SNS5PH`+^+%0:=29!0ESAA8A$ MF@6ZPFY"8MO!$>*E]E:]V%!)(QT..O!)M&&+(6Y0*5>;7%VP.TK_-35J_^EK M&ZQ')VQR%IIM_'#"EU)LS[M76^=H+QYI9I_UH/P:\#;PNP'3_!N:RM)/VY)5 M76/.,-S:F-^.8C)W>AH8X!A3P]<"/S^B5/\DZ_(1['GY5--[_&IUO_PW2#:E M:^`1TY@I';/4G(`KTT6+ZLH.^CN@EW&*3.@&GD25._!^!X5#H+EGO3A1Q-GM M!5E@/E*4"5]*R8]--'@,22J#M8\DXG!Z\77=UX8F9CPV94?IJN2F9#A%RX6` M;`VFNL0@"*,-^OCLE[UBL5"6/<5ZE$HFG)D\P/K$&'>FPA=$1F)N,3/B6U_Z,C)+D)9SI\0L["(]-V_G5?D!5?>L9_`T6 MG^<9O.6:$DW]]ZU3<,/G->@DU.6!0>G1IZ;5!I5.>KX*ZKA<]_SGX1#__*4X M)C\:+/-L>9F;FG00#O:O`9HR&IJD`GN=Q%G_>$4=4!"P+5U=W884>??!H";O M5Q!.TJ/#'W&+?[@6!4>-8N%B<7,LK=,A&X4]N>/6D8I147&7\-TJOL):W9W8 MGG@O]9#ZG?`,Z=Z:,30U95+WAN$]^D4B363?H^M6A3$'%M#"=4'`IUG?>=)B0ZYA%C/']F;F%*5"+]R_ MY/MY*`7.=OTO5L<-J`G9D'0R:?,L^AY5MF-84)4VSZ?`JJ&X/JG`;NX7S<'B M>V'J1/O5;\77AH@O5OV'(F@H)I.[H7PY%#"TO17$R@"%O%7`H\SN;JMD6B0N MTT+`9SAQN$*KT7.5N\Y6OCS9$7S27:^6D-\2QNO_XY=1X`X^=OKO,7F\2'-[ M`06Z8;CK#&`Y9'4_\63>BP;HDR(7CA='K['L0^U"ZQ8D1U(=E"N):GE6(D6<"UV22TINLQ8:UW7]L]5?[A^?HW6JXGU"4>!KN/RSBVION MK8Z[83/;<$O16%X@46QP,A;9,>F`!A4/4B!YYJF?2.FG'7@.3/_`)Y)+P&-H M_7"F^4N6AXH28ZENDZ)TR#>>4.S;\>LB34EG+03ZU4T"PR5MI)1/X$0I&MGJ MUB^.I28=%\"A MY+(?W(?%[Y70)ZD'6H:IY@#O>5JC9KAAX:&8EN#(F!@^X7@(R(Y,0&?.?H=%EC/0D?9 MAUEG"+].2J(@_B2H%/6%W*3.W\X[2Z8S155O?QR^=3LI>!FOO,,9^K&P4H`AY3EX)"D M'_.4(M;5NDJ-L`2SVVZ"]\V<3*V-JEVA!#4_$=;F>:R!^MB? M@V&C8GU>T1TY@)/M[J'1PO]@_5D@T%;:?U)QD"CMA`[Q;K"VA\-Z\CADJ[K>[I!8_O0">2$1&Y;*#4MNJ?`.):[Q M;"O[WK/IV;M;J?P9EFRB5':G7?+G?2N/-WQR@QIYJ"6-@PL^7"W&\>4O/\]W MHW1U5A7&#^VGF%_JP6D.F@YZ&8,C!8O9J$,-L$'_,7:.#!2<];RY^!@_U=;' M;HG&:]]][140M#T7'^MO&?J^AQP5FN@,=-D*5P1`]7ZHM0;47=IVS)YJ313+ M<;NNL#*([F,).;J>\[;@MH!A[7=9$H%KOV#;-[.G*0%?;[B"P0BSF7"+:\?, M"66/>;4A6G@BC#D-;G8"/$-AVTGA`:5(,Q[+=-0=JA82+.+CQF;[$=FUY(-1 M5DM%!H!'D]D30/MCS5)XJ(QTI?4TLJ=^8E0*1G.S77E$I\V$"SO?-4SR1E-[ MWP!FT41`3&K'_PY5S,0ADVR"8H%F.$A91S4(89^0/(($?_1"?-8EJ#BO<40- MI[G]<7-5E-9-Y[:?*@V1L\,$M? M<3ZE'>G+C:9_XVGQ,8\%#[A+A?)^.?F(.[X\F%^%)CGDASR97EB"QQ+!"'P_ MT&@B4B?_X_&YM)F`__&G=Z;1D-^/V8G&UB+]#;9'3_?Q.8"Z\7(>V*H_&S:_ M/Y,.)W5>%LAD)8S;Y-EC&,)4;<#DQ&,C1 M@>66I'8H\BF8-ZBRO,%`3HAFA4K<1?MW6/I MI.@RX-?ZI.;QO*(^;!G?6EC\Q1G?ZEB'Q&BA14W)?]L-XA,*D,0-X@K6K4KM MQ7^RXG7^F:_'$=OM8L-F>\JDJNZD>AL#ZZO)_(N[6-+3[;`5"PAV5VZWPE$Y`]N5U:S8JQU,$Q6G&?O7)HK0!^9BH^60SYW++0(N-3N$ M^?_]^3]J76VWVZPV.F_^IRHZVXY=LXQ-L[23]2,N])6ZJ,[-N5,J$Y6%H[L. M7.*/)LWZ\TJFZN^N=\ELM]$]IX9V'H'L%!U$`LO]K[B1UY_T"Q(:_4T#]*"E MI>U,2E;$47+E?+M^8FSYS/7+#48,=A%/*>TNR^:R4%*0N!WVT MQ7,],!S1($W>35.D`G&4`LWQZ^FDXLD%..]8DX11L"4>] MPB.6C`$92V^0X?E1?)QXYX>HTR1J]2X5W%LW5YZLH0E2 MA"=5L6-FII.[E5BHD0]K@,ZR0HU6(#/6D\3`JS(S##UW0#O<+L4O1^C7QPP. MC)QI#Y2NG]X?+7U)D:T8/\OI;1>P3P$MJ\`RXL!%NZKXK#N3"2,\Z^48_;). M^%+_U;XRC0Z]PL;X26`"^M'!V8BB/*LKY/)0IM65GVFUACQ_%=`>AD>MZMTYCUDU=$L+]4&DQ=#R3ENW'4XZMJ/ M1L":=[0S].0QS[QVHP!D"A.X=W]XO2@Y'BRX((R-%FB7!9C)/#) M991U(],#=&:W@\=68?0"<1WPRS^TFH8B9MM3QEPD;I^.L,QVO)`0O^K#8N74 MM%18#<<450-/6;)ARU3'SX;ME'ZRQM/;*P&NPYI""S1"]4$WK>%1UZX)R@V M]9?#O("_TZM-(I!Q6TV$2A`0*C)J(QTUBA*&)LJL[&>@4@&:^2O&!*U14)P( M=A;#2FV.">J)6)"EZJ9G8"5Q?C&QM[G7Q9*,_#87_MZ2=GSAGV`.*:&6/!-- M`7R-)K7"$37A\0L-^?T3V#2LIA/@,EE:9J5,DACCSJM0.0AQ7!,/Z@F&G8#W MJD7ISR!^?^[R'E\HX^EUUI6**NB[Q_J>#!N[[GZJ;P6*=BOP;E"Q#RCJ+&B` M:E&SI-0>['$8(LN*!6"9.%[O(C18J)+*Y(CPB)PX'.R0<9?9;H.GU8%KP6H9 M\U>#<1UV&D%",1!VF))A:@#ZKAG&`_5QX7H!UZQMF-NPMJ\9O`*#7W(%[E(/ ME1ZL5@#D%8.M*4D,[436(0+GE-0'WM!0][JVQ)A#)RE,$ZE;@),HCWB>"9;<9H8HXJ@%R!I%+<,?$"Y1`-/,_AL\5 M\.`1&)YM@0'-JY-`0<0H3-=%;:W$D0MVHE@:!-&@=<+1F"FC`M5&0](XV-;/ M?19;TBF6UE19P3R_?0[F3]ITQ,22)PD$K^]=M/(]*EM-%7=:WFYG,D8VL1@* MEY>VU!EH#"43@U1W`M`4@BW3"U*X+6#!S_ZGX6!EZ+P.D-_OD%SWH4ZDH9I4 M))%PMW;1LPI6H5"0N4M7U MH/%TV%DBD6K:N)]W!9X-JT*FQ!>J>HK5E2C3"]LTZX%*M<0N1(T!;'F8HUO@ M:A9C#MO4!VZE'._8!CM#Z;QMO:-UF)RGRDRHU+G=FQCI;,R8:@5IQSG$(QU? M+FZ#+QT+KR*+,%<6(P'''Q%WUV.M^)=+#VQVSIF9N].3D-Y=`X'B%[;5@=@N MYWJ5WB+U=F%I6%13-[!RO!,%?P4AR?M]V!%8R2ZV[X99F5B36;W8;LW"@$7J MK4FE+V%L>%6SNRK/F[,=CTG^"TO$!I[D)K>[YX4SNE3=_-S< MGBI`68TR5_%C,LB.'FXLL$^&]?D'+!EVA+&=QX'Z:+\H!A_L`I#**K58PX,^ M>YLU/3U@(&V0X)28AX-:4F`HJ0U[#\ M]P/63I2"-_]T6[_`\+!$]5`W2Y[[&:L[Q8+--NYP7:')/I%>JB]NZ][G9FAJ MKOLJ%+0N=;`8(K-*PM6;J$JD9/*$WJ,R6:/K$S0NZ/Z-I4GM"GI.QPQ1XG? M_@DY9NGXY3N]2!"SW<;-F7S!+.DZ.+K5J7@L6;V#IXYLK/S75YY^QWK MZ[-ZN1P1-QZ%';UQ%84*;IL=E7Q''G=P32.0:NSG!]A3/AY'"=D[UF=TC>R1 M?ME/QM)ME2)3F"LYF&WL92[SUO:!XIWN/(1\9\%2GS+V`XSLS@.;JQ9'N'_L M/"A@,:"MVN>Z&RNZU3-;JA[^_&2U+V:]YU_@,(.P79GHBL";F3*_M>SGAD(" M^Y-'T,'B[<:.*ZF2*]ZRSB`H]&O%VDZM6`@:WWX[8.:79GNT$2K?&G(FLZE+<5[R.RF[J_P0X MP8`$;GN&1H@[?G/+\[)])N`=\\Q7?$)C^:L4@A+HCLRC'EA`AH616ZP9`*_7 M+U.C&.ZB"SX4@B`X("]DI8.$2R*VRAC`+PA(+W71,,7JKT`F%28)3BJ+G7',$#L'^*X]P'ZIN(NZ46@66P*\]+3G*PEJ#:[[A8E^ MK(GH?4FV61U<+7#8%3KY\BKE!I_PMG/.*%XU[D.JK4'9U%TY;,-RE@UA3+TO M75V`<'2#5+###1ZA;7>67':6$FQ[X9.80>'#>D?LH7^+?M6M6BL;=C.;[R) M)X;W7&&D-K"(1#RRBH">WW?I_\;\"()-4UB:`.PYS!ZG+5W6%1XW'3*5F7<> M-UH>^6$,J*82&LNLQT"P\EDD^`,V0VKEY&@M#7WG%)<0J"QL\?Y'K6!N@PL) M][33FVHK`G*F/3%)\L\0W)&P35"5'E%3NO9/><3&>'\&>?]I`OB2PS11929& MD`*1'LHW[_ M(O_+KO?.QYO[`WU4`P>.Z^WFH=6*)%,Y`YE^-=&!0KS)2<7T3RY! M**C(])_AESWYJYB695(!$19NQ\=HR8Z\]F2K9"#;/].(@O$PV0F3)%F6%AWR M<[+N'P4PP5I"EZF.1(RX^;AWDS5(=61-)Z$LZV,Z@0MENR5NZ?:@^5]J%VBZ M6S4Y]="_.M%\KS!-2?"#3"(NYL`&B+:79W#9@;9X<5Q/#!_8;6R),Q)M:);* M)S]>BH2.SVOT)-A*O]K)354V,&HSH/OC6?H\C9ZB6_U2$8BX M^"VL,V#SI/#85H]-#%B*Z1XIHUK6(:Q9?#@H!QTW2CK8]8T4K-M=.8'XL9A"%Y/WNN5Z:7$!NN<3EU"T]9">/GNPP&7A>A:`5,1+X+4C`'L__0D++LR.UR&FE_T$W=I/;J5XI]]E?M-"#22@` M]:A%@&V;6%Y%;?'`W]A/AR)9/+H'K@;W5AS';=VIF/THY7E1>T"VQ1#F%F?\ M'%"?!WYP[A9+:H6[\S)+/KY?&R766"#[)ARNGHJC:G1B_[7TC8<=Q46+\8<> M5'9<#_RY4R[N5&OLD)Y=W"_5=DKNQ:_E;T'EB<@*,"LJU^YM+#X7,__XKJW! M:I0M2>Y8JIO_8@$Q^CXGC[HL6,EQFT8(`AT],O^XZQ37"&,=_"H=SAH&ZWL: MUOQPD#_!X6?7`LTT,\X+\) M)C"T><(/[_Y'C[JC\UW=#5GP3Y\#79\#[4/=678L,FT M:-'$28'89,K/X'+X-`[.%+M6.;1K'8<23'F6CKMYE6GSHH0RV4M#^^$MI!/2 MO3`BR)>!/.3]EG&K=^`#JD`H588D]T]@,UOZ-2`6/0P4^6&A1[&@P0(+Z!,/ M>$:%P8`3:!9K$SMH0%+3,O6W4'L`JPRT8#7<8!G7,:[#CB7WN_02?YY_@8G> MOIM68TI=7$.H\\\X_+8NL;+G%8Z'<=>O!3;U;3"=4J842 M'&2_0[2[0QJ)T4J3NZ]$*3VL`S0%F/I%!)H#KCC(;%P>-1.:V^FS-1N,*?(F MZ,38G(.4I*/(157^0(ZDVX6Z]0_5W\(J-?8O`]CEQ"W9S-7/:[+<&OCQ[6'E M\OQ_8LMJS_6!!2N-+FF]"`VLR([:*F<_]W+9J=@DK*I$RF2O)WD7).;<);'G MX+PPM2K9J+4R_EL/,;,\9DE3XCI7,;2=^?43$PN5KIZ#.^8M6[UR.BVY3+6` M72I2GCJQ-'6T+/5$2>IT^GMV#3R@R3]@0L=`5W^U/08,-O,)%EM^42WSEZ$^ M:.^-D8D_^']^H%`[!0#PGP;&G9P9-W3Q\@&+?,%CQY?':;1^:6!H[(7^P%+_ M1,T5D-;M__L3+(+B;KG(B;$T)'(BW+CK7)R=-UK*Z.;4'%@YD*J2!ZDB8.=$ MG,;=W>M1_XUFX?CQE/Z;C4(#NQ4D4/'/?]=RH$X'\YOL"Q+Q[HVVMD( M$N69JL7P33H.2.!H$X12&?//JLJ/#Q8<>+:ZGHW?1PG-/'`4F@15&AWOE MNO%XK^.U8_S7_8MP5BB+(\0DM,((T7]I.W<71W<73?U..`EJXD@0A%,8\BAB ME&=BKA9=I#_Q*KR#3^*?YV+)4H>]HBB.+O.A((QB[0:.AQO4Z%GI']%F?8TW MA!.I))!(B5`+HXMSZYR>V.TQ/-1P^L*)4:X(7$IA6(61X!CN#N'BQ^W5Z+@Y M%JQ?".:(*+#"J/!*S'5J(\.]X4?HSAGRWJ5P^7I0KH@BR#2XA1'GBK3\X4?G MH3%Z;*0Z^IN^WP@C1P12<=OMQ?`<'K@Y/[DG0:WT1.M?@K;;"3B%D8`8[>X5 MK[61O=I*ZUE_%*^)E_?+HK@A'F1Q%DG_[>SQTL!K%_#468-E:ZVQ^(R%6)R2 MT6XYW:N7)R0U_G-_DH,/K"9(M9B`-1Q)G=BLS@^[_5U#(?[XXX_@`=0?[N]6 MZ*0AS!A-NS_))]ZK MT1.[U"][&*0'@H+(_8'*HD82-M`6MU2XN?(`Q?<4V;7QB&(J(QWS],;/+#XF M\/R,8L35K8Y^W9_\N-\Y^M5H_+K^+OT/,]6D4O]=HB28)7U%W*PN_,7HI!V; MMI/7Q[)S_P82]"30XGU+6(&$]20SZRR^N$S>4GD.*@>(*U[>B=@QA&X2"U,[ MPT1E414S<.06XBW$ZZ.'Q48=>\/-$U.\P-A)\_)E7FF:/.*$$5ZN984RPW:S M>OR+FX.]IT=\65R%F)\@WE>`,Z2%_1-K0*9-9Y(52[K0RXMD]B63)7=70+6T MGY\'8#4HE>OSRN6-0#GR-!-_L7U\C_5I]7>B[1 MF[DEYI:8`3E>7%R.;^D[F[[S6L<;[W2?H?VF&B'+/"Z@RF093>A@6SRW>*XA MGNNM8I:7$N91GKFYS.U:7?A#T;G:JQ[DA%/.._0Z$;%2+W]6(GHZ78JSD,QT M]3Y>V=\3K5*N(:V7Q["EM5CU$WL!NS`M=X)`W-2TB:BF/&UKFT(W]EJ$CDO. MI3FD$L`3C6.P`4TK$-X6;%&.5=I9!Y%>_"&^Q#MF^Q=X(>,Q-H:B7GL#1].Q M_GZH`K#/.:T0J1.3 MCS^"2CU`UO>W")3_"K%4H(U,.(LG.-@&XC>1LC.3MV=#'I*)RURN,9.5G)\S M]\1M5W8<`DFI-YN#00RWQ&?:;/@23TRKV=2EOM#Q76Z#9YZFM&[ZB3P9@=]( MS;-K3[7$9)@M]>8Z&IJ0E='@B3CREEN$BQ/:\=%R<\BG4 MJ<7Y:`O6YH*U<D]CQY_OKT/,'PSF"OERN3:W.)\O+"P[)9>` M=G'=D8[9A@/')8ONP`M0QOM7KPIU!+\*/X4 M5$O[Z5PZ:?DL-TS*]46E[[IB$BLV2K6*`+&QKBB7*KFQX1JI-'/U-$LCG!>? MB06D=+6RX-0L?6_*%?U*];=&/U88'6RB!I,KF4JE3Z[++.0^GKLK6Y8/K8%; MK[ZH:,S??;>EX6](PU@A710@I+>TSFRT;I3K.44GTJ074TS5S/TVTR`BQM@B MLT4F,S+KJ+^5\SS^3XRMGMNIF#ZDVA7;>]4#H8([,;;Z$]*N4B]_+MJ)/1'( M3N!8_:VROY>[!K?RF5@B%Y?60`)$1#_[N4#@>]Z]J)_.3QHC0^]AAY;K]Z;H MGDOEW:;;]._AU4NS\_8BMH%; M;GP3`3JO]N[FP'J\0]Z\>WX>=?KW8IOIYL0XDU#G1![K!:[`_Z_@$?RM=SH7 MIZ(I5"WMYT"C6-!S(M,#7&CCI!R?W37N[1?AO=S+]3R6V`38.9&G:;4?SAZI MN]K]U!-ASHM09_NOEI6,_L>[)(_/U0K@*5*GF0*=8 MR'.BDD'M4)]Q1Q@.+UO(Q&/11#K(@49Q<.=$HMX;N]V]'0T?7L=B&YJB."KE M0)\HT'G1!K?*4_IYV;[%63A]>Q3;;AXH5,]#&L6#GM>.AN/;'^]W'^>*Q;VQ<$4Z#_K$ M@)T3@4[0I'GKV>P"+.G>0Q,95S25]JIY;&-)T.=$K*.WF[,SN*V/&XT;2[@R M5"_G0*(PS'FY@[K.<^,%[C_J0V;>""?._EX>'J$)N',B$!O][KK7>'FYL,Z& MPI6@7)97%.IPS96?AB,;':VIJX>VK3KVMG%WF<;?/`!+C@`C@ M\Q<$RJ\64^*S2X-@^1.45`WJYN10DA58_;9&U:`4TW;HT2^E4MTK_B%]C;Y9 MDG;@D7+->^2;-%(MU2\B)=N2YO."3+R`E:6P?!3&P,O&F)V1[9=+>W_;4E/6 M94-1);NKJ@ZER5B8=VYCD2E\Q\`*4Z;YBLMFH"*$>+6M&;(N@2CKP*.VU)?' M5)7*4JF\AN28]%0007@15Z=DC@S5LKM:'Z^Y:B`5JZ/#"4KHLJ(-D:*`Y05?JE.";.!I,5Y"HAAC>U$;:N6 MI;;ND>D'ZE9A$Z*P[6V,PN;.OW2E*:IAJQ)GA*W>MA;SY$V/SJ?'8M/C:T!H"NR" M(;798VO9\'B^K:K,6I$``QTXK0",HH'6''G1Y2\P2UH)G,CT_:2[,29`A%=E MEU.#NK\+CL90Z6F&UAOT$G@ZU@R19'A$?>_#(F0631-_*OK`!EKL@I4-'P9) M,-`=MBS@2WT3@(>E&*0!EOF5?>QS7`>AFB[U7M M:6`S,9]HSVC5]V?5B(R<195H>>+&T+TU, M]D[,!$T\Q"9H5_II<$>[92--]39^&S:*2EB][(,:228E*?U,XP",*O*?3`- MW\D_KX^C*);W"_7)I0!O(2_2!AA8%FSJ`;>>"YO<8VS%4-'LZ$"3A!^KLF4# M&^JZ.4(`?7P#9D)0U7&N[IL$GAI]M<"&\_$GA6B^"\_2(1T M!S2/0C8.0`,J)@[MV54V<\6K,HLYN=(!D(!G/0`9@0D('N M&4>+`$S039]8!CQ.=>Z&(\1AF^JDEH'2J-BUTM+,@ MO>AZ\,^X%G/HAP\#_+CN4S(,KYE=2$'>MUQ.`,V/Y;X&:@A=MANX7_U6!P23 MEMD<>IX(:RP7.TR$!1;6P41`/Y\V-<5UL^ADS+"NEFE7Y6A1%5/.4S[VD\#I M6]Q:6HV=M%P+2>"ZS,D>FN'X\[>U[%M3;-95:#!W'#(6?KG.3S;6[*!@:TR9 M3)A2#K>>12ILKHTW%)$#%@"H[.]D"[IX\Z*W+X=O-7<;J!M%T`8PZJGE! M..FA2HG:^.:UW3B[4YZ(6-V,!5)BD,/S]!3(1>%*B9[!TF/@4O^A,8*[6"_D M(F-!LU@L2VFF,`&\E,@J1QB'A5%WHX\3_O1+'A.:!M58X%(BVG\\P\08]O^C M&^4\8PAD#);E_7JJ13D)6DH<;Y\_+N]?[CH/-P\9$_7'4?&;!J\@."DQHC^N M;D;OSF7C<7C>%A[.6$TG1Z-PI14U)^\GK8?CM\?WRXSYRXM3"G1 M8O*7?M[?-/IG#7@TA[E+B6`\=&EG\+Z!OU%;N+8NC^'VL]C"H(AH.1V3QL&6 M$LV;;NO^SCI&?:AW>MP3SJLI,8R`E1(Y2\%_=Y^;-_9=\T5LO;<,R$7`2HG< M$=QM-)]>7^XOWH\09SL,T'?G_A\_ABOGL98FB4G#EJ$GA$QL_0U M&'N\X`UW.'"ZID5)BSMI!Q0PY[-&SL#`\QW7Y0'T9R?'BCD[]#+L3RCYK]BTW MZUP`=_Z^DF=+CG5:":&7?]KV8`%EXC,(HD^+V-I)V*P&I50]*.P?%`O5P&I$[Q(D,HT]VY)O7A!(`3:+A6CTXD!:`2!1Y/0`4 M-6TH.RHF*U#035G@E5`M5=W! M7&AI)%M8F8R2&?H#2^EB)O6@CS_#8Y=WJS/'QM03N=.QU`[BT+%,+`AKF8JJ MMNR)7'#IGXQ=H#&ZRL5=_>J6'@@\CB0A%4TL*5*W2L9VW9X7'H+L<',`Z`Y M1N/O8A0^0XHE].J41`[3T52=$18\<*/9?5JY!6@]>C>I;@`KQZNYB3I#56K+ M&E?'619(>)A(A5_`TZ_&^Z4,&TC52RG9E;X^J"K6B5*!([U"='VLG86A]1[0 MO+:!"]FW2.VHY2^8!M7:C2P$KZZ`2N6]9%;J02.:V2JL'Y9A[3%(I+R9FY4O M*PIF7U#&":4_`3[.`"DBZU[:E.U1RYUR>AA3&#"Q0(Y9I@[F8V"&!Y#V*[Y) M8NIM8#I___,`_,*>_\47LW_S&Y42*-3VX1_@O0"W3%F9I4+Y`/ZI[PM:B5]* MNWM^]3:6HQ4D[Z!I*Y;6CZ1D@)C&EXF\E$.FR<;\)`P(/<,T=IJ6^:I:5$EC M`=)ZGYU)X'(%5*SB_`0NE0X*U6)%'(%KGJ!;A^7E%0V1-2KF)W>0THIL=PE/ MF#.J[N$6O>B9`U8C)8H6*+2NO"GX!3$Q_6CO+Z]*1Q*9O!2@2+:6EZ(X,:T% M8(L!*]!!!31GP5?>#X!'ZYUMF\&I9R`2HP7XH+1?+.SM)2^P)%P]2/B+-A4` M240HG(\HZ[;)IH1F`A8@;'NARBMM=0ZL2\5:?K.2N.3^3B*P3]-:O;!7J@NE M:2(XFZ1/K%HB_*0R01HK@^-,B(<(=Y5\'0-G@0L-V)M;O"H0"4<3QK%"LIL: M&[AE=KHR;"R\?F5;9^5V9%9($^O(!@H09=:C[%WI$&O2E M2W]+>WLUO/.-R37)[+-26:2[NT*$U4*;/428V8!)J72O[[-G8BB07^YV!KG1 M]&^D:;ERGM>%GERM9#KL!X;X4BGY/[\5>&U;5D98(AT/=&BJN.7+#2Q.#<)B MAP0"BXN9&'<"R_"'MO6B5\G\)P/+K8LW[P(H@XY<*54\GBL?H,Y<_\;4*3N@ MN/C2,681)`ZS*._/R^T3ZE(U9OV4JN6T:T`*+X+%/[==":M<"8>HA6N+[05@ MC1=KA3I8Y`F<7L"GF.I3!=N]LE^>NB;<9Y:T!,J52LAB2"OOIP[+_`H>R?9* MU4)YOSY=-%2JA?K!?H0,7.FD\B?N\W:F;0HVR^V:6V_5JQ3DG6JA4J\7#D"2 MSEYN97BN7*B7$I M^$@GD.\^;U1^4@47&N!H?*S+MOV[AO#/44\B5LI,+5H0=RZXR(EZ;H,O4F652-#:H>?.%QV9#OR:B M;\&8Y&DRTH].]J_%A2D'WDB*5\XL*U-'Q7H(ZI.!RXM:4R(C9B?@"E82K!X< M1"K[+0:OX!C;)7+E'-4?ES8UU?V#-:1X1,XDNKVF^Z]B2^P%GYQ9"6-TSOXT M!];Q(Y7V>C]M-3O9"G4P:3%1PXG_;Z*2G@B`LU/BD0KSG!AW\)33@'_=W8Z$ MUF*I8;D24D.S42`.T.SH-V_''\V+H7UQ<9.Q7&#L[)>%3'X0R.PH4Q$[_!?^ M`X]=GKQ>VQ?]M9ST!%BS$P%^/[Y^-!5:2HWWT:,BNG9F]0#T#U`_LA%@$L[L MN*,0Z="`XR86<1J^M!LG&6NNQG)_=1\4*M"GLI$@'MSL9!CJQT?-Y\[5"'^T M,_8GCIO_@VQX1^`3,._PS]L5DE`?73N=OIVQ7&$,SOL9<9X$,5B`BYVQT8`S M1[J[Q"VB?\OJ=HYPR%MX6C278Q/NZGY0QHN`,BW2QE7GH?5Z^]AXO\Y8#R\> MTW(U-:9!T-*BUSVYN6Q0]VZ+KET8&>=UBK%$=[;^MGEZ25Y6$HE@]*Y?I^*E1C($R++8YRA'2CS7H,SQY= M*T?"Q6QI+[68C8;65DT.K/@XW+E?W]8BHVGH0O-::D9)`] M>7=R^W!-.J9PA0@YN50ZJ!8KJ;"-A3$MQE?/??S/V6/C\;71%.O6(":NI6;B M"&AI,=0[S0=4&IO=%BZ+%[HAO!,$[CFE<>RTWLY;MS<92Y7'J1'[*6GBZ^2"Y=BVXG44&+DV$,"W*':*= M8].%T17>NWBG,<6+HF(M)>,F`YD6[?>F\G$Q.CN^.WU/%5:;R^0&@4J+&/W1 M)=K0O\[[-_>W^`09\WFLV%I]KY1*19H.:FH!=7\_?L95 M/%&WGNXE/&(]OEK/X@5M*:V;80*VU,;WVT?C8D@MP8@A:M6[^24S/CS?D935.2\QH*7 MV@J]:QV=PA-GW4N_A4IF$TWPY"8!F19IXHZA\7AW0W_=6;WQN7#YE`K3.,@R M;3(HXBZ/NH\64Z%;&56%Y.Z5`D!+B^B9,JXDXHT12.`I<7O M%M]_[#IMMA9ZMOB^69526APG@4N+YD?GI:/<,K_$4;?Z+;XALME@XJI51>W2E0 MIO8!7MW`S>[5\+5U/Q*O.90/#JKI_/5AP%+K#/>7E^^OQS8\1.>N^*\UFM`X M\%*;,STGPLJS5BU?[]6U\TQBV,V(I2AN*`)46 MM_/S$P<-(/WE871RFH/'+ZTA&@8L=5R-TNWV';MS2^$=8D,%";]J.6U831BR MM`C>G#2.>K@?G>BW=PVQ_=>S36`$LM3NKC.X]XR'Q:!2 MRYB7\=,C6;#&Q4T5)EQVU/'X_' M>42R'I0J^^54YF8RG&E1;_$VNLQ+\=Q_O&D(.&@1C'<2D&F1OG3PY_/Q_:43J)8-_?O=\W7 M-3&[(T!E.G\XONY_M$Z&GAQ`P9Z#<5-+Z_%,!#*U-7YQV6A9^L/C>_-JG1`- MPI5IDR'Y#8^UW5,X)NDZ7LQ6'D9=M9Y6DY@/YK04L>\^*(J4#MEQM-'5,(]4 M@UJI5CDHI<$_%L+4=@[<.E(ZC1[<(-_`J]BCJ+0J1@Q<`10/O8J8M[+6^FGP MH7_7BI/)=6R#!542BMJZ-35*Q5V_>L9:%KCU0/6G7\+YW_EI2)P#(AAL2Q&O M>*9HL4N_6/>&[>2LQ>3`:KDQAZPP4;E8K(?;U<@MLT\=[>`:WI78%/XT%&S_ M,U2E6UTVI*]^\,QL76CIJB679#47E\WQRH62VYIEJI0@S1J$P3$TU!L8[GH@>Y0/6;> MJ89CM2L=!JLWUXO%PE[U(*&)DML@$$@[Y*6J#UY M+#6Q#Q1\'5YRG^/DPDXVJM5C\,H.ZWYD8V^D4=F;)%[?E./"S5 M=T7M.W!7=N@1MQN*(AN&Z02_"P]096EXU,"RD7\57$I0ZQQ@BU?5\6MP!UOQ M$.JLY8[770G_IJ%Y)RCV8>!Z7<>O\OK5M&?ZK9GZP'(F8&#QOVS)[H,^0#/+ M6P*8D3YX!:DYP!YV[@U.3;^>MC\Z-87R"H*7BE3OW);:L"A"H'.PJ6L1)Y=+ M)`=;$[2TH=8"CK/=+DM(,<,T=CQ&"[`9(4S=C=PJX-BA#UG:1;8ME:MNEZIX M6`JLRY\)UA)PNH7X<`ISSHQ`Z7X!6::IPBSACR#%00VVQI*MO?/O^LP80!0Q M\E8.T17']0=5B4ND]D#7QZ'1M5Y/;6FL'OJ@#]1F!-U*[A5*[D.V_`\-4&5U MZ4PU5`O^>ZVJQ"@P1P\@)IA@W\>"<\5]>I[$'*_J'A&,K/#]D/&*#$MQ0O`S MGF)BC!8.KTN/CQD#^I;?54X>RII.[!,K-;DTI/7A2V$8M5PH[E6IR"B*C5+Q MKPB8H?Y];MM>@-4<.#;(>]3.HRW%"-.+`7;=Y;3(5B3?O=*TI'\%?W\RBV&1 MQ>".>S#O(HI?F@DMZ1/J>9NRUP]-MEES/514:%FY&R(,6//_A,71=_O,XON6VAGH,AN##]DP M+<##Y%__\:[`AMA180=5L%,R<*\^+N">(0_XZJ<-88?V.+\OGSL:PQ*;^`4@ M]5433R,)O61:H,D9@;VP!Z)F@$6&@[M14P7AH@:^PFA90/V!Q!-J%#`(28(= MUDH0\5<-FQ&=MS[E/3=2F5>2#FX8%QSAW<"Y9:L[T/`OL.N31?L5QS2&-D>&WY7 MMB(VKH,U[FME:E?L]RDFBPI6K"65^8X+#Y9K?\58:)/?(&>##'OL@'"@GN@. M[WOK[Y"%!%\!JHT[#PI($B`S/LEV.-C'5+T0U]BJ'NAJ-;#=;I5M4#/-$5F; ML(1[#+3OPO5ECWDV5FF>L?:F6Y=35U_\^IM5)+GQZS:Y7CG_Z`]0=Z@5\]!$ ME4_7G/',KZ.+3K52?]\C7C5"@%*I]M?*/CZ-^E$1N^2)CI\PU/CGIE82UI7= M$I-*F4=:8_HEM37AP]UK]NM.&T^R-401Y;4%$C$#)R;1J+A[4,_"X9M(^\6Z M*/"OG*#_%?U-8TW56W-3;.%*]5%"&IJ^O(\M-&OQ^V>BGL6TI1V<@N]2[:\% M]K:);=$'^E?P;.A@BJX%@CQ>V7)&8:>S[T4O2-4D!C%!G4T\Y0W$?PO19FN)VBS; M>\+*K$.)H$5?VMQKQ5B-.,6MK MXC=TDY^EZA1=JS)'1-VH:TH:*%&Z'3S()8VIG'!"BQEQ["A7A*)6+VZPV[&V M=3MNE:R4BLY>IBUHJV0E4VOK=EP3):NZ5;*V2E:*65LW)8OG+:S6HU5/3ES8 M`(_6]H!VJRFEUI0R'5]M-:5D:FW=4>NA*94SY=5L(NVWFM*GT91.!I:[GY,: M`A,$TMT=.IV]QRHI?3PB5E=E#A$N* M=.4AZ1E27P[4+?CBZR5\J!WIRXVF?\-:1W*G8ZD=6/,%^J(BVUW2Z8`'_1I& M7\K[@2&^5$K^SV\%7J0`/XSC&7Z:-_[TZ^#UL0X>7%)8';S)<2>P#'^(*7@@ MIV`F;$T)UV4(D]*C(JEVO"256^K(O5E@4P6D_N(G($32O3=:)6/"+KR.-O3< M_:@Q(D6`3!$^:!4J!_L%XK[^TLC0^9-Y)/.1'&W5EG+ M2=AN`)/O;C>`U9V%G+&S[M1K)4$/;&.Q6?+P:[V6ASR< MEPW7@P8@!P^60(%5,V\JY]D/]V!P_7QGHMP\7_G9\))<9_.NC4VD9'&W.J\9 MGP,9EV(?S=@#4HV090KGEW.91A,ZV"?!I(S+AJ9D]HR6P_COKIU<*!9]ALX.#+XXO)WAU;*A=KG<>Z6=DLUX;BLG?1;CL.,[`"(D]"?@_Q8[&Z=B+\4VVSA>=B<4(#-@WC3Y/F"T6L3J6RY M@[7645.E0K%>*]2V\6LKGPF0_.LY"1,"@5V8S%/-G!GGPQ2!9YNGV(J^%IF@ M)>U0$>8`P,74TK3+KQ`(KCDLS[X1YMX+:B) MQ&>Y39;'F8LR";(\#9%7.K%[FSFO/P)5G<3,JYBCMMGJS+]B[#=K&?)#(/>X M@E'<4"+6D7@$2P+'6D\,/_T4;A'<(O@I$12[`2U=FUT7,FX0G_R.NY$>*2,2 M4?(^(<:??DH_/8);GIUI9FTWK]]MF<1L7M%U,E>)J`U$/5E"_'8('[J%(#\_ MRI]L_6Z9.!L3K]^^IX==J0MAL\R-4(^6J_MLG#9E:[34GJP9FM'Y;#@G3[.: M@ATW&V.OVO#O@_*G7P]=WQZ3:H=.KI:[!?CE/ M4=<-Y+(INZ5B`I_)BC.0=;][QR="/7FN9U>S_53H4E7^WP?=3[J2M^R8R"V.6QP_-XZK]5],+]ST1W&W$E?.,=81,W?%HC3J1.+@$T0O)Y5M6@SH M3$RV2H),;GVEW7)<08_?A!X3#"*$I]>6'#/&%A"UNGDTV2"46%-?W/'/DE";W(K+N_5%2;V6F,4)B`U%+#32JI(ZMFMM MRY'KQ9'+LS"K-6E'@O_,/5MKHA.5%EL\FZ<6I;$TJW'%['X3>L2(H&I<)[-/ M0HZ-T9K7F45^>R&R733KN6CR,C5K<_L1EJ`C5I,J36^`ECC+U*SNUCX%9C$" M8F$>6A/$UD*Q7]FT?4ZL=C=5?JP%,R[/RJR5R6^A/6KS-*+% MK%F"CIC8SV@#M,3?^$!S81Y:$\360K%?U;25DKKE;3YJ6X[<$%.SGEW16JXR M5/O-SR`FM[7:`FZ=ST>/&-$C@*?7EAP;HRVO-8ML:1%8+I]9>FS,J;JL2)GD\<-KPQ^O):L\B6%EOS+N_MS'`1M9 M`*I<+!9J^W$-Z87@*&`!;`)9)Y4/V&TK6Z**Y=4\%^.FT33=)P7(]<].V*U@ M76NR;F7`IY;^#PXIO*ZTY1MM24I9J^O&K:,K:LD]1W_5B5+5G0ELRV=*(J*K66K)0*-'X!1G5D71H8@6\GP*;+V(4]&'O]QH^C?^+<+8';QCR0;_O`*_![H# MO^U=J0$4D7OFP'!PW-#G1YJN2\T050%"V4?)'`(E9*D/\V:V\'5G9$K4*`?H M)2E=V>BH.`'4.,_4Z0GXW#&01S;&4FN@(CBR\C;0;(V(-3('.M!/'L#H^"C2 M23,Z[IMA>@504GM]W1RK*H+7DEH:@.R8ELV&5U1=M8`>=(]]P5*1`@C;EUK- MQ[BIXL<`<*O#QF4?3.:X75H4_=4M"?QB$W\]R1:2(]K%;86@_3*DBX&A2F6V M5$JAN==L>X#\U.];YKO6@]G1QU)U=U^"3^I(8$;Y_L""V0!F&''T)-[B%`43 M3!_.;VB(\F[5&P(FK(;!'!^E M;FXM0F<_N/X9DP(`\&W-8B)`&ZI26]8L]E(!EV]+=52KIQGP;'-,_%SK M*PO%8FB?G.%TXELU?[D6V6)G[K"+[O*-7[\:H1`I1*>W^M[./3J!^OWBQMHN,GS&LA.P^UDK"NL/TV\SAK3+T9 M@7OWFOVZT[94V@Y`0-J.A)M]!CY,HE%QMWZ0A;\WD?:I_._7-K[.ZWF'!STTVO.I5IE MK33G&>P>+SZ:EO2OK?(M3*O8*M];Y7NK?&^5[_6A_5;YSE'Y7JXS]&1@N=H` MR@P))@BDT,1Q@B3S\P2S#0K00:%2JGBG`.6#@T*U6/\6H_*%]1RNZ,'X;=-* M'B:LY'7E(0(H2WV9*SUT'E#TU20-EPGF9S7!F>*Q?JI43N9,3VGEJ6Z"E4:_MY\%UTX`CGP>WZ M;-ZKE6J%RD%I1;RWL7;B)_+\_#2`#WJR[_R`64;[!$^>.>=(LN*`0N>,V0JB M-0K,QD(;;'1+M('4YLC>NA16[E+(INPGA"\M,$ZDZ$LT`HCF%Z_<#$CHFVT: MT8\5F!O&B9'7%]N$O)O+$UT-=EW[X9S+?%F:+K"&A"V"?VG&S@D_&4;P?/XWY MJ'6!2?X2F=1^%-]<2"!"4`B5#0OS0`;V262#^=_-\.H&0+SJK6'1V/:$.AV_ M!H[M@"V$-K'G"RW]+5W(QD"VQA)W:>0.E+B]10`,43XHEPKE`_BG'%>8(A\Z M9%;+/NE4%'?K<>TW5S\)VQU@\MWM#K"Z,^5#QY&5+LN_F(S]2;V$C@W1NKZ62H7]:J5P4(GK#+,F3$%Q M=S^N6.7*B+]5>"??W2J\ZR31$[S7TUT=>0FX#?&HU@NE8C73Z>,2`PP_]4PD M5&%=_21,B`%VPV-3[4CX<:^V_^]/Y?T_Q=)_>(#7?W"%_Z?QZS^5TG_#$]RZ`U1U2]F%;V(^ZCPNA,2_U^I5/LK M^,EE0C&%Z*&%M:Q)#4W.1(&+:01))&]EM^3_H&(7"Q-[S8D6[WN;IZ[%8AR6 M2.+B[D%=!`NO.YT74?"FU+"81I3T927&I2/O5^6&UW+1K5QD&2E/_\-,CY7BD6ASYU<'\/6,\Z0_GRN=]_:8GFL^N>_ ML4WL03U7FD50R)UD)ZW^^Y'R=O:F-[JPZ]UEH]G`;@5)5@22Y4JM*/3SD^O& M'!(&,.*-1E_V/[LU1+:&R`*&2+&T-42VALA&&R+5XM80V1HB"Q@B8K=8,=OV M3&WAMG%O/*A#U7@^N[Z&QZ[[.5@AQ3EU:L&8+(F$^,8=Z5H/^BGJJ=;HOG&] M(K,D!TR61,:+FTZ_P536Q^;Q&SR8BZU2G5/[%HS+DHAXUNJ\W%[:>NOY*>-" M3FVV"(-_?I)AB704H$AP_WMH.6VMEJW5,K>:L5_9&BU;HV5KM*P]G;=&RU*- MECFW5P'[]4S]8-B#*^/&9?/&5%]DHNN"R#E#J_B'\_OC0NSB\(H-N5&BWBT5D&*?LTC1='],4> MWGI#R^'!6)$%DP,F\Y/Q<-`9V`Z-N#5EMJ9,6E-F>_Z2HRE3VMW?FC)YFS*5 M_:TILS5E!)LR\^VNV7?KF9K"N'$\O&LV7_MTI763AQ4SIPHN#(

@-?Q]G-YY3&RIBD9B?>"XB^-;62-D:*2F-E#TA&M[62-F> MMZS.2*ENC92MD2+82)ES>Q6P7\]4%!JW=V]'G?,)J7N5@I.S-J2:*0F$9 M1#.4QLOK$^GYO?NWC'$XJ4]6A,&_#)*U'RQRM^.;'><9]5/\\^,E']NDFC<) M$_%9!C%M?.7>@`>N\.==[^9MO"(+12P2BQ,OFD"SM5&V-LIB-HJ0@)JMC;(] M2%F9C5(64A1BW>F\M5%68J/,W&"%[-FSE?R1.;8O;E'/NO@X?>[K>9@J"^H\ M0O!8#OF.2-MO7?6N*'(%'NR.L[2`WW5L`F`(%2' MB@,[F#/>FC)+4GL7UD;"!?A2OU[.]G[&UQ>'/JD@LZO_X---O)37AKU3>B;FY?I-(F!QMUI:%?5RM![BY7:J M%U/,TDPAE6D0$6-L$#+K+V"37$?3>\A_"OEQD,HME+];?>,(F4)7V2C_^E8@ M?QID5F:D+^8ZRLVX+1VDT3G7]?P;!,]>7JBLD3,5?_CK#V\/D?C<[EPDCE,!?6(#Z]5-ULJH/> ML.CBRY'F.5HN\])\O4Y\UQ2LS9"O\T4&1=T[Y=RA6H'^\7] MJ=EMV0`61H[AZ`YNXE_G)^TKS$"5A@I7E[.,;^MTWSN M-O&&(KQE4OD`%YH02DP"*XP.]]<7^/L9_X8'7\]>'O(H]5.;6G4E$[3"2`%W MC-&3\CHZ'AM9FR5/LL-.J2:,'\*0BI.6F#M[<3%^T96;WH6`'.`85MC!."(Q MHG(26F&4Z)X8]UVX;3\;;5QY&5/*8[BA7A/%#!.P"N4'?OVUV^I=CD_QBN#6 M?(PG:@?">"(&8F$4:5-AIQ>X#(\]PS^]1G-\))PY]O:$<4<\Q,((0I6:QI3C M_/CQ>/&D6&=YL$=U:MVS+-"*6RPPM--]8BTTSSHHHO'22#1S'`A4-A-`%D:3 MNZ,6C68?0!^&VR($PR1$# MK3!*T!^7HW.X_HB%%*S;IXS%'>+98D\()>*@%;>EX"_[NF%3P]0FJQ?1$KZE M5,7M*+$`"U4ZNL1NRKE^:3^TK=P4T:HXI2,&8F$4Z;]2F7;J<$:?Z?A_-;+V MP(MAE4JY)HA59D`N5IP\G3=9T1_\5_/]]$47W\Y\!P\HQI_A%N/PGE&H&T[#6YAU'%8E[;+%U;&![>Y!WA:[^1BW(AAF428A5&E M<>;]5.C?Y&QJ'@^%V[^E8KU6$Z3&)D,MCC`HLO2Q@D\T+IIO5BX^,D'DF(`U MG@QS^^8/C=:3;&&DGOW+NL?/_,9%J`YJP<.:^EN+1:WXYUC"?>?OR#?95YO1X]W$(D?\ M_*H?I<<"`4SK7QO&F\N]#9U*'@E%\D'L5*X^XEZ(6!`4BW>0\?W42T%4+&'6 M`5:-P*9/P!;^+?Q+@C_OT+2M7-[*Y>@$A%4-TC[<,J:3^LAFHKCI4[3I\&]9 M;/EY:5M1+U[43^'C#!6?UPO7Y"7[^3$\['0LM>-VK/D$.&[LBMMR83HN7-7> M$H.&F^F7`HM\MI\8&+V*\1O/3E.V*$OMR9JA&9V-1S)Y(M7TS+8I*&J&8VF& MK2F?&,?/LQYC<;0=RX1E&.57__)G0C8STZ[17D9=-M*T$UG:3I:^X\EZL=*4 M?0R/X"U9<0:R[O?IW&173<$/UN3@,^/W65;CED,W8=/*$/]`R'W) ML+&M;=7"U!Z0;1NE*7OP5^IF_2W]PM]2ES/FERW%%J28(,FU)>M60F[7\-I2 M+*UB\7G"%R,#++Y,(P,LSDRB44@1*K-V.'R":=BBL$5AV2@LV1*.+:?L*X[% MW>%(I6666)ZP/$N[Y>R5.S>'`!,L())CUP#_&0.F M#:9;9Y2WJW[+].O&]$(VVXDY2]F:0;@3/U6;M8SLDMOQ9WFWGEO+B^5.2WH. M63HFH==SC_#>KHXM2PD&?DG65+7F_]H)W5AT6E:I;I12+8EUUCC2V%G5\F]$ M@!A)4EVT!_0ZX[]^*N?Z3?GOM^RW7/\I#*W:HL9Q7NI7-4TSH_50)2=WP.IN M;3-1B5G5:3GDDVO%2YZ F#F=RT,4O\4]I8M;+_*V1CU:H;9&.5]\0TOEL? M96-Q&ZNRNR^Z6^@Z$R!N7Q+&LFN`__IIF^LWY:7J7HK>K9^*!%NNWT@;*V6S M7N'J5ZJ&L>NA2G[NPZRT'/+)M>+E3D,I>VOPM<%ERU*K-;3JPM24)6@5M=_- M=SVYF=06=TQL,@%BY(4XCET#_-=/L5S#*?]$\YV"WS_5>E\_?L_%D*JORV%5 M*55<[7KHBG'Q&AMSQC-3[4W+(I]<[=TNCRU/;:HI)2R6;!FFU/9DJO*Y5*LT MIM1GBGY7IMZ3BYY<.65]E2,2,W+F&IK2\1TWTGK3#^/'3;BL+UHN-V$6_P(LZF M:"7I>=/A+(<4+P%JY;R?R\%"6/33DW[#0K%>2R&'LH,BSO#8(/K'QE1EM^6V MM$_#^]C8?DOZU8B=4K507#AA:TM],=3?JZ=1/;?4%R9VLN>1;$F?AO3[]<*> M@()TXHD?T8/93[FIJWCE?_^E==Z=[P]*5VT-=/57^Z$K6^J1;*NM8[/75PU; MQGX5#XZIO/YBK2L.%4<;:L[XT&@]R98E&X[]R[I'NGJW&CA\0WUWCG1X[]_X MV?^-^TYSZG>2QW]1+?.7H3YH[XV1B3_X?W[@4Z?:4'VQ6P\O5R=G=T]/MQ)V MAP%8[M7V__VIO/^G6/K/A6P,9&O\GW*Q5/Y/X]=_*J7_G*B*BAVFZ-J?TL#0 MV`O]@:7^*;541>O)N@WT_O/?6(,LGFY+P6<%Y!S?V-WKU][)Z_W[1S9R#NQ6 MD)K%/_]=K@%C+YF<07Q60,[3,?Z[^Z`8I^;`>GI0AZH!S^!%XF[?P@/+B7+;M/*1O==E\&\9H!20=-G4T8!IXT>:; M[%FC+5KREE8A>A-P6P&5+]L-^AMEE`Y/OMTB8",C!Z=/M;QD*B?AM@KG+_Y2 MCFX>;J[:^%MW\I`1]66[@">P6H4C^/T%)]@^?L/+K='IS:<0$9-HK8"V;SK< MN\95T\1_G;9(6VS0OS\#`T_#;P7DMI3GZQ'.>N<1X=+OLPFD5D#8 M^[Y!6RU<;SR^D=@2+B6JQ>4+B3B\5F%:V!\7)^_M<[H`3UKP@'#6Q8K'R[8M M8O!:C;_L_ORRI0_QZLO3,)=#N15(ACB\5G$:=_6"PO_MMF>]/,/-,]&28=EL M.X'0"HCZ>OU"?Y^_7%T^G/3AV1PX=NGR=A*K51C&]-?;$\[QX^,1;JU]6D)Y MR(1EVVR)R*WBO.UBW'U\0A"./\[Q/ZT\*%Q=]FG;!%8K(.U)[_S&.6O!`S?"3^'W5J".36"U"D_#\!BVTO?VJ].'AX0S+%8%7[:7(831"DCZ2'^-&Q^M M1U<3M-&4^0S2(`FW%9#YBHY'Z`SJCBZ.&OIE)P_A4*JB1V?)E$Y&;S4FA7%_ M_#!Z'5]W\$;W,_#R!%(K(.R=Z7'SJ1NV6UK?/'T&4)S8A%;`8&/\&2Z M#?='3Z_Z\UM&]^-ZB(4H3JL@Z^O-];\'`>P0M+EQ%Q>*TD_/F^\=C%KU^2!9ZQO-/J M/0P3"*U(=+[#$Z%"$HK(&JWU\`CNSY)HQ/XLP=/Y!$FAE6J METS=)-Q6X0\[?WHB,!XZ!OY6'.'NA7*Q6-O?7[97;!*O%5"W_3'L]HY0]K\^ MG]AY)+'7*TLF;`2E%1"U8S_`_<8=RONWIIX7=+/W./1VT%1/X@<&[O/\[> MW]MT=9A'8-.R63<&K55$C.$OY%?21<>C5,J58M+3P*.1VT%-#YO MWO>,C_;SR0CN"/#SQE0AJZ]`:YA$:T4>L@X&N-O#\6G3@U@=0* M"*L\7CS=CMHOC>MCX147]NM[2R\D'<2'D7-@[W1DN1^$`+_5-?66:MD_W@8P M[(WIJ-%/>K7HTY#EWU2Y'TO:2TW3@@\A021%U?6^W&II1L?[;?=EQ?W-"_FS M-W:HS/]WJ:G+RNO?DG]1E_NV^EUR__I;:@-\.[;V`1=+Q;[#+[3EGJ:/OTN. MUE-MR5!'DF7V9*-`OPNV:FGMO_VN",5BL#G!?&VO^+NUG'HY-'[=)G7)^O'> M5Q5';4E#4P?VT6$*9WXTL=WX?)_U*%6=;!ZS]]?BO_G6)4M>V%2KSG))ED!7[C7[->=-NH0&F*AVHYDR<[\Y$SNASQ! MX.)N_4`$`Z\[G1=IPW<"NTU+-5K26%/UUMQ$6;@9S<1D&)J^\%2D_6KZ!C"9 M]]183<=]^E'6!Z047`P,7C.4;_/PUR]6JW6J$G![?_WV?CHD4Z`--\_$'U>7 M=DN3F7(Y(I`OP=[NG^AO9?B,CW>&C]D(-HYH@I/^^AQ!SY=4S<:QX[Q8E\=T MI2W8"51E!Y_U25,D-P3R)5=[?#_LV&?CX1MKZI+_T7MNH$\CU*R/A;M;;2V* MK46QM2BV%L76HMA:%%N+(JZE9*IM-5]-!GZS\L.C5RK?:+\U&^*/`/.U*V)Q MR)=LO;LCA=2G^];%TSG]74)0;UZ0QQ_[S.50<<]%MJ9%_EKHPNI!UH[3[OOE MZ):.3S?QTLT`9U$RVS1D,SKB_#"F[<>=/XI/*CX)NK\\5"VYH^:/ZN87!6KQI9#:*EO>EV()W8^?OKDW_`E=H2=;'$$SE4J%\`/^4*PO*^>S`I%6" M/MD,%'?K]36D_58B;P98:R*1\85#QY'182,Y)IH/0]D!,T*7%;6GNC93&MX6 MOVB3I6%AK[I?*-5KF1>DJRR/`ROP+AQUB2U_MK:&C^%C,`*G7>`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`Q!V=[&A:F\/>0Z/K6B]BBX*5 MLN*>"*<`&K":8B]DKUUB63']MM7.AG\OZGRO9L0_%D8!N,.=V]NK%EY[;3O# M_M,Z,OX$D`(0;[8Z[>L3X[9CX&HZ$HNV,&D7@5(`WB/RE3TH#V?GQ%)/3QE/ MFF)P+P/FQ3XM:L;`GI#Q>H#F:5>(K`""'%_?_%V M#1<->*1_V:-6Y'3A M")X[=5XS>EIR6^FQL`J@`>M1C(D@2N` M$CC6Y6V?/_?X_-9[O5Q'@1<'IP#T7^FO\[R4'$Z=6S+X88F$5 M0(,3PWBZIXWT\NS]$0W(C!U^!W;K/Y-48(9P.2,18H`50(++^XMC^XG,B=8- M/'8L=@_(BO0$>`)0[AUU3A^/CE_/NT/Q9Q;%W7+6?2\(GXB%WKQ]O+O&OX9G M5T>-K($_$8?93H7I]9F7>!1*`9C;^OGCJ(TKI7\_ABGF[[#6*L[$%1B=MZ M5B]6%%(!R!_W^NWCE_;%B:$(-NFR;N=!R$09,PXC'`NR)8\`<9$AV(X,)`B MO+6.TGA^;C3[5B='JZ64U5L;@%*$N7+>?Z$U\W[,]803UB)PO>1<(I@"2-`^ MNGYZ/5=H^-Z-G9'?\Q%S41A%"#9V:]A!?TCO4GGKB(U*(4-&P#J/@5/43G=+ M_^XHQ&'TMW'3_%A3C78*Q`+H\]_S<'V5!1C_DX`*P/[NV7[NP^WA^ROQUUB$TS-IXI0 MD,-`BM"(^N_&S?4Y#\SF=F=^CB_>[CJ9PSQ$*T1 M3$G(E@7?[W>P^7.X]#"M=1:1YD7`Z8`Y*][H[%SI3>/SI&T9VOI%HC`*"9, ME8)"'LX;#Z_C,TN`LAL3QB/D<"L.4A$"#RZ<-_K]Z]?7CZ.,QE^LF-_;$[#3 MA:$4@/:Y37\^8\@S_77>TE%IREB'(J?)3X16A*+?0.+>?LQ(C"S]9\(JHB$C89Q/#RBORXI@B"O M-MO"`!2`M*M$/PP?X;EG#(BF3%&Q^7`X]^7][/R?"*T`2N!-=*(\PQ\X9OOC M[O'\3(CR&R5%I22`%LGPBG",*\[-J]4_'RM*1I]/3IP0!%``OE>7KSWF1<3+ M^N.X*;9&G;!9CP%4D-7O=/7[M\:HT3TBMA*.OH@C_TDP11T!C#\H#4YO'L.# M_LF3<"K4#@2H@E,`%D"/L[?3CBM-C`>C<<$O`HY!8N`4@'WW1!GAR*/3E_=>ZT$XY@<",(_`*.K,!W?0\P8K MV`*/7CY99QG3&.(\`'N"#GSBH!6A`9_8"EQKMTG"6/0INBF\.D)F53@14A&6 M\=U)#Z[!`WB9/]$:9PR1R4D2)`$KHGB!<8$K#2[?OMS053I5$9#3&;'^&QFZ.SC('P46?)3AWTI/VB`'])'*R"%$5*,!A=WI$AIKV/ MVV>"RQ$C%UM#P"5!%Y+K?O9,8 M?M`O'I4^DEBX0-@7L5M.PBE*87@BJ3*\@R>/&\[+2\:Z+G%KH")B"<0#*$L M.J)!B:A7]!5\TFID5)MR(T0BO&)\1SI+JNP:=#)SHCQG+[Z7FT2(!5?0!MEX M?2`ZW[6&W>YQ/JZ$4JTB9H>,`59$U1NG8=^_O&*IN+.WAN@2Z=3N(%`F5!24 M(D3"4QL/Z5Y;;W3I!6/1Q",?K&HN$E(1.<&,G>"9]MG=S>T(KV5,AW+Z[/OIX[%Z<-#,S?WS$H`@.B,(IPGF$HO0-#?(/N/5\M7.('"X*\!Y'@!3!Z]W>^5'GW+8;KQD-P3BF^]*TS@CX2'^D%#(1$>A%(#XQ[`QOKFZUS&^.A^51L1L1Z$4 MH]F2R.#;Q8OB7)_D$1X1+BPM%%H1$2*WK^]W=Z?.\<=IQGS@^,30@U)E/VL@ M9!!&$4Y0O3%6SNX?FL<"S/O\L(Z`*0#QUOGCXPW+.;3O3JXSEK3*80N/`B@B MT8-BJ4Y8&LU8:=_=B3_\*%<$&&TQ@(H(](8+KXTS&A%6+#'Q]:Q?=\Q[CXRAG_%6RZ5 M:OT@ZR87A%%$8:?'!BVGD\9MOW'5RVBPBS_JB\(G0INCOWIMX^KUNL-.47/9 MUD,=KT0"*^*L]P57T'WG\JC+MA):0AG#_1/,]6*Y7LK*]0GPBLCTL,>/G5OO MTA6&V&8T87.D0RRT(E0`N'!R`_]JOAX=4W)!QKJU.6@^,3`*P-RZ>STAK8(= M%.,E"K#(>*(3:^35!(0`)L(KZFCKY?$.O<+.XS/>>Q&O`8NA0RRL(G0`U+'> MSH\Z#;;Q/&;<$N/MW6I=@!XT":J(]3!FJ0;W1Y1'ZU)Z/,HC`[)4JQQD385+ M!%A$__S04LZ>^28&YL)0O1DJZ,9WS6C M"_>=OX.0^J"RJ9=@[E4[`G,_#'(0AU`K^F22Q5-)[O7_-IIV?Q[*)#Z[-`B6 M/S=\2AR<$LE2^Z;EJ"VII;7;JB6U87#)Z:J2W#,'!GHD>OT!WF^.);G?U\>P MFNB^[X#MU))&74WI2H:)["XU54-M M:XXM=>4A;/"J:H!RH>`&W9J37L*$WDS6KM3W%^?L[+O`DM"LE>;ET$\GB'^\ M*ZIM2V8;#.@^L)\FH[TLF4-0F15F+8..:#LP)NBYLJ&HPH7TPM.80C17\I3+ MF6=D%:3Y6O[=A+)I[(!H'2B.A@:5^MY7#7MNG6-YHK;TF27M;RMG_S$8[ZDM MV.1M5;9`#Y"-%DC=H:J;_9YJ.(NRY%J($8]MRWM;&3MA"E;FM02%$&*=I&T# M%-R`M$5?'.D5;"=3RR`=WY7`?S3&*JV0W(6C2_%4EN: MLTG"Q'T**S)-%14_]'7`M=;:ENU MP-HELU>V;15N*3K\`48#"W^BJ"=S8"DJO:/"")9LC7GDE&HHZLQP)W=JMK%* M\_'L-E9IIC_9#5-::'O81BAM?H32DMPFZ:W^_'PD:4<2-M"&X[9V.GIHN"M5 MMM6NJ;>DG[V^90[5'NW3>`RHO@TT.@3,ZKM<<0A<:3,/`7,(>YL[I.C3'?W% M1K\ILF6-VZ8UDJWUBVXK%\I[GSGJHEPH58OY(;7>4O?31UZ4"I5B:2/%;I[D M*0'/_[;1%QCK9JGM@=$B@]P_\%YS07Q0JGYB,;Q?W%N^$!;+<=OSP<]P>+4E M\?9\,.VKV_/!]=S_9VC!FZG$>8I!M5`KUKA(3<8<%"4@C M=RCN`XF4$T9#.!KJ7VD&V`PZ)N, MVAW5H.-N]GI[X`PL>HL.7_@@$]2W<:Y801@@*Q`Y/O"RJ;+7O5S:7>DZCH@4 MQ*ETX3&=3CJ'<%'6D]#1-393&C"IU+?,_ZIT0!H+>H&.2_&MOBX;!F)A.U@; MKP-O(Q(]^96A!M1A3(&P[4I'P#HMB=)\&90>B0!80%@#C,,\T961OIBWIAG( M.3CKJF$..EUI`-2P'%DS@+O4=\UVL,2?#B,.52S1%V#!P$>2IU)JRKI,!(:7 M><8<*P_8[^N!9#H9:`+\$[M&*<1V8O6P"I;]H$S9V+#8J.[-I7A7Q6WD__ZL MUOZ,UY*FR.')(2(R>LE%(T$0`,>/\%_'P(@M#20.\CL&:`'3:+"&C+B`%N2- M/CST3B($9-67_4+EH.B)2.DKR>P=ZH5[<]ZY_H]'AX5J]'OMPM;(7>-A2 M[3ZL3>!R?5Q@"Z(GCU&6$:,"9\L=6!0VK!/9PK5I!T30&*[9N](_CA9=%[$H MP?*U!TT4!;@H;)@$RBN%A:%K/`ID%*V'SCN[SM8[]8R=48Y&Y_=320I M_R+)YB858]%(/#959X2%L,K%\AZ]4RY6RKO28:B`0!+\2!@:":MIM7$;@4?' M$F"`WQ@0%4#VA]>GJP>T0DP_1X54EX-+V1=!J3;?>PM"]AF6YZ$=IPN5"\0% MQV:O+QMCV#9:L,,GACR@]H*1!9.K;;]8":PUS)VF_?A+.?`PK`J//37DS-)> M`9XH5:8]L@^/E`ZF/G*`C^S7ISQ2+M(C>],>*3%Q4@)\ICQ5IJ<&"T1",96O M4*W'D:U2J-?J`<*--(>JVM%7F9QI@5#\?5::>,A6LA&&=79>GS"BKY%M@.HT MUBJ$'>*#E"NF.BD*EE9&)1!U>53FJ*HA:E!C)OW1W@#)O.6,3>(,S\_RCQ&8 M=*SP<\1+6$;<+]N)W8R);03VT):ILG6-.P!H@+AQ#H+S'2I9"OHA5_P":B(L M7>`N']<\ M9JZ=`2BE%KFUR!HTL'<#2"F+^Z4DV6L($_0(86EF'(T-W>)?VI4>X.NZ;#'+ MVR>;9@<&5F'RJ,0=T`+IB;G56H^5>V;V"/V)[^&GR(+7F!%/=9]18O9EC;LD M67XU>=/(C+$'/9A,F%D["`&QV__LETM[?]L\[QO'#A*=+5=\!^^0(X!]VU)[ M,DQHP-!7_37-C7K0]2)CQ;NZQ'>]P-\M;>@N"05,$M6*^*,VQYEV$$HQGW[J M&#X@X8BG.BD,B>Z+X#Q..R6+_SY'I!X^9YEUS)(>#_>#U<0O2@E_3NQ74Y"- M/0I:<&J"T)VJZ-S6P30F?Y>\;.HF$`V6:)'$@&G$9GN()L.M[]_;D>X&:E-5 M-I02\8+J7R"9\/?__FN>_E_A3F$/_&CF5_M'N\UV+._E>]E1[T'1!M+IK/YZ M`S_]NW82D^!_B9PH2=[M:(0&VQ5+]6*86T)OI"["D=O@D;/\!;Z3N1R$)/G# M3NT/%/Q^'B"5EX;[LHD\46I#',/,)EI(JBUM5<7F(!$2?B7X*<'`U0 M6I1YYPB_G_B2P!O MBVT!E$R2K()M,=ZNU/<%L'9JJ9\SRK72H@RYB:(X8\>?]$)D\9G**HHK2Y## MV2=EF63Z6O[$(G>.!C\KD"JQG%GZS'+T=Y"BJ:O*K*E@B.72\MY6@D8)5:Z4 MEH?_RF1IVO8]*Y`VL9R[\XG%Z\YO(%YG=^M94_$0[Q*H[7TVCT"^6FJM(I@V M:Z2F+M"N9P7"92M-V^,3/S!__,#I^T4 MWGTY'K[0#PLO7[3AX>99FB@<:6!H[(6!#=1KJ8K6DW4;8VW^O5,OUO[W7TL# M/S]JT1^ZWL:_G^B'`\\W3LV!=2*>:`?5?(@V#8O\:/?1.KLY:MS?:/`IYTT1 M3:Y*?3\?:D7@SH]`^`7\;X==@=EXQDOMWNN1(9I:M5).O#4-B?Q(U^A:JGJ$ M?SDCY_&<,?CEJ7`>RX=F"=#G1ZZCRR']?4=?;ERAU#RY$"[`ROF0*Q[Z_*B% M3'QT?=JY[O9'#XHMFDREG.16!.S\Z#-ZAGMG#7CFO..V8TNS=P]=IEX?>.<%)52OF0*@[X M_$CU>OSZ]'#3>+A]/<7KHJE4S(=&$:CS(P_<>=`;5N,5KYX]73UO"($FX,YW M8QNW;OJCQE7C&K6T)^$J0&TOO\TM#'I^9$*C\I+^>C]K]F[AEW#C9:>6D_2. M@3T_0C4_'KO/>.7E01VJ1G_T>+PABRX&\OS(]/2!]ZZ&C\_WO><-$MT3<.=' MHO/G%[CYWACBC]X-7:>9V1!2)<*?'\G>GVS\C]*]?*4OT8WWNPTA6`+T28F% M)[QX#WSLD*I5'AJM*[_.XS:G8YY251L8/V)@K57$E%';1_!P&;HEGV"B1. M+.<>^%O@)Q2R^\6])8M8(0RVCN9 MDKI00%5L$-N,$6;'/6/8U]L;/$"7KA[NK9-GX3E)IW M_NO-=:/5I"EXU(6OJ7*I.AD5*AKH_&1.^_W]J@UW1JW`Y0\6R=QN.9?"L[)*I:IX*L6#G@N5+LZ?+JSA;5_OVGG$]!_D()@C M(.="EN.C:[NAG[]>]W3AZ=C[QHY/'1_1#>$I\S6 MBG7AI(F%/!<:62PC_HKR*(\ZE&QRDTO^1[54G,Q2SP_\7*C%MLCV%=UK/=R, MS_O"\]-R8:@8P',AT,M0&;:H"@7^Z_KR'!X03Z$\."D.\EQ(Y&2@?N',AT?O3S1G<[3T;RL.5\"('XDD3AC=`$B]/:^80P^MN$^VU MRZ/[UP9=%9O0N5-A$KA8=-'/!%LJ'%^NKD?TX_KIK:FWQ=:^(@2+U33X1>%* MA9R?2]=Y?VA0)1X2NN]O8JU`Q'._R$T\ONZ?FH*9XUBY54DB8*6"KTNHW+!^?4?KIX<0M1",>OG&KZ)@%+A=^; M,^SAR\85B>$+*@LHWO@B/$NIYC$9PE0(VY>CXXN'QA5=.'IL"T>S=)`*S2A< MJ9#SE.3&:?^):'1Q]7C_+A['_52;10)XJ5!];ER/:8@3WYN#K-&_S@';5-M' M,H2I$#YZ/'^CX5Y.X+F/]Q'>%8]KJ90&UUC@TFV8+_!F6874?3G*1N-5J M/=V6.0E;*AQ/>D/7;'4TX[MF=.&^\W<,)@%?@B.5US8,M&RTYBBL1%D!6^14(!X[\GK-C,!''BB\XL3)`?KT7B9N-?3?_FFH,[8]Z7+-YC ML]ZFB*I#V"]Q4Y=U?[^"V5?_`13W%)M1^K+6ERYCWR^G)B($?Q<4D)&>!KF5_CR MR`.8@'?REB15XI_/:8/+(Y%C*5P0E]"QL@F=F+,UGI=8>924ZC&?CRZIWJ[[ M]L.@W]?)92/K)YJMZ*8]L+;U=GUVF+X+I-L!Q'I6%O2JY`#3HHI`CIZ4.;PH M>0(U[UI?JN=D65Z3Y7E,$@5EHE\^U0I=A+KIYF11U3>=FV'M09PRGTL2OW-X M/K)Z/;)`DVW)B[+N<['L?V_\ER3)%O=D"+#W1=CZ`NS\SX+)&@I)X1Z*)7HG M9GDF%E&F\C)@$[T1E5FY*_$\+'72*FL^!Q-R),G#D-);$)NK,V.$ MF2%+2O^<`GY'-V_4AM%XR;\5L'B8VOV`'YC$DT95)PSI*_$Y(^'F)1,()?0VEF-.U^(L@)4":^%P]" M.MK.!&Y.>BXMZY$J6O MZ/:1=J0O5>_:-_B@)9E]FF^I`Y./K."8\(`J'7J^D'W<'^^J,L`&==ZX`P-6(CU1+A;KTH.#0N(7C2'=ZK+!/ERNQ'RY5)S] M:<,T=M1>7S?'JBJU-$M5'-.RV6KJAZ=\-;R^?`Z*@+HP%7[;Y=91#=6")8%, M*+=ZFJ'9#A[@`#>[O4AH^;EL)K55N&*V@5-+U1C^W=^+\*_L.*K1PKJL\"=L M4K+5DGJJBD=$K,.4/&AI6*"BU]/@4=6[N>7G+3_/1ZQ#R>Z:EB.!0=^3=!/D M*_+G?LUGSZ8*&XG1`8;G1C^P8NDOJ4][@#'H22/9EK#SF=9B(A;&<"5L01IU M34D#9M5MNF%R*0\?H4W`[/5E8UR00+C?8.\TT/&D@X*$*V)7:L`3!)+<,P>& M4X#!.RJ\9@'YG&X`($6Q!FJK0)!8*CHEO%V&?0#'/U6;%NJ54GF?/E#>+I+M M(IE7Z!,SC6$E2"IVHI)<@T2JE!@ST0.,3X$Q_3T">!.OP0J1QV2QD-AF#"OI M?LD([SXPKMV%70-;"JJ6S580[B*TA/CZL2<6$*RQ+S>:'E"&_+UDR^A;1I^/ M6"AQY28(8A"CS"#LDT'H!`Q"J2O#_::J@KVARFC,MW!+0&Y4WY6N;'2\A3#J M:DH763.P.#CC@MEOPX9AL?KS(,6!^36[BV/A`NE8*OPYZ,.]YIA>"`($ZV51 MGD[RC"W@J@BX?)+>FNDS,2X;#?0@W<$-^'_;@J?'PK,)`ZF$8B$508*3=N>I M#[?A_\VG,2:@YE#6)3O^DV"*0/Y\2*5%X#+EWW:P-"UEY(HM,R>*"9+!%4&, M4^>(,H_QG^]L07]R@7!$A""8!%8'_ M!ZL*`<]TN6GKG@&P/SXS"2(AU4$%5[I7R>/V3+ M0-?KK6H]H/V^/>',=L)9%7?"N6R/@XO#D6QK"MFS)YH^0./URK1M"3@$_38] M$/+$*1$\MWZ:K9]F%K%\SFIQSM*1L]`GKS#.(A\BNEX465<&S'72E&WXM\F< MF2,5Q1KZ6X:J)7=4R1B00]-LLW=MR1PXM@/?0.=_:T!G`/@B?$0S6\P[/Y(M M/%IEAU$V'=6Z9ZZ^ETA]Y^[0-F#-G#\<)G3]P/?,'S8^;_-!QM MAQX%,2S*_9,HM2/95H.FK;X-5,/Y`;N?8V^%>S;A7MM\X>ZSA,1X8BO&MV)\ M06(%>`C0G7G&5)`J]7(![#A?[HY4"]WNJJ5H*-LQ:,!])K@1D#A&`2ZC_QQI M/%#IH->/F*%W%4R"";OFX2FYW[?,=U"F'54?2U]*>V7OK8($@P]TAQT0XPDO M"&U+A8V&?OKI-7@HNP.7%);:.F/8*.^L8G)$;3&)>T%GQ?B)\^QIV72_IK^/*> M2P%Y$$7%]#.>`&46Q'LW=!9W^G@R;N"A5"J],T>4)^`#9/_W7^]-2X<__O]0 M2P,$%`````@`G7;V0J&-J$/9#```KZ8``!4`'`!I9WAT+3(P,3,P,S,Q7V-A M;"YX;6Q55`D``XI_[5&*?^U1=7@+``$$)0X```0Y`0``W5U;;^,V%GY?8/^# MUGW9`NLX3MI.)YALX=P&67AB(\FTQ;X,&(F.N95)EY0<>W_]DKK9DDB)DG5A M%A@D$_&0_`Z_0QY>CJA/OVQ7KK6!E"&"+P?CD].!!;%-'(1?+P>^MQC^/+"8 M![`#7(+AY6`'V>"7?_[U+Y_^-AQ:UV2U=A'`-K1^7U/(V!N@T+K'(@-_=D-L M?P6Q9RT];WTQ&KV]O9W8299MDD,\'%G6$Y.14)8'87`X\\M M!WCP8OS3Q8\?+L8?K,]?GH>G/YR>'A1P3=8[BEZ7GO5W^WLYS']8T^G\Q)JX MKO4H))GU"!FD&^B<1`6Y"/]Q(7Z\``:M+4,7S%["%9@2.X!Q.3C0:_M"W1-" M7T=GIZ?GHR274D+\-8S%AN+1<'PV/!^?;)DSL#@IF`5U:U02BW.$*>FW\UAV M//K]R_0I`#]$$3M)KEPM4;[QQX\?1T'J@+>&987M08D+'^'"$K^_/MZG,B+L M0?<5XFU`J`>V!)/5;B1$1U?`%;4^+2'T>-5!6=YNS2V*(L1U1+PM@#L)6A8GPU?`5AS8L9G(^AZ+'XB-#X;GHXC,_@N M>OSM&K#E!#OBU^V?/MH`EW:!.] M/*.^FF'"&/38M4\IAY515YH6J95.2\,_,)P)36L"J!T7Q/^;LYIT7XPD1LQ? MK8+2ALB#JSC_@I*5"B/1YLIG'`%9B]*!.[`(=2"]')P/K#O?(C6T3 MGX-^A#;D"KRX\`%Z"JHT1&/FBD0-)+)8-3E_/QC!WYS"-4#.[78-,8-RX@IE M(L;D,@92I5!&SM&/1G`T)0`S/DY,(7?Z!S;V"'EC0F<.J(?X["Q-6K5,$8N: MF0RD55==.<\_&<'S,]CRF:Z#PO%_02B?KCJ3E1A9,N1J2$:,%DD:2&.A8G+N M/AC!7:B1='(BG97TWO@I]Y6F0][./QO1SG-*UI!ZNSF?GGN\OXMYTUJL-1]@ MWFV5BR;>JT#4)*:*=9(3]]$(XNXQ7WV^(CXDAUIQP+=;V_7%AL-G0IPWY+H9 M`JMDB8C4RF(2H7HZRHD=GQK!;#SYG8.=\+C<*OD3ZD-GBL`+0XG4>X@=A7K(F*A2+Z M%$*F4JC22<&6(8NCO4KJWJ7N5F:0D5K)Z/<7,Y8M&;-Y(-C6Z3)Y.7FO.9`S MCJL"E124F;%:.5"'#]1/'K'_6!*7(V1B0NGMU#VI4#S?O>3B1O!8K`G)<*Z@ MTXQ%T359K0@.M)$>"2B2X]W_;')O>I0:8JGI&65LQ>:59T5N8V=C(VQLXC@H M1#8'R+G'UV"-/)!=LI5(Q;-WA92I5"FU4C!V9@1CC]`#"$/G%E#,5Y.,S\?] ME1]LAW*_A6R4==#Z&2(>-3*82JF.K@IVC3EXBP'/O"6D(M:!PB7$#&W@/;;) M"DX)$_L)L\4SV.97WG5R[U??E7*;:@256T%A$07K5E,G-[)4A7:2==ZG45:Y M*?^[@6B1L-&?/$[)ZG!E4#5@)%M.)S$CV4I[&_C)#KC>+EJ49`=Y:6(\H*<3 M>W1=`8#LBC[[.'%#T>/^NEX.&%-IL@6Q^%BV(!TP_]@0,9)..20B M2C&P_6/,)L?(S-:05X MPP&[)#BLCH*O7*Y`B2L#LE M@49BJ31Q_N,S3VB0)4Q/.`D^*!0VE,HR%4T.*GF"KBL")2#F"KH!\A7"B'E" MW0V4CS/5,L4;RWJ9#.585V6CXTRFX(50CCT*Z9236RP4KT[D0H:2IU))0989 MQP75NF2UOOA..V'=WF?&#L&S#?L-5(<4,L4FA2)U'WZ>2C64K9P2U8/5#-H)DZA:'JW5IX4]0$^Y M2RE-BZPKG=8?'W*,1$&4@@LS-A#N\0:&.QTAY+AGY'I]L5C2_15B_9D:P21- MBGQ8*Y6+35`IUZ,YEF(G10Q6C[HSHJ\5:&UT5-I>FSNNX#7!7`&?ZQ"-'01' M,X5D6Q*R+P@3BKQ=S!E?0:=+"0-8OD!O29P]T?*]W$YK3FT,=U.S@:;::<,; M';27:!CUU2N(X2(7AUDBE3UMR$@9:P`2A,%^XK#D.BE7JGR,2;X*VKSY`PL;HFYV-;@"9Y'T8OOB;<=N/P%6#9_,!5!R6HDN,K7[+)_752)5)M9V*$+SD\C!#'=P<;W`6G M+@I)R2%,5M),P@IU,SE:]FG)1^5[E5M2,R`S$Y;)<[9BHNTKN!X>][G#?B M_*:%=I;]#D9Y%H/:(*%8_NZS?@:E_KD,_9EY!6V(+ON&AP5G-(AN"HWO^(CV MKOC,)UA32J,[CBM$:19:A;Q?4]%K(Y/CD"4M(*#O;;_<4%09U&-%-L/[-8"\ M[D8'(JL'NZ++S[3]I4XAI1ZTL)#W:REZ;50>&=UO@%%6J\PU4J66HI!7&D56 M_OWRG].\/&8Z1[7YBP6=5BJ/2^[UZ$SZ98,YI$@ MCR[J:$BJ&9/1$=-<`QM")SC(OV?,%U]:F2T.+L3*F(2V_/YM@Q)YTS95[A#F M(&MLJA1D+-Y4D64T;IPLTHYHV871-V<>XO\-4`K$*[20VBC_YK".J,3Z*\WBU=LJDZEML?$E\3EC^64R3'QW+9Y/=&15Z_&F'6[]C/2IO'Z.AFODH* M-IN?R<3F#4"A\O,!V=&F9-/6U[5-0QZGZ\A[G7?]3LS97G>L(>0MI=^0')K(6$%5T%6 MC0U37K#<.;*7/&!_(_F&KA:?1TW>GUPQQ.1'9'W M*2VP4*&RCBFHB>SX]L_L5[?:_/IU==SZ]8`=W_AB(PB%X3;"R0?O'?%,HMNU M2D2]>CLFY7B0#;B)G%-_(%Z[G:1RE5T[BV/P'<^(XDL'+1"A6U/'[5\'5A-N M.GI!KF7_7%Y+YXZY&J3CF_K@@\"';_VTZQ%J5-HQ$4!7<_5\!5QRA MA6]5/P=OMC7/0B,P.F:J<0A_"9]6_VI.2Q=#W^M`&^2W&`R?K6[=@%KQ1_I M5=0;+=JH&FWSY*VUR`8F;X"&'S.:!9OH3'PM+SP>8,Q?A<_:[UQ-XNJ/T9:4 M:+S39=$\D`U$(;\U[\A)3,,^;\.N&\&4K\=N5G\K3/^+S]$PLDZ MP,;_UQ/=%?&8Q?41X%LG>N*_^LR[%4>A)O!<#8Y9--?'WCK+?*$4C#9WQ*%@-FX,<# M[X?<"7:B0&PVHX_"UQC)>V68[\`DCM*I\9$_=TJ9Q=;^4%\=0K]C^W%XFV0P MJCBU0N`>9=;YVOHH(+VQV1CJ[GME,F+TWSN54`SOI5JXFV3V=K&`HL[]>?DC M\'CI-L$VA!`_7OB\F#_Y'U!+`P04```` M"`"==O9""B9;80MH``#$MP<`%0`<`&EG>'0M,C`Q,S`S,S%?9&5F+GAM;%54 M"0`#BG_M48I_[5%U>`L``00E#@``!#D!``#MO6NSXCCR-_A^(_8[U/;S9C=B MJZJ[YIG__*=C9I\HH(#B5EP\P/*F`VQS66P#MKE^^I5D..=@*WV59=DXHOL4 M6"*5ROQ)2JVXHL\ M-]5//PW\`_2LMI./NFK8G]:VO?_SZ]?S^?Q%?OO)Y>T7^.'73Y\^?W[0'3O\ M_/D)\?/E=US@-&>JG_E/\O.IO_]Z=.I__ETW=-^S3$-:U/0]52S9.J?+D3TC;&]D_\ M9S&WU$\7:_.G):]5?=[9R82-?__VH5^7A:E]V9FKK]]^__UO7]]^!=;`WSX_ MJGW&CS[_\>WSW_[X_/>K^\77:[8P(\Y\W M=^V\_[3)T=T?")D_[>L>(VW3W?"_QG^]/*R M,>RORD;_>J_S%?_@:\I,H?94`P/VLZ(NYT?-CL:B]^<<&=[I\XT1FU_GUZFS M2YKYK*OZ0C4C\OKTT[0972,2IGQK%50U&51X.8,)M>D?8?'&@[^:E9#4_A M.Y.J9J*N&IX.[)>X7GWKPC MXKOYW"\T$A[$[H,BW!Q__\W2W.F^#.Z\2CA:J(W='G,S1X1VIJ*:R!3Z_=N7 M;^AG9(C_*6L[2U7^_9MM'M7WASL$SHO]0R/4T-A15_A#4LU9JOQEM3M]5=2- MHS3TP:TK].BOCKJ::P[POU\V;B4!I7<-N4O35`]U5J2JZWE4["B=H.OJ;[Q$ M[K!2NR^:3_*F%=V%_524IJ0IALA'.4.0V+FYITOY?PHFY;^^^<@9%7*2]!.; MD02-.Y"QJ!]+J(3(ND1-*[H+^JDH53$_6W[AY_AGYNE"_B]>0OZ..%$P-W5M MOG))F5IV%_-SF9!R=K%/%_0_N`NZIEJRN=E_-&_=\J94<8O]8Q6QI?_4&;H2 M_IOWE-)7S9*#74!F%NH=5R3S',=(?4`=(>NB'_R4H1DSK$;;W35%SO- MI0!JV5WPSV5""MS%/F3!\S58ANIJ8]GFW+![<]V->+\J3^:+JXJ0XJ=W!M#" M'WRU4$5,FW/MIZ&HE[9ZI:H!J/.D!W<=@17AZ0Z@";=)G)HFJD?3Q#;!QI+G MVO^KSDWZ*A!4[:X/L)J0*H$[!6B%\\MK?:.I9A4QM-J9]-%!K?$T-IYK"*D& M:E<`#7!^L:WN='UGC.R=O!VMYZ9J_3K:9(L-K6CTZ2K$#Y[G+K\?"*PN_XX" MVOL[9^TYXWNH[G>FC6T0U*^CV_D6INJSQNA51=85T#E`2]Q>MAWNQCOM:-AS MTYD!Z.H!ZCSIQ5U'8(5XN@-H@MO;N,/61-6TMK$[&R-U;NT,5?EI6H"ENK^P.>_WC0MO(=6TWMZG:H90_:>1CN.H&('EN M[^@/S\&[N5A'3]SS54`ME\/$74M(78!=HFOD&[=W^6?&'(].L$XH]:A:^5@O M!WIYZA:@F_D ME[$(92Q"JK-F&8M0QB*DL$.>VOYX_!GINV6IMO5]@3W?LMM0IA<^]A6?"X5< M_MT=`.:CK,5_=S[X:@&H\Z0,=YV,=`+`9@=V!3#%LE-+=6ZMOQL*_N?'X;@Y MS37$K_7=KLY-\[HQ5N.Y=O2X_Z/\YK$7$.HWF:H1PMTN=(]36E@2##I9WAT1 MIT-55A'7:&'LJ?:]G^ZQ%Z+J8PCZ5155A?[]$VZUZIOJ?KY1?ESV:#%6Z2KS MK7/7%;V.J$H">D373N+]@_C:Z>SFAH4FA(XZM]0/D!JJ&EJDE?[JQYB. M]*.'C1WN1Z(J-&R?4PKTBZ]A:7ZIFJJR<:;XY">CM# M#C.$O/7HH^A#O>R5%6($?>Q76F&33`81/'K@82.H"IYX3RL",L&.UD[7-[9. M-F@,I;HS<)"S:LA>)82H^=B]\JDII.GNV[6T8B>31`OMY.UZIR%&+.PQL:^` M"1]<\2UZ"*PHI,+\.I969&6R,7;/]Z!N$`/%'T;34W%F&@D$TX[6F8!XRBS> MJ!1EX[#3GV^4GT9UOM_8<[?G+J#6XTT)J"6TDL"N`;K*T%TQ5&W45U7Y,3<- M-"E;Z/7MJ!_)=A@R;C;RQCWGA?_!78,A?B"T,L-T&-!KMEZ-!Y>_[+5JXL,K M376-8^E.ZD]#WNEJ9V=A+_*OI32_>#T;<7[][MV(]&NAU1]9%``6,O1R>#L: M:,<$VB]B*XW6(4`O8G@UD%DGQX0=+*'W&&^AOS MOSV)*$(*B9L.CRP2=YN9IV&4B21E(DDLS96)).\S99E($FE%*F@BR=WU#`4` M0,5O+V>N8B&-`F\GA$LH&>ZN@BL]V8Z0_4$U(Y/IX3+`"%OT*.Y]L:C-Q;3K\I=/=0J M0DY<],X(MX80-IV7!)HVGDL^*N%>(J[L'ZP+E[/Q&-'`<@TLTV)*^IUIX1(G M?B'S>HYW&^])/)"9%%CO@7JPGI":\>F6<-D2^-XDU&&REXO>(I0_%(FL M@N<^B)=Z\5W'!_[>"'^_EN[L1G<\2JC*;Q>O^%8666E!_10O,Z.^,]7-RG!R M%.2K9,X-"W4*,=A`DL"1,15UB>IX8XQB_/*NX"B_%%G;D20@7O('@J=JJA;P MB@Z4ON=@/Y6*K"9/3\1+[?#T(\B]%>36$EHAE-Z(E_CQQN1[C""D%&\-MUH^ MU!#;S_BQ*^(E=O1VQNZ9TSN"`*]PZ/IW?077%U)[(;HI7M+'3^.D.DXTA^7' M+.U9AORKO:U'0+6,%!8>>3N_/HJ7&P)V+.S0"SOD^,N[GZYO%6K>[&V)GD1G4'D=\-Y9F*$]3;5>WU3GF',7VO@&O+ M3QL/?%H6NG4?EQ750'KQ+C*^M=R;6*Y:`NN=TB7QTEMZJ@W: MV-2RQ]+Q5":D%ESLBY?"$B8EJH]]6DB0MFUN%D<;QS%+N_[XSM.*0;QI9H=ZWVT,((B024VT[`*_IM)V5PX?Q4/<9 M"BGI#!@P&7H#*7T'\GQ#U'P_)0&L61SH^,H#4'2&/L8)PO/:5I7O)V2,K]3> M$0OIU])SZ6EE;FUDE^IC_?8.AFB_%7*]C-A]0/<9^C(?QQ'T59,P7=MH1_L] M/_21>>5?ZY&$!=024G-@EX!LAX>/,JW$8'P-1UW;G=^9C)H2_$Z!1S+P>VN9 M)]&6:B<_$X*CT_@W9T6E8"0]D4<00B7CIQKGV@"*(;VF8H1=XK#ES^$_+D4 M%:(F)2K573.72O3MNG!IS>0]!+TIJ@IV(*#UA:9-_TH/LY!>*91HMHR:^*:^F.O]^Z-O]1%/`EHS^P_6200"/!/0`A0?I*1\F/@FJITFA!$S.9VL7V_#_5QZ<$CKLUP#D:E)NXD M(P)"(A21G(,DG*"$2Q^G=!_S^P[U8(A`/X`7"?#G]`/?UC3$WY`2;4"$(^./# MCT">-J%\!2'>X0"(?5E5%9+T\=.RCHAW]=?RPQ5&+O6'KO]^)DI`?;$F@3`X MWH42@WBG`7QD>C(WS3D^J4XUY8TW&SU,58J&/55SKUQOYUD>+0`YW]_CGJL[ MR^M\!XH?SG=W<2Z5X.VD>`<(A.]A[$4T]N*93ZU'$8R`AQ?0N7<2*!,85R$( M^./#CT">C"M?08AW`$)_?B4;A]+NNWPX;DP5]0>])MC7OH;6E.^&@M-L]Q_O M*GHLOY%_^%B,P_]0K/DA#,1WT00CWLD*'NX#SE0+71_2OB@GJS%6>MA3U[(\ MBB%\EV.O`;'G_GS"((I@Q#NF`+..;]9&_^`YZC37,*3[JKG!)RP\NQ9=B(CS MTT=.8)2?"FD)1.N\>$8Q_E-_[: M=/TF3TIU=S<@^SZMI$^?VW>C9G^"-_.FFP9*:3;S;$J'#QPMOC.(MKTY>Z'J MNG,LJ76S3QYEF_XJ3$9B@(K"Y4JEEO6G+N='S0;ZX@LJ;#<\E_MG`V;H"P#X M?#8`_>H\+#UJG?QUZZ]O83KVE_N-GF?J:3(,X@X*A$/.Y;=I_7__?09>OG[ MF3.N\HPL%?^ALJ/V1+B\P^^*LG&XZ<\WZ.WV'E=$U4RHNH_4*-^ZHFHLH(?" MI1@.51OU0%4>IY]0U>9?Z>T^/&HE414%]4FX#/SOLGS4C^0^*>AD*OI8B_J[ M]Y3$D+\35;41>B[<_:WE"3"/$V#^]EMY`DP>3H!)/#66)\`$GP"3Z8P$N:3> M9B309_68D0!/E&"N05I'A'OY<4X2Q.&;GD/Y:$4?SW]X%(DI_"?F`;%_R5#P MY7'!!3XN.-XAV'Q/_LUX"7"&9NUHHK;;)7TU#,I\=JI$7[S<:$(_(V0 M$`G97>'>_P&^G=DXHFZ!'_DKU_VC/&G7TV%`O?&6+2#._A[B):3:$XJ'PX%4*^S)?[#I=@!1"Q]> MGN="(<7O[D#Z!T@]M^@,;U^I/E>ARO9>)0<2?G0&D',JL]@C1\G]+@.6NV:; M]W(A!4SI!L/CN,+*E@KD@%J0G$6&,]@E0.9,$?T\EB!3C`\8"VD7*GP M]J\$R%AD0$,=`N2=I6O0[^4_W!F^L0F$$R(=?9O?#=*M'-_,\RH]?46),%# M&`IAO"T%0(2_*`!(9#E'Y/KD?`:WB?Z1]GU)O9VM6M+NGG4_U]YXMGZ9J[EQ M/^6]BI:4G;91'B?`]Q&*4!WR]=>2\N/:QL+Q!T=3E=2+7=$^GA83-22?(XL\ M0OTY=B?S<)SR2JGGBAO!2%M%UI'A+,^U//]H@7LT331;XZ&[*3ISDWM^EUQ M>"6#.56[)!8?&5LLL7C.W!(H;9G2EBEMF=*6*6T9!GMI"5;/MSVW)"OP8V\N M_NHIFM$43QRBV56CS),`G:BE2\]F: M/I%8S=Q\*`V@T@`J#:#2`"H-(!;W!T9>(M_O$XR^NK[=+QAU913,)(K6>=$, M(_=E.WSLH3"M9FL&A>$P<]NAM'Y*ZZ>T?DKKI[1^$L]($=;!NS:BK)R.DL*O M>H*9.*&Z*IIE4U.7JFFJRE`]J<91Y6/8A&@T6[LF!(.9&P6E65.:-:594YHU MI5F3>$8*OPC>E1%AU714%'K%$\RF"=-1T4P:?,O-AAR/:^&;^79D]TTU\-X; M'_,F(@/9FCH1FTNPIS1XF%]]%7R@_W(H78Y5]OS(O\@HI MF&D450"BF4G>ZTEP73X64OBV,XYP#LUGYE9%:1>5=E%I%Y5V46D7I7!%6<#* M"-Y<%K2B0A>:^:^&@AE"$;HMF@T$7*^;IND3V&2V%D\@>YF;":6A4QHZI:%3 M&CHO;>A`%UB$7,\>=UB$7?[NUUB$6[H$,T^".RF:5>*US-?QTA(I+9'2$BDMD9>V1%@%%@6\1Q2%6QT#*)IBQXM\YT0R5 MZMQ:U[7=^7XTHK%ZV%9IGS,8LN&,(VO",9FY$5":,:494YHQI1E3FC')(VHB M+8B/2)IHJ^@]@B;*"BB8D1.VPZ*9.T-50Q^5_MRTKQ\N;N<451RE]6P-GRB< M9FX[E-9/:?V4UD]I_9363^(9*<;Z>-=*G)7545KT55$P8RA2UT6SB'[,30/9 M;U9?-$8*7.D>.@A<$>\* M"5C-!+-2?+HEFDTR.BXL]7!$'W^<\/=4\YC`MC+.6P+YRGQ%+VV2TB8I;9+2 M)BEMDN0S4M!*]YB8`E?$^_P4L)H)9I/X=$LTFZ2S.1PW"L82EZTBW^:RM4Q\ M6\!^S"KXWT,!*]L@EDI_IT3S5`9JK(V MMRQR>179ADHWH@5L+.L`%I"QS!?XTD0I39321"E-E-)$81"OXIKF/5$I0/E; M[(F[7$@+A-(-TB,9OY@E^:+*7)4IHLI%6YQP7B<^"AW]@\\!/:&! M':C42+_YD/L:_!LA%1NRNW35_CT[U4KF7%$1X[_LM6K>7SJQFUQ%74"6JM,! MEVHC_>:NVG"_$5*U(;M+5^U_,9Q9?QHGU;*=MXA+U5253=`@C/"+MY-U@G\A MI)9"=96NHW]D-_S`V]/]]1KU9W;`;?.YT'#X3M/5_-]9GH+U?(-L'A?S7T08RX4 M"7<*T%,LMQ1@O?_',!TOYDU5$`L5U4!""3+@H_WHX9<*]R,A512VPX#"$F^3 M)-A3Q.F3E;FE*M6=OE?1%(&9^T581-,$PA[J,UIUL/EJ4:V^!!0>NY(Q*`@) M@UBB`#`A4'*Q_V`/61M(-,[%\`[L(J####UD=61!CN?:4>VJ? MAVC$.ZN91_*5L8AE+&(LS96QB&^J*F,1HRVCPL4B`JZG1_R/\A]+71XU[/NV M?AG26JVI,OHUFM8K<_0B+2.;W5[O%-]#S9G0>F@J$2TA+:2$XA$M?P/<*CS::*[O(IGI1[VCSBVU/[^2E:&^,^^WQ)''EJ_SB1W! MQXR7G*"0AA8+0?F/V0QV[FS$UGJG(38L;#C:5UR7IPT6E8.,]^\BI>556EX,+2^R"E2N57Q26+!9Y5O;8S/1:PMN$`%=]%FPI9UYT,(0L'J).,H>^6==2=9R$=2RR)>PTF%L1%MZ^8")#A03E`4)S+ M(G3SUMN=B!"D\ZZ'.HS^F:GF[I>AHO_"0HD-7;K9G8"NZ`!**K;T3^()8+9U M=/A"-#YPBCXE`4Y$HN%0$Y9H'B$36F`,3P6*AY?OQ]71LG]L5FN;&5RBT0R' MEI`T\PB6L.)B>+10/*S45)GTO;X[FLS`$I%H.+2$)9I'N(06&,/SBY+AY M:\2$)AL-,\%D\XR:$$(3[Y`AFH7_\7"&CSW^+MN;$WJ9C/S.%8^@SWM61(*B MHRJVH%@>1!0\$85F\[NA3.:F.3=LZYMB)W%8"6(5OJS"(BR!>EJ`B>N.Q]/KY!H=)3.+,Z$+)O*RH:%0$MZ(BBB2C@Y'?.>K-<6+XK^7=%M@95DVUYQLMOHD4AC8/ M^R<,'YF;!J5Q4QHWI7%3&CZ^/:;MRM-`(M:S[1O!H<[GO"M__(>&Z M]>H2/!-:CTL<$M$2TGY)*![_\XHSP4)O,$/EY&M_UL,! MNMTMKI`4%T%TXV($I%L,O,!B\S_H,1/L3"8-$Z<7X<^F?FG7UDE1`U.,BQ<* MQ6(@A2:J;,Z@>G^!"'<'"KL7IVCM\7V9BL9;YJ\GY0M6^8)5OF"5+UCE"Q8E MN-5O*@]^,`45#3"3-#T M1+B`,'H6'$-C(A7\+#KME88>CG1RAL2D6N M-!YJ^%D5_QG.F.(*)L\$5Q3R!<0538@>IO*^,U).*;$I4P!2:@:TP02/<2@$!Z"-2#N=J M)6+=[MOUFK6\XF1T>\\4:'323-#E(EU`2+F%Q^&\K43\5E'I"3V\]3OGZN+* MUMD%$6>")0_Q`J+)*T"6YW"E`J@MF47K%IY9#YA]4M+`DVR;*;C"-,0$:+X- M%1!T_H+E<7!7(O8[^,_J=%N-I/-8\J0,I$&;"R+:[]H3%N&_A9"]5JD"'"=O?1KP4VVY#4%@J( M,D"4`2>(90^RY5*QUYW9!(\,_/^PQM;U!9)GX_/RDB\@MFA"##A>)?UXYI^& M/3=6FX6F.B=]4,Y>8Q?,'*$QOI',$1C+/`BX#&,NPYAC::X,8WY351G&'&W! MS$L8LWL>OZ_)9$>3^-30!_Q,NRC.U2Z#D;F2I_B12^P,*-VUE(22D%90(M&D M'WX"0!-:;VPY",B`5?DKE&AK^PT@_]#FWKKAL=13?ME3O=-QF1J%AX M)I)O[;L$DIDM`+^?S\BGPW9"&)_UMDK]'$[]\6CZHR$BS3R!(ZJXT@^SC9JMVNMR),;JJB-W+O? M;(G&10B=:#&``@@L_1#6R)RB0F+]**A*7T9_6B3-H[B%>((]JJN[Z\&WQ]=:'YRMS5W?IK"^=]:6SOG36E\YZK\'T MF,8[&QDQK-YG<\B!4%.(_TBKDZ>]9D[_IC1E9((XF=T-)W\$?C M%=EO51(ZO6B?24'-R0OO)8)-(-58J(&I%@`T/B)+?Y,@&JOC?0U;^\1'C;\O M*^.9^TV>(<586*%3+`!.`%&EOT'@RR;\NGB[+E%YM7[629CJYD*.KHR"EKBT MP^`F,NW\(2BZ^#*V;6"&]=EB6S&FN,[U>F*#(3K-9-AQT2P29MSB2G_S(2:C MQG6QK%U0E7[;D"ILL$*GF0PK+II%PHI;7/Z;$ND[!ZL[7=_8N)?XQK[JCL0G M(P-]HZ8;UQNO7;Y.PW@\9NY^*QV(I0.Q=""6#L32@>@UG#Y,Z<&1):BT-M*4 M]NG0&[@/0TM.Z*ZC!(2$M(N2""9]1V`4[JZ][5)J#.0)<3JMI00(@$C%P("' M5.Y1X!5.^LZ]*/P93F09>K0?26=4BJJ>6N[3@!E2C($*B&+NP0&**GWG7A0V MY0I^I\.NH_.M=J_M/I&5&;T8^*#3RSTZ`#&)94?LQPT<4^;\5^G)3;>GEPVQ M&*B@$,L])&@"2M\A%X7#_O36'LX&JU%O9"9``HU,#`P\D MR(=.[WRQV]+XU'3?><*"5`S]>TCE'@->X:0?R1O)I*E=:LJH>AA?VNXT@*1D MXEB.'\GD7O?/0DG_0-@HO#FO-^3KL"?M&Q*JFF@6\"<8`PL`P=RC`A)4^@>] M1L+N4,+?27:CV:ZBXJG[]$U6Y.+,$S1RN4<&74@<#FR-PF1OK0P'9A5'M^CU MJOLT0P:48L#!32GW2/"(AL.AJ5'X,V7\=SU=]*S!8I;$&0E0B@$"-Z7<@\`C M&@Z'G4;AKX)*I<5D.QNV+A7WN=_)"<6`@(M0[A'@%DS`H:0<;H^V=_)VO=-0 MN]:/PW%C7WL[.]TDKLA-L;'>1[7=AA!#D@^3B`5),8TC)L+B$+D1 MA4^CLQHIV_Y8NG0]+I2D=.(@XHE._F'P+!8.T1I1F%O7>FV)A.6;Y%G+2#0_ M^)"+@P0:N?P#@BHD#A$:47@<=FZRDW=ZNE:7'@<*`U)Q\.`FE7\L>(0CF`U1 MO:SL>OU"]@26M8''B\*"5APD>&CE'PI>\7"(Q(ADSW1/#1PR-'+N+KTI'??I MC:S(Q;(C*>3R#PJJD#A$:D3B\7ZA[(@5`!%>`7&( MV(C$X0!O&6,V+TNMT29[RHD@X4,O%BIH]`H`#*J8.$1U1&$2LU?!\"6;"_@2 MV4I7=B?7,J08!Q\`Q?PC!!(5A\B.*&R.FLH>E=IC2SX;M-N\&%&+@PT*M?SC M@B8B'E$=D7ATSC!!GQ:#6G]$+C$_)?)5^%.,!0XZQ0(`!!`5CZB/*'QVIGO\ M3V,LC;?2PGVX.`M2<6#A)I5_/'B$PR/R(PJ#VFHQ(D=AK15R[!$IP`^20"*0 M:!QPP$3S#Q,?@7&XOC:::83^/ZP.DN'X7UJH?.'>J61',)952B68?Y``@N)P M[6PD-G7=J-K*H:GT>YX\A*1TXL#AB4[^4?`L%@[7P4;C3JJUMU/C/)J,AXF4 M3Z$32_D?Z11`^4]B";BRE;OR*WCM(G,3*NF,)KT;L8:[GIQVID3CP`(FFG^, M^`@,`$QF_L\5P;1MD0?G#BYK70BW21`33#4.9'RHYA\S?B(#0).98_2RD&^M M)WB5;*_'J['GB.X&)"*9:JZ2.4?%Q[A`$#( MS`NZ;TX'H\YM3QY,QHGSPL?"8D!?G#X[D M+AX3[,Z79S6_A<@JI50+7XFU^WEB(L%T="$M6/=T8S!^'58972TGU7*;L-MP MJX3CL+A40,X19]K#X1;9@G*N13JP/*HHL8L[\TU2T7E5T)PGUL*W1/W.K@7/ MI;U=&=#UNKLQ1-_/Z:O(8MEF;R/-/5L-#0*F@/B;;P[FPK6Z+ZO`.B"9C^Y:2U4;\7TM()_$^96Q7KOW&X/\8-E6 MG[Y:E'K%[?NVW)J=E2!?*#$5Y/,EFG9[8;ML03YDE`[(Y^I*[/3.U&Q4]V45 MR`D#4UVLJ>$^6*1J4`? M$&G:\\4MLP7[H%4Z<)^O++'K.U,M$,&A59`?$LV'?JVU=LT$@!;L3Q0!RN"O M/P2,H?]T^5:8;*Z'Q7BJAOD\0:F0_D60:??FM<(6JH=LT8'ESRH2NZ\SI>A2 MNZ<*;K\*Y*.UUG*M.MU9"T9+^+,R,NMR:&-X[+_1GW1>S](_K2?T$9>1]XS ME.!90FXJM!;)->WM$FVTA>5BTW1`NT!C\BG`SA1"PW)U%>07RN<3@=92H@9# M0PLO)(\-99HP%1RZ:`->X'4J/;;HR+=9F\]OP_XD"7>D%BY#(,F%:PZ5U*TU M1"5I[$/@D\1J?Z@55.E#(`&QI%`"K*_26D#3=,Q@<`Q6T"0E&JM18YYLVFP0 MI+!JD*L.=(E9HYYH"G\ZR6HTPY5L+5Y$[;1.,(!Q6MF%I_.'6L^5TN=1>(6O M`2`5TZMV]06)7D9)$"5X=*([3,QS2;]^N?;+QWVY7&O@<`A/HAIWO$BT%@Z\ M=EGGBI!16CGB6=;)AOS=GE_[`_;QS3^?V@,5$_QC#6R]C"%7C ME+!0:]$!M,XZBT3MTDH?(74_U-KKY*Z-0A@1X0!3F%Z"K246]%*$7##@<8/& M:+#PVD'^VU8HQ2U.U<-DL]\AO7*`5.8!NM$P37-+VO&!&-/]1* M[52>CO-JP9$/D(7I1=NZ0D/S*X5L;""^3F@-#AG6N#UP]K#''_L^>^*?^U\F M'Q\;\N1_^],?1XO#_GZ$\LN??OGUMU]N#',[_%^MZ<=NE/O8CX;Y]7(S6NW9 MH_FVVY%'-Z*/*G?YNN2V;<^WT\=N^/8QV[4_%I^C;_O]YY(Y[OX?Y\UH_X.&V9 M\@Q&U]J*'Z3;*`@O#_\>F$?-9I;BNW MIY>58M8_Z-?+S^,UZD5/9O0_(VWO`5I-3_6>H,^B.WI^&PYG01Q[]8_9$?9 MRGMD3Y&\Z6:.][#'^\4C)GF__>D/'@G:WQQ;%6@@7(4O(SKUV]K@;18$7GU6>O2&"O]=1Y/.=%LI.?>*,WV_G`J-?:^VW+)C1MYO M(*5:7VXB2EU-?:"GX_IK#<=NF^\T87/TY#MNK477'9\FWF:BRFWM>^1`/%M] MCY$,:&,O,=8C.J-#/LW9?OZV&XU^7QU&)`@.N@=\1/IT#/=P];DWV"-Z+.X. M]0!6VQGHX1ES1P%Z[IG-;F>]'3GMP%N/D;C2.]##5YUNRRKGWH&NQV&7 M?AM;=$N+Z79LY!4(T*GU#2BLT]6$"7@VKK__1,VV^?H3LD9/KN16M17-H6GB MY2>BV]864?9#V>JKCUPL&WOSL1W,&7WQN7^R+")*7>Z+*;>VXY4`\6WWQD0QH8V\^UB-:'WO7UL?1LC_:D2;3-4K)GDO=;ZY8 MI81NL5HEEU5CRFH:4B['YMC*M:.`IJ=EC-WQ[4=A>62ST+#A;I?WI[]G8MZZ MKF!.1/WH1J1;1/1#!3].*F`F^I.G!#]$^#N:']`[&BQE:BW>Z*?CW:GI5PWF M"&(##.0)@`%NPX7XJ64C7P#;8#]GX)NF$3CX1(D.)I+E&N3C1]\?FGW\UMRH<$\`E9N((?@*'<;+N"GE8W<@6N_ M_;PA:I9&@'![4I6N8#:7+_",2+>:[X<*?@?R!.GH-YPCN!+^CN8'Q>&D5W_? M+X;=CLE1")Y:`SG!BUJW`8'WA+*1!X0LMY\!/!ND,?C=GEJ`'Z[F6/]5O2M+ M2JV$MP-,+Q'?ACG>?H#K8_?R)WL&+(/Y>BI?O\%/Y;@D1R[^>[^THL<7Y*]D M#*]%M1S+XZK6#@5:GI0QML>V'H7Q48U"`P5JE??;GQD@_,GQF05ZPC<1ZR.; MX,JL`FOACL/^)N(]>0:0\8!W,0-@2(>V89R"8$3;"<2D"6 M:8(+M^<9:(QK0TD$;(T5J8RAU@#=*<.L`$.8T;L4\M`\B!J@^7L`31-$VBX/55!9W`;RA\$AK@R M?<$R&-C.()*B@W3,Q@P(_51/2/J-Z5F0M68AN' MZG4'=W*"SW)T.\CK;U6:Y-!#N]VU0(^0*PX=0_0>HUTSRT/:W06$F.?E/N?# M#;!+_8!=NC#"[1D)VL+93"(`6N'*/`2;X6\Y+4@6_P:S`W<`P,$DX;AD"53M MV.G=GLS9U`<`D6K-Z0%7M;O@('I2[B<&@/5VLP*>4;H0P>W)!7KBUTP^P#?! ME2D%UN+=!:I0L7W)XGH"F(S:0"@`VNS`ZP%_26DX$D46\P&W`E[/6E M`X71@-5;H`U+]FS\>F.;FYROY(I=OY(L$<#6*I<"H&G5C@/8S\<8[2,:CD+X M6/:@Q?S=(.]?,S$7`#U0$]$\GG979@+8"&P<:M<0@0=R;S`N<"7S]*4'P1)(]'O+W95^NTW2I?'WK M;A;I,@)4UPK$?-!E",PL>$W_Z4J8D"N"&<*AE`,L&U M*0/&0QXW%=`9\^DS@0P'O9N90(X-O@PKRPHKHT0NG)[827,90:P)^C,#V`2G MX2+VR64B4Q"UPGK&`!JG$42R,1=!3Z@;RR`$IK@V1\$:--C/*))B@]G,PC%P M<#/#H'D7^Z/R?MZ0RZK+8C'E\@-T]?HS"[YZIZ%#^,0RD5%`+;">37`-TP@6 MV9B]@!_6QK((P`S79BY8@0'[V4,2'#";.3@$!&YF#6.649U:PTN)#N7,`P$- M:I00 M8F(!@P62FL@L]'?W&-C]('CQ$F MDHH>=`XR&S[VIES0I2_E\J6W&-269>DUHQCR<:9;<.3;CB=!FUUA)+Z)1B9: M1#6C!-=?L\Q-HBA!G63!T\-GJ;^ZQE**465F@H5T6.%/KS`?5]9(:UI8-:?D M]+Z[&M//G%*%C]2EHQ!65+KMP`+;ZPI9\0PT0541O2@!]6]9)BHX-C!IBJ.% M3U+_YAI)*<62$8J2#29T@C(>35;?J6['Y]/A\OWR1H^GL;Z[1&4*D&7OOD@\U+>]> M%F+-&L&-6;7^'CE,+NN2_Y9^_Y)#Y3>Q"A1Z`U38CCEQRUTA-]!*$]S&5XX2 M;G_/,K7%!`TFLT&J^,3V=]>(33W(C/!:HBA#IS4[86:-U5BU^0M;B-V^MLN= MP:Z(2FD"^2A\QI-O.\X$;7:%R?@FFJ`QCF:<]9"_9IG$1&&"R6!1;XZ`>IS8RW8AC;CX0?WL""H#^,V]>AH(`6?FRV.RB,/_]&@K MY*S172,W9(T-M@RE`XJ%XG&)2G9B%2A4!ZBP'7?BEKM"4K>]<+9#]J,RFH" M^2B4QI-O.]`$;7:%S/@FFF`RCF:?%4 MX\18IBMP"&,%D[[XB@#^A$;ZU[[J[^G"!+\? M5.,?XDYH%*K`F=#(5V$[UL0M=X7*0"N-3&CD*L>)MTP7[8B)&M09C8`J@-*< MJ^*A'F9FIC0FB3/\*8UV`LWJ4K0I>P$=E!;O^]9X][)P'FTIFD`'VE(TG@[; M01?3=E?(#3;3U%(TCG:/J`@C.R0(@BK%F;#&:?+!I68QF M(]JL<=QF3G_FN^P<;??DZS=R+2K72>I"X;PX7;;C4?)9N,*!\>::X,(8*W"B M--,E1F1##),;8W4"'.E<_1'$F#3"E>F"$ITS;4>EW;&[3JG/WH/9C_[YK;?` MW>PE3@G>&!Y/B>V0C&N]*_PHL-/8>!Y'/4[L9;IB26S\H(_K<94!'.A[57U[?OEK-SLQPZW-):<*IQ"_49#L8I9Z# M*Q089ZR1LOTB&W`B,],U3N0""[6JOU@C0(O.E3Q!BT0S1?]3A"+^'@!68]$: M2QY8,Y?O/3KQY[2F\UA;Y.K%!)4A8[6@L".LQ78\QK;?%584&6J"$4'].)OO M9KI82GP083*A0!NPR;5SA5-0HLX(`R8-.W3VLQ=WUIC/+S[^'+"?],]!/W_$ MW6$@7@T*]PG4V`[#^"?@"OL)+35!?[`!.'&8Z;(J$I&$28`B=0`#.E=:!2?T MC%!@XMA#YT"+P6>/!.FPY^(RH%?XY?YVA[N=-BP>A_2BXJU''-AB9TB.9Z$1 MLC&%3UKF@PJ'K*8?NU'_8S\: MYM?+S6BU9T_DZ0GLOZV&G8_=[F-UV'_?-6E[]])/I;8]F_:'%R39_\$C]GEW`[WO M.R\P\6DXQ!G:-H\#(+4;-`48R]3*_D[B1O(,P39PB+.(GQDY,I";7&K[:76^ M+,R;YZNEW(1G@N'34% M^#21W=PD+6XXEIM(`(?%W,1QY,A`;O)V82N*6P-66+[#)@70Z0#DH*541<(B MPYF+R*+L`)+$<\U>7B-NE%MICL!66]CE3BE?VZYO*0D26L;/B?16"[;=#QE, MD9)CD,6,*5L@E($$ZKRCQ<:"DBS-P^EQCOW86\JAY(PRG$;%&)4=&)-[NME+ MIF+;Y58^)3;7%IJY4U_:@1BPE%7%&<=/K/26L7:@-S*86Z6")(OI5>8P*0,9 M%OLEMZOZ](]EZS()UFF2T+.47<4;9#BS$AB4'0R+?ZK9RZB$;7(KFX)-M85: M[I0VMXTF=K(HD6'\#$IOU?0,H(]CV5-B^+&8.64*?S*0-9$S?9J+5ON#YO%0 M;\PM)4N@'89SI*@=V0$G\!EF+R/B-<6M1"ABH2W\<:?VO26`L)/V<.SA9SMZ M2^B["RB.)3FRB&(QM\D"I&0@I=D,#IO+(ABRI!_8IL>>K0$VD2F&$QNN*=F! M(M&3S%YZ`[3&K0R'9Z0M1')G,P-[>&$GS^&;Q$]U].Z$X#2^.);M)``8BPE/ M1A`F`SD/.5E\V^5I]M@JLV?99C]M+22+M<=P]@/;DQV(BGVFVQQ*DI,AC,4O*$O1D(%4B9_++<7^0 M+TS/95MS@_A&F!_K>C8B.X#$?WK92W\B[7`KYWDUSQ;:N+-1B0U$L#:X]6(, M/Z71N[N)HPCB6!XC!2%VQ[3],XBR:.93&2<&(Q MC\D"GF0@E>GVR+D]^WSUSAYHI4#/7P2[RMFUQW!R`]N3'5R*?:;92W=$37(K M[P$MM098/TDYYW@DL9,)">P"4J(,5WI&@1['B\72N36EOY-SY-J^I4Q( M8(GA-(AG279P2?`.X2'6E@L9CF9`-9 M,I#@7,X]FBKN\UMZ>'AZJUE*<&!##"@L-MBUL)3M1$:S#T MDY1=%L"$G02'9Q"0X&2XTK(:KCB6X$@#B\4$)QO(DH$$9[L@YZKT(UB?_G@; MLBH`/OMI*=61,`SS%Z*Q&N*6WE1Q$);`/2GGZ3P,XP0=C(@CCW\M.=/&2[]K`0ICN4Z MLIAB,<')!*AD(*MI;E;T[STY[K>W;'#1UCB8R!3#N0W7E.Q@D>A)9B_#`5KC M5I+#,](:)/TD]9V%@&$GU>&;!&0[&:[JK(HPCB4\"2#&8LZ3%8S)0-ISV%_+ MA?.XQ`Z0*W?D`DMIC\@4T[4+>:9D!Y1$3S)[:0_0&K?2'IZ1UB#I)RG=+`0, M2P4,N28!:4^&RS:K(HQC:4\"B+%9PS`C&).!M(><:9;>AXLC/=KK'.DQ2VF/ MR!3SFZY'39/;2'J`U;J4]/".M0=)/4K99"!C6]F3GF`2D/1DNW*R* M,(ZE/0D@QNXV[9G`F`RD/>=*C\Z"VM:7NUZ7G"Q:RGE`.PPG/%$[LH-%X#/, M7JK#:XI;>4[$0FL`])-4& M?0VSE.?$VF-Z!PO0GNR@4^PSS5[R(VJ26SD0:*DUP/I):C7'(XFEO2Q@NX#$ M*,/5FE&@Q['\*"GVV-S1(DO@DX%L:5.^3-L=^ACSUQ+]9V@I38(-,9P?<0S) M#CK!3S%[&1&W+6ZE0E$3K<'03U*P60`3=I(?GD%`UI/A@LUJN.)8NB,-+!;S MG&P@2P82G,*R5#L4A^2"VI[M\F$IOP'M,)S>1.W(#@J!SS![R0VO*6[E-A$+ MK0'03U*J&48(.YD-QQX@L^8[W6.Y_'\ ML"$764II^$:8WE_KU8CL(`__Z64ODXFTPZTTYM4\:W#SDU14!B#!TEY:(6.` M["7#59/38XACJ8L4B-C883F1` M<[(#1W%/-'O)C:!%;J4YD*&VH.K//TG5Y%@0L9/ZP&;QDZ`_9[B&,@;J.)8. M)80=BXE1EG`G`RE2I34ZCE8%>JS!#I[\Q?O$XK!5O$&&TR2!0=F!K/BGFKU4 M2=@FMY(EV%1KL/63%%^6@!,["9/(,"!ERG`A9AS\<2QI2@Q`%M.F;"%0!A(G M5+H!WFJQ.&[,@..H'/,'M)$:\I;N5"$0NM`=!/4H@9 M1@AKY0C#]@`)3X9+,"M!BF-YCBRFV*U"Z#ZH9""K:0Q*N16Y8EAMMEG&>+64 MUL"&&,YK.(9D!X7@IYB]S(;;%K=2FZB)UF#H)ZFV+(`).\D-SR`@N\EPI64U M7'$LO9$&%HOY33:0)0,)#ONED6=;SO?\_6G1*%C*<`26&$YQ>)9D!XL$SS%[ M20Z_,6YE.1P;K8'13U)O6805=O(LR`[L`,\O>_E+M"%NY2\A^ZR!SL]2"AG` M!4N%D,/6`/E+ELL@IP<2Q_(7.22Q60+9?2C)0/ZRG4ZWFR9]AN7JVYR?I+(Q%P@LK>)^,86?K?QKABL8IT4.QQ(5">BPN6;;<>S( M0'KB$RM&E>*P.AF7%FS=.[E\82E1$1MC.&4!C,D.!(F?9O;2&+`];B4T?#.M MP=-/4H4X!CKL)#F044"ZD^'JP^I8XUCBDPAL+*9`V4&;#"1#Y,RQMKGTV9RD M'"W=O-]92H5$IIBO.QPU)3O0)'J2V4N"@-:XE0+QC+0&23]/#6(8,*R5(>:8 M!"0_V:Y$K(0PCJ4^"2#&;CWB3&!,-M*>26O/_B2_TB$_^@\YT::/M6PO`Y*Q MRGPR)+0J4Z@E\WPSF2+%-,RY;$EDKS50^TD*',OBC+4<2FP=D$YEN/0Q(C"Y MEUFE0":[25;6H"D#^5;.KXS?S^22RV!>RMM:9\XUPO0R\U7O5PI MT@ZW4J-7\ZS!S4]2`QF`!$LKS$/&`'E.ABL?I\<0Q](:*1"QN;S<>13)0-)" MSEPJS<6D=NU6_(:];T(<(\Q_`GHV(CN`PW]ZV4M:(NUP*VEY-<\:W/PD!8P! M2+#VM>;%&"!IR7#)XO08XEC2(@4B=C^].(XB&4A:V"\Y]I--E"K/Z;7TMV*G M,K24Q,@996.'*MBH[`"4W-/-7M(3VRZWDB"QN=;@[">I>"P),18WMA(8!R1- M&:Z&C(=)CB51J4#)]LY7F4*E#"19^?WVO4>/+"[GW+QE*:L"K#"<1H6MR`Y& M`<\O>XE2M"%N948A^ZR!SD]2-QG"!3NY3\0:(-G)<-UD!2!Q++N10Q*+Z4P& MH"0#^0LY62]4ISXY?LEUN[:J]$!F&,Y@(F9D!WF@)YB]'(;3$K>2F+"!UJ#G M)ZF>#(*#G30F:@Z0QV2X?K(*FCB6R$C"B<5,)@MXDH%49K@[30>UP8!<,9U/ M+24R?",,IS$A([(#._RGE[T4)M(.MQ*85_.LP_E\[(_7%E*7L3&&$YB`&.R`T3B MIYF]I`9LCUO)#=],6_#TEY^DNG(,=-A)=B"C^$G/7S)<<5D=:QQ+?A*!C<4D M*#MHDX%D:'O83#:'\?"ZI"OLV=0D2YF0P!+3&V%Q+,D.+@F>8_82('YCW,I^ M.#9:`Z.?I/JR""LL;8G%LPA(>C)<=UD17!S+>.31Q>;&6-F`EPSD.C6VSHW6 MK-Z_^;2XT&Z^JF\MI3MB8PQG/(`QV<$E\=/,7MX#ML>MU(=OIC5X^DE*+\=` MAYT$"#(*R($R7'Y9'6L<2X,2@8W%3"@[:).!9(@^O_-F0?^ILZ1RZ/K M8XUCR5`BL+$Y"I89M,E(,N27WX\=?TJ/]\G%58NI$&2*A40H8DJVH`EZDME, M@CBM<2\%"AMI#9)^DBK*0L"PE_Y$30*2GPQ75%9%&`=3'TF(L9SX9`%C,I#V M'/9-OSVE3_"=[:]1MY3S@'883GBB=F0'B\!GF+U4A]<4M_*9+CVLA*D.);;R&**Q<0F$Z"2@:R&_E<\CY>'0;_T7EA:7-C% ML<+"BJYG*[(#/L#SRUXV$VV(6[E,R#YKH/.3E$J&<,'>96NRHG\/#K8VUQ)88GIO M+>S[EO(1XIYH]G(<08O<2G8@0VU!U5]_DM++L2!B)_V!S>+G07_-883I%`<[(#5G%/-'LIDJ!% M;J5(D*'6H.HG*=$<"R)V4B38+"!%RG"Q9@S4<2Q%2@@[%E.D+.%.!E*D[:*W M9^.)$_K7\KS8VOJ`)+#$]#X5'$NR@TZ"YYB]=(C?&+/VV)S;6O3%,\%P M=O-B0G:0A_?DLI?/A%KA5B+S;)PUB/E)RBMS@KID:[!*;(WIL2K`FNR@4,SSS%XJ M`S?(K:P&L-,:2/TDY9/C\,/2,!5D%9#V9+B(,@+@.)8!)4,LZ-'2SF1P!+#^1#/DNQ`D^`Y9B\/XC?&K1R(8Z,U,/I)*BN+ ML,).[L.U",A[,EQ=61%<',MYY-'%8KZ3$7C)0*Y3H&EC8]?>3^CA+=N4=5&T ME.Z(C3&<\0#&9`>7Q$\S>WD/V!ZW4A^^F=;@Z2>IQAP#'782(,@H(`?*<&UF M=:QQ+`U*!#86,Z'LH$T&DJ%2O[E<7SNAA^P!$IL,EU=6@A3'\AI93+&\`;KSH)*!K&;0+G?JIW'/K^9K MEA(:G@F& MWXYL%&Y,3A8G8#YB0&)1 M:[P__?8'CP3F;YXSM?1,A"64#FC5S>=_K47Q'`GCQ'QO/HZ%!/^C!+);5+UM M=MCO@V.77CXYMO53-:Q3'U5S=#H9X_"S<9JJN69;H^JH-?@1[DS%-Q-AJ9VJ M>;KY5*VUB)LC86R/JJ7CV`Q56PYDMZBZ[^^6J=#'/A$W*:J"'+K;$UUZ#_/2*M&J7:>1M0G^5Q:>6HML?@2<+: M#(W;CVNWN'S9R`U8/M,H%8)7GO$+!F]9FC9 M:OBZ1&LXT&-EAXQ8@1%H:V70."Y+56["&! MN,K*3P$%KN8-T^K@6*M5SO5!#I-9$MO.AU'!]XSR@C.4+(=`?2@V>+ M#,&!,\/EIN+78%+PJM_"L+E#\>Y"*B`1\*:S`+::ITV0S>Z+\5 MDTD`I-M$(A#1[3@X0,\J(PD!QWP'DH*P589@PIF!>I,Q;3`YB-I@8?#>,0QP M(4F0!`'3B8)[*.!JLC#=5,C)8"O$72%'KF6GR&5&OQW$6F'D2P)LA>,P$O_\ M,I)4"!OB0'H!VV<(8IR9@F`'!4Q^CQ!88V&R@K.HX4(:DA@VC'^YH!+IIC3K6))"2LVG$,`9Y41M*-J/4.Y!@AHPP!Q%]^X,0" M"F>#V43$!'X*\9>,I1`*X>]"WB`7_Z:3!><`P-4,84$.3,E_02VC2=4O]FJS M53@6;)I@(F.`3'`<.F*>7$8R"+@5#F02@'&&`.6O/W!&$1?V!C,+T!1@%[N, M91@(,.%"II$,)TQG',X"A:N91[=8[>3ZR]II61B83#=X>DWD&"]Z'4<,WC/* M2#81,MV!%.+9(D-P\&\_<-[`C5^#R<*K?GZ&\&\9RQ#2QKL+:8%$P)O.!=R* M>%<3@#,]2Y,E>K3=]8OURWEJ,A,0&F`B)>`;X#A6")]:1I($J`T.9`M,)1+*X.!"1I$$'4RG%H["@ZLYQJ#<7A6*O6)A MXW=-IA8\O28RBA>]CF,%[QEE)'\(F>Y`VO!LD2$X^/L/G"UPX]=@DO"JGY\; M_#UCN4':>'-.9@%L1[VH"L"HMI_3`N-EBQ\B5;7K<9#(09X.)Q`"T MP7'0B'MV&4D8!,UP('F`K#-5(>;7'SB3B`U^@UD%;`M0.^K7C*48&&CA0KJ1 M$"Y,IQX.XX6K>4AKPK[:L!_+8.'*=)#OF)YK*6&&B6Q$9(;C$"/Q!#.2DXA; MXD!:(C#0%-+\R'4L9;#`8'(B-`?(3[)6W!()/%Q(49*CA^DLQ6WX<#51(2>G MN5KO_4!7T-`K+^R4R20EQ@03"0ID@N/X$O/D,I*8P*UP("D!C#.%*#]R^8C("F`(E(UJIJ(@"%"TE(,J0PG8"X"Q6N)A_!S!;Z6V/3[C4[G7K-Z-<1 M6+V1KR(<]8[CB.")9239X+?`@42#8Y@IY/B12W&*8MSDUPZ>&4!RD;6*G(J@ MX$)B(8\*QK]J.`D+KB84N:T_G?=:VR--P:KTE,E\`M9N(IW@:'<<..#GE9%D M@ML`!W*)J%VF,.-'+K8I"&^#F03/"B"1R%IU334\<"&/D`8$TVF$DXC@:A:Q M7/3>:J4R.5QFQ]ZW)K,(6+N)+(*CW7'4@)]71K((;@, M5P$;8&A6!<<`Q^%#^-0RDE%`;7`@J>":9@I%?N3ZFN)H-SN7@F<(D%UDK;BF M,CRXD&`DP0<+LRB:;0Y4*)#A0BJ2%#-,IR,N M@X:K*4FOWSNS#5FN@WUO\&8R$0%4FT@_PJH=1Q#@264DU8A:[T""$3+*%$+\ MR&4\H7@VF$Q$3`!2B*S5[E0``!<2!SD$,)TNN`Y^7$8-4<4%F:+&7NZ\<\F?^RQ/W;T<'E,O_04P>1`O\I(4J!1)286Z'\R M.I(`K58G)7]]QMPC/A#L$' MNQ&WB;G;>.`*.3O3D>L.%[-?%HLQ_;W#_CB0ZWV:NA3T4K*,9CW,+-3L7*#+ M/"=G>3K&>"MT+;()*_:=*==@+E2UDK?8`CZ':ZW-X%1HVZ'R%+&MG]$M![<[ MQ'X=%FLYOTFK7OF'+;S3IDYE>N@[K,RYL`:>AK,D';77"B^'S,"*5F>*&FB- M-*WL&U'*)URM]0IL1Z8=CI4+3?VT:CXVW6%2VF@V`R`X0CRV2P^-E_/<2B^M MRFC6P[%"S9"52M)BRW@,[;6P@!.A;8= M^DX1V_JYW')PNT/L;!)?COYV.!W:I>#3P3L\3KA9T"G<\$M?C;.LC-HMA5RYEN#%=?.+&TW$8Q:J1G2 MS6=FK>O7'0E>.\2<*'KU\[*U\'6'ENDW@USU;5*=;DZMP5XO'P/*]!!Q6)ES M00P\#6>I-VJO%+HUH?A+)MR#+9"IV$[L&+6F17, M>L--*Z%&M?(95>LR9>OA:8=2)>-3/Z=:"%!W2+5;O[V;!\5I=[MMX5TOL8HT MZB%7KD;G(ECT7)PE6C<]$L>B[.$C!@M!4" MYMF"5B#@UQ^*@84QJ)6!^9J!RAZ_.D_!JD%KAX(31*U^"K85MNYP\#P_[[1J M?JL^?Z/']=(OH$P/\X:5.1>_P--PEF^C]EJAVI`9:.'Z8U70@D)-*\%&E`+< MZG[9+(78M$.K@@UJLZYL`6? MB+.DRK/8"JU&#$$+W1^KR!4<=%JIE:,6(%?WZUDI1:D=>I4-4_T$:R5.W:%8 M^HY^&=8V)[_B5^EZY([^:<5\??IF%H?T.1>_\#-QEF:Y)EN;8OQJ"5H`_U@E MK`21IWVF<5@O0+7N5[)2"U5[$XZE8M7,G&/SP>H.V])*U^_LMW.QOZR3OS17 MB!0HU,.W/(7.1;'@J3C+N'R;K5`NQQ2T,/ZQRE.)PD\KZ7(5`ZSK?C4JQ7BU M0[OR`:N?=RU%K#O$V[^VIUUZI,?VD]R0J="V3!4W&6>/DV M6R%>CBEH8?QC%9<2A9]6XN4J!HC7_:I2BO%JAWCE`U8_\5J*6'>(MW.EYRK' M=K>Y9`]"+^V"ZO20;E2=)4HI2.S0K&Z;Z2=9*G+I#L:5NCYP\^T?ZQ[+&CK-L0R_5QJK50[FP6N>" M.O8).4O!(LNM4#%H$%JH_U@UI>*#4RLU"]0#%.U^H2F4:+9#U4G#63]E6XUG M=ZC[W-G3?P;3]SEK/3MQ;N@E[ABE>F@;4NI[7:C(3'@VWX_.NR_ MK8:5V4>?6'"8C?:Q[6>-WF[)!>Q0I=7<%;KP1@AZU46(69,ZS'#6^T1TD+$V MBY/2L!Y#8D+WKI2="-1Z1*_WI-AS9F&OYG"#2%>76H!N=;*M_?!,S+-&XU/( ML%D,4"=8M5*=7LNL5%>S_-:F<\*'VBA5H`N=3WFZ7(I6P;-PD4GYYIJF48X5 M""'JS!I>G?&EBT"Y.OGLJ77QKN5X-$Z=\@&IE3>-1Z03I%D=](>-MUUM7V2; M$VHC3$`/.EF&];@4F,`S<)$DHZ::)LB0!0BAZ,RZ6UVQI(L8(_KXI*AUF:W% MV#-.B'+!IY4,C4:?$T2XWZ'O:RRD")T*(XI.4H#H]XY11=2X%J?B)N,B5H,56QBDCAB`$K3,K6C6'F]9Q M2HY:/H=J7H$JVY92P_D\#68H3P>'M[A'77TJL-_ MZ^2KC,FE)=L:2+)"/Z^.RH==&HQ=@S3HMRP:>5#XU&GQ-$F,]5]_ZB-*\N%V_: M6)"G!)T"7Y2X%(.\UKM(?B$[33/?LWJ$P'-F;::6X-'%>:_*^(2G=>FEK6`S MSG82T::5ZLR%FQ,\-\B=AILYK?9?(AA5:;9IC86,PED'_^J,PK40, MZJ);D6J@8,&O+I,N3M`:9][$4:N5?JV%K1,D',PK'E?8N6&K=BEMM+&O0!D M5OHT'Y-.\&;O.#@.Z3O[F/ZHOI?(!=J(4Z0,G3FYREP*5-'3<)$[`7M-DR?/ M#(Q(_6&J_PBC3!=]\I4"_.ET`2#5L#1.H`GB4BN#6@A,)RB4_<)>M,F9>K'4 MK!]7G:,V$A6K0Z=10)U+$2M^(BY2*6BQ:3+E&X(1M3],O:"8>--%J)!:@%*= M+A^D'J#&2351A&JE52LAZ@2QGCNU(CF[[*X&K?.YD959L2J_5PJFUI1=WSJ@>2H#Y5$2+4 MH`HS)O4]"1V$J,7:I*2(;\0].EL$"IA`&I-4C4?U[+W?5^/U;AEL./0/.5B<:8PXB31TJ+6QQ8C=&$W.GL2`5\NBE-=Z%SDT9*=I]GQ6KS,BG1G@U!)5NACS59F%#4UL M1:%QEI0(0ZW\Z$@L4P1WW MQ^BOZ4.X';R]CNMY"CJ:GZ#=KPW6T]"G3QBW)_JMOS_L/@;(?2_4$_]`X-OO M#^GN#_\,7_H_]#\\W0\MY/L26K\,[I?_/HL[D>]?[[_A@[`;^O=:#99!8`VN/B[C]6>`#U) MI(H?LU5EO=_G1B2WHGNCXSZ>9(KCGV`">?>'?+O%&YT'4R)\Y)&4$!W*OF]& M.Y*8KB;_.&]&JSVVE_'$QS^LR%TA>EOO#T'TW<]K>RK!>!'M'DW/Y45!@B?S M==_]V=#?/?KR[-TN6J_0GTMMO5J_6G#K`3TYI8RZ^&<6*^7^!+\?IJ.==QLB M_.?8V]#!#M1HZ*FJ/; MW6A*'O?L.`K4$E7?Q^CT)U84_U0$]S_>YYXOT?*T"B.B8#!C4$A2NV_+]>XP MN[Y\H<)Y6F)%\4]+*WAWOKU MS8TDX%Z?GO8&3^>Q'A+[;,@P[=OP__W<'^@G.B30@43#CX1[1^@KTM<);#\A M<;P;D0==&`7__K[Z-ABL/XFFYF@PFAT_^@MDJI+4&.]#,H(>H78[X^T>I[Q_ MEA&`GA!$E=9WH\W';'B?KW3/2%9#QK;AA,:]I[Y>SFWB"]PPR_[&9'3X6VI]@5%^J)Q@2 M\YSNW=[19ZN;&S*_7.C[!DETTN&C^FY]G`U'P]SE/P@#/IGX;7"8'35\GTVD M5RI]EA3W_+#9P-G]'J]_\1[7>U\WX&8`7Q]LV.<'S`P@*CHN`PC=\<@`OHX' M'TD,.=W;;/6Q&IAW.K[>U$['$2=TNL?U&ISN;FK]X\)R.7_];;#]G.U&Q`#B MZX=+G;3Q0)B1?G/>+-%'IA+IC7_B\N(>6=AP.&/?L+S#VMOURD*6L"0NSWU7&TMT!/?+VID8(C[B47 MH$CQ2=](23HPNU_K?6A#"6HC"2+Z#PVDX\>"ND1]M)NMA^$T!OE#43+-$E^. M$@A\6M7!_J:/FZ$TA0GVRY,(,\]_=E"4[G M8T=2F_\;,353M2,FCU,2?^^RNQ`O MD.)1`/H^]B*Y(#U([O78S1Z1=OOM<0RU![]-J'?<;4/LDHC@F&?\>OV##-E1 M[WY88]/9UTM]#^`A/M%C".X"'H87G-42T/\XCW:#&6%'Z+%LR\!ZW1(+I M<4;O8T#W#EA#TD?RZB/1!Z/#35Z]5(>SP!H2!5#$<<(QI,=_`",T8TQB7Q+> M'OO$=#C6=S8)7XM'<43'/)[P'8\/L<%Q3;X3UHKN-*""A(_CU4TB#P79/5XF M3P8I5.%S1U[7@E>.]L?B'Z7KHTT$B?W0^Y!;$2D0`4;4C!F>4Q-][YB'$"Z1X3`QYB?*((.\A MR;N)\@)9WG\R:1X5YS%Y_P]J#WXM:V*><\-,&N3,;6KKXVC9'^W\TYH66[PM M92(O?N3_VGH3TZ:8GD53]8B_IT5:P023.PT]A'IWJ1Z1YU&Y[!S8S6EZNY[!UOL<6[>__PH;D.*EV^KX?W;R/==DR+2XY0) M-]!BI[QOX*OG.@Q5XS$]WK.BD"?=!;*:<(\/5M]W7J#OZ[PQ-[H9\9+R$#_^ M;CZY3VN)M"ND4L#K[)N@<%9'P_^[_>S]95+4CIB>5 MQ#^FR3`AM`_O8KZ"CXY-/Z+Q\4N0E%-Y7G/B53PJTJ,RO:[=7JPU>O8+-'!39A]RZD"J6G:U[#ZSU-6ZB3OVI!UEZ=LZOM]GVG4]S1;S]L M2\WE^;V0J&@2=J]SK<'N[Z@2E)[ND/\5=\&'M)MH[]TK3'$Y=S99S<:S`9US M&BS?H9_EUXO90*:D<+W0;I6H@76P" M5ZA[!:_MM;R2=]/B$34.^4&AU2A1")H6]LU*$7O.F0[;M/H#1R6^3Q2(/S2( M1S!%7F'O-4D*4-0P<4WM66P7]??AJOIVJ+6WSOA$R"BMSO"L"]T+M@N"#42\ M5_7>#B0/:&\=ZOI^Y7VR(`=;2S9&T,DA+&/@$`HH2=:BUO M`S,=+W=VR">:@ZK?;B[HL3S]T4Q4>5JK3W!-T^H348WX--$<$&SP2?;07`3G M\L$_3:_GD%ML>N-#HYQKE/N+AC,.$3)*JRL\ZT)W@HU'I)-DH>SEZ,_^PFLX MU/&J](0SGB6R4*LS@8K1_6=,J(AY M!E/F$6T$DI@^FL&2"QQRF$/]\%;8CR]T*.6P<<9+(F9I=8U7;>C^/ M:@B&G`X;ASP@3\X>R<%KO7+*]R_N?-/@&*;5"\+Z\'DE3R\[TE-7\D9;.7E4 MC4.N,&<@];:GX+6EIK(S10IC[\ZX18R16EU$I!O=7>8WSGC;,S;9!LX3G"\& M7\S?'7*>"OTQ.5XG+?_4]E&'J9'MTNHB(77X(%+Q[AJ\%KF`O/3Z%-Z)1PVMO^>B5V*4U\F_!:WHW50XY!0.R!AL? M'E/@&@^&W47;&<<`S=/J''RM^(`1L$@C&#S=57G?AM1URD>UF6VR_K^BQ M,KFJR)S8&0^!K-,[J,)3BC^ZLMF2=*+MO:^",V5V1S%`$8<<9#P>'J:57H?Z M+_VO67#&.[BFZ?V8$=&(_Q6#JB#91L_K!,DF^]'T"J@^$2Y;=6LY^\;'%>5W\25.RS:JV3Z==Z^`3%ULM,;]PIS8`J;]>Y:;L*J_J43%>Z^#Y M'I.$_#U9MC4^PWMVR%].+C38*>>PB7T6.BW&'*0N%&E)VZ'^;:0@.$[%!L@9 ML&HPA]%.#Q,.J4Z+E>%R=YA@3EA,;0!6+[[(3=UOE`*]ZI1TTDV2B5Z"*;[' M?MO..\S07FT^?#OI[[3$]J3KPV1J)+HT]BVHY]T$DW0FZ/J>1X1[;R>[W;PB M!]I^<55;[,[7NLT.CEB"W;6O"A`Z=<4.M@GD%E<>D^K5[?8F^_I7K>XG[,B5 M7+AH87X*13,(NV^Y>C#B-OC<2=(D(CLX?J4W+;P6[E?/Q"TF)UFB,"27U`?D M1YG-1D`>;$%.1,0W9Q?<#^*=\F7N`/IM^WH*C,!G0+BML& MAU#B41BR5&_QQHX.Z*%Y8XS\;HIH4DSO8VFZ]_Q=GG<3>-\Y,B81*PR##'KA MO07G!NSXW&N,\=]BD[69.%^>C?;UWT_L1"&8YUJSUM\BBU"[&U2DV-LTGO.W M\SO]J9`(8:]&-*_Q[EV#Y/.<:Q![6>N$L4^;F](?S*I MP:LPD^OE2.;6PR5Q85-A%KM>:+GE_-MIR<9E9F>VX,U4/Z>P2Z7'DZJ3[_LX M.B?RV75Y\M*UO(U-D5N"=8`N^,&RUY_G5EUZS>5RM-__$7OT]/NK&KS^7GI$ ML)=;>=W@7?KCPIE<4G]?^3G[O1RQ1T\OOZK!ZV4JURNSG4;LZOE\M9L+5A_-G`5?+(EAS8M_T3.DDN/9Y:I0ZM>!EV,LR9+@TY4` M[^-6W%6*29JY:1?IQ]K@_[G:H(3YVJ-L"&)_1N4K=>:&O+P6V9?HQW\YKS;P M2LAO,DF:6.]>WYN]QJ15:^TL]6+(!,3^>Y:LEO;4O>[5>Z=K@[T&G4-=\UH[ M:WW&?JG43N?#N]\^EC"KRRB:@=AW8>EJ_1?\6O&H/-*/OM<^>B7<0C&)4H#" MN3!LY;?M\SOF\*V""9CYS9-DQ:2&O"(6AB3<\ENO36L\X8[4)FE4D"BS/YLU M?U/TR:76(@\T!K$7^3K4HO#VMA$<:1(0]3=TTC"[T68T-GWZ-YO!M7O/D]-= MS*5K"*9@1B='@V*4-DD7LH/!1+4="=0\N[*+O-@L23MKTV&SL[:^ZT2M M0.R]D'"EWML-V#]3K]OW:GNOT2=YJKUO.CERUN]WYKUF^9S#7!NN9`1BU[W* M5HN[7+"\O^]UYJ33FEZ9O!3BKN_.?VQFAX\%*X`="%J^=CIFLFZ5WN6[MD&(D%[8V)#WQ]OWN5,PFEVG=]OKY55E MTAK.ZVW_7$7-=!1LP.S/9]&*G;CR*N1]?S@G/=;V_+-7Q4YIDK1K6JB]^VR4 M=,>.E5?6`I-O"F8GE1>=Y-H) MM0^I//**\78./@J,26@V;*8]U6.1#M:T@AIQUV$%<[$3@BFHZ4Y4@WJJ4SUZ MQ6!+XCO[/&FM,_FVH/8G1X5ZES9N'UIO^>FM?1RU0'F]#H<:S`[EZ]$M7M9O.98R`8?'X*J@3FO.L">69>D ML:W2<$/.'MK[P6F%79U%W1+,?HTJ4.W3ED=$TLL.'A.JH;I*LA8&<_[);_U& MH=YB=5"/UEY`06M0.Y6K1+UC;XL=J%R"RP7Z.>A6YO5H\5VTTMW0?XIMOSWW M^Y@+QQ7-P.S2D'35OJQXW4WP6Y$M*F[//2+57A\N)OT66Q8U';+5.>P$/6"K M-T4&8?8KJ$>QAXE<.M\GD'Q;GW0[30]:S)W(?]O)UE\%+^5E ME442)4*A->SI08E:Y1?>Y]W5J=5I-ZUUVJL-J)WV)%JUTPA+%KSWN4?$$63M MT!U8[/5;CFT53P.?G*FT.K5K4.0?=04"ED&8/0KJ44747$"2`9C2"RJLEVO7 M^W8&R,L1DC1ZPASPL&<'3A5ZKGQF9MGJ;J%%F/T-*U+L$EWDQP<.]'RC_2* M\CGH<'N]?>X/KN53,=]X.V,NP%>Q`;-'GT4K]B$5Y95/Y!TF3S_^GG%7V"=J M%?MERCR'_2AM:LTZO8*-QMOJQEBK,#M6K$P5GP/I-S`.?I8V)'EJTAV3Z;5, MB\5,JMF\="F%U*?-:1MU/:Z:&:CYU*MTY92JZ34O7C=@WOK4:TY)5H6\+#=) M\S:E;J-5N6[8@4[;VJ"`XMO-*1\:KE\=-@&BLYNEL6WNB92VEC;?@4,@:S9[DZ M%+OV/FF72:45XFZS'8ADBP.GC6'NC5Q1G+X_CMD<>I/4[KWW+2]"[Z$#ZU]>@"M07_;B2A!>>$)DN-W+S?UB.3@&]/0 MYN>(XNJM4Z[O:S2ONW:LO<)&S<#LT)!TU9XLK@@`=\A+3WU/PI0)]3H6WUOK MU(3V]#`.F&>Y1RV^H&P)9D]&%:AV9CWX,DAE/BB6B+77F]=);S*H!_,XS(L7K$?KQ./R".]>9^I0F5:'%]K+JJG^:,2-+/PC+E#)XXUJ&-N M7"6JHV]><^$1L<\UL`/)R+MM)FHJ_:-/?["TOE/-E\GE'7;:5A>+3<+L9X$F M52QFHK]&V@BY=KRJER?13&_O!)=:G%98J9&3T\IQ/FR>K'V>B%B!.I'P1;CR M#$):5HQ>-O6H1(^(M/@EHOG^?I[G]^0B^F>3_K#V%8)O"^H7"(X*]:\/3?+N M0L1Z^7VP/<&,K3FF_U@>2&+36F MUPZ]+BU]?&/:G%>TRZ_E^7Z^O=3\X]A:=T;-P.;1)^D8W.D%\NBWH^/89@>6 M2H4#'8=:]%JGPINM_HM8@=E]K$5>Z]$_D?D!5NQ];S6B7Z_MU@$9S"=;@[[ M29U5&1G8ZL"H&:BE<%ZEJU;#N4FCKZ#!6+B][JL5_-R2OBL5%O6&?[75?5$S M,+LO)%TU`FMTCRPOMPS>,0L+TH\-S[]:G"A6).>Z=!7T6^&=KGJWQH-<2U`G MBT44*$\7*[)KNL%:[S>ZJN*VQM]F6M.[=-ILI'95OO9M3DGA6H*:W$04*.!27' M@J^X;*.K.1O7OB]![%R)"^3M=?KP5OO[Y)4NW0FB1K':[@*9]P/]LYMOUHJ5RM9:W96H&9B]&I*N&KCOA^!0U\NS M$N9%K^)5MC:+K)3VYYQ//T_O!U??&BI'K$!]#WT1KOP>NJ<;K_C!]W8BD?QJ M$6S9%13]Z1\GY^!S<'L4$"+8L_>+F53>9E@>M?%(Z*MON0<@K/D M)TW^<_L>@_V%M<7]`GLP^QA2H]C)A\=5]-_@S2>WI]^3F'B;10"FI?YR.*!; M1ODKW]J;;,0*U*J\+\*5"_(&TH(+Z2Z@%E]K_T;?NX;6.A&T M!G7J/5>)\N3[0"JMR,'DTD^%["UV:+5[9^=>E[U>U6O'93`)=5"SUKV0-:C= MRU6BW+VTNBM)?X-75=+)Q^5M3N_`JUF<479B?E=FIK"O,B5RR;9C[:559!#J M'#-(C^IDL]-ME+1\Z^KV?12'BOM9=E:$$?-P.S7D'3% MWAQ[E>/M&Q/IS[W76I)_+89KOD*-&>QJS7.C/[=&LU$S4(NFOTI7KIE.9QHQ M@;1A+)WAZ<%9/Y#TJVBL@09X>11_LOJ&XZ,=>AO/+%*4=Z`;B\]P>[=P>@[_2YU2YPG3U72 M['G(OG&E_P1KZJE!I\K1VC8)D#&8_<_5H=C=>Z]Q#4K%WHH(L*X]D83+XI8) MM.I%;C#QE^0$FRPPM[9>BF\*ZA!/5(/R,$^P/?M@XOE+=L%-+FJ/?AL.9X?9 M>O6QJ'_,AK/5S=A;>]FN'O>5)O38;D,,(69=Z0M>\[U=Q7RWQ;`EID^55=P[ M]4N0%TCR[MW\Z.!@`Y.O]32!0-:35&3P%LMF>K>]*NZK;,)FTM$/^B\ME/!6 M8J&W3W.L`.MPVPL2 MD+S%[H8-PNUL0(]B5W]]E0PJSPZW7N^1:GEYJUV])&9UZG8%$KS=E!\ZD/\M#F_U9;'0'?LT_'XEA-(^TUYT<2W![,ZQ`M3/I M@JKN@(`MZ=7SD?8L2YEM]F9^,;@>FH-SKC7`W.!8S0K<7GP6KMJ#3)9'A!$. M;0V0MSA.V*[>P>_2?]L3O_1&Y\G;ZS^>*;B=&-&@VI,]DN^2Q(?]WB8OKR3O M?0L6!5@-QV6CLST,QMTS3-R2:"5"?2ZYR"IQ?V>G+!Y MU5PA]W;J]O?7AL5O#R$K<'OP6;AJ]U4)G!;H:\G)HP*]AM4/#8/^A?W=9Q^= M6V/V1[`#"/V!N4X'WS+<3HY3J-CQ1'QPJ'^;.M$:WRZY[8K"E-CTA[^:%;A]_"Q?F_8M@R:O>ZCZS43HBVF8'7X_7U6-T8[LXG(N8);50 MC,'M7(X.Q:ZE$I]&=*A,NCVG5?(];0?DN'\ML*^@DZ5%MN68@DRO80VJ?$KD ML9/^E9:,8-][)TN;W=D>GZ[GPNK@E_:8.]&K68';B<_"5:&6R?*(,/I"ND?> M<3YANZ8#^I/`_:1;*`XJ9N28"P.O(I7QBT# MDC31HU^GIY,)_?UM,EY5+2:T'%.0L]JP!M74-O@43R3>!M.(3*]JLSLON]W1 M]^NKP8DXF<5/11$[<#OR5;QB+U)A!%I]C\ICJ:S5ST3U4_'RUF8N2KBZWR/7 M6'Q%`:S![4Z>$E76K)^\XL5[\]I?X]Q]KT>OM_J"-R]^W22%3V%O&$)FD&X MO0KH40U5"KFM$^E:(IE586(3S=A%Z!N6)!UBZB^7V]*IMJIT,8L4JEF!/(KV M)%QY`(W*\DHGK[8BF6T7N4!APH9MV-*M4JUUK=+!P:G%=(AG"FXO1C0H=N7F MMO"M1,LS7[UJ,`PZM9L:L3(59_^-?9@J#TML*("]6=F=_P?:A#\%D*\*8Q;@ M_,S6F@?3N,M#.LF7C;$:VA"IJXL?!"DLNEUJ\$%1.ZK(!0M6"LHY-:I=3?B90EZ/:X=367 MBU?KD[SJ7CRB>ZO35/4*3CC`EGZ-Z50*;('8>'(U]W$XF4V:.C^B"K'KMZ?; M3.X*+3Q\5^!$KQ\6].>9X=!QV?*#.I`FIQZFLTV3%X`J$;WAL+AM?733XK4( M)GQM'^B$6PR8;3U64^6=$N*B/L1<18EMER9WX*I#=(7!+4_HW2O,O`>)`I$X M-+G>4EA(J5ZO#.FQ^?APW'0<<`*>39H<(*(*L?/9!77RO\K0>RCP.DYT>W\X M&5<+J_J$?2+$+(^+9Y&F+@\I0NQP*IFF>RN/"`^F-./6SDW;Y!.;A-0:M(K! M.M1.Q]S7MJ16:>IUCC+$GC_=YF2U"."3-[_;@ER2$':,?I*#FT__J$TZ]`+Z M>I*?3QV#:#;+VRHYN"*7 M;-Y1-ZM%-$F3%X0U879^D_ROO*5?YHE\>OG&>T?>T#9MLU?E=J<_.0\ZIY4; M[X$1@S3U]ZL>Q-ZFE;':'I/M$>'.O.4U#UN:A939@1R=7WZ8FYO5D-PN77'. M4X<:[(=MD.Z5;T=SP9S[P]SH5`CX";!?:JRB$]U0E-K:;.5V"P=\06":)G>` M-&)Z1/!K+2BB%>RURARD2?)#HLH)IZ`&O=UR;FY!>6*S-#D#3QNF M([!>?_?JFZ][VA[58G0E.MS^.?OM4I@W)^0Z-J5ZV7/`"R"[-+D!5QVB'\R# MWR]>8>XU)_26P:T$3,\)-RBL5IU@)=I[\=RF0YCFUGXDM4J3"W"480(!$4_> M!&\+\P@B%&E=`'+)"-S\]V8YO^^P\8LAW4,><[B<8(!K2:5OD)MRMF=(V?9F;O+5S^7EI>CPXT.DA>KD) MF]:>\_)SCPIWHHOG_7J[4:6_'8N5G&^P!%0RFW2Q>U@5)K/WO3KI[X9797\> MV:YY.<-%HN"F[Q>E]FE,>6;3I!OTNC#(R[-)4\]'5"'V_'[AE3PBG;'XQFNR MO8K=&-7ML"RC6"#'_5O=X,ER6':@[V'+-'D`H!"3WCNWI*Y(MR`_K;]J*A-% M7MD)AV@MK[4A]=-M=3I9N$#S48MT#?&_*D(=X%]>O=J0Q?_68]*=Z.P>_6NS MN#;RVWR#'C"W;#BA4;J&]R*Z4,?UO)MX0OKYK95](EDKWPB MW4^$TUO<2/7JU=V^T"N3:_S=T%R9RP0&:>KI5SV8/5WWB&CR)M!WNWY_LYNX,#@3,D?7;-TG+9A3=0\#5DRZZS'1KHS!E#8]1BGG_.U; M18&=<^&CG<@V76,RD$K/-P0!`F5.>,8X5^W,2P-FY;*V M=P'I.29I\H.P)L3N'Y,WNJK7F7NE0>`"2X\H<*++>\&IXX1.(5F^#[:3K0.] MSK=*5SH758;[(>=VR7'"YNDL/:;"B=YGO]39S\F`@2'[?57KFRLWEM8ZG:]Z M?*7X4_?JWDW1G24"71Y1YH1_!/NZGD[L0/N8JZ\,UMU-;)8FC^!IPW2%VX:V MI]/M8/M(Z((J<<(%Z,L/^Z,XWO<[C6IPI0-.`!JFR0WX^C`=(7@3#`Y0)5Z' M#?C?[G/"&YBG3B\#<@6=PICK+W==!WP!,$N3)_"T8?K!77Y0))C>0E5X72<\ MH'P)R+$:[/P1K&P/M@$QMS5C:O-T88-`*RI"7.XI`UWS%>R,2> MCH+A<&K5=#=G_Y;FG6&37,O..N`C0N-TS0\`=:).%;AIN7E%:>YUAG0V,+F/ M7>6$;]39QK7+P:#YSA+LLPL?GKA&Z?JJ'-&%^V4YV+V7R*?;

XML 122 R15.htm IDEA: XBRL DOCUMENT

Additional Paid-In Capital

Additional Paid-In Capital [Text Block]

7.	Additional Paid-In Capital

	Stock options

	During the three month period ended March 31, 2013 a total of 50,000 (2012 - nil) stock options were exercised for 50,000 (2012 - nil) common shares having a par value of $0 thousand in aggregate, for cash consideration of $23 thousand (2012 - $Nil), resulting in an increase in additional paid-in capital of $23 thousand (2012 - $Nil).

	Compensation expenses for stock-based compensation of $18 thousand and $15 thousand were recorded during the three-month period ended March 31, 2013 and 2012 respectively. Of the amount expensed in 2013, $13 thousand (2012 - $14 thousand) relates to stock options granted to employees and directors, and $5 thousand (2012 - $Nil) relates to options granted to independent third party consultants. In addition, $1 thousand was expensed in 2012 related to stock options granted to investor relations firms as compensation for investor relation services. As at March 31, 2013, the Company has $50 thousand (2012 - $69 thousand) of unrecognized stock- based compensation.

	Warrants

	During the three month period ended March 31, 2013 a total of 362,500 (2012 - 1,206,418) warrants were exercised for 362,500 (2012 - 726,830) common shares having a par value of $0 thousand in aggregate, for cash consideration of $172 thousand (2012 - $233 thousand), resulting in an increase in additional paid-in capital of $171 thousand (2012 - $233 thousand).

10.	Additional Paid-In Capital

	Stock Options

	In November 2006, the Company adopted the 2006 Stock Incentive Plan ("Plan") for the purpose of issuing both Incentive Options and Nonqualified Options to officers, employees, directors and eligible consultants of the Company. A total of 1,600,749 shares of common stock were reserved for issuance under this plan. Options may be granted under the Plan on terms and at prices as determined by the Board of Directors except that the options cannot be granted at less than 100%, of the fair market value of the common stock on the date of the grant. Each option will be exercisable after the period or periods specified in the option agreement, but no option may be exercised after the expiration of 10 years from the date of grant. All options granted to individuals other than non- employee directors will have a total vesting period of 24 months from the date of grant, with one quarter of the total options granted vesting and becoming exercisable every six months. Options granted to non-employees may vest and become 100% fully exercisable immediately upon grant.

	At the Annual General Meeting on September 8, 2008 the shareholders of the Company approved to amend the 2006 Stock Option Plan to increase the number of shares available for issuance under the Plan from 1,600,749 to 2,074,000, or 10% of the Company’s issued and outstanding common shares as of July 28, 2008.


	A modification was made to the 2006 Stock Option Plan. The life of the options was reduced from 10 years to 5 years to comply with the regulations of the Toronto Stock Exchange. Accordingly, because the grant-date fair value of the modified options was less than the fair value of the original options measured immediately before the modification, no incremental share-based compensation expense resulted from the modification.

	At the Annual General Meeting on June 3, 2010, the Shareholders of the Company approved an amendment to the 2006 Stock Option Plan to increase the number of shares available for issuance under the Plan from 2,074,000 to 3,308,127, or 10% of the Company’s issued and outstanding shares as of April 5, 2010.

	On May 12, 2011 the Company granted 50,000 stock options to an employee to purchase common shares. The stock options are exercisable at $0.52 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $16 thousand, using the following assumptions:

	Expected volatility	115%
	Expected life	3.1 years
	Risk-free interest rate	0.96%
	Dividend yield	nil

	Expected volatility	101%
	Expected life	3.1 years
	Risk-free interest rate	0.40%
	Dividend yield	nil

	Expected volatility	83%
	Expected life	3.1 years
	Risk-free interest rate	0.40%
	Dividend yield	nil


	On August 8, 2012 the Company granted 50,000 stock options to a consultant to purchase common shares. The stock options are exercisable at $0.55 per share and vest over 1 year at 25% every three months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $12 thousand, using the following assumptions:

	Expected volatility	81%
	Expected life	1.8 years
	Risk-free interest rate	0.38%
	Dividend yield	nil

	Expected volatility	78%
	Expected life	3.1 years
	Risk-free interest rate	0.34%
	Dividend yield	nil

	Expected volatility	70%
	Expected life	1.8 years
	Risk-free interest rate	0.25%
	Dividend yield	nil

Information with respect to stock option activity for 2011 and 2012 is as follows:

			Weighted average
	Number of options		exercise price
			$

Outstanding – January 1, 2011	1,698,088		0.53

Granted	290,000		0.54
Forfeited	(150,000	)	(0.76	)
Expired	(65,000	)	(0.59	)
Exercised	(775,000	)	(0.41	)

Outstanding – December 31, 2011	998,088		0.59

Granted	195,000		0.57
Forfeited	(45,000	)	(0.49	)
Expired	(32,500	)	(1.15	)
Exercised	(50,000	)	(0.55	)

Outstanding – December 31, 2012	1,065,588		0.58

Details of stock options outstanding as at December 31, 2012 are as follows:

	Outstanding options				Exercisable options

			Weighted			Weighted
		Weighted average	average	Aggregate		average	Aggregate
Exercise	Number of	remaining	exercise	intrinsic	Number of	exercise	intrinsic
prices	options	contractual life	price	value	options	price	value
$		(years)	$	$		$	$

0.31	25,000	1.25	0.31		25,000	0.31
0.37	75,000	2.67	0.37		75,000	0.37
0.45 - 0.47	175,000	1.42	0.46		175,000	0.46
0.51	40,000	4.50	0.51		0	0.00
0.52 - 0.54	270,000	3.89	0.54		147,500	0.54
0.55	50,000	2.67	0.55		12,500	0.55
0.60	55,000	5.00	0.60		0	0.00
0.61	125,000	1.51	0.61		125,000	0.61
0.62	50,000	3.00	0.62		0	0.00
0.85	200,588	0.63	0.85		200,588	0.85
	1,065,588	2.60	0.58	114,050	760,588	0.59	86,725

Warrants

	Expected volatility	117%
	Expected life	3 years
	Risk-free interest rate	0.69%
	Dividend yield	nil

On June 21, 2011 the Company issued approximately 0.3 million agents’ stock purchase warrants exercisable into approximately 0.3 million common shares at $0.74 per share which expire on June 21, 2014. The stock purchase warrants were issued in connection with the June 21, 2011 private placements described in note 9. The stock purchase warrants were valued at $153 thousand based on their relative fair value, as determined by the Black-Scholes valuation model using the assumptions below:

	Expected volatility	117%
	Expected life	3 years
	Risk-free interest rate	0.69%
	Dividend yield	nil

Information with respect to warrant activity for 2011 and 2012 is as follows:

	Number of		Weighted average
	warrants		exercise price
	(All Exercisable)		$

Outstanding – January 1, 2011	21,291,223		0.66

Attached to private placements	2,748,165		0.74
Agents’ warrants exercised	(299,406	)	(0.47	)
Exercised	(4,366,904	)	(0.51	)

Outstanding - December 31, 2011	19,373,078		0.71

Agents’ warrants exercised	(219,313	)	(0.47	)
Exercised	(1,205,668	)	(0.48	)
Expired	(11,843,932	)	(0.80	)

Outstanding - December 31, 2012	6,104,165		0.59

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2012

Revenue Recognition [Policy Text Block]

	Revenue Recognition

	The Company recognizes revenue from research and development contracts as the contracted services are performed or when milestones are achieved, in accordance with the terms of the specific agreements and when collection of the payment is reasonably assured. In addition, the performance criteria for the achievement of milestones are met if substantive effort was required to achieve the milestone and the amount of the milestone payment appears reasonably commensurate with the effort expended. Amounts received in advance of the recognition criteria being met, if any, are included in deferred income.

	IntelGenx has license agreements that specify that certain royalties are earned by the Company on sales of licensed products in the licensed territories. Licensees usually report sales and royalty information in the 45 days after the end of the quarter in which the activity takes place and typically do not provide forward estimates or current-quarter information. Because the Company is not able to reasonably estimate the amount of royalties earned during the period in which these licensees actually ship products, royalty revenue is not recognized until the royalties are reported to the Company and the collection of these royalties is reasonably assured.

	In August 2010 the Company entered into a joint development and commercialization agreement with RedHill Biopharma (“RedHill”), an Israeli company, for an anti-migraine product based upon the Company’s VersaFilm™ technology. In accordance with the terms of the agreement, RedHill made up-front and milestone payments in the aggregate amount of $600 thousand, of which $100 thousand was received by the Company in 2012 upon production of pivotal batches. RedHill is required to make additional milestone payments of up to $700,000 as follows:

	$200 thousand upon the filing of an NDA and acceptance of the filing by the U.S. Food and Drug Administration; and

	$500 thousand upon receipt of U.S. Food and Drug Administration marketing approval for the product.

Product Sales [Policy Text Block]

	Product Sales:

	The Company launched Forfivo XL™ in the USA in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP (“Edgemont”). Under the terms of the agreement with Edgemont, the commercial launch of Forfivo XL™ triggered launch-related milestone payments for IntelGenx of up to $4.0 million, of which $1 million was invoiced by the Company to Edgemont and recognized as revenue in the fourth quarter of 2012 and the cash received in February 2013. Additional milestones of up to a further $23.5 million are payable upon achieving certain sales and exclusivity targets and the Company expects to commence receiving royalties from sales of the product in the first quarter of 2013.

	Upon entering into the licensing agreement, Edgemont paid the Company an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over the period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $923 thousand at December 31, 2012 that has not been recognized as revenue.

Use of Estimates [Policy Text Block]

	Use of Estimates

	The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management’s judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, the investment tax credits receivable, the determination of the fair value of warrants issued as part of fundraising activities, and the resulting impact on the allocation of the proceeds between the common shares and the warrants.

	Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions.

Financial Instruments [Policy Text Block]

	Financial Instruments

	The Company estimates the fair value of its financial instruments based on current interest rates, market value and pricing of financial instruments with comparable terms. Unless otherwise indicated, the carrying value of these financial instruments approximates their fair value.

Cash and Cash Equivalents [Policy Text Block]

	Cash and Cash Equivalents

	Cash and cash equivalents is comprised of cash on hand and term deposits with original maturity dates of less than three months that are stated at cost, which approximates fair value.

Accounts Receivable [Policy Text Block]

	Accounts Receivable

	The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible. In the first quarter of 2011, the Company wrote-off a receivable in the amount of $53 thousand that was owed to the Company by Circ Pharma Limited, Ireland, which was deemed to be no longer collectible. The Company records recoveries of trade receivables previously written-off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2012 accounts receivable (2011 - $Nil). The accounts receivable balance of $1,282 thousand as at December 31, 2012 includes $1 million from Edgemont that was received by IntelGenx in February 2013.

Investment Tax Credits [Policy Text Block]

	Investment Tax Credits

	Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed.

Leasehold Improvements and Equipment [Policy Text Block]

	Leasehold Improvements and Equipment

	Leasehold Improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows:

	On the declining balance method -

	Laboratory and office equipment	20%
	Computer equipment	30%

	On the straight-line method -

	Leasehold improvements	over the lease term
	Manufacturing equipment	5 – 10 years

Intangible Assets [Policy Text Block]

Intangible Assets

Impairment of Long-lived Assets [Policy Text Block]

Impairment of Long-lived Assets

Foreign Currency Translation [Policy Text Block]

	Foreign Currency Translation

	The Company’s reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company’s Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows:

Assets and liabilities - at exchange rates in effect at the balance sheet date;

Revenue and expenses - at average exchange rates prevailing during the year;

Equity - at historical rates.

Gains and losses arising from foreign currency translation are included in other comprehensive income.

Income Taxes [Policy Text Block]

Income Taxes

Unrecognized Tax Benefits [Policy Text Block]

Unrecognized Tax Benefits

Share-Based Payments [Policy Text Block]

	Share-Based Payments

	The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation—Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company estimates its forfeiture rate in order to determine its compensation expense arising from stock-based awards. The Company uses the Black-Scholes option pricing model to determine the fair value of the options.

	The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year.

Loss Per Share [Policy Text Block]

	Loss Per Share

	Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share.

Fair Value Measurements [Policy Text Block]

	Fair Value Measurements

	ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires new disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

	Level 1:	Quoted market prices in active markets for identical assets or liabilities.
	Level 2:	Observable market based inputs or unobservable inputs that are corroborated by market data.
	Level 3:	Unobservable inputs that are not corroborated by market data.

Fair Value of Financial Instruments [Policy Text Block]

Fair Value of Financial Instruments

Recent Accounting Pronouncements [Policy Text Block]

Recent Accounting Pronouncements

Subsequent Events

Subsequent Events [Text Block]

10.	Subsequent Events

	Subsequent to the end of the quarter, the Company's board of directors granted options to acquire 680,000 common shares under the 2006 Stock Option Plan, as amended. Of the total stock options granted, 480,000 were granted to the Chief Operating Officer and Chief Scientific Officer, Dr. Rajiv Khosla, and 200,000 were granted to the Chief Financial Officer, Mr. Paul A. Simmons. The options have an exercise price of CAD$0.67 (US$0.65) and expire on April 23, 2018. All of the options granted to Dr. Khosla vest on December 31, 2015. The options granted to Mr. Simmons vest over a period of two years at the rate of 25% every six months. In addition, 37,500 unvested options that were granted to Dr. Khosla in November 2011 expired upon issuance of the above options.

	Subsequent to the end of the quarter, 995,500 warrants were exercised for 995,500 common shares having a par value of $0 thousand for cash consideration of approximately $472 thousand, resulting in an increase in additional paid-in capital of approximately $472 thousand.

15.

Subsequent Events

Subsequent top the year ended December 31, 2012, 362,500 warrants were exercised for 362,500 common shares having a par value of $0 thousand for cash consideration of approximately $172 thousand, resulting in an increase in additional paid-in capital of approximately $172 thousand

Document and Entity Information	15 Months Ended
Document and Entity Information	Mar. 31, 2013
Document Type	S-1
Amendment Flag	false
Document Period End Date	Mar. 31, 2013
Trading Symbol	igxt
Entity Registrant Name	IntelGenx Technologies Corp.
Entity Central Index Key	0001098880
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	FY

Comparative Figures

3 Months Ended

Mar. 31, 2013

Comparative Figures [Text Block]

11.	Comparative Figures

	Certain reclassifications of March 31, 2012 amounts have been made to facilitate comparison with the current period.